

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
**WO 01/34628 A1**

(51) International Patent Classification<sup>7</sup>: **C07H 21/04**,  
21/02, C07K 5/00, 14/00, C12Q 1/68, C12N 1/21, 15/63,  
15/85, 15/86

(74) Agents: **HOOVER, Kenley, K.** et al.; C/O Human  
Genome Sciences, Inc., 9410 Key West Avenue, Rockville,  
MD 20850 (US).

(21) International Application Number: PCT/US00/30653

(22) International Filing Date:  
8 November 2000 (08.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/164,735 12 November 1999 (12.11.1999) US  
60/221,193 27 July 2000 (27.07.2000) US

(71) Applicant (for all designated States except US): **HUMAN  
GENOME SCIENCES, INC.** [US/US]; 9410 Key West  
Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RUBEN, Steven,**  
**M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD  
20832 (US). **KOMATSOULIS, George, A.** [US/US];  
9518 Garwood Steel, Silver Spring, MD 20901 (US).  
**BIRSE, Charles, E.** [GB/US]; 13822 Saddlevue Drive,  
North Potomac, MD 20878 (US). **NI, Jian** [US/US]; 5502  
Manorfield Road, Rockville, MD 20853 (US). **MOORE,**  
**Paul, A.** [GB/US]; 19005 Leatherbark Drive, German-  
town, MD 20874 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.
- With (an) indication(s) in relation to deposited biological  
material furnished under Rule 13bis separately from the  
description.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: 35 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding re-  
gions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing  
human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating dis-  
eases, disorders, and/or conditions related to these novel human secreted proteins.

WO 01/34628 A1

## 35 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides, polypeptides encoded by these polynucleotides, antibodies that bind these polypeptides, uses of  
5 such polynucleotides, polypeptides, and antibodies, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or  
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic  
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in  
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
30 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of



the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

### ***Detailed Description***

#### **Definitions**

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As

shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA<sup>+</sup> sequences (such as any 3' terminal polyA<sup>+</sup> tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

### **Polynucleotides and Polypeptides of the Invention**

**FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

The computer algorithm BLASTX has been used to determine that the  
5 translation product of this gene shares sequence homology with sialomucins,  
particularly murine endomucin (see, e.g., Genbank Accession No. gb|AAD05208.1|  
(shown as SEQ ID NO:223); all information available through this accession number  
is hereby incorporated herein by reference). Sialomucins are expressed in multiple  
tissues including vascular endothelium and hematopoietic progenitors and have been  
10 proposed to be involved in processes as diverse as glomerular filtration, inhibition of  
stem cell differentiation, and leukocyte-endothelial adhesion (see, e.g., Sasseti C, et  
al., J Biol Chem. 2000 Mar 24;275(12):9001-10). Based on the structural similarity  
these homologous polypeptides are expected to share at least some biological  
activities. Such activities are known in the art, some of which are described elsewhere  
15 herein. Assays for determining such activities are also known in the art, some of  
which have been described elsewhere herein.

The polypeptide of this gene is believed to have a transmembrane domain at  
about amino acid position 194 to about 210 of the amino acid sequence referenced in  
Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 211 to  
20 260 of this protein has also been determined. Based upon these characteristics, it is  
believed that the protein product of this gene shares structural features to type Ia  
membrane proteins.

In one embodiment, preferred polypeptides comprise a domain selected from  
the following group: (a) the soluble extracellular domain of the amino acid sequence  
25 referenced in Table 1 for this gene; (b) the soluble extracellular domain and the  
transmembrane domain of the amino acid sequence referenced in Table 1 for this  
gene, (c) the cytoplasmic domain of the amino acid sequence referenced in Table 1  
for this gene.

In specific embodiments, polypeptides of the invention comprise, or  
30 alternatively consists of, an amino acid sequence selected from the group:  
NSTGVLEAANNSLVTTTKPSITTPNTESLQKNVVTPTTGTPKGTITNELLKMS  
LMSTATFLTSTKDEGLKATTTDVRKNDSIISNVTVTSTLPNAVSTLQSSKPKTE

TQSSIKTTEIPGSVLQPDASPSKTGTLTSIPVTI  
 PENTSQSQVIGTEGGKNASTSATSRSYSSIILP (SEQ ID NO: 224);  
 NSTGVLEAANNSLVTTTKPSITTPNTESLQKNVVTPTTGTPKGTITNELLKMS  
 LMSTATFLTSKDEGLKATTTDVRKNDSIISNVTVTSTLTPNAVSTLQSSKPKTE  
 5 TQSSIKTTEIPGSVLQPDASPSKTGTLTSIPVTIPENTSQSQVIGTEGGKNASTSA  
 TSRSYSSIILPVVIALIVITLSVFLVGL (SEQ ID NO: 225); and  
 LYRMCWKADPGTPENGNDQPQSDKESVKLLTVKTISHESGEHSAQGKTKN  
 (SEQ ID NO: 226). Moreover, fragments and variants of these polypeptides (such as,  
 for example, fragments as described herein, polypeptides at least 80%, 85%, 90%,  
 10 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides  
 encoded by the polynucleotide which hybridizes, under stringent conditions, to the  
 polynucleotide encoding these polypeptides ) are encompassed by the invention.  
 Antibodies that bind polypeptides of the invention are also encompassed by the  
 invention. Polynucleotides encoding these polypeptides are also encompassed by the  
 15 invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
 4. Accordingly, polynucleotides related to this invention are useful as a marker in  
 linkage analysis for chromosome 4.

This gene is expressed primarily in the following tissues/cDNA libraries:  
 20 Soares\_total\_fetus\_Nb2HF8\_9w and to a lesser extent in Morton Fetal Cochlea;  
 Stratagene endothelial cell 937223; Human umbilical vein endothelial cells, IL-4  
 induced; Endothelial cells-control; Stratagene lung (#937210); NCI\_CGAP\_Kid3;  
 Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Lu5;  
 Soares\_parathyroid\_tumor\_NbHPA; Soares melanocyte 2NbHM; Morton Fetal;  
 25 Human Umbilical Vein Endothelial cells, frac B, re-excision; Tongue Tumour;  
 Human 8 Week Whole Embryo, subtracted; stomach cancer (human); Smooth Muscle  
 Serum Treated, Norm; Human Soleus; Healing groin wound, 7.5 hours post incision;  
 Human Umbilical Vein, Reexcision; Human Umbilical Vein Endothelial Cells,  
 uninduced; Human Adipose; Hepatocellular Tumor, re-excision; Human Gall  
 30 Bladder; Bone marrow; Human Fetal Heart and Endothelial-induced.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 differential identification of the tissue(s) or cell type(s) present in a biological sample

and for diagnosis of diseases and conditions which include but are not limited to: disorders associated with proliferating cells, for example, cancer; disorders involving endothelial cells or endothelium. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
5 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endothelium, proliferating cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endothelium, vascular, proliferating, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal  
10 fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

This novel endomucin shows elevated levels of expression in a variety of endothelial cells. As such this protein may play a role in modulating cell-cell adhesion  
15 in the endothelium. The presence of three putative protein kinase C phosphorylation sites in the cytoplasmic tail indicate a role for the protein as a signaling molecule. The homology to sialomucins indicates that this gene and/or its encoded proteins would be a good target for antagonists, particularly small molecules or antibodies, which block binding of the receptor by its cognate ligand(s). Accordingly, preferred are antibodies  
20 and or small molecules which specifically bind an extracellular portion of the translation product of this gene. The extracellular regions can be ascertained from the information regarding the transmembrane domains as set out above. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their  
25 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 2



In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group: QRELIMLVIIIMTALVSHVPSVHSVPHAVPFTSS (SEQ ID NO: 227); and MSQASTLCLMLFPSPAVSSPSNLSSEKGRAVTAPTLQMRKLRLGGKSLPEVN  
5 GQVGGRCQDPCLGHTPSRVLTMGFRVSRGYGGPPHLQSSLEVRSGTAGLCNF REGLYSLPHSLHQ (SEQ ID NO: 228). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
10 conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:

15 CD34 positive cells (Cord Blood).

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the hematopoietic system. Similarly, polypeptides and antibodies directed  
20 to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g.,  
25 serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression primarily in hematopoietic progenitor cells indicates that  
30 polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia

since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow  
5 transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and  
10 in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
15 immunotherapy targets for the above listed tissues.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

20 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with membrane receptor signaling proteins, such as sensor proteins and chemotaxis proteins (see, e.g., Genbank Accession No. gb|AAA81939.1| (shown as SEQ ID NO:229) and gb|AAD21535.1| (AF088896), all information available through the recited accession  
25 numbers is hereby incorporated herein by reference. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

30 In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:  
LTFQFISLIIAAWYGAKLLSRPIQRLSAAAERLSVDLDSPLVETGPPEARQAA

STFNLQMQRIREQVSQRARMLGAVSHDLRTPLSRLKLRLEQIEDPKLQGQMR  
QDLDDMIGMLDATLSYLHEQRTSETRHWLDVQALVESLSENAQDQGRDVQ  
(SEQ ID NO: 230),

5 SRPIQRLSAAAERLSVDLDSPLVETGPPEARQAASTFNLQMQRIREQVSQRA  
RMLGAVSHDLRTPLSRLKLRLEQIEDPKLQGQMRQDLDDMIGMLDATLSYL  
HEQRTSETRHWLDVQALVESLSENAQDQGRDVQ (SEQ ID NO: 231),

ETGPPEARQAASTFNLQMQRIREQVSQRARMLGAVSHDLRTPLSRLKLRLEQ  
IEDPKLQGQMRQDLDDMIGMLDATLSYLHEQRTSETRHWLDVQALVESLSE  
NAQDQGRDV (SEQ ID NO: 232) and

10 PQGSAIDQDGTRRRLPVRRPGYRLMRAPFNTLFGRLFGLLLVAIVLAHXLAFF  
WFHHYGPPPPXXAXFVEQPDGSLTLRKAPRPWFGGPVVPLTFQFISLIIAAW  
YGAKLLSRPIQRLSAAAERLSVDLDSPLVETGPPEARQAASTFNLQMQRIRE  
QVSQRARMLGAVSHDLRTPLSRLKLRLEQIEDPKLQGQMRQDLDDMIGMLD  
ATLSYLHEQRTSETRHWLDVQALVESLSENAQDQGRDVQFFFGGXPPGGGX

15 PKTPPPF (SEQ ID NO: 233). Moreover, fragments and variants of these  
polypeptides (such as, for example, fragments as described herein, polypeptides at  
least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides  
and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
conditions, to the polynucleotide encoding these polypeptides ) are encompassed by  
20 the invention. Antibodies that bind polypeptides of the invention are also  
encompassed by the invention. Polynucleotides encoding these polypeptides are also  
encompassed by the invention.

This gene is expressed primarily in the pancreas; in CD34 positive cells (cord  
blood) and other cells associated with the immune system.

25 Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
disorders of the digestive system, including but not limited to, diseases of the  
pancreas, and/or the hematopoietic system. Similarly, polypeptides and antibodies  
30 directed to these polypeptides are useful in providing immunological probes for  
differential identification of the tissue(s) or cell type(s). For a number of disorders of  
the above tissues or cells, particularly of the digestive and/or hematopoietic systems,

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., digestive, pancreatic, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in hematopoietic progenitor cells indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, GVHD, transplant rejection, bone marrow repopulation, autoimmune diseases, immunodeficiencies, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. In addition, the tissue distribution in pancreas indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention and/or diagnosis of disorders of the pancreas, including inflammatory disorders, such as chronic or acute pancreatitis; diabetes mellitus; pancreatic cancer. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

In specific embodiments, polypeptides of the invention comprise, or  
 5 alternatively consists of, an amino acid sequence selected from the group:  
 SSGGQVGYYLLPPSLASCELACDRISCPRCLPSCHRAKAFDLMTVSSYLWMLT  
 GVISGSTGAMALSLASLSAHCFAFRCLAAPFYFFAGLGKHGRRILISFLFSAW  
 (SEQ ID NO: 234); and  
 MSSLLPSCKSIRSVDREFLFVDANWGNLREYWGHGSFPCFSFCSLLCFQVLS  
 10 CSFLFLCRTGKAWEEDFDKFLVLCVVMGWSEGQVNKPTFGYYPGKLRVDGR  
 VMIVACVFAIFLCQCGFLSSSFFSSEGSATVSIPWFLQKTAKCALRASGDVLCC  
 SPSS (SEQ ID NO: 235). Moreover, fragments and variants of these polypeptides  
 (such as, for example, fragments as described herein, polypeptides at least 80%, 85%,  
 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides  
 15 encoded by the polynucleotide which hybridizes, under stringent conditions, to the  
 polynucleotide encoding these polypeptides ) are encompassed by the invention.  
 Antibodies that bind polypeptides of the invention are also encompassed by the  
 invention. Polynucleotides encoding these polypeptides are also encompassed by the  
 invention.

20 The gene encoding the disclosed cDNA is believed to reside on chromosome  
 11. Accordingly, polynucleotides related to this invention are useful as a marker in  
 linkage analysis for chromosome 11.

This gene is expressed primarily in the following tissues/cDNA libraries:  
 CD34 positive cells (Cord Blood) and to a lesser extent in Activated T-  
 25 cell(12h)/Thiouridine-re-excision; Stratagene lung (#937210); Human Prostate BPH,  
 re-excision; NCI\_CGAP\_Ut3; Hepatocellular Tumor, re-excision; Apoptotic T-cell;  
 Soares\_pineal\_gland\_N3HPG; Bone Marrow Stromal Cell, untreated; Activated T-  
 Cell (12hs)/Thiouridine labelledEco and Soares fetal liver spleen 1NFLS.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 30 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 and for diagnosis of diseases and conditions which include but are not limited to:  
 disorders of the hematopoietic and/or immune systems. Similarly, polypeptides and

antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and/or immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Enriched expression of this gene in immune and hematopoietic tissues indicates that polynucleotides and polypeptides corresponding to would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have

commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

This gene is expressed primarily in the following tissues/cDNA libraries:  
CD34 positive cells (Cord Blood); Apoptotic T-cell, re-excision.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the hematopoietic and/or immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and/or immune systems; expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression of this gene in hematopoietic progenitor cells and in T-cells indicates that the protein encoded by this gene would be useful for the diagnosis, prevention, treatment and/or detection of hematopoietic and immune disorders including autoimmune diseases, immunodeficiencies and leukemia. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below,

in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

This gene is expressed primarily in H. Whole Brain #2, re-excision..

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:



disorders of the nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at  
5 significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, neuronal, nervous, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
10 individual not having the disorder.

The tissue distribution in brain indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the  
15 "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal  
20 cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in  
25 normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a  
30 nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

- 5 In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:  
QKLQLARLQVDTSGSKEFGTSSLSLSRFFQMLVLLSLLASGGLPLLLVGDVLA  
SKSSTVLFLPGDSSPGCSMITPLPPSRMCLKAGSSGEQTVVPLSLLLXSKSSK  
(SEQ ID NO: 236);
- 10 MVKTRDDFKIYNEDVSFLSVNQNNYSRNPTQSLEPNVGSKQPKHINNLSLSSSL  
GDAQDEKRYLTGNEEAYGRSHIPEQLMHIYSQPIAILQTSDLFSTPEQLHTAKS  
ATLPRKGQLVYGQLMEPVNRENFTQTLPKMPIHSHAQPPDAREEDIILEGQQS  
LPSQASDWSRYSSSLLESVSVPGTLNEAVVMTPFSSELQGISEQTLLLELSKGKP  
SPHPRAWFVSLDGKPVAQVRHSFIDLKKGKRTQSNDTSLDSGVDMNELHSSR  
15 KLEREKTFIKSMHQPKILYLEDLDLSSSES GTTVCS PEDPALRHILDGGSGVIM  
EHPGEESPGRKSTVEDFEANTSPTKRRGRPPPLAKRDSKTNIWKKRERERE  
(SEQ ID NO: 237);  
MVKTRDDFKIXNEDVSFLSVNQNNYSRNPTQSLEPNVGSKQPKHIXTNLSSSL  
GDAQDEKRYLTGNEEAYGRSHIPEQLMHIYSQPIAILQTSDLFSTPEQLHTAKS  
20 ATLPRKGQLVYGQLMEPVNRENFTQTLPKMPIHSHAQPPDAREEDIILEGQQS  
LPSQASDWSRYSSSLLESVSVPGTLNEAVVMTPFSSELQGISEQTLLLELSKGKP  
SXHPRAWFVSLDGKPVAQVRHSFIDLKKGKRTQSNDTSLDSGVDMNELHSS  
RKLEREKTFIKSMHQPKILYLEDLDLSSSES GTTVCS PEDPALRHILDGGSGVI  
MEHPGEESPGRKSTVEDFEANTSPTKRRGRPPPLAKRDSKTNIWKKREREREL  
25 VPNSLDPLVSTCRRASCFC (SEQ ID NO: 238); and  
LLNIFCLLFYSRDKCGTPQKRERNITKLEVLKRDQTTSTTHINHISTVKVALKA  
EDKSQLFNAKNSSYSPQKKEPSKAETEERVSMVKTRDDFKIXNEDVSFLSVN  
QNNYSRNPTQSLEPNVGSKQPKHIXTNLSSSLGDAQDEKRYLTGNEEAYGRS  
HIPEQLMHIYSQPIAILQTSDLFSTPEQLHTAKSATLPRKGQLVYGQLMEPVNR  
30 ENFTQTLPKMPIHSHAQPPDAREEDIILEGQQSLPSQASDWSRYSSSLLESVSV  
PGTLNEAVVMTPFSSELQGISEQTLLLELSKGKPSXHPRAWFVSLDGKPVAQV  
RHSFIDLKKGKRTQSNDTSLDSGVDMNELHSSRKLEREKTFIKSMHQPKILYL

EDLDLSSSESGTTVCSPEDPALRHILDGGSGVIMEHPGEESPGRKSTVEDFEAN  
TSPTKRRGRPPLAKRDSKTNIWKKRERERELVPNSLDPLVSTCRRASCSFC

(SEQ ID NO: 239). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%,

5 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the  
10 invention.

This gene is expressed primarily in the following tissues/cDNA libraries: Stratagene fetal retina 937202; Human Whole Brain, re-excision; Neutrophils IL-1 and LPS induced.

Polynucleotides and polypeptides of the invention are useful as reagents for  
15 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the central nervous system, ocular disorders and/or immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell  
20 type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, retinal tissues, and/or immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., central nervous, neural, neuronal, nervous, retinal, ocular, immune, cancerous and wounded tissues) or bodily fluids (e.g., tears, lymph, serum, plasma,  
25 urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates that polynucleotides and/or  
30 polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the

"Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. In addition, the tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted

factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the gene is expressed at elevated levels in retina indicating that polynucleotides and/or polypeptides corresponding to this clone may play a role in ocular function, and would be useful for treatment, prevention, detection, and/or diagnosis of retinal disorders.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 8**

This gene is expressed primarily in the following tissues/cDNA libraries:

Human Pancreas Tumor; Human Pancreas Tumor, Reexcision.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the digestive system, including but not limited to, diseases of the pancreas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., digestive, pancreatic, cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pancreas and pancreatic cancer indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention and/or diagnosis of disorders of the digestive system,

particularly disorders of the pancreas, including inflammatory disorders, such as chronic or acute pancreatitis; diabetes mellitus; or pancreatic cancer.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 9

The gene encoding the disclosed cDNA is believed to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

- 10 This gene is expressed primarily in the following tissues/cDNA libraries:  
Human Amygdala and to a lesser extent in Soares infant brain 1NIB;  
NCI\_CGAP\_Lu5; Nine Week Old Early Stage Human; Soares fetal liver spleen  
1NFLS; Human Prostate; normalized infant brain cDNA; Human Chondrosarcoma;  
Human Testes; Soares\_fetal\_lung\_NbHL19W;  
15 Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_fetal\_heart\_NbHH19W; Morton Fetal  
Cochlea; 12 Week Old Early Stage Human, II; Human Fetal Lung III; Stratagene lung  
(#937210); Human 8 Week Whole Embryo; Human Cerebellum; NCI\_CGAP\_Pr3;  
Human Substantia Nigra; 12 Week Early Stage Human II, Reexcision; H. Frontal  
cortex,epileptic,re-excision; Soares\_parathyroid\_tumor\_NbHPA; Soares melanocyte  
20 2NbHM; Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_pregnant\_uterus\_NbHPU;  
Soares\_testis\_NHT; Hippocampus, Alzheimer Subtracted; Human Adrenal Gland  
Tumor; 12 Week Old Early Stage Human; Human Fetal Heart; H. Epididymus,  
cauda; Healing groin wound - zero hr post-incision (control); Human Amygdala,re-  
excision; Human Osteosarcoma; Human Manic Depression Tissue; Temporal cortex-  
25 Alzheimer, subtracted; Human Hypothalamus,Schizophrenia; Human umbilical vein  
endothelial cells, IL-4 induced; Stratagene endothelial cell 937223; Spinal cord;  
NCI\_CGAP\_Br2; NCI\_CGAP\_Kid11; NCI\_CGAP\_Co8; Human Testes, Reexcision;  
Soares\_multiple\_sclerosis\_2NbHMSP; Human fetal heart, Lambda ZAP Express;  
Osteoblasts; Colon Normal III; Human Brain; NCI\_CGAP\_Pr18; Human Fetal Lung;  
30 Whole 6 Week Old Embryo; Dermatofibrosarcoma Protuberance; NCI\_CGAP\_Thy1;  
Human heart cDNA (YNakamura); Human retina cDNA randomly primed sublibrary;  
NCI\_CGAP\_Co9; H. Kidney Medulla, re-excision; NCI\_CGAP\_Ew1; Human Brain,

- Striatum; human ovarian cancer; Stratagene fetal retina 937202;  
 Soares\_pineal\_gland\_N3HPG; Human Hippocampus; Soares breast 2NbHBst;  
 NTERA2, control; NCI\_CGAP\_GC4; Human Placenta; Human Osteoclastoma;  
 Soares\_senescent\_fibroblasts\_NbHSF; NCI\_CGAP\_Kid3;
- 5 Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Endometrial Tumor;  
 Soares\_NhHMPu\_S1; Human Hippocampus, prescreened; Human Fetal Brain; H.  
 Adult Spleen, ziplox; HUMAN Fetal Brain, normalized 100024F; Human  
 Hippocampus; Human Fetal Brain, normalized c5-11-26; 1-NIB; Human Fetal Brain,  
 normalized A5002F; Morton Fetal; Brain, normal; Testis 1; Larynx Normal; Pharynx
- 10 Carcinoma; Human Normal Cartilage Fraction IV; Normal Prostate; Human Infant  
 Adrenal Gland; Brain Amygdala Depression; Human Normal Cartilage Fraction II;  
 Human Prostate, subtracted; Human 8 Week Whole Embryo, subtracted; STRIATUM  
 DEPRESSION; Soares\_NbHFB; Liver HepG2 cell line.; NCI\_CGAP\_Brn35;  
 NCI\_CGAP\_Pr10; NCI\_CGAP\_GC5; Frontal Lobe, Dementia; Normalized infant
- 15 brain, Bento Soares; H. Striatum Depression, subt; NCI\_CGAP\_Pr6; Human (HCC)  
 cell line liver (mouse) metastasis, remake; NCI\_CGAP\_Lu24; Human Cerebellum,  
 subtracted; Human Cardiomyopathy, subtracted; H. Atrophic Endometrium; Hep G2  
 Cells, PCR library; Human Placenta; Human Thyroid; Amniotic Cells - TNF induced;  
 Human Lung; Human Quadriceps; Weizmann Olfactory Epithelium; NTERA2
- 20 teratocarcinoma cell line+retinoic acid (14 days); H. Whole Brain #2, re-excision;  
 Human Whole Brain, re-excision; Human Epididymus; Stomach cancer (human),re-  
 excision; Human Synovium; Human Colon Cancer,re-excision; Human  
 Hypothalamus,schizophrenia, re-excision; Human adult (K.Okubo); human corpus  
 colosum; Alzheimers, spongy change; H. Kidney Cortex, subtracted; Human
- 25 pancreatic islet; Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm,  
 Low Malignant Pot; Stratagene ovary (#937217); Human Frontal Cortex,  
 Schizophrenia; Human endometrial stromal cells-treated with progesterone; Human  
 Whole Brain #2 - Oligo dT > 1.5Kb; Healing groin wound, 7.5 hours post incision;  
 Human Adipose Tissue, re-excision; Human Osteoclastoma, re-excision; Human
- 30 endometrial stromal cells; Synovial hypoxia; Myeloid Progenitor Cell Line; H.  
 Meningima, M1; wilm's tumor; NCI\_CGAP\_Alv1; NCI\_CGAP\_Ut2; Stratagene lung  
 carcinoma 937218; Mo7e Cell Line GM-CSF treated (1ng/ml); Human Umbilical

Vein, Reexcision; NCI\_CGAP\_Kid6; Human Fetal Kidney; Human Umbilical Vein  
 Endothelial Cells, uninduced; Human Fetal Dura Mater; T-Cell PHA 24 hrs; Stromal  
 cell TF274; Merkel Cells; Human Rhabdomyosarcoma; Human Thymus Stromal  
 Cells; Stratagene hNT neuron (#937233); Human Whole Six Week Old Embryo;  
 5 Rejected Kidney, lib 4; Human Liver, normal; Human Ovary; Pancreas Islet Cell  
 Tumor; Fetal Heart; PC3 Prostate cell line; Resting T-Cell Library,II; Human  
 Placenta; Early Stage Human Brain; Human Ovarian Cancer Reexcision; Pancreas  
 normal PCA4 No; human tonsils; Endothelial-induced; Soares retina N2b4HR;  
 Human Microvascular Endothelial Cells, fract. A; Smooth muscle,control;  
 10 NCI\_CGAP\_Kid5; NCI\_CGAP\_Brn23; Hodgkin's Lymphoma II; Activated T-  
 cell(12h)/Thiouridine-re-excision; Keratinocyte; Colon Tumor II and  
 Soares\_NFL\_T\_GBC\_S1.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 15 and for diagnosis of diseases and conditions which include but are not limited to:  
 neurological and/or developmental disorders. Similarly, polypeptides and antibodies  
 directed to these polypeptides are useful in providing immunological probes for  
 differential identification of the tissue(s) or cell type(s). For a number of disorders of  
 the above tissues or cells, particularly of the nervous system, expression of this gene  
 20 at significantly higher or lower levels may be routinely detected in certain tissues or  
 cell types (e.g., neurological, nervous, neural, neuronal, cancerous and wounded  
 tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial  
 fluid and spinal fluid) or another tissue or sample taken from an individual having  
 such a disorder, relative to the standard gene expression level, i.e., the expression  
 25 level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue including amygdala indicates that  
 polynucleotides and/or polypeptides corresponding to this clone would be useful for  
 the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease  
 states, behavioral disorders, sensory disorders or inflammatory conditions.  
 30 Representative uses are described in the "Regeneration" and "Hyperproliferative  
 Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,  
 the uses include, but are not limited to the detection, treatment, and/or prevention of



Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive  
5 compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission,  
10 learning, cognition, homeostasis, or neuronal differentiation or survival. In addition, this gene is expressed at elevated levels in many cancerous tissues including the colon, prostate and ovary indicating a usefulness in treating, detecting, and/or preventing neoplastic progression in these tissues. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to  
15 isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 10**

This gene is expressed primarily in the following tissues/cDNA libraries:  
CD34 positive cells (Cord Blood).

25

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
30 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

types (e.g., hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression primarily in hematopoietic progenitor cells indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

This gene is expressed primarily in the following tissues/cDNA libraries:  
Human Whole Brain, re-excision.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the central nervous system. Similarly, polypeptides and antibodies  
5 directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., nervous, neural, neuronal, cancerous and wounded tissues)  
10 or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression of this gene primarily in brain indicates that polynucleotides  
15 and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to  
20 the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive  
25 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition,  
30 homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions,

in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

## FEATURES OF PROTEIN ENCODED BY GENE NO: 12

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

10 VHLWAALAPTLPGRPPQALNGAGSVLHVRWVRASLCHPPDGSVFLCMAGLG  
LLSLVQFSVTGGHWTGIADSLVATLGCRLSGSVPPPLLAPSGHSRALHQTLT  
WCLHLLSLSPSSNPWKSLV (SEQ ID NO: 240) and  
WAALAPTLPGRPPQALNGAGSVLHVRWVRASLC (SEQ ID NO: 241).

Moreover, fragments and variants of these polypeptides (such as, for example,  
15 fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,  
97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the  
polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
encoding these polypeptides ) are encompassed by the invention. Antibodies that bind  
polypeptides of the invention are also encompassed by the invention. Polynucleotides  
20 encoding these polypeptides are also encompassed by the invention.

Expression of this gene is enriched in the brain with expression primarily in  
the following tissues/cDNA libraries: Human Cerebellum and to a lesser extent in  
Human Whole Brain #2 - Oligo dT > 1.5Kb; Brain Frontal Cortex, re-excision;  
Human Cardiomyopathy, subtracted; Weizmann Olfactory Epithelium; Spinal cord;  
25 H. Frontal cortex,epileptic,re-excision; Soares melanocyte 2NbHM; Soares placenta  
Nb2HP; Brain pons; Larynx Normal; H. hypothalamus, frac A; Human Cerebellum,  
subtracted; NCI\_CGAP\_Br1.1; Human Skin Tumor; Human adult small intestine,re-  
excision; H. Whole Brain #2, re-excision; NCI\_CGAP\_AA1; Human Synovium;  
Alzheimers, spongy change; Stratagene schizo brain S11; Jurkat T-cell G1 phase;  
30 Spinal Cord, re-excision; Human Brain, Striatum; Monocyte activated, re-excision;  
HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Macrophage-oxLDL;  
Human Hippocampus; Human Placenta (re-excision); Soares adult brain

N2b5HB55Y; Human Adult Heart, re-excision; Human Gall Bladder; Smooth muscle, serum induced, re-exc; 12 Week Old Early Stage Human; Human T-Cell Lymphoma; Human Substantia Nigra; Human Fetal Lung III; Human Fetal Heart; Human Adult Pulmonary, re-excision; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human  
5 Amygdala; Spleen, Chronic lymphocytic leukemia; Human fetal heart, Lambda ZAP Express; Bone Marrow Cell Line (RS4,11) and Human 8 Week Whole Embryo.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:  
10 disorders of the immune and/or nervous systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or nervous systems, expression of this gene at significantly higher or lower levels may be  
15 routinely detected in certain tissues or cell types (e.g., neural, neuronal, central nervous, nervous, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
20 individual not having the disorder.

The enriched expression of this gene in the brain indicates the protein product of this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative  
25 Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction,  
30 aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep

patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 13

In one aspect of the invention, preferred polypeptides comprise, or alternatively consist of, the following amino acid sequence:  
KVPSPTLIDPGCESICPLQLVRREGTRLPEQRPSMLLLRCAPSLGTHLFLNMLR  
PPRWALMAASSHPPPLWSWVLGLAAHPTGMSPGTGPHHGWVSASSSSS  
(SEQ ID NO: 242). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
Rejected Kidney, lib 4; CD34 positive cells (Cord Blood).

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the renal and/or hematopoietic systems. Similarly, polypeptides and

antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal and/or hematopoietic systems, expression of this gene at significantly higher or lower levels may be

5 routinely detected in certain tissues or cell types (e.g., renal, kidney, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution in kidney indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful in the treatment, prevention, diagnosis and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney  
15 stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. In addition, the expression of this gene in CD34 positive hematopoietic progenitor cells indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment and diagnosis of hematopoietic related disorders such as anemia,  
20 pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow  
25 reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed  
progenitors of various blood lineages, and in the differentiation and/or proliferation of  
30 various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional

supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 14

When tested against sensory neurons, supernatants removed from cells containing this gene activated the EGR promoter element. Genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading  
10 the cells to undergo differentiation and proliferation. Thus, it is likely that this gene activates neurons to undergo differentiation and proliferation.

The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

15 In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:  
SCRSSPQDLAKLQRMSPSRLCPMGYKRSCGTRRMTRRKRRAMPLQRRVKVK  
TTSSRCLPGTTWDLSSPCSAASGHWALLPSTSPRGPARPSPKGTSAWPAPPP  
AGPSS (SEQ ID NO: 243);  
20 PPRDHLGLTLFSLMLCCFWPLGIAAFYFSQGTSKAISKGDFRLASTTSRRA (SEQ ID NO: 244); and  
LVPEQPTGPGQAAENVTIQTVSYGVQEELRDQEDDQEEEESDATSTESESEDN  
FTLPPRDHLGLTLFSLMLCCFWPLGIAAFYFSQGTSKAISKGDFRLASTTSRRA  
LFLATLAI AVGAGLYVAVVVALAAYMSQNGHG (SEQ ID NO: 245). Moreover,  
25 fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides  
30 of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.



Expression of this gene is enriched in brain and in kidney with the gene specifically expressed primarily in the following tissues/cDNA libraries: normalized infant brain cDNA and to a lesser extent in Human Hypothalamus, schizophrenia, re-excision; H. Kidney Cortex, subtracted; Soares infant brain 1NIB; Human Kidney  
5 Cortex, re-rescue; H. Striatum Depression, subt; Human Lung Cancer, re-excision; H. Whole Brain #2, re-excision; Human Frontal Cortex, Schizophrenia; Human Whole Brain #2 - Oligo dT > 1.5Kb; Human Hypothalamus, Schizophrenia and Stratagene lung (#937210).

Polynucleotides and polypeptides of the invention are useful as reagents for  
10 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the central nervous system and/or the renal system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
15 a number of disorders of the above tissues or cells, particularly of the central nervous system and/or renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., central nervous, neural, neuronal, nervous, renal, kidney, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
20 tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The enriched expression of this gene in the brain and activation of EGR promoter in sensory neurons indicates that polynucleotides and/or polypeptides  
25 corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,  
30 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal

cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. In addition expression in kidney indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful in the treatment, prevention, diagnosis and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of Bovine Chondrocytes to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of bone cells, such as, Bovine Chondrocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating bone cells, such as Bovine Chondrocytes.

This gene is expressed primarily in the following tissues/cDNA libraries:  
CD34 positive cells (Cord Blood); neutrophils control; Soares\_NFL\_T\_GBC\_S1;  
Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for  
5 differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
disorders of the immune and/or hematopoietic systems. Similarly, polypeptides and  
antibodies directed to these polypeptides are useful in providing immunological  
probes for differential identification of the tissue(s) or cell type(s). For a number of  
10 disorders of the above tissues or cells, particularly of the immune and/or  
hematopoietic systems, expression of this gene at significantly higher or lower levels  
may be routinely detected in certain tissues or cell types (e.g., immune,  
hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from  
15 an individual having such a disorder, relative to the standard gene expression level,  
i.e., the expression level in healthy tissue or bodily fluid from an individual not  
having the disorder.

The expression of this gene in the immune system and the increased  
permeability of the plasma membrane of treated cells indicates that polynucleotides  
20 and polypeptides corresponding to would be useful for the diagnosis, detection,  
prevention and/or treatment of a variety of immune system disorders. Representative  
uses are described in the "Immune Activity" and "Infectious Disease" sections below,  
in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the  
expression of this gene product indicates a role in regulating the proliferation;  
25 survival; differentiation; and/or activation of hematopoietic cell lineages, including  
blood stem cells. Involvement in the regulation of cytokine production, antigen  
presentation, or other processes indicates a usefulness in the treatment of cancer (e.g.,  
by boosting immune responses). Expression in cells of lymphoid origin, indicates the  
natural gene product would be involved in immune functions. Therefore it may be  
30 also used as an agent for immunological disorders including arthritis, asthma,  
immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis,  
granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia,

neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

This gene is expressed primarily in Human Whole Brain, re-excision. Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., nervous, neural, neuronal, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

LSLLMCVHRCEVCVMRACLCAGVCMCIASCLGLPMNVVEC  
CYTWRVLFVHQ  
FQDEELHDTVDLETIPLERQPRDVQHPVSTRILYLHVYFVA  
VTLTLRILQLWT

5 EAFSP (SEQ ID NO: 246);

CVHRCEVCVMRACLCAGVCMCIASCLGLPMNVVEC (SEQ ID NO: 247); and  
MCDFQIPFRSERNSKHLRFSICSPVALRNALSIRSTSSAEPLPQTL  
CGFIYMYFHI  
SFLCVTAALVWQQVTKCYRSYYGHQVRCNHTKQSQFHELPMICIAE  
VTFYPG  
CAIAVI (SEQ ID NO: 248). Moreover, fragments and variants of these polypeptides

10 (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention.

Antibodies that bind polypeptides of the invention are also encompassed by the  
15 invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In a further aspect, the polypeptide having the amino acid sequence shown in  
SEQ ID NO:248 has been determined to have transmembrane domains at about amino  
acid position 49 to about 65 and at about 97 to about 113 of SEQ ID NO:248. Based  
20 upon these characteristics, it is believed that this polypeptide shares structural features to type IIIb membrane proteins.

This gene is expressed primarily in the following tissues/cDNA libraries:  
Soares infant brain 1NIB and to a lesser extent in Soares adult brain N2b5HB55Y;  
normalized infant brain cDNA; Soares\_fetal\_heart\_NbHH19W; Human Manic  
25 Depression Tissue; PERM TF274; Human Brain, striatum, re-excision; Normal  
trachea; Atrium cDNA library Human heart; Stratagene neuroepithelium NT2RAMI  
937234; Healing groin wound, 7.5 hours post incision; Synovial Fibroblasts  
(II1/TNF), subt; NCI\_CGAP\_Ew1; Stromal cell TF274; Hemangiopericytoma; Bone  
Marrow Stromal Cell, untreated; Fetal Heart; Human Synovial Sarcoma; 12 Week  
30 Early Stage Human II, Reexcision; Human Fetal Heart; Human Testes;  
NCI\_CGAP\_Lu5; Human 8 Week Whole Embryo; Keratinocyte; Nine Week Old  
Early Stage Human; Soares\_NFL\_T\_GBC\_S1 and Soares\_testis\_NHT.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological disorders. Similarly, polypeptides and antibodies directed to these

5 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

10 types (e.g., neural, neuronal, nervous, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissues indicates that polynucleotides and/or

15 polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the

20 detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,

25 learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal

30 differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a

nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

## **FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

10 NSLCVKTIKMLLPLFTLLILLRLRVFPKEIIQNRKKLKAETC (SEQ ID NO: 249).

Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
15 encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
CD34 depleted Buffy Coat (Cord Blood), re-excision.

20 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the hematopoietic system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
25 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
30 sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



Expression of this gene in cord blood indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 19

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

SSLLGLPKCWDYRCEPPHLATLHFKITLITTENDVFICLSPYVLFPYSPPRNINF  
MRARTLPPSLCLWCLAPYLNICWMNG (SEQ ID NO: 250),  
YRTIFSREWKGKRIIYQPLILSRVPECRLMPWSSCEFPLGPSGILFSKEPDAGCT  
GRSAGLEGYNPHLPFSSWQYSRIPHSLQQGSFLSWVGRGYGLNVALRSVSND  
LWPSCLVSVSWGEGSFTQVKNESVKLESCR (SEQ ID NO: 251); and  
MPWSSCEFPLGPSGILFSKEPDAGCTGRSAGLEGYNPHLPFSSWQYSRIPHSLQ  
QGSFLSWVGRGYGLNVALRSVSNDLWPSCLVSVSWGEGSFTQVKNESVKLE  
SCR (SEQ ID NO: 252). Moreover, fragments and variants of these polypeptides

(such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention.

- 5 Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in CD34 positive cells (Cord Blood).

- Polynucleotides and polypeptides of the invention are useful as reagents for
- 10 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the hematopoietic and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of
- 15 disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual
- 20 having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The expression of this gene in hematopoietic progenitor cells indicates polynucleotides and/or polypeptides corresponding to this clone would be useful for
- 25 the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein.
- 30 Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can

be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

This gene is expressed primarily in Human Fetal Brain.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, neuronal, nervous, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

This protein is highly expressed in the brain indicating that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described

in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

This gene is expressed primarily in Human Whole Brain, re-excision.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., nervous, neural, neuronal, cancerous and wounded tissues)

or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5           The tissue distribution in the brain indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,  
10   15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,  
15   mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse  
20   formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may  
25   show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 22**

30           The translation product of this gene shares sequence homology with short chain-type dehydrogenases (see, e.g., Genbank Accession No. gb|AAB66216.1| (AF016685); all references available through this accession are hereby incorporated by reference herein). Based on the sequence similarity, the translation product of this

clone is expected to share at least some biological activities with short chain-type dehydrogenase proteins. Such activities are known in the art, some of which are described elsewhere herein.

- In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:
- 5 AREESDMARWLLPCLPLHSVTSWLLTVPTSCGAMGSAVCLCGRGLCRQNC  
(SEQ ID NO: 253);
- EQAPGKCGKSPRPKRKSSPGILSSRALSSALSNAQTLSLCILPCLPSPVVCVP  
ADPNILSLSGKVLPSCDLARRYGLRDVDGRPVQDYLSLSSVFSHVSGLGWLA
- 10 SYLPSFLRVPKWIALNTSKF (SEQ ID NO: 254);
- LASYLPSFLRVPKWIALNTSKF (SEQ ID NO: 255);
- DPNLSLSGKVLPSCDLARRYGLRDVDGRPVQDYLSLSSVFSHVSGLGWLAS  
YLPSFLRVPKWIALNTSKF (SEQ ID NO: 256);
- DPNLSLSGKVLPSCDLARRYGLRDVDG (SEQ ID NO: 257);
- 15 VALTLPSASPQCDKLAADCAHELRRHGVSCVSLWPGIVQTELLKEHMAKEEV  
LQDPVLKQVGKGRAKEAENRGVGLCILNNKIRYSHSPGAYCGRCAEHGTHI  
ISFNPVREIPAPFYRWQN (SEQ ID NO: 258);
- ELLKEHMAKEEVLQDPVLKQVGKGRAKEAENRG (SEQ ID NO: 259);
- CDKLAADCAHELRRHGVSCVSLWPGIVQTELLKEHMAKEEVLQDPVLKQVG
- 20 KGRAKEAENRGVGLCIL (SEQ ID NO: 260);
- KVQTLFGTTTSFHLAKTADPGARAQSGPGCEEWLWHLPIWVLQALLEVF  
GLFGLWSFSPGTEVEMGRRPGQCSWKLT LHFSAPVFQFKSAFSSAETTELSGK  
CVVALATGEVWGQLVIRKGMEDV (SEQ ID NO: 261);
- FSSAETTELSGKCVVALA (SEQ ID NO: 262); and
- 25 QFKSAFSSAETTELSGKCVVALAT (SEQ ID NO: 263). Moreover, fragments and  
variants of these polypeptides (such as, for example, fragments as described herein,  
polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to  
these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,  
under stringent conditions, to the polynucleotide encoding these polypeptides ) are
- 30 encompassed by the invention. Antibodies that bind polypeptides of the invention are  
also encompassed by the invention. Polynucleotides encoding these polypeptides are  
also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

This gene is expressed primarily in the following tissues/cDNA libraries:

- 5 Soares fetal liver spleen 1NFLS and to a lesser extent in Soares infant brain 1NIB; Stratagene fetal spleen (#937205); Soares melanocyte 2NbHM; Soares\_NhHMPu\_S1; NCI\_CGAP\_GCB1; Soares ovary tumor NbHOT; Colon Tumor II; Soares\_pregnant\_uterus\_NbHPU; Aryepiglottis Normal; Healing Abdomen Wound, 21&29 days post incision; Activated T-cells; Breast Cancer Cell line, angiogenic; NCI\_CGAP\_Kid6; Stratagene pancreas (#937208); Stromal cell TF274; Human umbilical vein endothelial cells, IL-4 induced; NCI\_CGAP\_Br2; Human Thymus; Bone Marrow Stromal Cell, untreated; Human Testes Tumor, re-excision; Soares breast 3NbHBst; NCI\_CGAP\_Co8; Human Fetal Heart; Human Primary Breast Cancer Reexcision; NCI\_CGAP\_Kid5; normalized infant brain cDNA and
- 10 Soares\_fetal\_liver\_spleen\_1NFLS\_S1.
- 15

- Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the immune system, and/or cancers. Similarly, polypeptides and
- 20 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, lymphocytic, cancerous and wounded tissues) or
- 25 bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution in spleen and in a variety of other lymphocytic
- 30 populations indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the

"Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. It is also enriched in a number of cancer tissues including breast and colon indicating a role in neoplastic progression.

The tissue distribution in breast and colon cancer tissue, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment and diagnosis of tumors, especially breast cancer and colon cancer, as well as cancers of other tissues where expression has been indicated. Expression in breast tissue indicates the gene or its products would be useful for diagnosis, treatment and/or prevention of breast neoplasia and breast cancers, such as fibroadenoma, pipillary carcinoma, ductal carcinoma, Paget's disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. Likewise, the tissue distribution in



colon cancer indicates that polynucleotides and polypeptides corresponding to this gene would be useful for diagnosis, treatment and/or detection of tumors, especially of the intestine, such as, carcinoid tumors, lymphomas, cancer of the colon and cancer of the rectum, as well as cancers in other tissues where expression has been indicated.

- 5 Expression in the colon tissue indicates the gene or its products would be useful for the diagnosis, treatment and/or prevention of disorders of the colon, including inflammatory disorders such as, diverticular colon disease (DCD), inflammatory colonic disease, Crohn's disease (CD), non-inflammatory bowel disease (non-IBD) colonic inflammation; ulcerative disorders such as, ulcerative colitis (UC), amebic
- 10 colitis, eosinophilic colitis; noncancerous tumors, such as, polyps in the colon, adenomas, leiomyomas, lipomas, and angiomas. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed
- 15 against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

20

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

- This gene is expressed primarily in reproductive system tissues as well as
- 25 immune/hematopoietic system tissues. More particularly, this gene is expressed in the following tissues/cDNA libraries: ovarian and breast cancer, umbilical vein, dendritic cells, T cells, Soares\_fetal\_heart\_NbHH19W; Human Endometrial Tumor and to a lesser extent in Human Amygdala; Soares melanocyte 2NbHM.

- Polynucleotides and polypeptides of the invention are useful as reagents for
- 30 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the reproductive or immune/hematopoietic systems. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune and/or hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, vaginal pool, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

This protein is expressed at elevated levels in endometrial tumors indicating a role in neoplastic progression.

The tissue distribution in ovarian cancer tissue, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment and diagnosis of tumors, especially ovarian cancer, as well as cancers of other tissues where expression has been indicated. The expression in ovarian cancer tissue may indicate the gene or its products can be used to treat and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis (e.g., caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth). In addition, expression in breast and breast cancer tissue indicates the gene or its products would be useful for diagnosis, treatment and/or prevention of breast neoplasia and breast cancers, such as fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. The tissue distribution indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in

Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB; normalized infant brain cDNA; Human Cerebellum.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, neuronal, nervous, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another

tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
LMEMRLTIAKTPVETQQSWPAFLWYF (SEQ ID NO: 266). Moreover, fragments

and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
CD34 positive cells (Cord Blood).

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression of this gene predominantly in hematopoietic progenitor cells indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it

would be useful for the treatment, prevention and/or detection of immune disorders such as infection, inflammation, allergy, immunodeficiency, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 26**

15

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with transporter proteins (see, e.g., Genbank Accession Nos. gb|AAB47236.1| (SEQ ID NO: 267) and/or gb|AAF34240.1|AF075704\_1 (AF075704); all information available through these accession numbers is hereby incorporated by reference herein). Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

25

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

WYLNNGNYLVLLVSLVVILPLSLFRNLGYLGYTSGLSLLCMVFFLIVVICKKFQ  
VPCPVEAALIINETINTTLTQPTALVPALSHNVTENDSCRPHYFIFNSQTVYAV  
PILIFS FVCHPAVLPIYEELKDRSRRRMMNVSKISFFAMFLMYLLAALFGYLTF  
30 YEHVESELLHTYSSILGTDILLIVRLAVLMAVTLTVPVVFIPIRSSVTHLLCAS  
KDFS WWRHSLITVSILAFTNLLVIFVPTIRDIFGFIGASAASMLIFILPSAFYIKLV  
KKEPMKSVQKIGALFFLLSGVLVMTGSMALIVLDWVHNAPGGGH (SEQ ID

NO: 268). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention. The above polypeptide is predicted to be a fragment of a larger novel transporter protein.

Predicted transmembrane regions of the novel transporter comprise the following amino acid sequences: YLVLLVSLVVILPLSLF (SEQ ID NO: 269), SGLSLLCMVFFLIVVIC (SEQ ID NO: 270), VPILIFS FVCHPAVLPI (SEQ ID NO: 271), ISFFAMFLMYLLAALFG (SEQ ID NO: 272), ILLIVRLAVLMAVTLT (SEQ ID NO: 273), LITVSILAFTNLLVIFV (SEQ ID NO: 274), IFGFIGASAASMLIFIL (SEQ ID NO: 275), and LLSGVLVMTGSMALIVL (SEQ ID NO: 276).

In specific nonexclusive embodiments, polypeptides of the invention comprise, or alternatively consists of, these transmembrane regions, as well as, intra-and extracellular regions.

Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Based upon these characteristics, it is believed that the novel transporter protein shares structural features to type IIIa membrane proteins. The extracellular regions of the novel transporter protein can be ascertained from the information regarding the transmembrane domains as set out above. Accordingly, preferred are antibodies and or small molecules which specifically bind an extracellular portion of the novel transporter protein.

The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

This gene is expressed primarily in the following tissues/cDNA libraries:

- 5 Soares placenta Nb2HP and to a lesser extent in Soares\_pregnant\_uterus\_NbHPU; Bone Marrow Stromal Cell, untreated; Human Placenta; Osteoblasts; Human 8 Week Whole Embryo; Soares infant brain 1NIB; Stratagene HeLa cell s3 937216; Soares\_total\_fetus\_Nb2HF8\_9w; Stratagene neuroepithelium NT2RAMI 937234; 12 Week Early Stage Human II, Reexcision; Soares\_NhHMPu\_S1; Human Placenta (re-
- 10 excision); Human Chondrosarcoma; Synovial Fibroblasts (control); Stratagene hNT neuron (#937233); Human Liver, normal; Human Gall Bladder; Human Placenta; Human Osteoclastoma; Breast, Normal: (4005522B2); NCI\_CGAP\_Ew1; Ovarian Tumor 10-3-95; Soares\_senescent\_fibroblasts\_NbHSF; Soares melanocyte 2NbHM; Soares fetal liver spleen 1NFLS; Human Liver; NCI\_CGAP\_Ut4; Stratagene ovarian
- 15 cancer (#937219); KMH2; Stratagene fetal spleen (#937205); T-Cell PHA 24 hrs; Human Pancreas Tumor, Reexcision; NTERA2, control; Hepatocellular Tumor, re-excision; NCI\_CGAP\_Pan1; Adipocytes; Human Bone Marrow, treated; Hodgkin's Lymphoma II; Keratinocyte; T cell helper II; Colon Normal III; NCI\_CGAP\_GCB1; Human epidermal keratinocyte; Liver HepG2 cell line.; Human colon carcinoma
- 20 (HCC) cell line, remake; H. Atrophic Endometrium; human colon cancer; Human Soleus; Human adult small intestine, re-excision; Human Tonsils, Lib 2; Stratagene placenta (#937225); Human Umbilical Vein, Endo. remake; Glioblastoma; Stratagene ovary (#937217); Human Stomach, re-excision; NCI\_CGAP\_Ov2; Human Osteoclastoma, re-excision; LNCAP prostate cell line; Human endometrial stromal
- 25 cells; Morton Fetal Cochlea; NCI\_CGAP\_Alv1; Stratagene lung carcinoma 937218; Human Prostate; Stratagene fetal retina 937202; 12 Week Old Early Stage Human, II; Human Heart; Stromal cell TF274; Stratagene endothelial cell 937223; NCI\_CGAP\_Br2; Epithelial-TNF $\alpha$  and INF induced; Human Thymus Stromal Cells; Rejected Kidney, lib 4; Stratagene liver (#937224); CHME Cell Line, untreated;
- 30 NCI\_CGAP\_Kid11; Dendritic cells, pooled; Human Synovial Sarcoma; Human Ovarian Cancer Reexcision; Anergic T-cell; Smooth muscle, control; Soares\_multiple\_sclerosis\_2NbHMSP; Pancreas Tumor PCA4 Tu;



Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Lu5; normalized infant brain cDNA; Colon Tumor II; Soares\_NFL\_T\_GBC\_S1; Human Pituitary, subtracted V; Human Fetal Brain, normalized CO; Human Fetal Brain, normalized AC5002; Human Leiomyeloid Carcinoma; NCI\_CGAP\_Br7; Messangial cell, frac 1; Human Kidney Tumor; Larynx Carcinoma; Human Pituitary; NCI\_CGAP\_GC1; Human Microvascular Endothelial Cells, fract. B; NCI\_CGAP\_Lym3; Human White Fat; Thymus; LNCAP + 30nM R1881; Schiller meningioma; NCI\_CGAP\_Kid1; Lung, Normal: (4005313 B1); HepG2 Cells, lambda library; Frontal Lobe, Dementia; Human Gall Bladder, fraction II; Jia bone marrow stroma; Ficoll Human Stromal Cells, Untreated; HSC172 cells; NCI\_CGAP\_Ov23; Adipocytes, re-excision; Pancreatic Islet; HUMAN STOMACH; NCI\_CGAP\_Lu1; Activated T-cells; Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic; Human Thyroid; Human Quadriceps; HSA 172 Cells; Lung Carcinoma A549 TNFalpha activated; Messangial cell, frac 2; NCI\_CGAP\_Ut3; NCI\_CGAP\_AA1; Apoptotic T-cell, re-excision; Healing groin wound - zero hr post-incision (control); HEL cell line; Human endometrial stromal cells-treated with estradiol; Human Colon Cancer, re-excision; Hepatocellular Tumor; Alzheimers, spongy change; NCI\_CGAP\_Co9; Human pancreatic islet; Human Adipose Tissue, re-excision; NCI\_CGAP\_Co14; Synovial hypoxia; Breast, Cancer: (4004943 A5); Myeloid Progenitor Cell Line; Synovial Fibroblasts (IL1/TNF), sub; Healing groin wound, 6.5 hours post incision; Human Manic Depression Tissue; Ovary, Cancer: (4004332 A2); Prostate BPH; H. Lymph node breast Cancer; NCI\_CGAP\_Ut2; NCI\_CGAP\_Pr3; T-Cell PHA 16 hrs; Human Umbilical Vein, Reexcision; Human Bone Marrow, re-excision; Gessler Wilms tumor; NCI\_CGAP\_Ut1; Human Osteoblasts II; Human Pancreas Tumor; NCI\_CGAP\_Gas4; Human Hypothalamus, Schizophrenia; Ovary, Normal: (9805C040R); Human umbilical vein endothelial cells, IL-4 induced; Human Activated Monocytes; Liver, Hepatoma; Olfactory epithelium, nasal cavity; Human Adipose; Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma; Spinal cord; Ovary, Cancer: (4004576 A8); Hemangiopericytoma; Soares breast 2NbHBst; CHME Cell Line, treated 5 hrs; Human Ovary; PC3 Prostate cell line; Fetal Liver, subtraction II; 12 Week Old Early Stage Human; Human Substantia Nigra; Soares

breast 3NbHBst; Human Testes Tumor; B-cells (stimulated); Human Testes, Reexcision; Pancreas normal PCA4 No; Bone marrow; human tonsils; Human Adult Pulmonary, re-excision; Human Primary Breast Cancer Reexcision; Human Microvascular Endothelial Cells, fract. A; Stratagene lung (#937210);  
5 NCI\_CGAP\_Kid3; Bone Marrow Cell Line (RS4,11); H. Frontal cortex, epileptic, re-excision; Human Endometrial Tumor; Soares\_parathyroid\_tumor\_NbHPA; Nine Week Old Early Stage Human; Soares\_fetal\_lung\_NbHL19W; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_fetal\_heart\_NbHH19W; Soares\_testis\_NHT and Primary Dendritic Cells, lib 1.

10 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the reproductive system, developmental disorders, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing  
15 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, developmental, cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, vaginal pool,  
20 lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The expression within reproductive, embryonic tissue and other cellular  
25 sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly,  
30 developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure

to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The protein product of this clone indicates it would be useful for the treatment, detection, and/or prevention of the following non-limiting and exemplary diseases and/or disorders: chondrosarcoma, osteoclastoma, ovarian tumor, ovarian cancer, hepatocellular tumor, lung carcinoma, leiomyeloid carcinoma, adenocarcinoma, metastatic, colon cancer, testes tumor, endometrial tumor. In addition, the homology to transporter proteins and predicted transmembrane localization indicates that the novel transporter protein would be a good target for antagonists, particularly small molecules or antibodies, which block binding of the receptor by its cognate ligand(s). Accordingly, preferred are antibodies and or small molecules which specifically bind an extracellular portion of the novel transporter protein as mentioned above. Also provided is a kit for detecting cancer. Such a kit comprises in one embodiment an antibody specific for the transporter protein bound to a solid support. Also provided is a method of detecting cancer in an individual which comprises a step of contacting an antibody specific for the novel transporter protein to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise

antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

This gene is expressed primarily in Jurkat T-cell G1 phase.

10 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the immune and/or hematopoietic systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological  
15 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
20 plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The protein is found at elevated levels in T-cell populations indicating that  
25 polynucleotides and/or polypeptides corresponding to this clone would be useful for the treatment, prevention, detection and/or diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease"  
30 sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of

neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 28**

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 2 to about amino acid position 18 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 19 to 161 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in the following tissues/cDNA libraries: Human Cerebellum and to a lesser extent in Human Amygdala; Human Whole Brain #2 - Oligo dT > 1.5Kb; Stratagene hNT neuron (#937233); H. Whole Brain #2, re-excision; Early Stage Human Brain; Nine Week Old Early Stage Human; Human Hypothalamus, schizophrenia, re-excision; Human Brain, Striatum; 12 Week Old Early Stage Human, II; Human Hypothalamus, Schizophrenia; Stratagene HeLa cell s3 937216; Human Fetal Brain; Human Testes; H. Frontal cortex, epileptic, re-excision; Human Fetal Brain; Human Fetal Brain, normalized AC5002; Corpus Callosum; Human Fetal Brain, random primed; Human Fetal Brain; Human Cerebellum, subtracted; NCI\_CGAP\_Lu1; Frontal lobe, dementia, re-excision; Human Skin Tumor; Human Pineal Gland; Stomach cancer (human), re-excision; Stratagene schizo brain S11; Soares adult brain N2b4HB55Y; Stratagene fetal retina 937202;

Soares\_pineal\_gland\_N3HPG; Human Hippocampus; 12 Week Old Early Stage Human; Brain frontal cortex; Human Fetal Lung III; Primary Dendritic cells, frac 2; Human Placenta; normalized infant brain cDNA; Human 8 Week Whole Embryo and Primary Dendritic Cells, lib 1.

5 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
10 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., nervous, neural, neuronal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
15 tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in normal and diseased brain and amygdala tissues indicates that polynucleotides and/or polypeptides corresponding to this clone would  
20 be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, sensory disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,  
25 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,  
30 learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in

normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

When tested against a human chronic myelogenous leukemia cell line, K562, supernatants removed from cells containing this gene activated the Serum Response Element (SRE) promoter element. SRE is the downstream signaling mediator of most growth factors and proliferative cytokines. Thus, it is likely that this gene activates immune cells and may be useful in treatment of disorders of the immune system, including but not limited to, cancers such as leukemia, ATLL and CTLL; immunodeficiencies such as SCID, AIDS; or autoimmune diseases such as rheumatoid arthritis.

This gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB; Human Fetal Heart.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, neuronal, nervous, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another

tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain and activation of the SRE promoter element indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 30**

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:



MATNFSDIVKQGYVKMKSRKLGYYRCWL VFRKSSSKGPQRLEKYPDEKSV  
 CLRGCPKVTEISNVKCVTRLPKETKRQAVAIIFTDD SARTFTCDSELEAEWY  
 KTLSVECLGSRLNDISLGEPELLAPGVQCEQTDRFNVFLLPCPNLDVYGECKL  
 QITHENIYLWDIHNPVKLVSWPLCSLRRYGRDATRFTFEAGRMCDAGEGLY  
 5 TFQTQEGEQIYQPVHSATLAIAEQHKRVLLEMEKNVRLLNKGTEHYSYPCTP  
 TTMLPRSA YWHHITGSQNIAEASSYAGESLPCPTPTCQEALWRMRPIGQGSFD  
 LALSSEPASVPTGEGYGAAQASSETDLLNRFILLKPKPSQGDSSEAKTPSQ

(SEQ ID NO: 279). Moreover, fragments and variants of these polypeptides (such as,  
 for example, fragments as described herein, polypeptides at least 80%, 85%, 90%,  
 10 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides  
 encoded by the polynucleotide which hybridizes, under stringent conditions, to the  
 polynucleotide encoding these polypeptides ) are encompassed by the invention.  
 Antibodies that bind polypeptides of the invention are also encompassed by the  
 invention. Polynucleotides encoding these polypeptides are also encompassed by the  
 15 invention.

This gene is expressed primarily in the following tissues/cDNA libraries:

Soares fetal liver spleen 1NFLS and to a lesser extent in normalized infant brain  
 cDNA; NCI\_CGAP\_Bm25; NCI\_CGAP\_Kid5; Soares\_NFL\_T\_GBC\_S1;  
 Soares\_fetal\_heart\_NbHH19W; NCI\_CGAP\_GCB1; Stratagene neuroepithelium  
 20 (#937231); Human Pancreas Tumor, Reexcision; Human Fetal Brain; CHME Cell  
 Line, treated 5 hrs; Pancreas Islet Cell Tumor; Stratagene colon (#937204);  
 Soares\_senescent\_fibroblasts\_NbHSF; Soares\_multiple\_sclerosis\_2NbHMSP; Soares  
 ovary tumor NbHOT; Soares\_parathyroid\_tumor\_NbHPA; Soares melanocyte  
 2NbHM; Soares\_fetal\_lung\_NbHL19W; Human Cerebellum;  
 25 Soares\_pregnant\_uterus\_NbHPU; Human Cardiomyopathy, subtracted; Smooth  
 Muscle Serum Treated, Norm; NCI\_CGAP\_Ut1; NCI\_CGAP\_Pr22; Colon Tumor;  
 NCI\_CGAP\_Kid3; NCI\_CGAP\_Lu5; Activated T-cell(12h)/Thiouridine-re-excision;  
 Human 8 Week Whole Embryo; Nine Week Old Early Stage Human; Human Fetal  
 Brain; Human colon cancer, metastasized to liver, subtraction; Stratagene colon HT29  
 30 (#937221); Larynx carcinoma III; Palate normal; NCI\_CGAP\_Co9; wilm's tumor;  
 Gessler Wilms tumor; Stratagene NT2 neuronal precursor 937230; Stratagene fetal  
 spleen (#937205); Human Pancreas Tumor; Stratagene HeLa cell s3 937216;

Stratagene endothelial cell 937223; Ulcerative Colitis; Human Thymus; Rejected Kidney, lib 4; Human Liver, normal; NCI\_CGAP\_Pan1; Human Fetal Kidney, Reexcision; Human Synovial Sarcoma; human tonsils; Keratinocyte; Colon Tumor II; Soares\_total\_fetus\_Nb2HF8\_9w; Colon Normal III; Soares\_NhHMPu\_S1; Primary

5 Dendritic Cells, lib 1; Human lung adenocarcinoma A549; Human Pancreas; H Amygdala Depression, subtracted; NCI\_CGAP\_Mel3; Rectum tumour; Osteoclastoma-normalized B; Pharynx carcinoma; Human Tonsils, lib I; K562 + PMA (36 hrs); Schiller meningioma; Saos2, Dexamethosome Treated; NCI\_CGAP\_Lei2; NCI\_CGAP\_Co16; NCI\_CGAP\_Br15; Human promyelocyte;

10 Human Fetal Brain; Human Colon; Barstead spleen HPLRB2; Human OB HOS treated (10 nM E2) fraction I; Jia bone marrow stroma; Human placenta cDNA (TFujiwara); Human Adult Retina; Hep G2 Cells, PCR library; Fetal Heart, re-excision; Supt Cells, cyclohexamide treated; Human Fetal Bone; Lung, Cancer (4005313 A3); Invasive Poorly Differentiated Lung Adenocarcinoma,;

15 NCI\_CGAP\_Thy1; Human Thyroid; Amniotic Cells - TNF induced; Early Stage Human Lung, subtracted; NCI\_CGAP\_Co12; H. Epididymus, cauda; Human Soleus; CD40 activated monocyte dendritic cells; Palate carcinoma; NCI\_CGAP\_GC3; NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Human adult small intestine, re-excision; NCI\_CGAP\_AA1; Human Epididymus; HEL cell line; Human

20 adult (K.Okubo); human corpus colosum; Smooth muscle, IL1b induced; Human pancreatic islet; Human T-cell lymphoma, re-excision; Human Amygdala, re-excision; Healing groin wound, 7.5 hours post incision; Human Adipose Tissue, re-excision; NCI\_CGAP\_Co10; Human Osteosarcoma; NCI\_CGAP\_Co14; Human endometrial stromal cells; Synovial hypoxia; Jurkat T-cell G1 phase; Spleen metastatic melanoma;

25 Ovary, Cancer: (4004332 A2); Human Adult Small Intestine; H. Kidney Medulla, re-excision; Stratagene ovarian cancer (#937219); HM1; NCI\_CGAP\_Kid6; Apoptotic T-cell; Human Uterine Cancer; Human Umbilical Vein Endothelial Cells, uninduced; NCI\_CGAP\_Pr28; NCI\_CGAP\_Gas4; Human Hypothalamus, Schizophrenia; Human Hippocampus; Bone Marrow Stromal Cell, untreated; Human Adrenal Gland Tumor;

30 Stratagene hNT neuron (#937233); Human Whole Six Week Old Embryo; Ovarian Tumor 10-3-95; Human adult testis, large inserts; NTERA2, control; NCI\_CGAP\_Co3; Human Gall Bladder; CHME Cell Line, untreated; Human

Substantia Nigra; Colon Carcinoma; Normal colon; NCI\_CGAP\_Co8;  
 NCI\_CGAP\_GC4; B-cells (stimulated); Human Microvascular Endothelial Cells,  
 fract. A; Stratagene lung (#937210); NCI\_CGAP\_Brn23; HUMAN B CELL  
 LYMPHOMA; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human fetal heart,  
 5 Lambda ZAP Express; Bone Marrow Cell Line (RS4,11); H. Frontal  
 cortex,epileptic,re-excision; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares placenta  
 Nb2HP and Soares\_testis\_NHT.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 10 and for diagnosis of diseases and conditions which include but are not limited to:  
 disorders associated with proliferating tissues or cells, including but not limited to  
 developmental disorders or cancers. Similarly, polypeptides and antibodies directed to  
 these polypeptides are useful in providing immunological probes for differential  
 identification of the tissue(s) or cell type(s). For a number of disorders of the above  
 15 tissues or cells, particularly of the reproductive system, or proliferating cells or  
 tissues, expression of this gene at significantly higher or lower levels may be  
 routinely detected in certain tissues or cell types (e.g., reproductive, fetal, cancerous  
 and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma,  
 urine, synovial fluid and spinal fluid) or another tissue or sample taken from an  
 20 individual having such a disorder, relative to the standard gene expression level, i.e.,  
 the expression level in healthy tissue or bodily fluid from an individual not having the  
 disorder.

This protein is found in elevated levels in wide variety of cancers including  
 tumors of the pancreas, brain, kidney and ovary, indicating a role for this protein in  
 25 tumor progression. Moreover, the expression within embryonic tissue and other  
 cellular sources marked by proliferating cells indicates that polynucleotides and/or  
 polypeptides corresponding to this clone may play a role in the regulation of cellular  
 division, and may show utility in the diagnosis, detection, treatment, and/or  
 prevention of developmental diseases and disorders, cancer, and other proliferative  
 30 conditions. Representative uses are described in the "Hyperproliferative Disorders"  
 and "Regeneration" sections below and elsewhere herein. Briefly, developmental  
 tissues rely on decisions involving cell differentiation and/or apoptosis in pattern

formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

ESSLPGPSMPYADHYSTFSPRDRMNSSPYQPPPPQPYGPVPPVPSGMYAPVYD  
SRRIWRPPMYQRDDIIRSNSLPPMDVMHSSVYQTSLRERYNSLDGYYSVACQ  
PPSEPRTTVPLPREPCGHLKTSCEEQIRRKPDQWAQYHTQKAPLVSSTLPVAT

QSPTPPSPLFSVDFRADFSESVSGTKFEEDHLSHYSPWSCGTIGSCINAIDSEPK  
 DVIANSNAVLMDLDSGDVKRRVHLFETQRRKEEDPIPFSDGPIISKWGAISR  
 SSRTGYHTTDPVQATASQGSATKPISVSDYVPYVNAVDSRWSSYGNEATSSA  
 HYVERDRFIVTDLSGHRKHSSTGDLLSLELQQAKSNSLLLQREANALAMQQK  
 5 WNSLDEGRHLTLNLLSKEIELRNGEVKKLNLSASCLMYLFSAAASWLYHY  
 (SEQ ID NO: 280) and

MNSSPYQPPPPQPYGPVPPVPSGMYAPVYDSRRJWRPPMYQRDDIIRSNSLPP  
 MDVMHSSVYQTS LRERYNSLDGYYSVACQPPSEPRTTVPLPRFSESVSGTKFE  
 EDHLSHYSPWSCGTIGSCINAIDSEPKDVIANSNAVLMDLDSGDVKRRVHLFE  
 10 TQRRKEEDPIPFSDGPIISKWGAISRSSRTGYHTTDPVQATASQGSATKPISV  
 SDYVPYVNAVDSRWSSYGNEATSSAHYVERDRFIVTDLSGHRKHSSTGDLLS  
 LELQQA KSNSLLLQREANALAMQPEVEFP (SEQ ID NO: 281). Moreover,

fragments and variants of these polypeptides (such as, for example, fragments as  
 described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or  
 15 99% identical to these polypeptides and polypeptides encoded by the polynucleotide  
 which hybridizes, under stringent conditions, to the polynucleotide encoding these  
 polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides  
 of the invention are also encompassed by the invention. Polynucleotides encoding  
 these polypeptides are also encompassed by the invention.

20 This gene is expressed primarily in the following tissues/cDNA libraries:  
 Soares\_NhHMPu\_S1 and to a lesser extent in Human Fetal Brain, normalized CO;  
 Kidney Pyramids; Human Osteoclastoma, re-excision; Jurkat T-Cell, S phase and  
 NCI\_CGAP\_Pr1.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 25 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 and for diagnosis of diseases and conditions which include but are not limited to: ..  
 neurological disorders and/or disorders of the immune system. Similarly,  
 polypeptides and antibodies directed to these polypeptides are useful in providing  
 immunological probes for differential identification of the tissue(s) or cell type(s). For  
 30 a number of disorders of the above tissues or cells, particularly of the nervous or  
 immune systems, expression of this gene at significantly higher or lower levels may  
 be routinely detected in certain tissues or cell types (e.g., nervous, neural, neuronal,

immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
5 having the disorder.

This protein is highly expressed in the brain indicating that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described  
10 in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital  
15 malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the  
20 brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. It is also expressed in T-cells indicating that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune  
25 system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation  
30 of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune

functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## **20 FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

25 The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 24 to about amino acid position 40 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 41 to 63 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

30 This gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in normalized infant brain cDNA;

Soares\_NhHMPu\_S1; Human Fetal Brain, normalized CO; Stratagene schizo brain S11; Human Manic Depression Tissue; 12 Week Old Early Stage Human; Human Amygdala; Soares\_multiple\_sclerosis\_2NbHMSP; H. Frontal cortex, epileptic, re-excision and Human 8 Week Whole Embryo.

- 5 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
- 10 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., nervous, neural, neuronal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another
- 15 tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution indicates the protein product of this clone would be useful for the detection, treatment, and/or prevention of neurodegenerative disease
- 20 states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,
- 25 encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and
- 30 perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition,



homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies  
5 directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 33

This gene is expressed primarily in A-14 cell line.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
15 and for diagnosis of diseases and conditions which include but are not limited to: tumors, and/or disorders of the immune system, including but not limited to, immune cell tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,  
20 particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression  
25 level in healthy tissue or bodily fluid from an individual not having the disorder.

The elevated level of expression of this protein in Reed-Sternberg cells indicates a role in tumor development, in particular in malignancies of the immune system. Further, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention  
30 and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the

expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

PGVSGSAPHLHPPGVSVDLLPTSILLGESWFFRWLPGKKKTEAYLPDDKNKSI  
VWDEKKNQWVNLNEPEEEKKAPPPPTSMPTVQAAPPALPGPPGAPVNMV  
SRRAAGTRXRYVDVLNPSG (SEQ ID NO: 282);

VHSPGVSGSAPHLHPPGVSDLLPTSILLGESWFFRWLPGKKKTEAYLPDDK  
NKSIVWDEKKNQWVNLNEPEEEKKAPPPPTSMPKTVQAAPPALPGPPGAPV  
NMYSRRAAGTRARYVDVLNPSGTQRSEPALAPADFVAPLAPLPIPSNLFVPTP  
DAEEPQLPDGTGREGPAAARGLANPEPAPEPKVLSSAASLPGSELPSRPEGS  
5 QGGEAPGDLPAAGGPPSGAMPFYNPAQLAQACATSGSSRLGRIGQRKHLVLN  
(SEQ ID NO: 283); and  
MPKTVQAAPPALPGPPGAPVNMYSRRAAGTRARYVDVLNPSGTQRSEPALA  
PADFVAPLAPLPIPSNLFVPTPDAEEPQLPDGTGREGPAAARGLANPEPAPEPK  
VLSSAASLPGSELPSRPEGSQGGEAPGDLPAAGGPPSGAMPFYNPAQLAQAC  
10 ATSGSSRLGRIGQRKHLVLN (SEQ ID NO: 284). Moreover, fragments and  
variants of these polypeptides (such as, for example, fragments as described herein,  
polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to  
these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,  
under stringent conditions, to the polynucleotide encoding these polypeptides ) are  
15 encompassed by the invention. Antibodies that bind polypeptides of the invention are  
also encompassed by the invention. Polynucleotides encoding these polypeptides are  
also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
9. Accordingly, polynucleotides related to this invention are useful as a marker in  
20 linkage analysis for chromosome 9.

This gene is expressed primarily in the following tissues/cDNA libraries:  
Soares fetal liver spleen 1NFLS and to a lesser extent in  
Soares\_fetal\_heart\_NbHH19W; NCI\_CGAP\_GCB1;  
Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_pregnant\_uterus\_NbHPU; Activated  
25 T-cell(12h)/Thiouridine-re-excision; Soares\_NFL\_T\_GBC\_S1; Human  
Rhabdomyosarcoma; Human Placenta; Stratagene colon (#937204); Activated T-Cell  
(12hs)/Thiouridine labelledEco; Human Endometrial Tumor;  
Soares\_parathyroid\_tumor\_NbHPA; Nine Week Old Early Stage Human;  
Soares\_testis\_NHT; NCI\_CGAP\_GC5; Hepatocellular Tumor; Human Prostate  
30 Cancer, Stage C fraction; Soares adult brain N2b5HB55Y; Macrophage-oxLDL, re-  
excision; Human Synovial Sarcoma; Endothelial-induced; Human Testes;  
NCI\_CGAP\_Lu5; normalized infant brain cDNA; T cell helper II; Colon Tumor II;

- Human Cerebellum; BL29 Burkitt's lymphoma, Pascalis Sideras; Human Fetal Kidney; CD34+ cell, I, frac II; Activated T-Cells, 8 hrs, subtracted; Human Prostate, subtracted; NCI\_CGAP\_Br3; Human OB MG63 control fraction I; NCI\_CGAP\_Pr9; prostate-edited; Human promyelocyte; Human Adult Retina; Normal Human
- 5 Trabecular Bone Cells; NCI\_CGAP\_Thy1; H. cerebellum, Enzyme subtracted; Human heart cDNA (YNakamura); NCI\_CGAP\_Co12; Human Quadriceps; Human Pineal Gland; NCI\_CGAP\_AA1; Smooth muscle, IL1b induced; NCI\_CGAP\_Co9; Human Fetal Epithelium (Skin); Human Whole Brain #2 - Oligo dT > 1.5Kb; LNCAP prostate cell line; Synovial Fibroblasts (II1/TNF), subt; H. Lymph node
- 10 breast Cancer; Human Prostate; Mo7e Cell Line GM-CSF treated (1ng/ml); NCI\_CGAP\_Pr22; Stratagene fetal retina 937202; 12 Week Old Early Stage Human, II; Soares\_pineal\_gland\_N3HPG; Human Osteoblasts II; Human Pancreas Tumor; Human Heart; Stromal cell TF274; Olfactory epithelium,nasalcavity; Hemangiopericytoma; Human Thymus Stromal Cells; CHME Cell Line,treated 5 hrs;
- 15 Human Whole Six Week Old Embryo; Human Gall Bladder; PC3 Prostate cell line; CHME Cell Line,untreated; Colon Tumor; Resting T-Cell Library,II; Human T-Cell Lymphoma; breast lymph node CDNA library; Early Stage Human Brain; Normal colon; NCI\_CGAP\_GC4; Human Ovarian Cancer Reexcision; Bone marrow; Human Fetal Heart; Anergic T-cell; Human Microvascular Endothelial Cells, fract. A;
- 20 Stratagene lung (#937210); Soares\_senescent\_fibroblasts\_NbHSF; NCI\_CGAP\_Kid3; Monocyte activated; Human Bone Marrow, treated; Human fetal heart, Lambda ZAP Express; Soares ovary tumor NbHOT; Hodgkin's Lymphoma II; Human 8 Week Whole Embryo; Keratinocyte; Soares melanocyte 2NbHM; Soares\_total\_fetus\_Nb2HF8\_9w; Colon Normal III and Soares infant brain 1NIB.
- 25 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
- 30 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.,

immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
5 having the disorder.

Enriched expression of this gene in the immune system indicates that polynucleotides and polypeptides corresponding to this clone would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious  
10 Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the  
15 treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis,  
20 acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's  
25 disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell  
30 types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional

supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 35

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

10 GPPPADTLQCPLCGQVGSPPEADGPGSATSGAEKATTRRKAPSTPSPKQRSKQ  
AGSSPRPPPGLWYLATAPPAPAPPAYISSVPIMPYPAAVYYAPAGPTSAQP  
AAKWPPTASPPPARRHRHSIQLDLGDLEELNKALSRAVQAAESVRSTTRQMR  
SSLSADLRQAHSLRGSCLF (SEQ ID NO: 285);

MPYPPAAVYYAPAGPTSAQPAKWPPTASPPPARRHRHSIQLDLGDLEELNK  
ALSRAVQAAESVRSTTRQMRSSLSADLRQAHSLRGSCLF (SEQ ID NO: 286);

15 YPSVSPVWSSWVSPRGRWSRLSHLWGREGHHEEKSTFNSQPQAEQAGGVV  
ATPTPRTVVSGNSAPSTSPSSLCLHLLGSHHALSTCRCVLCACRTYLSPTSCQV  
AAHSLSPTSPETPALHPARPGRGAQQGPEPGRAGCRERPLYHQADEKLAV  
SRPAPGSQPAGLLPLLTSLGAQRQMGGWVGRWPARGVGWSC (SEQ ID NO:  
287);

20 WDRPLIPFSVPCVVKLGLPQRQMVQAQPPLGQRRPPRGEKHLQLPAPSRGA  
SRRGRRHAHPPDCGIWQQRQHQPLQPLPTSPRFPSCIHLPLCTMRLQDLPQ  
PNQLPSGRPQPLPHQPGDTGTPSSSTWAT (SEQ ID NO: 288); and

MVQAQPPLGQRRPPRGEKHLQLPAPSRGASRRGRRHAHPPDCGIWQQRQHQ  
QPLQPLPTSPRFPSCIHLPLCTMRLQDLPQPNQLPSGRPQPLPHQPGDTGTPSS  
25 STWAT (SEQ ID NO: 289). Moreover, fragments and variants of these polypeptides  
(such as, for example, fragments as described herein, polypeptides at least 80%, 85%,  
90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides  
encoded by the polynucleotide which hybridizes, under stringent conditions, to the  
polynucleotide encoding these polypeptides ) are encompassed by the invention.

30 Antibodies that bind polypeptides of the invention are also encompassed by the  
invention. Polynucleotides encoding these polypeptides are also encompassed by the  
invention.

This gene is expressed primarily in the following tissues/cDNA libraries:

Human Pancreas Tumor; Resting T-Cell Library, II; Dendritic cells, pooled;  
Stratagene lung (#937210); CD34 positive cells (Cord Blood);  
Soares\_fetal\_heart\_NbHH19W and to a lesser extent in Human Old Ovary; CD34  
5 positive cells (cord blood), re-ex; NTERA2 teratocarcinoma cell line+retinoic acid (14  
days); Apoptotic T-cell; breast lymph node CDNA library; human tonsils; Human  
Neutrophil, Activated; Human Adult Pulmonary, re-excision; Spleen, Chronic  
lymphocytic leukemia and T Cell helper I.

Polynucleotides and polypeptides of the invention are useful as reagents for  
10 differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
disorders of the immune system. Similarly, polypeptides and antibodies directed to  
these polypeptides are useful in providing immunological probes for differential  
identification of the tissue(s) or cell type(s). For a number of disorders of the above  
15 tissues or cells, particularly of the immune system, expression of this gene at  
significantly higher or lower levels may be routinely detected in certain tissues or cell  
types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph,  
serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample  
taken from an individual having such a disorder, relative to the standard gene  
20 expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
individual not having the disorder.

Expression of this gene primarily in the immune system indicates that polynucleotides  
and polypeptides corresponding to would be useful for the diagnosis, detection,  
prevention and/or treatment of a variety of immune system disorders. Representative  
25 uses are described in the "Immune Activity" and "Infectious Disease" sections below,  
in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the  
expression of this gene product indicates a role in regulating the proliferation;  
survival; differentiation; and/or activation of hematopoietic cell lineages, including  
blood stem cells. Involvement in the regulation of cytokine production, antigen  
30 presentation, or other processes indicates a usefulness in the treatment of cancer (e.g.,  
by boosting immune responses). Expression in cells of lymphoid origin, indicates the  
natural gene product would be involved in immune functions. Therefore it may be

also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity;

5 immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the

10 differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers,

15 to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.



Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HGBAJ60	PTA-883 10/28/99	Uni-ZAP XR	11	1500	1	1500	103	103	117	1	20	21	260
1	HGBAJ60	PTA-883 10/28/99	Uni-ZAP XR	46	2583	112	1604	201	201	152	1	20	21	261
2	HCWHX82	PTA-883 10/28/99	ZAP Express	12	1149	1	1149	16	16	118	1	18	19	29
2	HCWHX82	PTA-883 10/28/99	ZAP Express	47	610	8	610	29	29	153	1	18	19	29
2	HCWHX82	PTA-883 10/28/99	ZAP Express	48	249	1	249		249	154	1	1	2	56
3	HCWEB58	PTA-883 10/28/99	ZAP Express	13	980	1	980	247	247	119	1	27	28	244
3	HCWEB58	PTA-883 10/28/99	ZAP Express	49	888	1	888	155	155	155	1	27	28	244
4	HCWHV88	PTA-883 10/28/99	ZAP Express	14	1632	1	1632	209	209	120	1	32	33	56
4	HCWHV88	PTA-883 10/28/99	ZAP Express	50	1674	260	1649	468	468	156	1	31	32	56
5	HCWAU23	PTA-883 10/28/99	ZAP Express	15	1594	1	1593	27	27	121	1	24	25	58

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
5	HCWAU23	PTA-883 10/28/99	ZAP Express	51	603	8	603	27	27	157	1	24	25	58
5	HCWAU23	PTA-883 10/28/99	ZAP Express	52	1016	1	1016		553	158	1	1	2	134
6	HBXED80	PTA-883 10/28/99	ZAP Express	16	1859	1	1859	231	231	122	1	17	18	56
6	HBXED80	PTA-883 10/28/99	ZAP Express	53	459	1	459	276	276	159	1	17	18	54
6	HBXED80	PTA-883 10/28/99	ZAP Express	54	994	1	994		74	160	1	12	13	37
6	HBXED80	PTA-883 10/28/99	ZAP Express	55	1000	1	1000		620	161	1	1	2	85
7	HBWCM83	PTA-883 10/28/99	ZAP Express	17	1672	1	1672	93	93	123	1	23	24	76
7	HBWCM83	PTA-883 10/28/99	ZAP Express	56	964	1	964	93	93	162	1	23	24	76
7	HBWCM83	PTA-883 10/28/99	ZAP Express	57	546	1	546		153	163	1	1	2	42
7	HBWCM83	PTA-883 10/28/99	ZAP Express	58	609	1	609		194	164	1	1	2	64
8	HTPBG16	PTA-883 10/28/99	Uni-ZAP XR	18	2433	1	2433	148	148	124	1	27	28	48

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HTPBG16	PTA-883 10/28/99	Uni-ZAP XR	59	894	1	894	154	154	165	1	19	20	48
8	HTPBG16	PTA-883 10/28/99	Uni-ZAP XR	60	666	1	666		269	166	1	1	2	70
9	HETAM53	PTA-883 10/28/99	Uni-ZAP XR	19	3478	1	3478	10	10	125	1	17	18	99
9	HETAM53	PTA-883 10/28/99	Uni-ZAP XR	61	1512	105	1512	119	119	167	1	17	18	99
9	HETAM53	PTA-883 10/28/99	Uni-ZAP XR	62	2598	1	2593	1915	1915	168	1			5
9	HETAM53	PTA-883 10/28/99	Uni-ZAP XR	63	1924	761	1924		129	169	1	1	2	255
9	HETAM53	PTA-883 10/28/99	Uni-ZAP XR	64	2248	50	554		2246	170	1	1	2	491
10	HCWFZ59	PTA-883 10/28/99	ZAP Express	20	2987	1	2987	17	17	126	1	27	28	53
10	HCWFZ59	PTA-883 10/28/99	ZAP Express	65	636	1	636	40	40	171	1	27	28	53
10	HCWFZ59	PTA-883 10/28/99	ZAP Express	66	898	1	898		371	172	1			12
10	HCWFZ59	PTA-883 10/28/99	ZAP Express	67	449	1	449		448	173	1	1	2	60

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HBWCB95	PTA-883 10/28/99	ZAP Express	21	2827	1	2827	107	107	127	1	25	26	53
11	HBWCB95	PTA-883 10/28/99	ZAP Express	68	1192	1	1192	171	171	174	1	25	26	53
11	HBWCB95	PTA-883 10/28/99	ZAP Express	69	626	1	626		576	175	1	1	2	53
12	HBXAM53	PTA-883 10/28/99	ZAP Express	22	2476	1	2476	141	141	128	1	21	22	77
12	HBXAM53	PTA-883 10/28/99	ZAP Express	70	1913	216	1913	251	251	176	1	21	22	77
12	HBXAM53	PTA-883 10/28/99	ZAP Express	71	617	250	550		306	177	1	1	2	63
13	HCWDY64	PTA-883 10/28/99	ZAP Express	23	1292	1	1292	210	210	129	1	24	25	51
13	HCWDY64	PTA-883 10/28/99	ZAP Express	72	413	1	413	44	44	178	1			9
13	HCWDY64	PTA-883 10/28/99	ZAP Express	73	691	1	691		176	179	1			3
14	HBXFZ38	PTA-883 10/28/99	ZAP Express	24	2072	1	2072	125	125	130	1	39	40	68
14	HBXFZ38	PTA-883 10/28/99	ZAP Express	74	1313	1	1313	139	139	180	1	39	40	98

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
14	HBXFZ38	PTA-883 10/28/99	ZAP Express	75	814	61	811		523	181	1	1	2	78
15	HCWGU37	PTA-883 10/28/99	ZAP Express	25	2777	1	2777	194	194	131	1			10
15	HCWGU37	PTA-883 10/28/99	ZAP Express	76	1651	1	1651	187	187	182	1			10
16	HBWCF75	PTA-883 10/28/99	ZAP Express	26	1712	1	1712	484	484	132	1	17	18	118
16	HBWCF75	PTA-883 10/28/99	ZAP Express	77	770	1	770	167	167	183	1	35	36	43
16	HBWCF75	PTA-883 10/28/99	ZAP Express	78	622	1	622		335	184	1	1	2	111
17	HHFCP32	PTA-883 10/28/99	Uni-ZAP XR	27	2939	931	2939	977	977	133	1	18	19	95
18	HCUGC55	PTA-883 10/28/99	ZAP Express	28	410	1	410	142	142	134	1	17	18	32
18	HCUGC55	PTA-883 10/28/99	ZAP Express	79	344	7	344	141	141	185	1	17	18	68
18	HCUGC55	PTA-883 10/28/99	ZAP Express	80	312	1	312		41	186	1	4	5	8
19	HCWBP34	PTA-883 10/28/99	ZAP Express	29	2019	1	2019	210	210	135	1			27

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
19	HCWBP34	PTA-883 10/28/99	ZAP Express	81	712	1	712	211	211	187	1			27
19	HCWBP34	PTA-883 10/28/99	ZAP Express	82	1082	1	1082		62	188	1	26	27	28
20	HFCAA91	PTA-883 10/28/99	Uni-ZAP XR	30	2274	1	2274	262	262	136	1	17	18	71
20	HFCAA91	PTA-883 10/28/99	Uni-ZAP XR	83	1378	1	1378	255	255	189	1	17	18	71
20	HFCAA91	PTA-883 10/28/99	Uni-ZAP XR	84	789	1	789		357	190	1			10
21	HBWBR94	PTA-883 10/28/99	ZAP Express	31	2458	1	2458	100	100	137	1	16	17	43
21	HBWBR94	PTA-883 10/28/99	ZAP Express	85	539	1	539	95	95	191	1	16	17	43
21	HBWBR94	PTA-883 10/28/99	ZAP Express	86	621	1	621		620	192	1	1	2	79
22	HHFCZ67	PTA-883 10/28/99	Uni-ZAP XR	32	1692	1	1692	20	20	138	1	27	28	45
22	HHFCZ67	PTA-883 10/28/99	Uni-ZAP XR	87	1333	6	1333	18	18	193	1	27	28	45
22	HHFCZ67	PTA-883 10/28/99	Uni-ZAP XR	88	943	225	943		26	194	1	19	20	37

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
22	HHFCZ67	PTA-883 10/28/99	Uni-ZAP XR	89	846	1	263		797	195	1	1	2	162
23	HETAR42	PTA-883 10/28/99	Uni-ZAP XR	33	2160	1	2160	155	155	139	1	19	20	56
23	HETAR42	PTA-883 10/28/99	Uni-ZAP XR	90	664	1	664	241	241	196	1	19	20	56
23	HETAR42	PTA-883 10/28/99	Uni-ZAP XR	91	364	1	364		99	197	1			4
23	HETAR42	PTA-883 10/28/99	Uni-ZAP XR	92	517	1	517		290	198	1	1	2	53
24	HCEBN44	PTA-883 10/28/99	Uni-ZAP XR	34	1349	1	1349	223	223	140	1	22	23	25
24	HCEBN44	PTA-883 10/28/99	Uni-ZAP XR	93	1357	1	1357	236	236	199	1	22	23	55
25	HCWFT79	PTA-883 10/28/99	ZAP Express	35	2658	1	2658	1857	1857	141	1	18	19	60
25	HCWFT79	PTA-883 10/28/99	ZAP Express	94	897	1	897	320	320	200	1			11
25	HCWFT79	PTA-883 10/28/99	ZAP Express	95	755	1	755		305	201	1	1	2	65
26	HSBBT12	PTA-883 10/28/99	pBluescript SK-	36	3761	1520	3761	227	227	142	1	33	34	183

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
26	HSBBT12	PTA-883 10/28/99	pBluescript SK-	96	3963	208	3963	427	427	202	1	33	34	183
26	HSBBT12	PTA-883 10/28/99	pBluescript SK-	97	2196	1857	2196		893	203	1			6
27	HJAAJ58	PTA-883 10/28/99	pBluescript SK-	37	438	1	438	193	193	143	1	29	30	52
27	HJAAJ58	PTA-883 10/28/99	pBluescript SK-	98	1724	1	1724	201	201	204	1	29	30	37
27	HJAAJ58	PTA-883 10/28/99	pBluescript SK-	99	251	1	251		130	205	1			1
27	HJAAJ58	PTA-883 10/28/99	pBluescript SK-	100	1075	1	1075		2	206	1			13
28	HTEDJ85	PTA-883 10/28/99	Uni-ZAP XR	38	944	1	944	69	69	144	1	23	24	161
28	HTEDJ85	PTA-883 10/28/99	Uni-ZAP XR	101	460	1	460		88	207	1	18	19	113
28	HTEDJ85	PTA-883 10/28/99	Uni-ZAP XR	102	777	777	777		396	208	1			2
28	HTEDJ85	PTA-883 10/28/99	Uni-ZAP XR	103	878	38	878		483	209	1	1	2	75
29	HHFCW75	PTA-883 10/28/99	Uni-ZAP XR	39	1441	1	1441	14	14	145	1	35	36	41



Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
29	HHFCW75	PTA-883 10/28/99	Uni-ZAP XR	104	853	382	853	400	400	210	1	35	36	41
29	HHFCW75	PTA-883 10/28/99	Uni-ZAP XR	105	441	1	96		246	211	1	1	2	53
30	HFCAL39	PTA-883 10/28/99	Uni-ZAP XR	40	2805	1	2805	17	17	146	1	16	17	21
30	HFCAL39	PTA-883 10/28/99	Uni-ZAP XR	106	2181	1	2181	89	89	212	1	18	19	21
30	HFCAL39	PTA-883 10/28/99	Uni-ZAP XR	107	1466	738	953		274	213	1	1	2	74
31	HJBAR01	PTA-883 10/28/99	pBluescript SK-	41	1672	1	1672	113	113	147	1	19	20	42
31	HJBAR01	PTA-883 10/28/99	pBluescript SK-	108	904	357	904	462	462	214	1	19	20	29
32	HE8MH77	PTA-883 10/28/99	Uni-ZAP XR	42	1228	1	1228	227	227	148	1	46	47	63
32	HE8MH77	PTA-883 10/28/99	Uni-ZAP XR	109	1474	536	1474	768	768	215	1	41	42	63
32	HE8MH77	PTA-883 10/28/99	Uni-ZAP XR	110	501	1	501		4	216	1	22	23	31
33	HRSMQ86	PTA-883 10/28/99	ZAP Express	43	599	1	599	399	399	149	1	22	23	34

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
33	HRSMQ86	PTA-883 10/28/99	ZAP Express	111	408	1	408		95	217	1			9
34	HBXCT44	PTA-883 10/28/99	ZAP Express	44	2466	1	2466		3	150	1	29	30	65
34	HBXCT44	PTA-883 10/28/99	ZAP Express	112	2510	1	2510	33	33	218	1	34	35	70
34	HBXCT44	PTA-883 10/28/99	ZAP Express	113	641	1	641		349	219	1	12	13	53
34	HBXCT44	PTA-883 10/28/99	ZAP Express	114	1036	711	1036		820	220	1	6	7	13
35	HCWUFU77	PTA-883 10/28/99	ZAP Express	45	1446	1	1446		1376	151	1	12	13	23
35	HCWUFU77	PTA-883 10/28/99	ZAP Express	115	619	169	619		546	221	1	12	13	24
35	HCWUFU77	PTA-883 10/28/99	ZAP Express	116	899	417	843		442	222	1	1	2	128

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also  
5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the  
15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the  
20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.  
25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

Table 2 provides preferred epitopes contained in certain embodiments of the invention and polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column refers to each "Gene No." described above in Table 1. The second column provides the sequence identifier, "NT SEQ ID NO:X", for polynucleotide sequences disclosed in Table 1. The third column provides the sequence identifier, "AA SEQ ID NO:Y", for polypeptide sequences disclosed in Table 1. The fourth column provides a unique integer "ntA" where "ntA" is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer "ntB" where "ntB" is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both ntA and ntB correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where ntB is greater than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf ((1988) CABIOS, 4; 181-186); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE

(Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 2 as "Preferred Epitopes".

- 5 Polypeptides of the invention may possess one, two, three, four, five or more antigenic epitopes comprising residues described in Table 2. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

- 10 Table 3 summarizes the expression profile of polynucleotides corresponding to the clones disclosed in Table 1. The first column provides a unique clone identifier, "Clone ID", for a cDNA clone related to each contig sequence disclosed in Table 1. Column 2, "Library Codes" shows the expression profile of tissue and/or cell line libraries which express the polynucleotides of the invention. Each Library Code
- 15 in column 2 represents a tissue/cell source identifier code corresponding to the Library Code and Library description provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. One of skill in the art could routinely use this information to identify tissues which show a predominant expression pattern of the corresponding polynucleotide of the invention
- 20 or to identify polynucleotides which show predominant and/or specific tissue expression.

- Table 4 provides a key to the Library Code disclosed in Table 3. Column 1 provides the Library Code disclosed in Table 3, column 2. Column 2 provides a description of the tissue or cell source from which the corresponding library was
- 25 derived. Library codes corresponding to diseased Tissues are indicated in column 3 with the word "disease".

Table 2

Gene #	NT SEQ ID NO: X	AA SEQ ID NO: Y	nt A	nt B	Preferred Epitopes
1	11	117	1 - 1486	15 - 1500	Thr-35 to Gln-48 Thr-55 to Thr-63 Thr-92 to Asp-98 Gln-119 to Lys-132 Asp-144 to Gly-151 Glu-173 to Ser-179 Ala-182 to Tyr-187 Cys-215 to Ser-236 His-252 to Asn-260.
1	46	152	1 - 2569	15 - 2583	Thr-36 to Gln-49 Thr-56 to Thr-64 Thr-93 to Asp-99 Gln-120 to Lys-133 Asp-145 to Gly-152 Glu-174 to Ser-180 Ala-183 to Tyr-188 Cys-216 to Ser-237 His-253 to Asn-261.
2	12	118	1 - 1135	15 - 1149	
2	47	153	1 - 596	15 - 610	
2	48	154	1 - 235	15 - 249	
3	13	119	1 - 966	15 - 980	Pro-54 to Phe-63 Gly-115 to Gln-121 Gln-136 to Ala-141 Gln-164 to Leu-178 Glu-194 to Trp-203 Glu-215 to Asp-223.
3	49	155	1 - 874	15 - 888	
4	14	120	1 - 1618	15 - 1632	
4	50	156	1 - 1660	15 - 1674	
5	15	121	1 - 1580	15 - 1594	Ser-52 to Ser-58.
5	51	157	1 - 589	15 - 603	Ser-52 to Ser-58.
5	52	158	1 - 1002	15 - 1016	Ser-1 to His-12 Gln-44 to Cys-60 Thr-75 to Asp-84 Ser-91 to Val-99 Leu-109 to Asn-117.
6	16	122	1 - 1845	15 - 1859	
6	53	159	1 - 445	15 - 459	
6	54	160	1 - 980	15 - 994	Pro-18 to Asn-28.
6	55	161	1 - 986	15 - 1000.	
7	17	123	1 - 1658	15 - 1672	Gly-34 to Gly-39.
7	56	162	1 - 950	15 - 964	Gly-34 to Gly-39.
7	57	163	1 - 532	15 - 546	His-1 to Tyr-7.
7	58	164	1 - 595	15 - 609	His-34 to Arg-41.
8	18	124	1 - 2419	15 - 2433	Leu-38 to Gln-45.
8	59	165	1 - 880	15 - 894	Leu-38 to Gln-45.
8	60	166	1 - 652	15 - 666	
9	19	125	1 - 3464	15 - 3478	Arg-15 to Ala-26

					Glu-40 to Tyr-57 Asn-91 to Gly-96.
9	61	167	1 - 1498	15 - 1512	Arg-15 to Ala-26.
9	62	168	1 - 2584	15 - 2598	
9	63	169	1 - 1910	15 - 1924	Pro-53 to Glu-59.
9	64	170	1 - 2234	15 - 2248	Gly-5 to Arg-12.
10	20	126	1 - 2973	15 - 2987	Gly-25 to Gly-33.
10	65	171	1 - 622	15 - 636	
10	66	172	1 - 884	15 - 898	
10	67	173	1 - 435	15 - 449	
11	21	127	1 - 2813	15 - 2827	
11	68	174	1 - 1178	15 - 1192	
11	69	175	1 - 612	15 - 626	
12	22	128	1 - 2462	15 - 2476	Pro-68 to Trp-73.
12	70	176	1 - 1899	15 - 1913	Pro-68 to Trp-73.
12	71	177	1 - 603	15 - 617	Ser-49 to Pro-55.
13	23	129	1 - 1278	15 - 1292	Ser-14 to Leu-19 Gly-36 to Gly-42.
13	72	178	1 - 399	15 - 413	
13	73	179	1 - 677	15 - 691	
14	24	130	1 - 2058	15 - 2072	Pro-2 to Arg-15 Thr-42 to Ser-56 Pro-63 to Ser-68.
14	74	180	1 - 1299	15 - 1313	Pro-2 to Arg-15.
14	75	181	1 - 800	15 - 814	Gly-7 to Gly-13 Ala-36 to Glu-48.
15	25	131	1 - 2763	15 - 2777	
15	76	182	1 - 1637	15 - 1651	
16	26	132	1 - 1698	15 - 1712	Asn-52 to Gly-59.
16	77	183	1 - 756	15 - 770	
16	78	184	1 - 608	15 - 622	
17	27	133	1 - 2925	15 - 2939	
18	28	134	1 - 396	15 - 410	Gln-22 to Lys-28.
18	79	185	1 - 330	15 - 344	
18	80	186	1 - 298	15 - 312	
19	29	135	1 - 2005	15 - 2019	Met-1 to Leu-6.
19	81	187	1 - 698	15 - 712	Met-1 to Leu-6.
19	82	188	1 - 1068	15 - 1082	
20	30	136	1 - 2260	15 - 2274	
20	83	189	1 - 1364	15 - 1378	
20	84	190	1 - 775	15 - 789	
21	31	137	1 - 2444	15 - 2458	
21	85	191	1 - 525	15 - 539	
21	86	192	1 - 607	15 - 621	Glu-25 to Glu-33.
22	32	138	1 - 1678	15 - 1692	
22	87	193	1 - 1319	15 - 1333	
22	88	194	1 - 929	15 - 943	
22	89	195	1 - 832	15 - 846	
23	33	139	1 - 2146	15 - 2160	Pro-41 to Ser-47.
23	90	196	1 - 650	15 - 664	Pro-41 to Ser-47.
23	91	197	1 - 350	15 - 364	
23	92	198	1 - 503	15 - 517	Glu-6 to Leu-12 Pro-34 to Thr-41.
24	34	140	1 - 1335	15 - 1349	



24	93	199	1 - 1343	15 - 1357	Leu-23 to Arg-33.
25	35	141	1 - 2644	15 - 2658	Pro-21 to Ser-27.
25	94	200	1 - 883	15 - 897	
25	95	201	1 - 741	15 - 755	Lys-58 to Val-65.
26	36	142	1 - 3747	15 - 3761	
26	96	202	1 - 3949	15 - 3963	
26	97	203	1 - 2182	15 - 2196	
27	37	143	1 - 424	15 - 438	
27	98	204	1 - 1710	15 - 1724	
27	99	205	1 - 237	15 - 251	
27	100	206	1 - 1061	15 - 1075	
28	38	144	1 - 930	15 - 944	Ile-124 to Ser-130.
28	101	207	1 - 446	15 - 460	
28	102	208	1 - 763	15 - 777	
28	103	209	1 - 864	15 - 878	
29	39	145	1 - 1427	15 - 1441	
29	104	210	1 - 839	15 - 853	
29	105	211	1 - 427	15 - 441	Cys-41 to Tyr-46.
30	40	146	1 - 2791	15 - 2805	Gly-15 to Cys-21.
30	106	212	1 - 2167	15 - 2181	Gly-15 to Cys-21.
30	107	213	1 - 1452	15 - 1466	Ala-1 to Arg-8 Arg-23 to Gly-31 Ala-42 to Thr-51.
31	41	147	1 - 1658	15 - 1672	
31	108	214	1 - 890	15 - 904	
32	42	148	1 - 1214	15 - 1228	Thr-45 to Lys-54.
32	109	215	1 - 1460	15 - 1474	Thr-45 to Lys-53.
32	110	216	1 - 487	15 - 501	
33	43	149	1 - 585	15 - 599	
33	111	217	1 - 394	15 - 408	
34	44	150	1 - 2452	15 - 2466	
34	112	218	1 - 2496	15 - 2510	
34	113	219	1 - 627	15 - 641	
34	114	220	1 - 1022	15 - 1036	
35	45	151	1 - 1432	15 - 1446	
35	115	221	1 - 605	15 - 619	Ser-19 to Gln-24.
35	116	222	1 - 885	15 - 899	His-85 to Pro-91.

Table 3

Clone ID	Library Codes
HGBAJ60	H0050 H0244 H0343 H0412 H0413 H0427 H0574 H0587 H0623 H0662 H0674 L1290 S0045 S0046 S0116 S0330 S0360 S0366 S0446 S3012 T0042
HCWHX82	H0305
HCWEB58	H0046 H0051 H0052 H0100 H0261 H0305 H0327 H0438 L1290 S0010 S0036 S0051 S0112 S0260 S0282 S0346
HCWHV88	H0265 H0305 H0383 H0556 H0632 L1290 S0134 S0212
HCWAU23	H0305 S0218
HBXED80	H0438
HBWCM83	L1290 S0216 S0386 T0008
HTPBG16	H0039 H0341 H0622
HETAM53	H0008 H0012 H0013 H0020 H0024 H0032 H0038 H0040 H0046 H0050 H0051 H0052 H0071 H0100 H0123 H0124 H0144 H0150 H0156 H0163 H0170 H0171 H0175 H0194 H0196 H0212 H0244 H0251 H0252 H0264 H0294 H0327 H0328 H0329 H0352 H0369 H0374 H0375 H0392 H0412 H0413 H0423 H0428 H0431 H0436 H0438 H0441 H0455 H0486 H0510 H0519 H0538 H0544 H0545 H0547 H0550 H0551 H0553 H0555 H0556 H0562 H0565 H0567 H0587 H0592 H0595 H0596 H0615 H0616 H0619 H0620 H0623 H0624 H0641 H0643 H0648 H0657 H0672 H0687 L1290 N0006 N0009 S0003 S0007 S0010 S0026 S0028 S0031 S0036 S0038 S0046 S0049 S0050 S0051 S0106 S0110 S0126 S0148 S0152 S0194 S0214 S0222 S0318 S0336 S0346 S0350 S0358 S0360 S0378 S0386 S0388 S0400 S0412 S0414 S0422 S0464 S6024 S6026 S6028 T0003 T0067 T0109
HCWFZ59	H0305
HBWCB95	L1290 S0386
HBXAM53	H0013 H0014 H0024 H0050 H0051 H0052 H0068 H0090 H0163 H0170 H0194 H0196 H0341 H0402 H0438 H0445 H0549 H0575 H0590 H0591 H0599 H0644 H0674 H0690 L1290 S0010 S0030 S0031 S0036 S0038 S0049 S0142 S0222 S0260 S0282 S0328 S0360 S0426 S0464 S3014 S6014 S6024 T0041
HCWDY64	H0305 H0555
HBXFZ38	H0305 H0399 H0438 H0441 H0455 H0594 L1290 S0038 S0050 S0051 S0388 S6014
HCWGU37	H0051 H0305 H0402 H0438 H0521 H0589 L1290 S0038 S0042 S0052 S0386
HBWCF75	S0386
HHFCP32	H0008 H0009 H0012 H0013 H0024 H0036 H0038 H0039 H0041 H0042 H0046 H0050 H0051 H0052 H0083 H0085 H0090 H0097 H0098 H0124 H0125 H0134 H0135 H0144 H0150 H0156 H0163 H0181 H0194 H0208 H0230 H0231 H0242 H0264 H0265 H0266 H0267 H0292 H0318 H0333 H0341 H0370 H0373 H0402 H0422 H0423 H0427 H0434 H0436 H0441 H0444 H0445 H0457 H0486 H0494 H0506 H0517 H0518 H0519 H0521 H0522 H0529 H0539 H0543 H0550 H0551 H0553 H0556 H0561 H0574 H0575 H0581 H0587 H0590 H0596 H0597 H0599 H0600 H0604 H0615 H0617 H0618 H0619 H0620 H0622 H0624 H0638 H0648 H0649 H0650 H0656 H0657 H0658 H0659 H0660 H0663 H0670 H0684 H0696 L1290 N0006 S0002 S0003 S0010 S0011 S0026 S0028 S0031 S0035 S0038 S0040 S0045 S0049 S0051 S0112 S0114 S0116 S0132 S0136 S0142 S0144 S0152 S0212 S0214 S0222 S0242 S0278 S0280 S0282 S0310 S0330 S0332 S0344 S0346 S0360 S0364 S0366 S0370 S0374 S0380 S0386 S0408 S0418 S0420 S0422 S0424 S0454 S6028 T0006 T0010

	T0067
HCUGC55	H0402 L1290
HCWBP34	H0305
HFCOA91	H0009
HBWBR94	S0386
HHFCZ67	H0050 H0373 H0412 H0580 H0670 L1290 S0360 S0420 S0444 T0002
HETAR42	H0036 H0038 H0046 H0052 H0056 H0059 H0063 H0068 H0087 H0100 H0135 H0250 H0255 H0271 H0392 H0428 H0436 H0484 H0494 H0506 H0510 H0520 H0521 H0522 H0543 H0547 H0551 H0556 H0561 H0616 H0617 H0618 H0638 H0641 H0657 L1290 S0001 S0002 S0010 S0218 S0348 S0374 S0378 T0042
HCEBN44	H0052 L1290
HCWFT79	H0305
HSBBT12	H0013 H0014 H0015 H0031 H0032 H0039 H0040 H0046 H0056 H0073 H0132 H0135 H0144 H0170 H0171 H0239 H0250 H0251 H0263 H0264 H0266 H0267 H0316 H0331 H0333 H0341 H0351 H0355 H0369 H0373 H0393 H0412 H0421 H0422 H0423 H0427 H0428 H0435 H0436 H0486 H0488 H0494 H0497 H0509 H0510 H0519 H0520 H0521 H0529 H0539 H0543 H0544 H0545 H0546 H0547 H0551 H0553 H0555 H0560 H0569 H0572 H0574 H0575 H0580 H0581 H0586 H0587 H0590 H0592 H0593 H0596 H0598 H0615 H0616 H0617 H0622 H0623 H0624 H0628 H0633 H0640 H0642 H0644 H0647 H0648 H0649 H0651 H0653 H0657 H0658 H0659 H0661 H0662 H0664 H0665 H0666 H0667 H0672 H0682 H0684 H0685 H0693 H0698 H0704 L1290 S0003 S0026 S0028 S0031 S0036 S0040 S0044 S0051 S0114 S0116 S0126 S0132 S0150 S0152 S0192 S0194 S0208 S0210 S0212 S0214 S0218 S0222 S0242 S0250 S0280 S0328 S0330 S0342 S0352 S0358 S0360 S0364 S0366 S0378 S0380 S0418 S0420 S0438 S0452 S6024 S6026 S6028 T0002 T0004 T0039 T0040 T0067 T0110
HJAAJ58	H0555 L1290 T0041
HTEDJ85	H0013 H0038 H0170 L1290 S0010 T0006
HHFCW75	H0050 L1290
HFCAL39	H0009 H0013 H0036 H0039 H0052 H0059 H0087 H0100 H0144 H0235 H0253 H0264 H0266 H0294 H0506 H0539 H0550 H0553 H0586 H0620 H0622 H0643 H0693 L1290 N0006 S0194 S0346 S0360 S0372 S0444 S3012
HJBAR01	H0520 H0569 H0623 L1290 S0016 S0214 T0042
HE8MH77	H0013 H0170 H0569 L1290 S0010 S0222 S6028
HRSMQ86	H0394
HBXCT44	H0011 H0013 H0014 H0031 H0038 H0039 H0046 H0050 H0052 H0081 H0090 H0100 H0124 H0135 H0144 H0169 H0171 H0212 H0222 H0255 H0261 H0265 H0266 H0284 H0331 H0333 H0370 H0373 H0422 H0436 H0458 H0486 H0494 H0543 H0545 H0551 H0556 H0580 H0615 H0648 H0660 H0664 H0672 L0470 L1290 S0002 S0007 S0026 S0038 S0046 S0114 S0116 S0146 S0150 S0152 S0242 S0250 S0344 S0358 S0360 S0364 S0374 S0376 S0418 S0422 T0006 T0082
HCWFU77	H0028 H0039 H0255 H0264 H0271 H0305 H0436 H0445 H0457 H0487 H0542 H0543 H0547 H0551 H0556 H0575 H0580 H0589 H0635 H0656 L0470 S0027 S0134

Table 4

Library Code	Library Description	Disease
H0008	Whole 6 Week Old Embryo	
H0009	Human Fetal Brain	
H0011	Human Fetal Kidney	
H0012	Human Fetal Kidney	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0015	Human Gall Bladder, fraction II	
H0020	Human Hippocampus	
H0024	Human Fetal Lung III	
H0028	Human Old Ovary	
H0031	Human Placenta	
H0032	Human Prostate	
H0036	Human Adult Small Intestine	
H0038	Human Testes	
H0039	Human Pancreas Tumor	disease
H0040	Human Testes Tumor	disease
H0041	Human Fetal Bone	
H0042	Human Adult Pulmonary	
H0046	Human Endometrial Tumor	disease
H0050	Human Fetal Heart	
H0051	Human Hippocampus	
H0052	Human Cerebellum	
H0056	Human Umbilical Vein, Endo. remake	
H0059	Human Uterine Cancer	disease
H0063	Human Thymus	
H0068	Human Skin Tumor	disease
H0071	Human Infant Adrenal Gland	
H0073	Human Leiomyeloid Carcinoma	disease
H0081	Human Fetal Epithelium (Skin)	
H0083	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	
H0085	Human Colon	
H0087	Human Thymus	
H0090	Human T-Cell Lymphoma	disease
H0097	Human Adult Heart, subtracted	
H0098	Human Adult Liver, subtracted	
H0100	Human Whole Six Week Old Embryo	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0125	Cem cells cyclohexamide treated	
H0132	LNCAP + 30nM R1881	
H0134	Raji Cells, cyclohexamide treated	
H0135	Human Synovial Sarcoma	
H0144	Nine Week Old Early Stage Human	
H0150	Human Epididymus	
H0156	Human Adrenal Gland Tumor	disease
H0163	Human Synovium	
H0169	Human Prostate Cancer, Stage C fraction	disease
H0170	12 Week Old Early Stage Human	
H0171	12 Week Old Early Stage Human, II	
H0175	H. Adult Spleen, ziplox	

H0181	Human Primary Breast Cancer	disease
H0194	Human Cerebellum, subtracted	
H0196	Human Cardiomyopathy, subtracted	
H0208	Early Stage Human Lung, subtracted	
H0212	Human Prostate, subtracted	
H0222	Activated T-Cells, 8 hrs, subtracted	
H0230	Human Cardiomyopathy, diff exp	disease
H0231	Human Colon, subtraction	
H0235	Human colon cancer, metatized to liver, subtraction	
H0239	Human Kidney Tumor	disease
H0242	Human Fetal Heart, Differential (Fetal-Specific)	
H0244	Human 8 Week Whole Embryo, subtracted	
H0250	Human Activated Monocytes	
H0251	Human Chondrosarcoma	disease
H0252	Human Osteosarcoma	disease
H0253	Human adult testis, large inserts	
H0255	breast lymph node CDNA library	
H0261	H. cerebellum, Enzyme subtracted	
H0263	human colon cancer	disease
H0264	human tonsils	
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0267	Human Microvascular Endothelial Cells, fract. B	
H0271	Human Neutrophil, Activated	
H0284	Human OB MG63 control fraction I	
H0292	Human OB HOS treated (10 nM E2) fraction I	
H0294	Amniotic Cells - TNF induced	
H0305	CD34 positive cells (Cord Blood)	
H0316	HUMAN STOMACH	
H0318	HUMAN B CELL LYMPHOMA	disease
H0327	human corpus colosum	
H0328	human ovarian cancer	disease
H0329	Dermatofibrosarcoma Protuberance	disease
H0331	Hepatocellular Tumor	disease
H0333	Hemangiopericytoma	disease
H0341	Bone Marrow Cell Line (RS4,11)	
H0343	stomach cancer (human)	disease
H0351	Glioblastoma	disease
H0352	wilm's tumor	disease
H0355	Human Liver	
H0369	H. Atrophic Endometrium	
H0370	H. Lymph node breast Cancer	disease
H0373	Human Heart	
H0374	Human Brain	
H0375	Human Lung	
H0383	Human Prostate BPH, re-excision	
H0392	H. Meningima, M1	
H0393	Fetal Liver, subtraction II	
H0394	A-14 cell line	
H0399	Human Kidney Cortex, re-rescue	
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision	
H0412	Human umbilical vein endothelial cells, IL-4 induced	
H0413	Human Umbilical Vein Endothelial Cells, uninduced	

H0421	Human Bone Marrow, re-excision	
H0422	T-Cell PHA 16 hrs	
H0423	T-Cell PHA 24 hrs	
H0427	Human Adipose	
H0428	Human Ovary	
H0431	H. Kidney Medulla, re-excision	
H0434	Human Brain, striatum, re-excision	
H0435	Ovarian Tumor 10-3-95	
H0436	Resting T-Cell Library,II	
H0438	H. Whole Brain #2, re-excision	
H0441	H. Kidney Cortex, subtracted	
H0444	Spleen metastatic melanoma	disease
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0455	H. Striatum Depression, subt	
H0457	Human Eosinophils	
H0458	CD34+ cell, I, frac II	
H0484	Breast Cancer Cell line, angiogenic	
H0486	Hodgkin's Lymphoma II	disease
H0487	Human Tonsils, lib I	
H0488	Human Tonsils, Lib 2	
H0494	Keratinocyte	
H0497	HEL cell line	
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0510	Human Liver, normal	
H0517	Nasal polyps	
H0518	pBMC stimulated w/ poly I/C	
H0519	NTERA2, control	
H0520	NTERA2 + retinoic acid, 14 days	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells,frac 2	
H0529	Myeloid Progenitor Cell Line	
H0538	Merkel Cells	
H0539	Pancreas Islet Cell Tumor	disease
H0542	T Cell helper I	
H0543	T cell helper II	
H0544	Human endometrial stromal cells	
H0545	Human endometrial stromal cells-treated with progesterone	
H0546	Human endometrial stromal cells-treated with estradiol	
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)	
H0549	H. Epididymus, caput & corpus	
H0550	H. Epididymus, cauda	
H0551	Human Thymus Stromal Cells	
H0553	Human Placenta	
H0555	Rejected Kidney, lib 4	disease
H0556	Activated T-cell(12h)/Thiouridine-re-excision	
H0560	KMH2	
H0561	L428	
H0562	Human Fetal Brain, normalized c5-11-26	
H0565	HUman Fetal Brain, normalized 100024F	
H0567	Human Fetal Brain, normalized A5002F	
H0569	Human Fetal Brain, normalized CO	
H0572	Human Fetal Brain, normalized AC5002	

H0574	Hepatocellular Tumor, re-excision	disease
H0575	Human Adult Pulmonary, re-excision	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	
H0586	Healing groin wound, 6.5 hours post incision	disease
H0587	Healing groin wound, 7.5 hours post incision	disease
H0589	CD34 positive cells (cord blood), re-ex	
H0590	Human adult small intestine, re-excision	
H0591	Human T-cell lymphoma, re-excision	disease
H0592	Healing groin wound - zero hr post-incision (control)	disease
H0593	Olfactory epithelium, nasal cavity	
H0594	Human Lung Cancer, re-excision	disease
H0595	Stomach cancer (human), re-excision	disease
H0596	Human Colon Cancer, re-excision	
H0597	Human Colon, re-excision	
H0598	Human Stomach, re-excision	
H0599	Human Adult Heart, re-excision	
H0600	Healing Abdomen wound, 70&90 min post incision	disease
H0604	Human Pituitary, re-excision	
H0615	Human Ovarian Cancer Reexcision	disease
H0616	Human Testes, Reexcision	
H0617	Human Primary Breast Cancer Reexcision	disease
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart	
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0623	Human Umbilical Vein, Reexcision	
H0624	12 Week Early Stage Human II, Reexcision	
H0628	Human Pre-Differentiated Adipocytes	
H0632	Hepatocellular Tumor, re-excision	
H0633	Lung Carcinoma A549 TNFalpha activated	disease
H0635	Human Activated T-Cells, re-excision	
H0638	CD40 activated monocyte dendritic cells	
H0640	Ficoll Human Stromal Cells, Untreated	
H0641	LPS activated derived dendritic cells	
H0642	Hep G2 Cells, lambda library	
H0643	Hep G2 Cells, PCR library	
H0644	Human Placenta (re-excision)	
H0647	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	disease
H0648	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot	disease
H0649	Lung, Normal: (4005313 B1)	
H0650	B-Cells	
H0651	Ovary, Normal: (9805C040R)	
H0653	Stromal Cells	
H0656	B-cells (unstimulated)	
H0657	B-cells (stimulated)	
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	disease
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0661	Breast, Cancer: (4004943 A5)	disease
H0662	Breast, Normal: (4005522B2)	

H0663	Breast, Cancer: (4005522 A2)	disease
H0664	Breast, Cancer: (9806C012R)	disease
H0665	Stromal cells 3.88	
H0666	Ovary, Cancer: (4004332 A2)	disease
H0667	Stromal cells(HBM3.18)	
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	
H0672	Ovary, Cancer: (4004576 A8)	
H0674	Human Prostate Cancer, Stage C, re-excision	
H0682	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0684	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0685	Adenocarcinoma of Ovary, Human Cell Line, # OVCAR-3	
H0687	Human normal ovary(#9610G215)	
H0690	Ovarian Cancer, # 9702G001	
H0693	Normal Prostate #ODQ3958EN	
H0696	Prostate Adenocarcinoma	
H0698	NK CellsYao20 IL2 treated for 48 hrs	
H0704	Prostate Adenocarcinoma cell line cultured in vivo in mice	
L0470	Soares parathyroid tumor NbHPA	
L1290	Soares senescent fibroblasts NbHSF	
N0006	Human Fetal Brain	
N0009	Human Hippocampus, prescreened	
S0001	Brain frontal cortex	
S0002	Monocyte activated	
S0003	Human Osteoclastoma	disease
S0007	Early Stage Human Brain	
S0010	Human Amygdala	
S0011	STROMAL -OSTEOCLASTOMA	disease
S0016	Kidney Pyramids	
S0026	Stromal cell TF274	
S0027	Smooth muscle, serum treated	
S0028	Smooth muscle,control	
S0030	Brain pons	
S0031	Spinal cord	
S0035	Brain medulla oblongata	
S0036	Human Substantia Nigra	
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0040	Adipocytes	
S0042	Testes	
S0044	Prostate BPH	disease
S0045	Endothelial cells-control	
S0046	Endothelial-induced	
S0049	Human Brain, Striatum	
S0050	Human Frontal Cortex, Schizophrenia	disease
S0051	Human Hypothalamus,Schizophrenia	disease
S0052	neutrophils control	
S0106	STRIATUM DEPRESSION	disease
S0110	Brain Amygdala Depression	disease
S0112	Hypothalamus	
S0114	Anergic T-cell	
S0116	Bone marrow	
S0126	Osteoblasts	
S0132	Epithelial-TNF $\alpha$ and INF induced	
S0134	Apoptotic T-cell	



S0136	PERM TF274	
S0142	Macrophage-oxLDL	
S0144	Macrophage (GM-CSF treated)	
S0146	prostate-edited	
S0148	Normal Prostate	
S0150	LNCAP prostate cell line	
S0152	PC3 Prostate cell line	
S0192	Synovial Fibroblasts (control)	
S0194	Synovial hypoxia	
S0208	Mesangial cell, frac 1	
S0210	Mesangial cell, frac 2	
S0212	Bone Marrow Stromal Cell, untreated	
S0214	Human Osteoclastoma, re-excision	disease
S0216	Neutrophils IL-1 and LPS induced	
S0218	Apoptotic T-cell, re-excision	
S0222	H. Frontal cortex,epileptic,re-excision	disease
S0242	Synovial Fibroblasts (II1/TNF), subt	
S0250	Human Osteoblasts II	disease
S0260	Spinal Cord, re-excision	
S0278	H Macrophage (GM-CSF treated), re-excision	
S0280	Human Adipose Tissue, re-excision	
S0282	Brain Frontal Cortex, re-excision	
S0310	Normal trachea	
S0318	Human Normal Cartilage Fraction II	
S0328	Palate carcinoma	disease
S0330	Palate normal	
S0332	Pharynx carcinoma	
S0336	Human Normal Cartilage Fraction IV	
S0342	Adipocytes,re-excision	
S0344	Macrophage-oxLDL, re-excision	
S0346	Human Amygdala,re-excision	
S0348	Cheek Carcinoma	disease
S0350	Pharynx Carcinoma	disease
S0352	Larynx Carcinoma	disease
S0358	Colon Normal III	
S0360	Colon Tumor II	disease
S0364	Human Quadriceps	
S0366	Human Soleus	
S0370	Larynx carcinoma II	disease
S0372	Larynx carcinoma III	disease
S0374	Normal colon	
S0376	Colon Tumor	disease
S0378	Pancreas normal PCA4 No	
S0380	Pancreas Tumor PCA4 Tu	disease
S0386	Human Whole Brain, re-excision	
S0388	Human Hypothalamus,schizophrenia, re-excision	disease
S0400	Brain, normal	
S0408	Colon, normal	
S0412	Temporal cortex-Alzheimer, subtracted	disease
S0414	Hippocampus, Alzheimer Subtracted	
S0418	CHME Cell Line,treated 5 hrs	
S0420	CHME Cell Line,untreated	
S0422	Mo7e Cell Line GM-CSF treated (1ng/ml)	

S0424	TF-I Cell Line GM-CSF Treated	
S0426	Monocyte activated, re-excision	
S0438	Liver Normal Met5No	
S0444	Colon Tumor	disease
S0446	Tongue Tumour	
S0452	Thymus	
S0454	Placenta	
S0464	Larynx Normal	
S3012	Smooth Muscle Serum Treated, Norm	
S3014	Smooth muscle, serum induced, re-exc	
S6014	H. hypothalamus, frac A	
S6024	Alzheimers, spongy change	disease
S6026	Frontal Lobe, Dementia	
S6028	Human Manic Depression Tissue	disease
T0002	Activated T-cells	
T0003	Human Fetal Lung	
T0004	Human White Fat	
T0006	Human Pineal Gland	
T0008	Colorectal Tumor	disease
T0010	Human Infant Brain	
T0039	HSA 172 Cells	
T0040	HSC172 cells	
T0041	Jurkat T-cell G1 phase	
T0042	Jurkat T-Cell, S phase	
T0067	Human Thyroid	
T0082	Human Adult Retina	
T0109	Human (HCC) cell line liver (mouse) metastasis, remake	
T0110	Human colon carcinoma (HCC) cell line, remake	

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### **Signal Sequences**

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the

polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough  
5 endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of  
10 the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal  
15 charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of  
20 these methods is in the range of 75-80%. (von Heinje, *supra.*) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et  
25 al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

30 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence

shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

### **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the

complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

- 5 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%,  
10 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%  
15 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%  
20 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified  
25 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best  
30 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp.

App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the

deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window



Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not

matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1 $\alpha$ . They used random mutagenesis to generate over

3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic  
10 residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the  
20 genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino  
25 acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification or (v) fusion of the polypeptide with another compound, such as albumin (including, but not limited to, recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by  
30 reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

#### **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,

and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40,

41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel



chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5 In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope  
10 of the invention.

### Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID  
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses  
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower  
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide  
30 encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies

described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays  
5 described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985),  
10 further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30  
15 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,  
20 that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

25 Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any  
30 combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to

an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant

albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>-nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721;

5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

### **Antibodies**

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin

molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be

excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog,

5 ortholog, or homolog of a polypeptide of the present invention are included.

Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described

herein) to a polypeptide of the present invention are also included in the present

10 invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using

15 methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent

hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation  
25 constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an  
30 antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the

epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes  
5 antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand  
10 binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described  
15 supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent  
20 ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but  
25 do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists  
30 for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.



5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

10           Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g.,  
15   Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

          As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus  
20   or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438;  
25   WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

          The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include  
30   antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of

numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

5           The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal  
10       antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and  
15       potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

          Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be  
20       produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not  
25       limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

          Methods for producing and screening for specific antibodies using hybridoma  
30       technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an

immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are  
5 selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating  
10 monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody  
15 able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).  
20 F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which  
25 carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid  
30 surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage

gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic  
5 et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225;  
10 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and  
15 expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-  
20 34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999  
25 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal  
30 antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol.

Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entirety.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into

mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using

techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

#### *Polynucleotides Encoding Antibodies*

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library

generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe  
5 specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the  
10 antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor,  
15 NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light  
20 chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted  
25 within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of  
30 the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino



acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

## *Methods of Producing Antibodies*

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a

polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as

bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems  
5 infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO,  
10 BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole  
15 recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2  
20 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which  
25 direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include; but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic  
30 Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such

fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the  
5 GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus  
10 and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric  
15 gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad.  
20 Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and  
25 initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression  
30 of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.

Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt,

which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 5 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215; and hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. 10 (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

15 The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in 20 culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second 25 vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic 30 free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any

combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341 (1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to



identify antagonists of hIL-5. (See, Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred  
5 embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags  
10 useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., *Cell* 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used  
15 diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent  
20 materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No.  
25 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone,  
30 fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin,

and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports  
5 include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For  
10 Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results,  
15 And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

20 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can  
25 be used as a therapeutic.

### *Immunophenotyping*

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present  
30 invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific

epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

#### *Assays For Antibody Binding*

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A

and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., <sup>32</sup>P or <sup>125</sup>I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes

the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

10           The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of increasing amounts of an unlabeled second antibody.

### *Therapeutic Uses*

25           The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any

one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or  
5 conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the  
10 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

15 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

20 The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment,  
25 human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and  
30 therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention,

including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

### *Gene Therapy*

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other



desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific

5       embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or  
10       indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be  
15       accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun;  
20       Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target  
25       cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT  
30       Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination

(Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes; monocytes, macrophages,

neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

5 In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or  
10 progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

15 In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

## 20 *Demonstration of Therapeutic or Prophylactic Activity*

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition  
25 include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a  
30 specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

*Therapeutic/Prophylactic Administration and Composition*

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment;

this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when  
5 administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)  
10

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose  
20 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote  
30 expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by

use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,  
5 Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a  
10 pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic  
15 is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid  
20 carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering  
25 agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as  
30 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of

the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.



For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

### *Diagnosis and Imaging*

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level,

whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods

including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce  
5 diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of <sup>99m</sup>Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of  
10 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the  
15 labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by  
20 repeating the method for diagnosing the disease or disorder, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label  
25 used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

30 In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with

a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is  
5 detected in a patient using magnetic resonance imaging (MRI).

### *Kits*

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified  
10 antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present  
15 invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

20 In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically  
25 immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide  
30 antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may

also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound

recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

### **Fusion Proteins**

5 Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second  
10 cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur  
15 through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell  
20 or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and  
25 specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins  
30 consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).) Polynucleotides comprising or alternatively consisting of nucleic acids which encode these fusion proteins are also encompassed by the invention.

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

### **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,



pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-

mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some  
5 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A  
10 main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main  
15 carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., et al., *Yeast* 5:167-77 (1989); Tschopp, J.F., et al., *Nucl. Acids Res.* 15:3859-76 (1987).  
20 Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding  
25 a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal  
30 peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a

polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for

derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and  
5 may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated  
10 molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an  
15 average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000,  
20 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug.*  
25 *Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those  
30 skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may

be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ( $\text{ClSO}_2\text{CH}_2\text{CF}_3$ ). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,

15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional



embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence ( e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627

(hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves  
5 use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different  
10 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide  
15 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are  
20 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

25 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-  
30 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers

of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

5 Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the  
10 polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see,  
15 e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein  
20 technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic  
25 polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides  
30 of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into

liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

### Uses of the Polynucleotides

5           Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

          The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers,  
10       since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

          Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be  
15       selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

20           Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled  
25       flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety)..

          Precise chromosomal location of the polynucleotides can also be achieved  
30       using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see

Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g., Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or

estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide  
5 level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples  
10 include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred  
15 source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174.  
20 Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a  
25 method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the  
30 preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,

thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Gelman, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in *Neoplastic Diseases of the Blood*, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal



cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelman et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Gelman et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelman et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456

(1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while  
5 antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One  
10 goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

15 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for  
20 identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative  
25 to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an  
30 individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or  
5 surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an  
10 identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with  
15 tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

20 In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA  
25 antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The  
30 following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression

in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

10 In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers  
15 for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  
20  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a  
25 human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:  
30 The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also

be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

5

### **Gene Therapy Methods**

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

15

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldgrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

20

25

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver,

30

and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences  
5 that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such  
10 methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors  
15 include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving  
20 the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter;  
25 the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing  
30 naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA

sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.



The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5       The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant  
10       invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15       84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20       Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25       available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of  
30       DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.

Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a

suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., Biochim. Biophys. Acta, 394:483 (1975); Wilson et al., Cell, 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA, 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis

virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected  
5 include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any  
10 means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO<sub>4</sub> precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector  
15 particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and  
20 at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis.,  
25 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science , 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative  
30 (Green et al. Proc. Natl. Acad. Sci. USA , 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);

Rosenfeld et al., Cell , 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature , 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can  
5 be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

10 Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses  
15 may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr.  
20 Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678,  
25 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found  
30 in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including

lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.

- 5 These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

- Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

- Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

- 25 The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can  
5 be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such  
10 that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth  
15 factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

20 Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be  
25 homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct  
30 needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid

(tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
5 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting  
10 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue  
15 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a  
20 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.  
25 Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
30 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.



Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

### **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

### **Immune Activity**

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of

the present invention can be used as a marker or detector of a particular immune system disease or disorder.

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g., agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing autoimmune disorders. Many autoimmune disorders result from inappropriate

recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Autoimmune diseases or disorders that may be treated, prevented, and/or diagnosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following:

10 autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g, IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia,

15 Polyendocrinopathies, Purpura (e.g., Henloch-Scoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, Autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as,

20 as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA

25 nephropathy, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiomyopathy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous,

30 degenerative, and atrophic disorders.

Additional autoimmune disorders (that are probable) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are

not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional autoimmune disorders (that are possible) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated,

prevented, and/or diagnosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention.

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost  
5 immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

B cell immunodeficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-  
10 linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia,  
15 agammaglobulinemia, common variable immunodeficiency (CVI) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa  
20 chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic alymphoplasia-aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof  
25 syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

T cell deficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof include, but  
30 are not limited to, for example, DiGeorge anomaly, thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia,

immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity. In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are ameliorated or treated by, for example, administering the polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

Other immunodeficiencies that may be ameliorated or treated by administering polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID; e.g., X-linked SCID, autosomal SCID, and adenosine deaminase deficiency), ataxia-telangiectasia, Wiskott-Aldrich syndrome, short-limber dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome (e.g., purine nucleoside phosphorylase deficiency), MHC Class II deficiency. In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof.

In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, and/or diagnosed using antibodies against the protein of the invention.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed using polypeptides, antibodies, or polynucleotides of the invention, and/or

agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Moreover, inflammatory conditions may also be treated, diagnosed, and/or prevented with polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. Such inflammatory conditions include, but are not limited to, for example, respiratory disorders (such as, e.g., asthma and allergy); gastrointestinal disorders (such as, e.g., inflammatory bowel disease); cancers (such as, e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (such as, e.g., multiple sclerosis, blood-brain barrier permeability, ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (such as, e.g., Parkinson's disease and Alzheimer's disease), AIDS-related dementia, and prion disease); cardiovascular disorders (such as, e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (such as, e.g., chronic hepatitis (B and C), rheumatoid arthritis, gout, trauma, septic shock, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus (i.e., type 1 diabetes), and allogenic transplant rejection).

In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to treat, diagnose, and/or prevent transplantation rejections, graft-versus-host disease, autoimmune and inflammatory diseases (e.g., immune complex-induced vasculitis, glomerulonephritis, hemolytic anemia, myasthenia gravis, type II collagen-induced arthritis, experimental allergic and hyperacute xenograft rejection, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also be used to modulate and/or diagnose inflammation. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to treat, diagnose, or prognose, inflammatory conditions, both chronic and acute conditions, including, but not limited to, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, and resulting from over production of cytokines (e.g., TNF or IL-1.).

Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

Additional preferred embodiments of the invention include, but are not limited to, the use of polypeptides, antibodies, polynucleotides and/or agonists or antagonists in the following applications:

Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.



Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741.

A vaccine adjuvant that enhances immune responsiveness to specific antigen.

An adjuvant to enhance tumor-specific immune responses.

10 An adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, 15 or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, 20 Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever.

An adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria 25 or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as 30 an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meisseria meningitidis*,

*Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, *Borrelia burgdorferi*, and Plasmodium (malaria).

5 An adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an  
10 adjuvant to enhance an immune response to Plasmodium (malaria).

As a stimulator of B cell responsiveness to pathogens.

As an activator of T cells.

As an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

15 As an agent to induce higher affinity antibodies.

As an agent to increase serum immunoglobulin concentrations.

As an agent to accelerate recovery of immunocompromised individuals.

As an agent to boost immunoresponsiveness among aged populations.

As an immune system enhancer prior to, during, or after bone marrow  
20 transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific  
25 embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

As an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell  
30 function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are

not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

As an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from surgery.

As a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonization of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

As an agent to direct an individuals immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

As a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

As a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

As a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect.

As a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients.

As an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

As a means of activating T cells.

As a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leshmania.

As pretreatment of bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recover.

5 As a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

Additionally, polypeptides or polynucleotides of the invention, and/or agonists thereof, may be used to treat or prevent IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema.

10 All of the above described applications as they may apply to veterinary medicine.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, or ribozymes. These would be expected to reverse many of the activities of the ligand described above as well as find clinical or  
15 practical application as:

A means of blocking various aspects of immune responses to foreign agents or self. Examples include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and pathogens.

20 A therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythramatosus and MS.

An inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in  
25 disrupting immune responses, and blocking sepsis.

An inhibitor of graft versus host disease or transplant rejection.

A therapy for B cell and/or T cell malignancies such as ALL, Hodgkins disease, non-Hodgkins lymphoma, Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, and EBV-transformed diseases.

30 A therapy for chronic hypergammaglobulinemeia evident in such diseases as monoclonalgammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonalgammopathies, and plasmacytomas.

A therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

A means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

An immunosuppressive agent(s).

5 Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

In another embodiment, administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention, may be used to treat or prevent IgE-mediated allergic reactions including, but not limited to, asthma,  
10 rhinitis, and eczema.

The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

The agonists or antagonists may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of  
15 neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain auto-immune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes. The antagonists or agonists may also be employed to treat infectious diseases including  
20 silicosis, sarcoidosis, idiopathic pulmonary fibrosis by, for example, preventing the recruitment and activation of mononuclear phagocytes. They may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration. The antagonists or agonists or may also be employed for treating atherosclerosis, for example, by preventing monocyte  
25 infiltration in the artery wall.

Antibodies against polypeptides of the invention may be employed to treat ARDS.

Agonists and/or antagonists of the invention also have uses in stimulating wound and tissue repair, stimulating angiogenesis, stimulating the repair of vascular  
30 or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to treat or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii.

In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to treat, diagnose, and/or prevent (1) cancers or neoplasms and (2) autoimmune cell or tissue-related cancers or neoplasms. In a preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent acute myelogenous leukemia. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent, chronic myelogenous leukemia, multiple myeloma, non-Hodgkins lymphoma, and/or Hodgkins disease.

In another specific embodiment, polynucleotides or polypeptides, and/or agonists or antagonists of the invention may be used to treat, diagnose, prognose, and/or prevent selective IgA deficiency, myeloperoxidase deficiency, C2 deficiency, ataxia-telangiectasia, DiGeorge anomaly, common variable immunodeficiency (CVI),

X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome.

Examples of autoimmune disorders that can be treated or detected are described above and also include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prognosed, prevented, and/or diagnosed using antibodies against the polypeptide of the invention.

As an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

Additionally, polynucleotides, polypeptides, and/or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related

glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and



brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be detected and/or treated by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to neoplasms located in the: liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

## **Hyperproliferative Disorders**

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to: hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals

comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferrably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature

320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference.

5 In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes  
10 needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use  
15 of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts,  
20 which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the  
25 polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in  
30 tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for  
5 producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may  
10 be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of  
15 the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as  
20 described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or  
25 activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or  
30 polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those

with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the  
5 angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in  
combination with other polypeptides directly or indirectly, as described elsewhere  
herein. In a most preferred embodiment, said anti-angiogenesis effect may be  
achieved indirectly, for example, through the inhibition of hematopoietic, tumor-  
specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl  
10 Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).  
Antibodies directed to polypeptides or polynucleotides of the present invention may  
also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,  
Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by  
reference)).

15 Polypeptides, including protein fusions, of the present invention, or fragments  
thereof may be useful in inhibiting proliferative cells or tissues through the induction  
of apoptosis. Said polypeptides may act either directly, or indirectly to induce  
apoptosis of proliferative cells and tissues, for example in the activation of a death-  
domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1),  
20 TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related  
apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al.,  
Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).  
Moreover, in another preferred embodiment of the present invention, said  
polypeptides may induce apoptosis through other mechanisms, such as in the  
25 activation of other proteins which will activate apoptosis, or through stimulating the  
expression of said proteins, either alone or in combination with small molecule drugs  
or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins  
(See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33  
(1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12  
30 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by  
reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such thereapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

### **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus

arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.



Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial  
5 reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms,  
10 angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis,  
15 erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer,  
20 vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication,  
25 carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral  
30 arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural

hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*, described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

#### **Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound

healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors,

including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising

the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of

diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause),  
5 toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in  
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-  
15 angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent  
20 complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing  
25 front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed  
30 between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-

3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to  
5 a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other  
10 embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of  
15 administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide,  
20 polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a  
25 patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or  
30 agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,

pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born  
5 tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and  
10 uvietis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma  
15 fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (Helicobacter pylori), Bartonellosis and bacillary angiomatosis.

20 In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a  
25 peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

30 Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized



to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive

Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

- 5           Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

10           Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

- 15           Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

30           A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence

of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradeccasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

15

### **Diseases at the Cellular Level**

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or

agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis,

Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g.,  
5 hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

### **Wound Healing and Epithelial Cell Proliferation**

10 In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.  
15 Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat  
20 exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal  
25 loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists  
30 of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,

epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentum graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and,

thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

5           In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or  
10       prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

#### 15       Neurological Diseases

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which  
20       result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1)  
25       ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of  
30       the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is



destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists

or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motor sensory Neuropathy (Charcot-Marie-Tooth Disease).

Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to

stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or  
5 detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency,  
10 pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as  
15 ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral  
25 arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency,  
30 vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as  
5 Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome,  
10 Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic  
15 epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure  
20 hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural  
25 empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention  
30 include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as

Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uvermeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes  
5 bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention  
10 include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral  
15 sclerolitis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue  
20 Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's  
25 Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolysaccharidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett  
30 Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity,

encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention

5 include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia,

10 apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia,

15 broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia,

20 myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic

25 Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism,

30 spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron

disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).



**Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Bimaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papilloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or

diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*, *Nocardia*), *Cryptococcus neoformans*, Aspergillosis, Bacillaceae (e.g., Anthrax, *Clostridium*), Bacteroidaceae, Blastomycosis, *Bordetella*, *Borrelia* (e.g., *Borrelia burgdorferi*), Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacteriaceae (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), Erysipelothrix, *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, Mycoplasmatales, *Mycobacterium leprae*, *Vibrio cholerae*, Neisseriaceae (e.g., *Acinetobacter*, Gonorrhea, Meningococcal), *Neisseria meningitidis*, Pasteurellaceae Infections (e.g., *Actinobacillus*, *Haemophilus* (e.g., *Haemophilus influenza* type B), *Pasteurella*), *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, Syphilis, *Shigella* spp., Staphylococcal, Meningococcal, Pneumococcal and Streptococcal (e.g., *Streptococcus pneumoniae* and Group B *Streptococcus*). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,

meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.

5 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

10 Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, 15 Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS 20 related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used totreat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

25 Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the 30 polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### Regeneration

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues  
5 could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs  
10 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the  
15 present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel  
20 syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a  
polynucleotide or polypeptide and/or agonist or antagonist of the present invention to  
25 proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral  
30 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-

Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### **Chemotaxis**

5           A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then  
10   fight off and/or heal the particular trauma or abnormality.

          A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system  
15   disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

20           It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

25

### **Binding Activity**

          A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit  
30   (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural  
5 receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell  
10 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

15 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,  
20 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

25 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be  
30 identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein

polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opin. Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide

sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In  
5 another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a  
10 growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs),  
15 nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The  
20 biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the  
25 polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the  
30 uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of



3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of,

any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional  
5      embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### **Targeted Delivery**

10           In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or  
15      prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic  
20      protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific  
25      destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of  
30      toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes

known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the

present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound  
5 form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564,  
10 published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art.  
15 Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present  
20 invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

### 25 **Polypeptides of the Invention Binding Peptides and Other Molecules**

The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the polypeptide of the invention binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of  
30 the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

This method comprises the steps of:

- a. contacting a polypeptide of the invention with a plurality of molecules; and
- b. identifying a molecule that binds the polypeptide of the invention.

The step of contacting the polypeptide of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate  
5 immobilizing the polypeptide of the invention on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptide of the invention. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptide of the invention. The molecules having a selective affinity for the polypeptide of the  
10 invention can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptide of the invention to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

Alternatively, one may also separate a plurality of polypeptides into  
15 substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant  
20 phage). Individual isolates can then be "probed" by the polypeptide of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptide of the invention and the individual clone. Prior to contacting the polypeptide of the invention with each fraction comprising individual polypeptides, the polypeptides  
25 could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane; such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for a polypeptide of the invention.  
30 Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptide of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be

determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

5           In certain situations, it may be desirable to wash away any unbound polypeptide of the invention, or alternatively, unbound polypeptides, from a mixture of the polypeptide of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptide of the invention  
10   or the plurality of polypeptides is bound to a solid support.

          The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind to a polypeptide of the invention. Many libraries are known in the art that can be used, e.g., chemically  
15   synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature* 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer  
20   et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

25           Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R. B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157; Kay et al., 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

30           In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9022-9026.

By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al.,

1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a molecule that binds a polypeptide of the invention can be carried out by contacting the library members with a polypeptide of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptide of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a polypeptide of the invention.

Where the polypeptide of the invention binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

As mentioned above, in the case of a polypeptide of the invention binding



molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a polypeptide of the invention binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

The selected polypeptide of the invention binding polypeptide can be obtained by chemical synthesis or recombinant expression.

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is

heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,

forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication

NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end,  
 5 the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,  
 10 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,  
 15 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,  
 20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,  
 25 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl  
 30 phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded

hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).

The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990)). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

### **Other Activities**

5           The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed  
10   above.

          The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

15           The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may  
20   be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

          The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

          The polypeptide of the invention may also be employed for preventing hair  
25   loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

          The polypeptide of the invention may also be employed to maintain organs  
30   before transplantation or for supporting cell culture of primary tissues.

          The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5       The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to  
10   modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

      Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases,  
15   disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

      Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or  
20   decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

### **Other Preferred Embodiments**

      Other preferred embodiments of the claimed invention include an isolated  
25   nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

      Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of  
30   positions beginning with the nucleotide at about the position of the 5' Nucleotide of



the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of  
5 positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the  
10 range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

20 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X  
25 in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under  
30 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization

conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1,  
5 which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous  
10 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the  
15 complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule  
20 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
25 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X  
30 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

5 Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence  
10 determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic  
15 acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
20 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least  
25 one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a  
30 biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a

nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5           The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

10           Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID  
15 NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

20           Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

          Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of  
25 positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

          Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the  
30 amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
5 sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human  
10 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in  
15 Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA  
20 clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human  
25 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1  
30 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence

selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.



Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to  
 5 increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit,  
 10 goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 5, preferably excluded are one or more polynucleotides  
 15 comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 5 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 5. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences  
 20 referred to in the fifth column of Table 5. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 5

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HGBAJ60	11	1017036	AA464807, AW391174, AA770661, AI333225, AA081335, AA431894, AA426155, AI338446, W31695, AA426230, AI400254, AA347390, AA186695, AA918383, W04527, AA426573, AI051414, AA486620, AA425620, AA487066, AI374976, N36136, H88205, AA297537, H88204, N44141, AA297524, AA188323, AA248250,

				AI301726, AW438654, AA090513, AA090419, and AB034695.
1	HGBAJ60	46	863977	AW070211, AA464807, AW391174, AI333225, AA770661, AA081335, AA431894, AI338446, AA426155, AA486620, AA426230, W31695, AI400254, AA186695, AA347390, AA426573, AI051414, AA425620, AI301726, W04527, AA918383, AA487066, AI374976, N66734, N36136, H88205, AA297537, H87975, AI631919, AA188323, N44141, H88204, H88157, AI206014, AA297524, AA248250, AW438654, AA090513, AA090419, AB034695, and AL133118.
2	HCWHX82	12	1020761	AA837677, AI732911, AW188427, AI798521, AI354847, AA829199, AA831913, AA224525, AW405593, AI732327, AW089625, AI921744, AA486896, AA309530, AI114494, AI826857, AA584482, AI560241, AA128899, AI709211, AI065031, AI078409, AA577824, AA595206, AI961264, AI820992, AA640277, AA525818, AA626632, AI547110, AA601674, AA084401, AI174827, AA825954, AI791664, AA522897, AA618412, AI809745, AA845690, AA493546, AW085811, AA584360, AI732679, AA180056, AI433952, AA533066, AA584464, AI963600, N70044, AW021399, AL048626, AA425283, AI819419, AA086042, AA493245, AA426451, AA492496, AW055226, AW024544, AA595661, AW410409, AA659303, AI732720, AL044701, AI609984, AA600127, AA577706, AL042667, AL042670, AA601376, AW085751, AW021674, AI862802, AI610012, AI254267, AI828721, AI439525, AA826022, AI285651, AI889995, AI609974, AI311796, AI640717, AI567676, AI889177, AA779599, AA482323, AI343986, AC005796, U62317, AC002470, AL031281, AC005071, AC004834, AL022323, AC005231, AC005911, AL033527, AP000553, AC006312, AC009516, AL022476, AC004491, AL117694, AC005694, AC005529, AC005920, AP000359, AC007308, AC005519, AC004099, AL008712, AC004106, AC007676, Z86090, AF053356, AC005180, AC004230, AC005011, AP000555, AC006449, AL080243, AC005015, AL122020, AP000356, AL031680, AC005527, AE000658, AC003006, AF109907, AC005484, AC003688, AC007666, AC007055, AF207550, AL022336, AL109628, AC004890, AL121658, AC007057, AF111168, AC000025, AP000107, AL008719, Z95116, AC005808, AF047825, AL021546, AC004000, AF196779, AL022316, AL031311, Z99716, AC004381, AC002476, AC004878, AL021154, U85195, AC004263, AC006013, AB017602, AC005225, AC003101, U52112, AC005531, AC006511, AC007221, AP000065, AC002477, AC008009, AC004125, AC006006, AL031662, AF064861, U89335, AL008718, AC004447, AL035423, Z84469, AC005332,

				AC005200, U29895, AL035659, AC005697, AC006285, AC007637, Z81364, AF001552, AL132712, AC004841, AP000503, AC005839, AL009179, AP000280, AC007993, AL031657, AL096701, AC005821, AL139054, AL035420, AC004150, AC007226, AC005696, AL133163, AC007227, AC002350, AC005261, AC003108, AL133448, AC005914, AL079342, AC007686, AC006544, AC004972, AL049780, AL121652, AC004895, Z98200, AC003663, AC002314, AL133245, AF134726, AF129756, AL008582, AL049694, AL096712, AL022302, AC004966, AL031733, AC004675, AP000688, AC002070, AC006160, Z83844, AP000557, AC004253, AC003982, AP000501, AF001548, AC007066, AC005081, AC004985, AC004913, AC006547, AL109801, AL050307, AC003037, AC002044, AC004167, AC005291, AC004884, AL109613, AL034420, AL117258, AC005086, AF111167, AC010205, AL031602, AF088219, AL022238, AC004686, AP000117, AL121653, AC007386, AF111169, AC002418, AC004883, AC005520, AC004383, AC005562, AP000039, AC000353, AL022329, AL031774, AC004953, AC005500, AC006512, AC005041, AC003043, AC005102, AC004050, AC005666, AC005193, AF200465, AC004386, AC008115, AC006509, Z93241, AC005899, Z95114, AL096791, AC005046, AC008040, AL031283, AC005006, AC005602, AC007011, AL022322, Z93020, AC006057, AC004019, Z82244, U91321, AC007384, AC006011, AC004382, AC005765, AP000552, AL034379, AL022326, AC005033, AC004638, AC005778, AC004812, AC004257, AF001549, AL050308, AP000141, AC007421, AC004098, AL049757, AC006211, AC005004, AL035072, AC002299, AC007934, AL049872, AC006241, AC004854, L78833, Z93017, AC005695, AC005632, AC004526, AC004881, AP000010, AL009181, and AL049761.
2	HCWHX82	47	889046	AC005796.
2	HCWHX82	48	779620	AC005796, AF111168, and AP000501.
3	HCWEB58	13	1115089	N88782, H58760, N88601, AA247964, N89520, N84855, N83991, N83168, N83992, AA096066, AA247827, N84048, AA095359, AA096046, AA093224, AA471338, AA095641, N84718, N84712, N86694, N83993, N55698, N84830, N88518, N84829, S78798, AF103726, U48696, AF102850, AF039698, AF045432, AR066487, U39066, AF032922, and AJ243486.
4	HCWHV88	14	1027324	AI275161, T93096, AA722180, R16897, R16951, T93190, AW246099, and R12700.
4	HCWHV88	50	885098	AW246099, AA722180, R16951, T93190, AI275161, T93096, and R16897.
5	HCWAU23	15	1001616	AW022897, H46593, AI124706, AA224525, AI110760, AA640053, AI057103, AA298345, AW069819, AA601673, AA584088, AA806796,

				AA572971, AW161966, AA456937, AA577824, R79496, AA468456, AW263415, AA179290, AA706495, AA601125, AA342901, AL119001, N49368, AI433008, AA370455, R47235, AI523839, AP000553, AC007263, AL133445, AP000356, AC005663, AP000952, AP000493, AC000080, AL133244, AP000052, AC002467, AC006039, Z98304, AC006545, AC006013, AC003046, Z83822, Z95116, AL031005, AJ251973, AC005972, U91322, AC006160, AC008080, Z98257, AC005971, AC004051, AP000355, AL022163, AC006571, AC007652, AC005730, AL133500, AC004813, AC004662, AL031230, AC005548, AP000343, AC004996, AC003684, Z97989, AC004894, AC004025, AC007878, AC007172, AL049636, AL035089, AC005837, AL078583, AL049575, AC004963, AC004901, AL009177, X69907, AC006509, AC002522, AC002483, AC000095, AL008715, AB023051, AC002381, AL031320, AL008639, AL034549, AL031602, AC007032, AL137345, AL031118, AC004990, AL109967, AC008078, AC007304, X55448, U61375, AL049795, AP000095, AC007130, AL022316, AC007536, AC009044, AL022476, AL035458, Z68756, AP000239, AC007262, AP000404, AC005157, AP000100, AL049757, AC004253, AC007065, AC002080, AC006146, AC003014, AC005800, AC005192, AC007938, AC004805, AL080241, AC005318, AL022721, AC002480, AL121653, AC006530, AC005323, AC006153, AP000512, AL008730, AC005050, AP000120, AL133312, AC002558, AC006130, Z97055, AC006115, AC010200, AL031255, AC003103, AL078462, AL136168, AP000514, AP000111, AP000043, AC007785, AL121769, AL031282, AC005912, AJ003147, AL132712, AC005234, AC002378, AC002398, AC002074, AC007276, AC002119, AC005529, AC004033, AL031427, AC007687, AL008627, AP000330, AC005224, AC003029, AC002402, AL049540, AL109985, AC002301, Z94044, AL035252, AC004690, Z85987, AC004257, AL024474, AL031667, AC007298, AC005839, Z73417, AC005911, AC005233, Z93241, Z93016, AL109758, AC005225, AF053356, AC005512, AC004913, AB017602, Z83840, AC006063, AL117258, AC005209, AC002369, AL031864, AC006205, AC005412, AC002527, AC004531, AC006346, AC002316, AF205588, AP000155, AC007363, AL035091, AC004920, Z74617, AL121593, AL021329, AC007551, AC004615, AL136295, AL031120, AL031589, AC003101, AL078463, AL022330, AL022098, AC002312, AC003962, AC004081, Z94277, Z95331, AC008282, AL031368, AC006388, Z82901, AC004806, AP000211, AP000133, AL133382, AF111167, Z98044,
--	--	--	--	---

				AP000207, AP000129, AL117344, AC006211, AL034384, AJ229041, AC005058, AC004821, AF051934, AC002451, AL031407, AL035462, AL078593, AL096701, AL078587, Z99128, D87009, AL022328, Z84469, AL021917, AL049839, AC002288, AC005690, AC004104, AL031681, AC006075, and AL035562.
5	HCWAU23	51	825942	AP000553.
5	HCWAU23	52	815790	AP000553.
7	HBWCM83	17	1041982	AA663361 and AA663353.
7	HBWCM83	56	863578	AA663353, AA663361, AA471212, Z19935, N88601, AA247964, N88782, N84855, H58760, N83168, N89520, AA095359, N88518, N83991, AA247827, N83992, AA096046, N84048, AA095641, N55698, N84718, AA096066, N86694, N83993, N84712, N84829, N84830, AA471338, N87989, A75238, S78798, U48696, AF103726, AF039698, AF102850, AF045432, AR066487, U39066, AF032922, and AJ243486.
7	HBWCM83	58	794992	AI657485, N83707, N83963, U39066, AF045432, AJ243486, U48696, U48697, AF011573, X99058, X99056, X99051, X99052, Y16299, AF102850, AF001863, AF061744, and X99055.
8	HTPBG16	59	869837	AA295691.
9	HETAM53	19	1003026	AI888794, AI681772, AI697703, AA308673, AI001790, AI871647, AW299281, N24730, AW291103, AA887502, AI299106, N81015, D11922, W07843, AI300987, AI695033, AI683984, AI358195, AI299101, R19840, AA577472, AI220991, AI871754, H73422, AA348901, T83690, T84021, R16418, AA626318, AA095202, AA359596, R14543, R19232, T84721, AA359899, R41204, Z43766, R45939, AA336933, T84020, AW138974, N54300, T91591, Z39826, T91632, AA092058, and N55834.
9	HETAM53	61	897325	AA308673, AA359899, and AA336933.
9	HETAM53	62	902648	AI888794, AI697703, AI681772, AA308673, AI001790, AW299281, N24730, AW291103, AI871647, W07843, AA887502, N81015, AI300987, AI299106, AI358195, AI683984, AI299101, AA577472, D11922, AI695033, AI220991, AI871754, H73422, R19840, R16418, AA348901, T83690, T84021, AA626318, AA359596, R14543, T84721, R19232, R41204, R45939, Z43766, AA095202, T84020, AW138974, N54300, T91591, Z39826, T91632, AA092058, and N55834.
9	HETAM53	63	889320	AI338335, AI042353, AI949448, AI341668, AI767321, AI799985, AI972857, AI804647, AI378664, AI373234, H98990, AI338708, AI142871, AI436137, AI373768, AA421011, AA700696, AA682478, W96545, AI457396, AI304838, N30898, AI244653, AI090275, AA587335, AI082410, AA026152, AI016424, W42910, W96448, AW337402, R88993, D61094, AI288991, AI784503, N26233, AI262397,

				AA988382, AI824456, AI283803, W42855, AI919256, AI015148, R50121, H89991, AI248892, H59608, T66792, N73303, R89543, H59647, R85728, R50122, AI525556, AI932441, Z38740, Z28355, AI546855, AI541374, Z30131, AI546999, W80734, AA585439, AI525316, AI934110, AI541506, AI525431, AA026151, N25565, AI557084, AI540967, AI535639, AI546899, AI546828, AA585356, AI541510, AI526140, AI525328, N34164, AI557731, AI541017, AI547039, AA345218, AA585476, AI547006, AI556967, AA585453, AI541345, AI526180, AI541535, AI541514, T18597, AI541013, AI557262, AA585434, AI541523, AI541508, AI526144, AI524891, AI535813, AL038761, AI547071, AL040553, AI541205, AI546891, AI526194, AI540920, C15189, AI557082, R28735, C16300, AI526195, AI526073, AI541356, AA585101, AL040238, AI541534, AI526187, AJ239433, D59436, AI525500, AL045989, AI557807, AI557864, AI541365, AI525306, AI546971, AI535660, AI526184, AI541307, AI525339, C15069, R29177, AI546945, D59751, AL134524, D61254, AI526078, AI557787, R29218, AI546875, R28965, AI541509, D57186, AI557799, AI557238, AI526176, R45895, AI526196, AI557727, C15737, AI536138, D57491, C15406, AI557602, R29445, D60844, AI557763, AI526186, R28892, AI541527, AI541346, R28967, AI546921, Z32822, D60765, AA585325, AI557155, AI540974, R28895, AA283326, AI541415, AI541321, D61185, AI541517, AI557808, AI547250, AI546829, T11028, AW172956, AI557740, AI546996, C14391, AI557734, AI541390, C16292, AI557285, AI557408, AL042096, D55233, R29657, AA585329, AI557279, C16305, C14208, AI541422, C14322, D53161, AA585155, Z32887, AI526113, AL045211, AL040385, C16293, D54897, AI557533, AL037443, AL039432, AA585098, AI525321, AI541034, AI547196, AI557796, AI547202, D53472, AI541075, AA170832, C15120, AI557758, C16294, AI557809, AL037371, AL041210, AI541410, AL045328, AI541383, R47207, R29262, AI525320, R29179, D53447, Z33559, R29172, AI541353, AL037335, AA174170, AL037343, T41289, AL043440, AI541027, AI526158, AI541533, AL037323, AI540903, AF039568, AC010169, X81969, I44681, AR017907, AR038855, I66485, I66487, AR008429, AR038762, I13349, I08396, I08395, A91965, Y09813, I18895, A25909, AR062871, AJ244007, I66495, I66494, AJ244004, I08389, A85395, D13509, A85476, AJ244005, I66498, AR062872, AF082186, AR062873, I66482, Z32836, I66483, I66484, I66497, I66496, I66486, AJ244003, A20702, A20700, A43189, A43188,
--	--	--	--	---

				AR037157, AR035975, AR035977, I63120, A98420, A98423, A98432, A98436, A98417, A98427, A98767, A93963, A93964, Y16359, D50010, D78345, I19525, I15718, A70872, AR009151, AJ230935, A84775, X83865, A84772, A84776, A84773, A86792, A84774, AR054109, AR067731, AR067732, A58522, A91750, AJ230902, I15717, AJ230972, AC005913, A18053, M28262, E03627, AJ230951, I48927, I49890, A60212, AR054723, A60209, A60210, A60211, A35536, A35537, A58524, A02135, A04663, A02136, A04664, A58523, I84553, I84554, AR038066, A64973, A02712, I00682, AJ230867, A77094, A77095, AR035974, A11245, AR035976, AR035978, A81878, A11623, E00609, A11624, A95051, I06859, A18050, A93016, A23334, A75888, I70384, A60111, A23633, E13740, AR007512, A11178, E01007, A10361, E14304, I25027, I26929, I44515, I26928, I26930, I26927, I44516, E16678, I03331, A20699, I62368, E00696, E00697, A02710, E12615, AR035193, I18302, AR043601, A07700, A13392, A13393, AR031488, I13521, E03813, AF149828, I52048, A27396, A95117, AR027100, I44531, I28266, I60241, I60242, AJ231009, AR027099, I21869, A92133, A24783, A24782, A70040, A82653, AR051652, E16636, X55486, I01995, A90655, AR051651, and AR031566.
9	HETAM53	64	845281	AW028099, AI922855, AI361969, AA992606, AL119462, AW190507, AW026418, AA001138, AW026552, AI927710, AW054991, AW021538, AW021048, AW022118, AI126368, W25970, AA029603, W05590, AA082792, AI559467, AI620254, AW149384, D50948, AI421542, AW028917, AI818251, AI547267, AA770662, AI458264, AI680224, R25791, AI566287, AW021063, AI309299, AI422070, AA878328, AI365636, AI971273, AA613338, AW079779, AI361256, D51049, AI350323, AI880260, AW044214, AA973926, AI796767, AI492610, AA001919, AI492611, W57992, AA102442, AA452618, AI445573, AW022511, AW339259, AI929173, AA516126, AI056096, W58076, AA001282, AI362219, AI479728, AI299371, AI082412, AA583433, AA665090, AA977231, AI925177, AI613188, AA722603, D52365, D82171, AA744054, AI034036, AA865467, AA744004, N22103, AI270446, AI418961, AI582196, N67524, N39443, AI690057, AA176661, AI350243, AA935845, AW264534, AA846222, AI094769, AI423107, AI343538, AA001943, AI393109, AA988822, AI362138, AI955625, AA679935, AA922466, AA453239, N75882, AI301425, AA770004, AW451817, AW024046, AW244108, AA992503, AA610274, AI862675, AA650341, AW418627, H89870, AA150901, AI217610, AI359556, AI340177,

				<p> AW023969, T16991, AA651636, AI903724,  AA493436, W28703, AL119570, AI521167,  D57131, AA932042, AL039666, N67561, D53363,  AA325333, D57122, AI888986, T28749,  AW136009, D53116, H89871, AA176888,  AA532904, W04741, AA371457, M78202,  AA621607, R46713, D56786, AI625285,  AA329457, AA326242, T94885, D53312,  AA177059, AA229768, R25556, R97692, R17377,  AA327626, AA829788, AI915632, AA230089,  R96764, F04719, AA890020, N75299, T19071,  AA369982, AA370980, AW190631, AA327740,  R26489, R53266, T93566, F08503, H56545,  D58361, C05281, AI282379, AI749682,  AA334126, AA995390, AA551566, F02334,  D58273, AW389231, N48555, AA358304, T94933,  AA528397, D53216, AA383512, AA385766,  F05468, AA027274, AI203725, AI197986, R15017,  AA348060, AW339396, AA774852, AA570761,  D57796, D51280, AA371073, D56787, AA330159,  AA370044, F06081, AA670375, D57290, D57225,  AA318877, AA461513, T23523, AW190335,  N85713, AW385948, F01728, AA370749, R46790,  C04813, AA150932, R51004, AW243599, N45521,  C00856, AA358146, AI445783, R95995,  AA626597, R95961, AA883804, T92139,  AA683379, AA648060, N75567, AI092975,  R36841, H56546, AL040189, AI783838,  AA101126, AA933800, D82246, AA826833,  AA223622, AA927073, AI423198, AW204192,  R41457, AI358784, AA570812, I33608, X51406,  J04625, M31602, U23184, X04411, X61232,  AB006898, AB006891, L07273, L07281,  AB006890, AB006894, AB006892, AB006895,  L07275, L07278, AB006897, AB006893,  AB006896, AL137480, AJ242859, A08916,  A08910, Y09972, A08909, E15569, I89947,  I48978, Y11254, S68736, A93016, AL137292,  AF113699, A08913, A08912, AL122121, A18777,  AF162270, AF079763, AL133606, AF061573,  I89931, AL050024, X84990, U35846, I49625,  AF065135, AL133640, AL133098, I92592,  AL133075, AJ000937, AF113691, AF113690,  AR068753, AF113677, I33392, AR011880,  AL050277, AR013797, A08908, AR068751,  AF079765, AL049464, X96540, AF097996,  AL133031, AR038854, AL137283, AL049466,  Y11587, AL110221, U87620, AL133077, U42766,  AF118064, AL049283, AL049452, AF111849,  AF104032, AF026816, AL137479, AL122110,  AF113694, Y16645, Y10936, AF111851,  AL137459, AF183393, AL133016, AL050108,  AF113013, I80064, AL133565, AL110280,  AL133560, AB019565, AF078844, Y10655,  AL049300, A77033, A77035, AL137523,  AL117583, AL122118, I48979, AF118094,  AF090943, AL133093, Z82022, AL117460, </p>
--	--	--	--	--



				<p>A93350, AL050146, L30117, AL137550, AL117649, S78214, U80742, X98834, AF061943, A58524, A58523, AF091084, AF090934, I96214, AR034830, AL137557, AL133080, AF087943, I68732, AL049382, U58996, AF058921, AF125948, AF177401, AL080137, A03736, AF113019, E03348, AF017437, AF113689, AF067728, AR029490, AL133557, AF026124, AF158248, AL050393, X93495, U91329, A65341, S76508, AB016226, AL049430, X70685, AL137271, AF153205, AJ238278, AL137529, AF090903, A07647, AL117394, AL122093, AL117435, AF057300, AF057299, AL080074, U00763, AF003737, AF113676, AR000496, U39656, AF118090, AL117585, AL117457, AF106657, AL133113, AL110222, AJ005690, AJ012755, AL137463, U88966, A08911, AR059958, AL080060, X82434, AR038969, AL110196, A76335, Z72491, I42402, L31396, AF185576, AF146568, AL137527, Y07905, AL050092, L31397, AF008439, AF111112, I89944, I89934, AL137538, AL122049, I03321, AL080159, AL137560, AF132676, AL049314, AF061836, AL137488, AL122098, Z37987, E07108, Y14314, AL050149, AL096744, AL133568, AF139986, AL050138, AF106862, AL080124, R26511, and AA864190.</p>
10	HCWFZ59	20	1001637	<p>AA470097, AI421234, R85838, AI923409, AA835680, N51423, AA765513, T50785, AA829148, R16829, AL133736, AL040085, R08610, AA282266, N39533, AA469928, F09387, H23631, H52741, H49121, R69345, F29317, AL109967, AP000144, AC005531, AC007099, AL022163, AC004552, AC004525, AC007245, AL035088, Z95114, AP000326, AP000122, AP000054, AP000169, AC004962, AC009946, AL022313, AL022240, AC000403, AC006359, AC004887, AC004106, AC008372, AC009721, AC004915, AL132985, AC006041, AC004691, AC005612, AL109759, AC007671, AC008012, AC007677, AL035671, AL035698, AL031277, AL035691, AC005880, AC004047, Z98748, AC006568, AL035667, AC005069, AC005915, AL035542, AF152363, AC004478, AC009509, AC007919, AL008722, AC007528, AP000230, AC002069, AC006362, AL049839, AL118510, AL050308, AC005939, AC004957, AC008249, AC007051, AP000962, AC002529, AL023581, AC002464, AC005152, AC002382, AP000159, AL031683, AL049631, AP000403, AC007371, AF126403, Z97629, AC003695, AC004151, AC004174, AL049832, AC004836, AC004622, AC004042, AC007425, AL024508, AL035604, AL022576, AL021367, AC002996, AP000473, AC005157, AC007938, AL049561, AC002541, AC008014, AL121769, AC002428, and AL078462.</p>

10	HCWFZ59	67	753481	H23631, H49121, H52741, AI421234, R08610, AA282266, R85838, AC004552, AC007677, Z99128, AC008012, AC009946, AC004525, AP000233, AC009509, Z95114, AL022163, AL031683, AL109967, AL035088, AC009721, AP000147, AL118510, AP000144, AC004691, AC005915, AP000704, AL023581, AC008169, AC004887, AC005612, AL023802, AC008249, AC004478, AC006041, AC008069, AL132985, AC007245, AC004047, AC010170, AC004957, AL035563, AF130248, AC002069, AP000159, AC007051, AC004174, AL035691, AL035542, AC007919, AL035671, AC006515, AC007006, AC005880, AC005410, AC002529, AC004911, AC004486, AF152363, AL035698, and AC002541.
11	HBWCB95	21	1011489	AA862943, AI797190, AI026816, AI301139, T06649, AA909164, AW438574, T32714, AA663332, AA058566, AW050476, AL035469, Z84466, AJ229042, AC006062, AL008629, AC007100, AC006010, AC006370, AC006480, AC005345, AC004787, AC007690, AF027207, AC004540, AC005352, AC007773, AL049861, AC004626, AL031735, AC004382, AL049712, Z86064, AC004999, AC005799, AL132718, AL022720, AL031676, AL078612, AL033375, AC005042, AL031281, AL035246, AC004531, AC007253, AC004025, AL122007, AC000046, AC006328, AC004885, AL117329, AC005180, AC008372, AC005010, AC002990, AL031223, AL049833, AC018633, AF047825, AC003667, AL096803, AC007461, AC004648, AC002526, AC005252, AC010072, AL109847, AC004969, AL109653, AC005988, AL079352, AL009172, AC005529, AL008715, AL121877, Z84467, AL118510, AC007527, AC002395, AC009784, AF049895, AC006582, AP000086, AL121767, AC010209, AP000160, AL033376, AL049767, AC003036, AC005186, Z70272, AL035411, AL117257, AL022578, AL078613, AF001552, AC008125, AF064863, AC006287, AC002480, AC007919, AC008273, AL049829, AC007368, AL031390, AC000038, AC006952, AC007073, AC007425, AC005744, AC005053, AL032822, AL096757, AC004963, AC004028, AL031864, and AC008045.
11	HBWCB95	68	863588	AL035469, AC007536, AC004531, AC004858, AL009051, AF109907, AC007193, AL022238, AC006141, AC004605, AC005274, AL035071, AL121603, Z97876, AL009183, AC002301, AC005859, AC004019, and U91326.
11	HBWCB95	69	797033	AI657485, N83963, N87188, N83707, AL035469, U39066, AF045432, AR018815, AJ243486, U48697, U48696, AF102850, X99056, AF001863, AF061744, X99052, Y16299, X99058, X99051, AF011573, X99055, X99060, and X99057.
12	HBXAM53	22	1002109	AL118947, AW006372, AI693692, AI693714,

				AA600973, AI653165, AA617706, AI679166, AI129744, AA774192, AI589913, AA985390, AA347288, T03416, T06611, C14096, H67171, AA683418, AA347344, H67850, AA322957, AI916953, AW139805, AI654854, AI493341, R63942, AA317170, AA309507, AL120901, H50272, AA377403, R64040, AI284640, AI801482, AI281881, AL046409, AI431303, AW419262, AL048925, N73310, AI754955, AW193265, W02345, AI334443, AL120343, AL041690, AW303196, AW274349, AI061313, AA610491, AI457397, AI613280, AW301350, AA720702, AI076616, AI963720, AW028429, AA164251, AI350211, AW072587, AA469451, AA326642, AW021583, AI040051, AA631507, AI754253, AL037683, AL119691, AI754336, AW439558, AL138455, AI270117, AL042753, AA581903, AL044940, AI307201, AI434695, AI471481, AI610159, AA587604, AW270270, AI053672, AW072923, AI754658, AW238583, AA680243, AI305766, AI355224, AL040921, AL046205, AA857486, F36273, AI341664, AI745325, AW338086, AI357551, AA846876, AI192631, AI688846, AW265393, AW406755, AA491814, C05986, AW276827, AI799642, AI133164, AW023672, AW193432, AI254615, AL046898, AI732120, AA515224, AW339568, AA984708, AI684097, T40617, AI375710, AW408717, AA806796, AI061334, AL119649, AI358501, AI623898, AL138265, AL048626, AI110770, AI824562, AW440299, AW020992, AI732186, AW406447, AL120687, AI537955, W79504, AI708009, AI473943, AI865905, AA521323, AL038474, AA587256, AI355206, AI266133, AA908687, AW406162, AI370878, AA491284, AW148792, AW301809, AA533333, AW073470, AI358571, AA613227, AI679782, AA719292, AI339850, AA828042, AI367975, AW102955, AA598586, AA456976, AA862173, AI149478, AI281465, AL037910, AI733755, AW062724, AA493708, AA502155, AW261871, AI866908, AW270382, AL039958, AB007854, AC005747, AJ224876, AP000114, AC000353, AC002404, AC005808, AL035423, AL078463, AF077058, AC004808, AC020663, AC002425, AC007919, AL031662, U57006, AC004990, AC007151, D83989, AL049843, X75335, AL031670, AC005913, AC006277, AL031848, AL009172, AP000349, AC006449, AC008101, AC005081, AC005412, AC005837, AL049779, AP000509, AF015151, AC004827, AC005944, X55926, AL035659, Z70288, U07562, AC005696, Z98884, AC004019, X54175, AL022315, AL132992, AC002312, AC005548, X55923, AL033376, U57009, X54181, X54178, AC004638, AF015156, AC007298, X74558, U18393, AF015148, M37551, AL034343, AL022163,
--	--	--	--	---

				AF001549, AC004745, AC002045, AC005921, X54180, AC007663, AC007774, Z82244, U18392, AC002549, Z99716, AC004933, D84394, I51997, AC005409, AC006203, AC006138, AC005736, AC004751, U18391, Z68223, AL022329, AC006128, AL096712, AC005620, AP000354, X55924, U66059, AF134726, AP000557, U18394, X55925, U57005, Z84476, AC007066, Z92845, AD000092, AC005730, AL049872, AC006006, AC004475, AP000513, AC004895, AL035458, AC006111, AC005387, AC002310, AC004263, AC005940, AC006251, AC002430, U18395, AC005516, U18396, U47924, AF053356, AL121603, AL023575, AP000553, AC007051, AF015147, AC008079, AC007384, X54176, U57008, AL024509, AL096701, AC009516, AC005839, AC004832, AL049776, AC004825, AC010072, AC007376, AC005406, AC004099, AL049576, AC016830, AL109623, AL132994, AC007731, AF196779, AL022313, AL050318, AC004491, AB023052, AC016027, AL031003, AC005500, AC004984, AL133371, AC005251, AC006511, AB020858, AP000967, AC005332, AC007226, AC005071, U18390, AC004257, AC008064, AL139054, AC003085, AL031257, AL035410, AC006205, AC007221, AC004858, AL035407, AC004185, AC002301, AF015149, AF111168, AC002401, AC005300, AC005046, Z70042, AC002375, AC000379, AC007191, AC006948, AC004972, AP001053, Z94801, AP001068, AC005939, U18398, AL117338, U57007, AC005060, AL096829, Z98048, AL024474, AC006017, AC005261, AF200465, D87675, AC002365, AC006312, AC002402, AC005701, AP000018, AC006274, AP000961, AC004386, AC005212, AC005231, AC006509, AC006125, AC016025, AL050341, AL049766, AF064861, AC007450, AL021453, AF157623, AL117330, AL022323, AL031774, AL133353, AP000090, Z97054, AC005180, AF109907, AC004998, Z84469, AL121825, M87919, U80017, AC007324, AL035422, AF227510, AC006581, AC002544, AC006079, AC005923, AL031053, AC007182, AC002126, AC004584, AL049743, AC004792, and AP000044.
12	HBXAM53	70	863043	AW006372, AI693692, AI693714, AA600973, AA617706, AI679166, AI129744, AA985390, T06611, AA347344, AA322957, AW139805, AI493341, AA309507, R64040, H67171, AL120901, N56228, W02345, H50272, D20411, AL118947, AL118946, AC005747, AB007854, and AJ224876.
12	HBXAM53	71	796634	AI653165, AA774192, AI589913, AA347288, C14096, AL118947, T03416, AA683418, H67850, AI916953, R63942, AI654854, AA326642, AA377403, N73310, AW290932, AW290927, H50237, AA091216, AA297666, AA621381,

				<p>AW378968, AW341978, AW023990, AA508359, AI754544, R49677, AI733856, AI040051, AL042927, R73754, AA837767, AI354388, AA484143, AA502104, AA630672, AI310343, N23504, AI056177, AA503119, R58559, AA846876, AA610219, AI611569, AI611598, AW072587, AA491797, AC005747, AB007854, AC010382, AC007371, AC005037, AL024494, Z98200, AC003663, AL022327, X13368, AC006120, M63796, AL022721, AP000159, AC005280, AC004991, U96629, AC005740, AL023577, AC007537, AC005399, AL034553, AC005344, AC005695, U63721, AL020997, AC004158, AC005242, AL121658, AC005057, Z98048, AL031466, AL021154, AF001551, AC005212, Y12855, AL049636, AP000018, M82819, AL022330, AC004032, AL136295, AC006946, U78027, AP000557, AP000349, Z98036, Z97353, AL121877, AP000553, AC006006, AC007285, U62292, M17283, AL096755, Z93017, AL035422, AL031291, AB000931, AC001228, AP000502, AC002312, AC004821, AL034429, AC004865, AC004668, AC005701, Z99128, AC006387, AC010168, AC006972, AC007567, AC004760, AC006539, AL034420, AC005939, AC005220, AP000512, AC006144, AC005231, AC005197, AL133238, AC007227, AL033525, Z83844, AC007536, U29185, AC003688, AC006566, AC005529, AC005531, AC006385, AL132712, AC005065, AC004895, AC005871, AC011718, AC004796, AC006262, AC008132, AC004084, AC009516, X90590, S41458, AL109984, AC004983, AC002096, AC005953, AL136453, AC004836, AL031276, AL033521, AL049557, AC004982, AC000113, AF064865, AC006549, AC005013, AC002365, AF001552, AL049539, AC004874, AC009263, AC007242, AL021546, AL049779, U36341, AC005305, AP000281, AL031597, AP000039, Z82214, AC006965, AC004595, L13176, AC004812, AC005544, AL031283, AL022329, AL078603, AF187320, AC000090, AC004699, Z82195, AC004876, AL023806, AC002289, AC005696, AC008125, AL135744, AL049843, AC002128, and AL031311.</p>
13	HCWDY64	23	985876	<p>AW023111, AA602906, AA515728, AI340151, AI687343, F19606, AI250552, AA622801, AA084609, AA640260, AI755057, AI251284, AI251034, AI251203, AI284543, AA515723, AA642809, AW303098, AI254770, AI249853, AA632982, T74524, AL046885, AI801649, AW265342, F16345, AA362349, AA578621, AA847508, AI049709, AA584756, AA847427, H93975, AA938390, AL031846, Z95116, AP000704, Z94160, AC005071, AP000030, AC005529, AC002546, Z93017, AL031577, AL035659, AC005527, Z86064, AC003101,</p>

				AC005778, AP000113, AP000045, AL031291, AC004770, AC006211, AL022334, AL035420, AC007637, AC006241, U91321, AC006312, AL049709, Z95114, AC002303, AC007429, AL035405, AF129756, AC008119, Z98051, AC007057, Z98750, AC005015, AC007541, AC000353, AC007226, U95090, Z95152, AC005005, Z95331, AC007216, AF196971, Z94801, Z83844, AL020995, AL035683, AC005291, AL121756, AC004634, AC004882, AP000347, AC005519, AP000557, AF196969, AC004477, AC005011, AL031311, AL035086, AC005049, AC005632, AC004526, AC005914, AC007688, AL049631, AC007917, AC004134, AC005089, AL031668, AL049569, AL096775, AP000300, Z97181, AC006502, AC005067, AC000025, AC002059, Z84469, AL008583, AC003049, AC000026, AC007546, AL096761, AC008116, AL034549, AC005763, AC012085, AC006080, AC005821, AC004638, U96629, AC000085, AC005619, AL021393, AC005488, AC008372, AC003025, AL031587, AP000555, AP000558, U78027, AC004686, AL034423, AC005081, Z93241, AL050342, AC005088, AL035249, AC005324, AL031289, AC005667, AC004223, AC004024, AF045555, AP000692, AL022323, AC004966, Z82244, AP000193, AL035422, AC007686, AC002126, AL035652, AF139813, AC005736, AC005531, AL049570, AL049843, AL031255, AL031848, AC005180, AC001228, AC004596, AC005360, AL050332, AC006285, AC003071, AL031295, AC003692, AC004878, AC004832, AF038458, AC007308, AC004611, AL031277, AC004814, AL022331, AC004858, AL109628, Z98742, AL109984, AP000103, AL021366, AC009363, AC004883, D87012, U91318, AC005684, AC007685, AL049832, and AB000882.
13	HCWDY64	72	861536	AL031846.
13	HCWDY64	73	746457	AI340151, AA602906, AA622801, F19606, AA640260, AA467740, R98218, AI687343, AI583106, AA347969, AI249853, AA847508, AA362349, AA847427, F16345, AI801649, AW265342, AW104163, AA468494, AA515723, AL046885, AA584756, AI925869, AW245354, AI446259, AA484191, H29914, AI734119, AA829044, AA551268, AA525293, AA559166, AI471455, AA613162, AL031846, AC005778, AL031291, AP000347, Z94160, Z95152, AL049832, AL022334, AC005488, AC005988, AC005844, AC005255, AL034429, Z94801, AC003958, Z82244, AL031281, AL022323, AC006057, AL049569, AC006312, AC007955, AP000045, AP000113, AC005920, AC004134, AC002310, AF196969, AL035659, AC005288, AC004552, AL023879, AC006960, AC007637, AP000704, AL035071, AL031431, AC007358,

				AL035683, AL033521, AL021155, AC007684, AF196779, U91318, AC005005, M87889, AL034549, AC004882, AC004745, AC004821, AL049631, AC007938, AF200465, AL008583, AC005244, AP000359, AC004797, AC005015, AL109963, AC002115, AF134726, AF024533, AC005081, AB017602, AD000812, AC008044, AC004686, AL049643, AL022319, AC002126, AC007384, AC005696, AP000967, AC005736, AC006544, Z94056, AC005622, AL035587, AC004796, Z82243, AC005529, AL035703, AL035422, AF196971, AC004832, Z92542, AL035420, AC005697, AC000025, AL035652, AL035405, AC007546, AP000030, AP000115, AC007666, AL020995, AC002351, AC004638, Z68279, AC000026, AC007676, AF111168, AC002369, AC004967, Z99716, AL009174, AC007774, AP000008, AL021528, AC002563, AL096761, AC005527, AC004770, AL078638, Z74617, AC004834, AC005031, AC005082, AC003101, AC002059, AC004953, AL020993, AC005332, Z99943, AP000300, AB023050, AC004929, AC006211, AC005067, AC004032, AL031289, AC006449, AL031668, AC005102, AC005940, AC005599, AP000501, Z97056, AF029308, AC004921, AL023807, AF196970, AL121658, AC005071, AP000240, AL034402, M89651, AC005291, AP000512, AC008372, AC000105, AC006088, AL022336, AC005089, Z93020, U80017, AC005618, AC004787, AC004131, AL035249, AL031311, AL008731, AL031283, AC006146, AL031427, AL022328, AC006948, AP000272, AC007216, AL022324, AC005921, AC000134, AL132987, AC002550, and AC006014.
14	HBXFZ38	24	1011284	AI589047, AA664114, T75437, R51094, Z42817, F11085, R35525, R39222, Z41309, F13010, F02285, and AC005479.
14	HBXFZ38	74	883835	T75437, Z42817, R35525, F13010, and AC005479.
14	HBXFZ38	75	854616	AI589047, AA664114, R51094, F11085, R39222, Z41309, F02285, and AC005479.
15	HCWGU37	76	901913	AI243431, AI968404, AI809978, AI219140, AI208020, AI040969, AI016183, AW104523, AA907909, R10482, R11614, AI376647, AA936591, AW236872, and AC004797.
16	HBWCF75	77	861687	N88601, N83168, H58760, N84855, N89520, AA247964, N84830, AA096046, N83991, N83992, AA247827, N84718, AA096066, N88782, N84048, AA095641, N86694, N55698, N84712, N83993, AA471338, N88518, N84829, N87989, N87898, AA215908, AF045432, AF103726, AF102850, U39066, AF032922, AR066487, S78798, U48696, AF039698, and AJ243486.
16	HBWCF75	78	797032	AI657485, N83707, AJ243486, AF045432, U39066, U48697, and U48696.

17	HHFCP32	27	858077	AI799018, AI816416, R56189, AW269738, AW440598, AI273177, AA081736, AW072632, AI278284, AI247430, R11917, T15545, AI214358, AA733192, AW073485, H29352, AI902784, AA625980, H10049, AI274231, W69805, H20488, AI758962, T05084, R18697, AL048066, R39107, H20653, AI357437, H20576, H10102, R18695, AI832768, H20560, AW241211, AA987900, R40265, AA716098, H12157, AI473363, H29268, AI425094, R34767, H16358, T32784, Z30262, D62177, AA347888, R55916, Z45177, R56078, H46031, AI702524, R55830, R14317, AA972095, AI168749, R49641, AI815473, H16310, AA639062, H46104, AI382766, Z39892, D62364, Z43829, AI214293, AW386073, and AF075040.
18	HCUGC55	28	1001608	AW192762, N58206, AA176225, AW195898, and AL034425.
18	HCUGC55	79	842924	AW192762.
18	HCUGC55	80	853303	AI557262, D59751, AI525316, AI525556, AI541205, AA585439, N58206, R28735, R29445, T18597, R29218, AW192762, AA585476, R45895, AA283326, AA585101, D61254, Z28355, R29177, AI557731, R28895, AI546875, AI557734, AI536138, AI525306, D57491, C16300, R28892, R28967, AA170832, R28965, C14208, AI557808, AI546999, AA585098, D55233, Z32822, AI526184, AA585155, AI546945, AI541365, AI541374, C16305, AI525431, C16293, AI535660, D57186, AI541346, AI541535, AI526140, Z30131, T11028, AI557740, D60765, AI526194, AI541356, D61185, AI557763, AA585329, AI540967, T41289, AI541523, AA174170, AI541307, D53447, AI557787, AI557864, AI557807, AI557727, AI541013, AI541517, AI557602, AI526073, AI546891, C15737, AI541514, AI546829, R29172, AA585453, C14391, D59436, AI546996, AI556967, C14322, C14723, AI546971, AI541390, AI557799, AI547039, AI525320, AI541508, AI525500, D54897, C15120, D53161, AI547006, AI526180, C15069, AI546828, AA585325, AI540974, AI557533, T41329, C16292, AI541510, AA585356, AI557082, AI557155, AI526113, AI535813, R29262, C15406, AI557238, R29179, AL134524, AI541353, C16294, AI541075, AI526196, AI557796, AI541415, AI557408, AI547250, AI541533, D53472, AI541027, AI546921, AI526078, AI540920, AL043444, AL044529, AL044125, C15762, R29657, AA585434, AI526176, AL041347, AI525286, AI541017, T10982, AI657485, AI546954, AJ239433, AI541383, C16290, AI557084, AI540882, AL041233, AA176225, AL040193, AL041296, AI557802, D60844, AL041086, AL043496, AI546831, AL044162, AI541534, AL041246, AL041324, AL043538, AI541321, AL040621, AL041098, AL041163, AL041277, Z32887, AI526158, AL041358,



				AL041096, AL047012, AL041346, AI526195, AL040155, AL041197, AL040464, AL043612, AL039915, AL040463, AL047219, AL041227, AL047057, AL045328, AL047170, AL041210, AR038762, AC005913, AJ243486, U48696, AF011573, Y09813, AF082186, D50010, AR062871, A25909, AR062872, AR062873, Z32836, AR038855, AJ244005, Y16359, A20702, A20700, A43189, A43188, AJ244004, D78345, X81969, AR018815, AR017907, AJ244003, D13509, A98420, A98423, A98432, A98436, A98417, A98427, AJ244007, X83865, A98767, A93963, A93964, I63120, A85395, A70872, A85476, I19525, A91750, AR037157, A86792, I44681, A84772, A84776, A84773, A84775, A84774, AR054109, AR067731, AR067732, A58522, AF045432, U48697, AL034425, I05558, I13349, I62368, U39066, A60212, A60209, A60210, A60211, A93016, and A18053.
19	HCWBP34	29	1007830	AA410788, AA683069, AA715814, AI753488, AA127426, AI791185, AA701080, AI056177, AI923052, AA602906, AW302711, AA493808, AA084609, AI826761, AI609972, AW265468, AA487209, AA515451, AI628859, AW152115, AI821076, AI819025, AA613761, AC005808, AC006538, AC006571, AC006101, AL033521, Z93017, AC004593, AL121653, AC005755, AL022163, AC002316, AP000556, AC020663, AC005368, AC004778, AC011504, AL080242, AP000557, AC006388, AC004893, AC000070, AC005332, AC006449, AC002395, AC007488, AC005015, AL049709, AC004531, AC003101, AP001067, AC004448, AC005209, AC004895, AC003098, AC006057, AC005480, Z83826, AC005531, Z93020, AC005288, AC002288, AC005529, AC007546, Z98036, AC005291, AC009721, AL080243, AP000505, AC004217, AC002477, AC004821, AP000065, AC000085, AF129756, AC004815, AL035587, AC006211, AC005488, AL022328, AC005520, Z99128, Y14768, AC005696, AP000348, Z97056, AL049646, AC005527, AC007429, AC002369, AC005057, AC002468, AC004841, AC004638, AC005519, D87675, AL034423, AL133245, AC005823, AC002551, AC002400, AC005081, AC006088, AC007371, AC006511, AL035400, AC007406, AL139054, AL049795, AL031597, AC005225, AC002314, AC004685, AC006077, AC006116, Z83840, Z86090, AL023807, AC002565, Z98044, AC004382, AC005328, AL121825, AC004019, AC002350, Z84483, AL022721, AF045555, AC001234, AF196779, AL031276, AC004933, AL034420, AJ246003, AP000501, AC004585, AL035588, AJ251973, AL008719, AC005274, AC006013, AC005500, AF053356, AP000696, AC006208, AC008372, AC007731, AC005221, AP000512, AL035684,

				AC007055, AP001052, AL096712, AL132777, AL023879, AC016831, AC009510, AL020996, AF207550, AC006480, AC005701, AC005914, Z98200, AC002996, AL031311, AL121655, AC005841, AC005746, Z92542, AF003626, U95742, AL022322, AC006312, AC005071, AC002115, AL031291, AC006011, AC007216, AL096791, AC006597, AC005632, AL133246, AC005037, AL109963, AL034429, AF190465, AF165926, Z99943, AC009516, AL031602, AC009509, L78833, AL049869, AC007387, Z83844, AC006512, AP000555, AC005703, AC006226, AC004745, AC004750, AL096701, AC004922, AC006344, AC002985, AC000025, AL022238, AP000359, AC005031, U91325, AL109623, AL031777, AC005484, AC009336, AC000118, AC003102, AC004686, AC005837, AC007376, AC000353, AC007384, AP000088, Z98742, U85195, D86995, AB023049, AC005740, AC004605, AC004955, AC004929, AL049569, AF111168, AC003684, AL121603, AC007536, AL020997, AC004144, and AC002542.
19	HCWBP34	81	845781	AA733208, AI554289, N23874, AI246340, AI469166, AW069427, N73083, AA737154, AA366035, N26061, AA767963, AA077223, N45421, AI818620, AA653327, AW410116, N38789, AA639270, AI660594, AI460390, AI053429, AL009181, AF129756, AP000517, AB023054, AC007536, AC004760, AC007563, AC006111, AL021939, AC004448, AC004825, AC004745, AC008275, AL034548, AC005206, AL109754, AC005015, AL008734, AC004087, AL021877, Z73900, AC004217, AL049740, AC004821, D42052, AL035681, AC006387, AC007002, AC004382, AL035687, AF154840, AF190465, Z85999, AC005208, Z93020, AC007314, AL022238, AL049588, Z30979, Z97056, AC004019, AL021155, AL031673, AC007632, AL050341, AC005476, AP001054, AB001523, AC006454, AC005746, AL022237, AC004887, AF067844, AC007040, AC006013, AL049759, AL031668, AC004963, AL049776, and AC006211.
19	HCWBP34	82	904201	AL134524, AA410788, AA683069, AA715814, AI753488, AA127426, AA701080, AA602906, AI056177, AI923052, AW302711, AA493808, AW152115, AI609972, AW265468, AA084609, AI628859, AI826761, AA613761, AA487209, AI819025, AC005913, AR038762, AL033521, AC005535, Z93017, AC019014, AC005808, AC002468, AC004593, AC006571, AC006538, AC004778, AL121653, AC006101, AC004478, AC005368, AP000556, AC005736, AL049709, AC003098, L35532, AL031230, AD000671, AP000557, AC005520, Z84466, U07561, AC004893, AP000501, AC002551, AC006388, AC002316, AC005755, AC002395, AC002288,

				AC000070, AL109623, AL035587, AC005529, U62293, AC005911, AC005823, AL022721, AC002350, AC005841, AL021394, AP000696, AC005480, AC004531, AC006449, AL035684, AL022326, Z83826, AL035400, AC006057, AL049646, AC004685, AC002302, AL080242, AL133245, AJ011930, AF069291, AL031730, AC002314, AC011504, AL049795, AL035588, Z98036, AC007371, Z83844, AL139054, AC006226, AC005488, AP001052, AC006141, AC005081, AC005996, AC005527, AC007546, AF129756, AL022327, AC016831, AC005696, AC004815, AP001068, AP001067, AC005914, AC005209, AC006511, AL034429, AC004491, AC004765, Z93020, AF207550, AL080243, AC009248, AC006077, AP000512, AP000359, AC004638, AC020663, AP000505, AC004149, AL031276, AC005057, AC004382, AF111168, AC004895, AL008726, AL049872, AC005015, AC002477, AC005225, AL023879, AC007686, AC007201, AC007429, AL008719, AL031311, AC009721, AC007191, AC005274, Z82178, AC004132, AC005844, AC001234, AC000353, AL034423, Z93023, AC004841, Y14768, AC002369, AC005288, AC008372, AC006011, Z79997, AF196779, AP000211, AP000133, AP000009, AL022312, AC004584, AC005332, AC000025, AC004933, AC004144, AL035457, AC005531, AC004585, AF003626, AC006241, AL022336, AC005369, AC005363, AP000511, AC004587, AC004417, AC007993, Z82976, AC009336, AL078611, Z95114, AC005031, AC007488, AC004922, AC005701, Z98200, AC007055, AC004447, AC006116, L81850, AC004884, AP000555, AL121658, AC004686, U47924, AF053356, AL049569, L44140, AC004999, U80017, and AC004212.
20	HFCOA91	30	908126	AA338298, AA338297, AA649883, AW073349, AA843874, AA219042, AA773359, AW237905, AA719395, N79835, AI251576, AI583466, AI306232, AA747757, T74524, AW265688, AA825161, AI880736, AL036881, AC006115, AL078474, AC007676, AC003085, AC004470, AC004947, AF002223, AF126403, Y10196, AC001231, Z83820, AL121694, AL022401, AL135960, AJ131016, AC006204, U91319, AC007371, AL022577, AL035555, AC005188, AC005249, AC007637, AC007510, AC005908, AL121652, AC007436, AL031584, AC005274, AC002476, AL035407, Z97200, Z75741, AC006238, AL022726, AL009172, AC004051, AC002563, AC004010, AC005138, U78308, AC007671, Z99495, AL109628, AL078463, AC007655, AC004931, AL031429, AL030997, D84394, AC005015, AC007687, AL035690, AL023883, AC005696, AC005552, AC011592, AL031315, AC004911, AC005988, AF020503,

				AL049699, AC005747, AC006236, AL033525, AF042091, AB020873, AC004659, AC004025, AC004020, AC008125, AC006960, AL031599, AC007179, AL121782, AP000240, AP000014, AC005725, AL024498, AL117356, AC003667, AC004112, AC007425, AC007395, AL021407, AC007051, AL031274, AC004750, AC004673, AC002300, AC007377, AL121757, AL121852, AC005828, AL049760, AC004870, AC007677, AL078477, AL079306, AB020861, AC002452, AL031286, Z74739, AC005209, AP000085, Z98052, AC006287, AL049792, AC005045, AC004585, AL121767, AJ229041, AL022336, AC016831, AL035079, AC006484, AC005484, AC007773, AC005082, AC005280, U40455, AL035427, AC007221, AC007690, AC006543, AC004650, AP000344, AC004804, U96409, AC005245, Z83819, AC000094, AC002087, Z97196, AC005081, AL008710, AC004887, AL080239, AC006101, AC007022, AC002402, AP000949, AL022400, AC005013, AE000661, AL133448, AC003103, AC010205, U80459, AC002288, AC005962, AL022396, AC005370, AL023655, AL033397, AC005042, AC005095, AC012384, AC002040, AC002091, AC005200, AC004861, AF172277, AP000692, Z95114, AC005859, AC008282, AC005924, U85198, AL021307, AC004098, AC005014, X87344, AC006544, U82668, AC002994, AL117339, AC006600, AC004552, AC008040, AF001549, AC007327, AL031767, AL049553, AL136501, AL023755, Z99496, AC005399, AL049548, AC000403, AF117829, AL031427, AC005089, AC006597, AL022319, AL023096, AC002347, AC004216, AF067844, AL049691, and AC004699.
20	HFCAA91	83	905838	AA338298, AA649883, AW073349, AA843874, AA219042, AA773359, AA719395, N79835, AA825161, AI880736, AL036881, AA601264, AW242735, AL137994, AA427753, AW130042, AA101410, R10327, AI627862, AI301335, AI734140, AI732743, T51918, AI524521, AI272961, H73189, AA524883, AA745961, C15685, H97952, AI334099, AI216816, AA810208, AI560839, AI473716, AL119355, AI745077, AI184319, AI452403, AI927861, W95669, N79242, AI355405, AA280230, C06012, AI000705, AI700368, AI859670, AA309370, AA427754, R70972, AA703056, AI857879, AA331913, AA332099, R48563, M62281, AA578888, T50149, H91008, AA584018, AA857009, T95437, R91915, AA349270, AA933003, T95462, AI536702, Z69733, AC004931, AC003085, AC006385, AL078474, AC006974, Z99495, AC006115, AC005249, Z83313, AL096827, AC007676, Z95126, AL050308, AC004615, AC004470, AL031734,

				AL121767, AL049564, AC004947, AL023280, AC006204, AL023883, Z83820, AC005188, AL023875, AC007510, AL022401, Z95704, AP000705, AC006249, AC004911, AL035665, AL117356, AF002223, AL030997, AC005160, X90761, AL031599, AC003669, AC004946, AC005962, AF003625, AC004051, AC005704, AC006226, AC002449, AL023806, AC007436, AF064860, AL031429, AC004673, AC006384, AL079305, AL031075, AL033524, AC006257, AL022577, AC006972, Z98303, AL035551, AL035407, AC001231, AL121718, AC006984, AL009172, AC011592, AL049565, AC004949, AL132985, AL096770, AC007157, AB020873, AC002523, AL035089, AL034386, AF020503, AC005341, AF029308, U80459, AL031183, AC006236, AC007655, AL022161, AP000221, AC002461, AC004677, AC006288, AL049734, AC005045, AC006383, AC008082, AL135922, AC009294, Z82200, AL022400, L09709, AC003990, AL080285, U91319, AC004010, AC008125, Z93928, Y10196, AC002524, AC003951, AC005014, AC004981, AL117340, AF126403, AC002498, AC005699, Z97200, AC006432, U78308, AC004128, AF052041, AL050326, AL022397, AC004538, AC004028, Z70758, AL109941, AC006568, AC006456, AL049176, AL035690, AC005201, AB033055, AC007628, AC002452, AC007179, AC006070, AC004613, AC005279, Z76735, AL009174, AL034377, Z97629, AC006600, AL031393, AL009173, AL117339, AC004072, Z84816, AC005858, U85198, AC005013, AL049690, AL033525, AL023755, AC004054, AC008282, AL031116, AL049875, U58675, AP000014, Z99570, AL121694, AL133162, AF095725, AC002497, AL021329, AL109620, AC006227, U92032, AL035663, AC005741, AL049699, AC005552, AC006296, AC006265, AC000121, AP001171, AE000661, AP000949, AC000403, AC005908, AC006484, AC007364, AC004887, AL049792, AP000457, AL096712, AC004225, AL023096, AL109616, AC006961, AC000358, AC006197, AC004928, AC007919, AC003658, AC006963, AC005686, AL022726, Z81311, AC004969, AC005609, Z93019, AC007377, AL121577, Z82212, AP000520, AB023056, AC004920, AC004585, AL121782, AF003529, AL079352, and AL023580.
20	HFCAA91	84	886760	AA338297, AW237905, AI251576, AI583466, AI306232, AA747757, T74524, AW265688, AI791659, AL121655, AC006241, AL135744, AL022302, AC004953, AL121652, AL049830, AL050318, AL024498, L77570, AP000553, U95742, AL031295, AC004797, AC003663, AC006515, AC004967, AC007386, AC005089, AC004685, AC005529, AC005067, AC006344,

				AC007199, AC007283, AC005274, AC004659, AC005527, AC006538, AC005844, AC002432, AC007227, AC005015, AC005565, AC005082, AC004471, AC009247, AL049776, AF111168, AL031281, AL031311, AC005088, AC004813, AC007868, AL008582, AP000688, AC007225, AP000558, AF134726, AC004019, AC005484, AC002470, AL034553, AC005940, U78027, AC006530, AC002477, AC006064, AC003109, AL049748, AC004031, AF196969, AC007216, AC005972, Z98036, AL022336, AC007542, AL035422, AC006946, AC005180, AF196779, AC007686, AC005186, AC006121, Z98047, AL078581, AC005920, AL021918, AC006480, AC003962, AC005726, AC008085, Z83844, AC008044, AC005800, Z95331, L78810, AC007773, AC005081, AC007263, AC006040, AC006211, AC007193, AP000014, AC004253, AL008718, AL022329, AC006088, AC007308, AC002039, AJ003147, AC002350, AF001549, AC005924, AP000493, AC007277, AC004851, and AF047825.
21	HBWBR94	85	863607	AC005873.
21	HBWBR94	86	797042	AL109798, AC007308, and AL031005.
22	HHFCZ67	32	988942	AW084483, AW074071, AW015862, AI452723, AI580091, AW024599, AI129795, AI799662, AI246776, AI339600, AI870795, AI366761, H98552, AA918146, AA689295, AA458623, AA864637, AA689294, AA233737, AA283169, AW166375, AI275057, AA991240, AA235543, H97050, AA699312, AI360376, R44873, H51250, AI185595, AA074255, Z43633, AA430666, AA664204, AA777463, F08755, Z39696, T58049, T58116, H22572, AA626439, R60586, R18988, AA101651, H09168, H69209, H52535, T52503, N78905, AA101652, AA348184, H24479, AI191003, H75625, H72235, F05039, H69210, AA235022, W90038, AA740504, AI079568, T34005, T36154, AI762375, H52299, AA459747, AI584036, AA455530, H75695, H98571, H51818, AA410814, AI768686, AI925862, AI859633, AI873604, AI918677, AI638644, AI364167, AI499570, R39624, AL134958, AI568293, AI620864, AA829775, AI349482, AI540354, AI421328, AI909697, AI289791, AL037602, AL037582, AI658566, AI590755, AW085393, AW008226, AI582932, AI370623, AI863002, AI469505, AI884318, AI499963, AI421662, AA836665, AI345415, AI695857, AW087837, AI160713, AI445877, AW087934, AI698391, AI569440, AI866469, AI696583, AI884303, AI678446, AI468622, AI801257, AW083750, AW029265, AI500061, AI524626, AI784145, AI491710, AW082532, AI287252, AA761557, AI830024, AI651840, AW020328, AI685005, AI300304, AI440239, AW105296, AA764872, AA814343, AI590043, AI829893, AI926593,

				AI695726, AW051088, AI927233, AI744268, AI934011, AI538817, AI359787, AI273886, Z98484, AI679771, AW150762, AI863319, AI473536, AA830421, AA669325, AW163834, AI696714, AI524514, AI280732, AI828285, AI345612, AI811990, AI348821, AI355126, AI522052, AI635794, W15212, AI471429, T69241, AI345416, AI419826, AI744932, AI866040, AW192363, AL042098, AI524179, AI688858, AI886452, AL050217, AL117460, AF167995, AF013214, AL133084, AL021391, AJ005870, AJ131955, AL137533, AC002086, AF102578, X99971, L25851, I33984, A65340, A77033, A77035, AR038854, A65341, AL117587, U48245, X59813, Z30970, AF169154, Z82022, A76337, AL080159, S68736, AL122100, AF061981, AF116573, AF032666, AL137478, AR060156, U73682, U95114, AL137463, AL133653, AF072546, AL133067, AF038847, A57389, U70981, A41579, X83544, AL117416, AF061795, AF151685, AL133076, L19437, Y14314, AF110417, X93328, A21103, A86558, U89906, A31001, AL080147, AF162270, AF054289, X66871, Z49216, and AL049959.
22	HHFCZ67	87	862456	Z43633, F08755, T58116, R18988, AA348184, AA101651, AA626439, AA283169, H69209, AI079568, T36154, AI762375, AA459747, AW084483, H75695, H52299, H51818, AA455530, AA410814, AI768686, AI925862, AI859633, AW074071, and AL050217.
22	HHFCZ67	88	862457	AA101651, AA626439, AA283169, Z43633, H69209, F08755, T58116, R18988, H75695, T36154, AI079568, AI762375, AA348184, AW084483, AA459747, H52299, H51818, AA410814, AA455530, AW074071, and AL050217.
22	HHFCZ67	89	835076	AW084483, AW074071, AW015862, AI452723, AW024599, AI580091, AI129795, AI799662, H98552, AI246776, AI339600, AI366761, AI870795, AA918146, AA689295, AA283169, AA864637, AA458623, AA689294, AA233737, AW166375, AI275057, AA991240, AA235543, H97050, AA699312, AI360376, R44873, AA074255, AI185595, H51250, AA430666, AA664204, AA777463, AA626439, H22572, T58049, Z39696, R60586, H09168, H69209, H52535, T52503, AA101652, N78905, H24479, AI191003, H75625, H72235, F05039, H69210, AA235022, W90038, AA740504, H52299, AI079568, AA459747, T36154, AA455530, T34005, AI762375, AI584036, H75695, R18988, F08755, H98571, Z43633, AA348184, H51818, AA410814, AI768686, AI925862, AI873604, AI918677, AI638644, AI364167, AA829775, AI499570, R39624, AL134958, AI568293, AI620864, AI349482, AI540354, AI421328, AI909697, AI289791, AL037602, AL037582,

				AI658566, AI590755, AW085393, AW008226, AI582932, AI370623, AI863002, AI469505, AI884318, AI499963, AI421662, AA836665, AI345415, AI695857, AW087837, AI160713, AI445877, AW087934, AI569440, AI698391, AI866469, AI696583, AI884303, AI678446, AI468622, AI801257, AW083750, AI500061, AW029265, AI524626, AI784145, AI491710, AW082532, AI287252, AI830024, AA761557, AI651840, AW020328, AI685005, AI300304, AI440239, AA764872, AW105296, AI829893, AI590043, AI695726, AW051088, AI926593, AI934011, AI927233, AI744268, AI538817, AI359787, AI273886, Z98484, AI679771, AI863319, AI440509, AA830421, AA669325, AI473536, AW163834, AI524514, AI696714, AI280732, AI828285, AI345612, AI811990, AI355126, AI348821, AI522052, AI635794, W15212, AI345416, AI471429, T69241, AI744932, AI419826, AI866040, AW192363, AL042098, AI688858, AI886452, AI524179, AI673363, AI954721, AI524654, AL050217, AL117460, AF167995, AF013214, AL133084, I33984, X99971, L25851, AJ005870, AJ131955, AL137533, AF102578, X59813, A65340, A77033, A77035, AR038854, A65341, AL117587, S68736, U48245, Z30970, AF169154, Z82022, A76337, AL080159, AL122100, AF061981, AF116573, AF032666, AL137478, AR060156, U73682, U95114, AL137463, AL133653, AF072546, AL133067, AF038847, A57389, U70981, A41579, X83544, AL117416, AF061795, AF151685, AL133076, L19437, Y14314, AC006571, AP000250, AF110417, X93328, AB019438, A21103, A86558, U89906, A31001, AL080147, AF162270, AF054289, X66871, Z49216, AL049959, U52688, X68560, S82852, AC004987, AP000081, A32826, A30330, A32827, A30331, AL080146, Z13966, AF200464, X95310, AF183393, I32738, AL080148, A52184, AL050138, AF053645, AC002301, X61399, AL137530, AF206503, AF090940, and L30117.
23	HETAR42	33	1020551	AI887889, AI972875, AI692481, AI201497, AW139552, AI363023, AA687169, AA504044, F21566, W03367, AW204830, N67477, AA490280, H98817, AA025858, AI432618, AA973688, AA337083, AL120711, AW139361, F35631, AI681854, N23541, AI419092, AI935743, F31419, W94347, AW138091, AA954022, AA025857, W94346, AA490389, and AL110145.
23	HETAR42	90	842693	AA490280, H98817, AI432618, AA337083, AL120711, W94346, D80043, D58283, D80253, C14429, D51423, D57483, D80391, D59889, D80166, D80195, D59619, D80210, D51799, D80240, D59859, D80188, D80227, D80196, D80366, D80212, D80219, D59927, D80269, D80038, D81030, D80193, C14331, D80022,



				D80024, D59502, D59610, D59275, D80045, D50979, D50995, D80241, D80378, T03269, D59787, C75259, C14014, C14389, D80164, D59467, D80134, C15076, AA305409, D58253, F13647, D51079, D51250, D51060, D81026, AW178893, D80268, D80168, D80949, C14227, D51022, D81111, AW177440, D80522, AW179328, AW178775, AW378532, AA305578, D80251, C14407, AW369651, Z21582, AW352158, D59695, AI910186, D80248, AW178762, AI905856, D52291, AA514188, AA285331, D51097, AW177501, AW177511, AA514186, D80133, C14298, AW360811, D80064, D80247, AI557751, AW352117, C05695, AW177505, AW360834, AW176467, AW375405, AW366296, AA490389, D80132, AW378540, AW377671, D80014, AW179024, AW360844, AW360817, AW375406, AW378534, AW179332, AW377672, AW179023, AW178905, T11417, AW352170, D80302, AW352171, AW179220, D80439, AW377676, AA809122, AW178906, AW177731, D59373, AW178907, AW179019, AW179020, AW360841, AW179018, AW178909, AW177456, AW178980, AW179329, D51103, AW177733, AW378528, AW178908, AW178754, AW352174, AW367967, T02974, AW179004, AW179012, AW178914, AW378525, T03116, D80157, AW177722, AW177728, AW179009, D51759, AW178774, AW178911, AW378543, AW352163, C14077, D58246, D51213, AW178983, AW352120, AW178781, T48593, D59503, AW378539, C06015, D58101, D80258, D59627, AW177723, AI557774, D59653, D45260, AW177508, H67866, AI535850, C14975, C14344, C03092, AW378533, H67854, AW367950, AI535961, D51231, AI535686, AW177497, AW178986, AI525923, D60010, D50981, AW177734, AI525917, C14973, D59317, D59474, D45273, D51221, C14957, AA033512, AI525920, AA514184, C14046, AI525235, D59551, AI525227, D60214, Z33452, T03048, C16955, AI525242, AI525222, AI525912, AW378542, AI525925, AI525215, A62300, A62298, A84916, AJ132110, AR018138, X67155, A78862, Y17188, A67220, D89785, A25909, D26022, D34614, D88547, AF058696, AR025207, X82626, X68127, AR008278, I82448, AB028859, Y12724, AB012117, A82595, AR016808, AR066482, A44171, A85396, A85477, I19525, A86792, AB002449, U87250, X93549, A94995, AR060385, AR008443, I50126, I50132, I50128, I50133, AF135125, A30438, AR066488, AR016514, AR060138, A45456, A26615, AR052274, Y17187, AR054175, Y09669, A43192, A43190, AR038669, AR066490, AR066487, AR008277, AR008281, I18367, D88507, I14842, X64588, D50010, AR064240, A63261, AR016691, AR016690,
--	--	--	--	---

				U46128, AR008408, AB033111, AR062872, A70867, Z82022, U79457, D13509, A64136, A68321, AR060133, I79511, U87247, Z32749, AB023656, AF123263, A63887, AR032065, X93535, and AR008382.
23	HETAR42	92	570044	AW139552, AI887889, AA687169, AI972875, AI201497, N67477, AA025858, AW139361, AI419092, AA504044, AI935743, AW138091, AA954022, AA025857, and AL110145.
24	HCEBN44	34	901918	F10452, AA322296, and R45267.
24	HCEBN44	93	904757	F10452, R45267, and AA322296.
26	HSBBT12	96	906871	AI114486, AW149501, AI676177, AW366152, AI264321, AW007145, AL043600, AW262031, AI913362, AI809112, AW439637, AW274948, AA528650, AW365592, AI769386, AI861995, AW262046, AW304221, AW088767, AA488372, AW270549, AA131841, AI751098, AI417167, AA176233, AI279263, AA032181, AL042007, AI753126, AW361159, AW021494, AW370294, AI751099, AI635275, AI828400, AW298688, AI954976, AW088237, AA489879, AW088533, AI554278, AA994206, AI378180, N94529, AI956030, AI341810, AI283284, AW272723, AA179494, AA179544, AA947267, AI225127, AI961066, AA780586, AW029520, AI082442, AA131810, AA464824, AI129837, AI078756, AI753674, AI476626, AA082761, AI088460, AA122245, AI559651, N40983, AA613946, AA075711, N24153, AA131791, R51676, AW152173, AA248233, W46377, AA782289, AI621172, AW189239, AA447159, AA491455, AW150265, AI688932, AA443787, AA081106, AA100948, AW303903, AA715420, T71302, H12095, AI750347, AA081203, AA307456, AI888370, AA598996, AI927255, AW168975, AA554742, W46205, AA906052, AI651058, AA774052, AW069272, AA313231, AA580843, AA780297, H00132, AW380447, AI687631, AW022573, AA127351, N22607, AA127352, AA114152, N44992, AW302346, AA376293, H95033, AA370606, R13430, AI750372, H05061, AI200617, AI873904, AW130743, AA034524, AA424618, AI584085, T55687, AW058451, AI205266, T41217, D29471, AA214164, AA032011, AI888269, AW002146, AI760505, AA883641, R76714, AW074104, AA947363, AW178627, AW391541, AI434026, AA913305, W74015, AA374355, AA188816, AA385426, AA075745, AI446275, AA176321, H42622, AI866831, AL041995, AI440275, AW365485, AA352447, H93998, T54236, AA916890, AI669361, AA332015, AA642013, AI367281, AA844166, AA836530, AI382836, R76715, AI364432, AW178624, T48055, AW178626, AA033656, T40360, AA588571, AA728805, AA081604, AI272670, AW178540, R21187, T54140, AA730793, M85671, R22805, AI538202,

				R51588, R40942, R32731, AW178623, R27255, AA131777, A1873691, R32732, AW083738, N24862, AW182112, W30754, AW178635, AW196572, T71443, AI370633, AA345196, AA344263, R80048, AA344577, R33829, Z42531, AI750371, D29105, AA370852, AI968743, AA113863, R27457, R33830, T55605, AI582043, AA664787, AA084455, R34166, H12096, AW138087, AI698968, AA214323, AA599984, T29998, T35295, AI358614, N68134, AA331525, AA720525, AW023654, AA089634, AA334446, AA935302, AA214414, R21888, AW270246, D11838, AA903679, R65860, AW337297, Z38723, C75177, AA450296, D11627, N89171, AA129180, AW380427, AC008014, AB016226, AL137658, I89947, AL133113, A65341, AL117460, I48978, AL137488, Y16645, AL133558, X79812, AL049382, AF158248, A65340, X80340, AL137479, AL133067, AL122050, AL080234, A77033, A77035, AF031147, M27260, AL133665, X84990, AF111851, AL137550, A08916, AF114170, S36676, AL133081, AR013797, AL137557, AL050024, A08913, AL137459, X06146, AL133104, U53505, AL117394, A08910, AL110196, AL133075, AL133619, AL133637, AR034821, AF104032, A86558, I48979, AR020905, AL137271, AL050393, AF113019, X82434, A08909, AF100931, AF177401, AL049283, AF183393, AF090900, AF008439, AF113677, A08908, AL117457, X93495, I00734, X72889, AF113690, AF097996, X62580, U87620, I09499, E00617, E00717, E00778, AL050138, AF113013, A18777, I89931, AF090943, X72387, AF067728, AF215669, AL133080, AL133640, AL110221, AL133568, A15345, AB019565, AL117648, I49625, AJ000937, AF118090, AL137529, AF102578, AF078844, AL122111, AL133072, X81464, AL122110, AF090934, E05822, Z72491, Z82022, AL137648, AF090903, A03736, AR038854, AL117649, AL023657, A08912, AF017437, AL080137, AF106657, E02221, AF057300, AF057299, AL050116, AL133560, AF207750, Y11254, AL080159, AF111849, AL050149, AL137558, AF090901, AL122093, AL096751, AL117435, AL080163, S61953, A21103, AL050277, Y10823, I33392, E06743, AF090886, AL137533, AF079765, S76508, X53587, AL035458, I26207, AF118070, AF113699, AL133557, E07108, AL080126, D83032, I89934, AL137539, Y11587, AF176651, M86826, AL117585, AF061795, Y14314, AF151685, AL137256, AL080148, U42766, AL080124, I66342, AL122123, AF126247, AL137526, AL049452, I17544, AB007812, U42031, U96683, AL133016, AL122121, AF081197, AF081195, AF067790, Y10655, AL133645, AF017152, AL050108, AF039138,
--	--	--	--	---

				AF039137, S68736, AF185576, AF106862, S78214, AF113691, A93016, AL137463, AF065135, AR000496, U39656, L31396, AL096744, AF030513, AL133565, E01614, E13364, L31397, AL050366, AF113694, D55641, U88966, E12747, AF119337, AL080060, AF069506, AF115392, E02349, A93350, AL117578, AF125948, AL080140, AL137705, AL137548, X96540, AF091084, AF113689, AL080074, AF087943, X57961, AF210052, AJ238278, AF106697, S77771, I68732, U67958, I80064, AF026124, A58524, AL050146, AL133014, AF146568, M92439, I89944, AF118094, E03348, AL137283, AL122049, AL049938, E03349, AL049430, U58996, I46765, I03321, R21836, R34290, AA031981, AA228705, AA654510, and AA214413.
26	HSBBT12	97	879993	AI805055, AA524690, AI685113, AI056075, AA995071, AW009442, AI916446, AI763429, AI522323, W63778, AI858102, AI393294, AI970808, AI128302, AW084491, AW205268, AI928159, AI347937, AA442462, AI491774, AI356079, AI075142, AA449622, AA262393, AI685842, AA134531, N68412, AI221021, N70519, R73544, AA837139, AA280708, AI278882, AA134532, AI383507, AA676561, T86721, AA057163, AA618578, W05418, AI972938, AA401288, AI688282, N67686, AA436653, T90389, AA504397, AA243607, R69278, AA056954, R69559, T86756, AI457155, R22148, F34395, R72912, R69164, W94177, AA382721, T86579, AA476358, AA491105, AA741395, AA476310, AI825431, W03495, AA490922, AI572014, R22147, N84252, AA513147, AA917379, N91207, AI919315, AA382668, AI473437, T83137, and AI828918.
27	HJAAJ58	37	884441	AA354271, AC005336, and AC004523.
27	HJAAJ58	98	904785	AA354271, AI807237, AA905110, AC005336, AC004523, AL049550, and AL050309.
27	HJAAJ58	99	902232	AI798456, AI553645, AI335208, AI568138, AI698391, AW163823, AL036954, AW162194, AA464027, AW129264, AI950892, AI364639, AW303089, AI868931, AW008166, AI241923, AI670009, AW020397, AI627988, AI802240, AI251221, AI686576, AI815855, W38553, AI799674, AI818980, AL079963, AL046466, AI866090, AW089275, AI919593, AI537677, AW051088, AA731640, AI523806, AI590043, AI345688, AI613038, AI889189, AI440399, AW022682, AI687166, AI572892, AI621341, AI554821, AI475371, AI673363, AW150826, AW131294, AI890507, AW163554, AL036638, AI628850, AL047100, AA291844, AI628337, F27788, AW169604, AI887381, AI690748, AI095003, AW162071, AI538850, AI281757, AL038605, AI624293, AI933992, AI620302, AA916133, AW160905, AI567582, AI539847,

				AW020419, AI287449, AI537261, AW118518, AI859609, AI565172, AI582932, AI536601, AI559872, AI270183, AW161202, AI473536, AI288285, AI612750, AW411235, AL046595, AI801793, AI631216, AI884318, AL045995, AA127565, AI309306, AI917963, AI921254, AI446511, AW044367, AI802542, AI918435, AW023338, AI819976, AI468872, AL043345, AI184903, AI453328, AA983883, AI685080, AI571909, AI521560, AI433157, AI679550, AW088521, AI702073, AI766348, AW409775, AL039716, AW411225, AL046944, AI689388, AI637833, AI638798, AW238688, AI254731, AI624993, AI571439, AA641818, AI435253, AI633125, AI589428, AI570140, AI538564, AW167083, AI590020, AI554485, AI915291, AW152182, AI540458, AW149925, AW169784, AI270051, AI802654, N33175, AW163834, AW024594, AI923370, AI499963, AI345416, AI345612, R32821, AI648508, AL048298, AI927233, AW172981, AL042944, AI866469, AI612885, AI540674, AA853213, AL043084, AL038665, AI270295, AI345415, H41759, AI811644, AI540754, AI874166, AW238730, AW302992, AW087199, AA853539, AI500061, AI285826, AI453339, AI684369, AL080011, AI270706, AI352326, W74529, AI245008, AI348917, AI696570, AI289310, AI500714, AW083778, AI612913, AI340603, AI872423, AI587156, AI670002, W46378, AI572717, AI349957, AW132061, AL110306, AL047187, AW021717, AW051258, AI961589, AW007555, AW089006, AA100772, AI267185, AW081036, AI624548, AI634305, AI417790, AI824576, AI345005, AW083374, AA502794, AA420758, AW265004, AW079572, AI929108, AW170725, AI859991, AW129659, AI335209, AI355779, AW020095, AI538980, AW189301, AL036980, AI567769, AI590134, AI251208, AL040346, AI800341, AI345745, AW079075, AI335214, AL120300, AI868204, AL036802, AW148423, AI310940, AL046618, AW151786, AI310575, AA579618, AI307507, AI540759, AI561231, AL134259, AC005336, AC002454, AL050309, AC002060, AC000053, AC002564, AC004470, AC006453, AL078602, AL031274, AC002416, AC007458, AC009233, and AL049594.
27	HJAAJ58	100	902231	AA905110, AI809440, AI807237, AI373369, AI767532, AA654176, AC005336, AC004523, AC003986, AL049550, AC000385, and AL050309.
28	HTEDJ85	38	941981	AI371872, AI473536, AI524179, AA761573, AI695857, AI364167, AI866469, AA814517, AI445432, AI524626, AI828239, AI698391, AI095003, AI621341, AI568293, AI927233, AI288305, AL039730, AI635851, AI540354, AI620864, AW027374, T69241, AA767924,

				<p> AI582932, AW051088, AI147877, AI633125,  AI690782, AI918809, AI479292, AI538564,  AI500714, AI915291, AW152182, AI884318,  AI590043, AI638644, AI370623, AW021662,  AI889189, AI419826, AI499570, AI570056,  AI868680, W74529, AI491775, AI282673,  AI701097, N25033, AW004606, AI699823,  AI499325, AA503384, AI473426, AI358271,  AI433611, AW023859, AL118781, AI696583,  AW022808, AI863002, AW188525, AI635634,  AI470717, AW025279, AI872423, AW006032,  AI619820, AI919600, AI521560, AW026730,  AI758445, AI680369, AW238688, AL045859,  AI918677, AI357752, AI569440, AW029457,  AW150557, AI282669, AI802542, AI824688,  AI636507, AA001397, AI332957, AI472487,  AI160713, AA847452, AI440238, AA669325,  AI658566, AA808175, AI866691, AI919500,  AI349482, N33175, AI571439, AI828676,  AI687168, AI619525, AI521005, R32821,  AI309306, AW020397, AI598132, AW150750,  AI857760, AI815232, AI818240, AI699175,  AI620056, AI475270, AI797578, AI355779,  AI696714, AL134363, AI634751, AL035730,  AW075382, AI125884, W46378, AW089844,  AI308037, AI874261, AA580663, AI521465,  AI866780, AW168822, AI679266, AW118311,  N21402, AW131294, AI801152, AI648494,  AL048323, AI590755, AI524654, AA641818,  AI356982, AI699058, AI539260, AI590020,  AI401697, AW196720, AI860027, AW148693,  AI784214, AI866458, AA502794, AI553645,  AL120331, AL048340, AI819545, AI499057,  AI801589, AI366984, AI859991, AW195253,  AI802826, AL079799, AI690813, AW194014,  AW088560, AI281757, AI687944, AI345553,  AW002327, AI799313, AI250282, AI536601,  AI818562, AW104141, AI349967, AI868931,  AI635082, AL046466, AW087217, AW105296,  AA579618, AI955221, AW192363, AL038154,  AI648699, AI285439, AI630932, AI635067,  AI312210, AI299035, AI581033, AI699020,  AI926593, AI673363, AI860003, AW008353,  AW078735, AI267185, AI471429, AI439664,  AI678409, AI861973, AI801325, AI566613,  AI636588, AI374987, W45039, AI654276,  AW104162, AI687150, AI241923, AI628337,  AW194677, AI634457, AW263805, R10067,  AI567513, AW189424, AL135047, AI049856,  AW293496, Y14314, AF124728, AF054988,  AL133049, I48978, AR012379, AL050155,  AR050959, AL137711, Z13966, AR038854,  AL117587, I89947, A77033, A77035, E03168,  AL137533, AR034821, AC004470, A08907,  AF090934, AJ005870, AF026816, I48979,  AL117460, AJ005690, I08319, AR020905,  AF145233, L04504, A58524, A58523, X66871, </p>
--	--	--	--	--

				AF047716, AL023657, AL137530, AL137284, Z97214, X72889, AL122110, AF067728, A65341, A76337, AF141289, Z82022, X99971, AF124396, X93328, AF124435, A08456, A31057, AL137480, AL137627, A41579, AR029490, AL137271, AL080139, AF060555, U73682, I18358, I34395, AL133623, AF161413, D16301, X55761, AF087943, AL117429, AL080162, X66366, AL110199, E12747, A86558, AL080146, AL080159, AF080068, M85164, X75295, AL117632, AF106697, AL110158, AF013214, L35261, A18777, X70514, AF116573, AF113019, I28326, X63162, AF183393, AF172400, AF106657, AL080148, S82852, AL050393, AL110280, Z35309, I30313, AR066485, AL122104, AF200464, AL080234, AL122100, AF090903, A58545, AL050149, U75304, AF061981, AL137488, AL080126, AL133619, D83032, S66283, X82434, AB007812, A76335, AJ003198, AF125948, AL133029, U95114, A52184, U49908, AL137537, AL137463, A92311, X82397, AL133640, E12806, AL117416, AJ012755, AR038747, X83508, AL078630, AL049276, X00474, I25049, I25048, AF126372, AL133665, X52220, X97332, AF085355, A12558, AL049339, AF098484, X79812, AL137478, E03671, AL049430, AL137258, U97675, AF060866, A93350, A91160, AL110221, AF184965, AL110228, A03736, J05277, A91162, AL137479, AL137716, X99226, E06743, AL137550, AL137292, and A12522.
28	HTEDJ85	102	905681	AA191284, AA191255, AW392670, U46341, AW372827, AL119341, AW384394, AW363220, AL119457, AL119497, AL119355, AL119319, Z99396, AL119324, AL119443, U46346, U46351, AL119484, AL119363, AL119391, AL119444, AL134902, U46350, U46347, U46349, AL119483, AL119396, AL119335, AL134528, AL119439, AL042433, AL119522, AL134920, AL119399, AL037205, AL119496, AL119401, U46345, AL134536, AL142132, AL119418, AL134525, AL134538, AL142131, AL119464, AL042551, AL119488, AB026436, AR054110, A81671, AR066494, AR060234, AR069079, R88487, H92699, AA082952, AA191565, AA617897, AA663505, AA706640, AA706645, AA707435, AA984750, and F06214.
28	HTEDJ85	103	845264	AL039924, AL045794, AW013814, T24119, T24112, T02921, AL036630, D51250, D80043, AL040992, AL039109, AL038531, AL037726, AL039629, AL039625, AL039648, AL038837, AL039074, AL039678, AL039108, AL039538, AL039564, AL039156, D80253, AL039659, AL039566, AL039509, H00069, AL039128, D59787, AL044407, AL036973, AL045337, AL037051, AL045353, AL039386, AL039423, AL045341, AL042909, AL039410, AL039150,

				AL044530, AL038025, AL038821, D80219, AL036725, AL043422, D59275, D80227, AL043445, A1535983, AL043423, D80240, AL043441, D80210, AL044412, AL039476, T23947, AL044364, D51423, D80134, AL036196, D59619, D80391, AL037639, D80193, AW451070, AL037615, D80196, D80045, C14227, AL036767, A1535783, AL039085, D80949, AL036117, D59927, D80366, AL039521, AL037526, D80168, AL043586, R47228, AL036238, AW452756, AL036679, AL037601, T11051, D81026, D50995, C75259, C14014, AL036964, AL036733, AL036158, AL037027, AL036924, AL036765, AL037054, D59889, AW450335, AL037047, AL038851, AL037177, D80022, AL036998, AL036227, AL036418, AL037643, T23659, D80038, AL036133, AL037082, T11417, AL036163, D58283, D80195, AL036207, AL037124, A1557751, AL037021, D81030, AL036191, AL036167, AL037679, AL036132, AL037049, AL039842, D80188, AL036190, AL037600, D51799, D80378, D80522, AL036139, AL039459, F13647, T03269, AL036152, T48598, D50979, D80212, AL036900, AL039504, AA514190, AL037178, Z21582, AL048425, C14429, AA285331, D59502, AL039555, AW451416, D80166, AL037085, AL036650, D80269, D59859, D80268, Z25782, D58253, AL042334, AL037569, D80024, Z99396, D57483, AL036174, AL036808, AL036953, T23656, D59610, D59467, A1905856, AL036150, D80241, D81111, D59627, A1910186, C14331, D80164, C14389, C15076, H00072, AW366296, D51060, AL036268, AW178893, AW293068, AA305409, AL038043, C14298, AW450376, AW177440, AW375405, D80014, D51022, AW179328, D80251, AW178775, AW378532, AA305578, AL037077, D51213, AW352158, D59695, AL044413, AW369651, AA514188, D80248, D51097, D80064, AW178762, AW177501, AW177511, AL037002, AW375406, AA514186, D80133, C14407, AW360834, AW360811, T02974, A1557774, C05695, AW352117, Z25783, D80258, T23658, D80132, AW377671, AW176467, AW378540, AW177505, AW360844, AW360817, AW378534, AW179332, AW377672, AW179023, A85396, A25909, A44171, A85477, X68127, A86792, AR062871, A84772, A84776, A84773, A84775, A58522, A84774, AR037157, AR017907, AR062872, AR062873, AR067731, AR067732, A91750, A20702, A43189, A43188, A20700, AJ244003, AR036905, A58521, A58524, A95051, A58523, A10361, A98767, A38214, A95117, A95052, I56772, I95540, AR018924, AR031374, A93963, A93964, A18053, A63067, A51047, A63064, AR018923, A49700, A48774, AR031375, AR043602, AR043603, A63072,
--	--	--	--	---



				AR043601, A48775, A23334, A75888, I70384, AR068507, AR068506, A18050, A60111, A23633, AR015960, A23998, AR007512, AR000007, AR015961, I63120, I60241, I60242, I03343, AR020969, AR054109, AR022240, A81878, E12615, AR035193, A92133, A24783, A24782, A58525, E14304, A27396, AR027100, I28266, A49045, E16678, A82653, E16636, AR025207, E13740, A93016, AR038762, AR000006, I25027, I26929, I44515, I26928, I26930, I26927, I18371, I06859, I49890, I44516, A58526, A91753, AF156296, U87250, A64081, A67220, E06034, AF156294, AJ244004, A13038, A29289, AR008430, D34614, A02712, AF156303, X73004, I19516, AR029417, Z96142, A97211, V00745, AR036903, A11245, A02710, A07700, A13393, A13392, I19517, A76773, A22413, I21869, I13349, AF118808, A35537, A35536, A02136, A04664, A02135, A04663, I01992, D28584, I08051, AB012117, A70040, A92636, E16590, Y17188, E03165, E02221, E13364, E01614, I00079, Y11923, AR067733, AR029418, AR035975, AR035977, AR035978, AJ244005, AR035974, AR035976, AR028669, AR028668, AR028667, AR028670, AR067734, AR017908, A68112, A68104, I62368, AR031488, I13521, A98467, I52048, I44531, A84746, A17115, A18079, AR028672, I15353, AR038066, I50882, AR066482, Y11926, I66495, I66494, A51384, I66498, I66497, I66496, I66486, I66487, I68636, AJ230933, I00074, A15078, I03665, I03664, A97155, A07699, D88984, A71440, E08322, I74623, A71435, A60109, AF156302, I25041, AF156304, E00523, AR038286, I92483, I00077, A52326, A91965, AR028564, A20701, I00081, I07429, AF156299, AR027069, A98420, A98423, A98432, A98436, A98417, A98427, X13220, A04710, I01968, A13388, I19525, E00974, A00782, A02741, A14595, A18755, A25856, I12245, A02228, E00954, E00952, E00953, E00955, and I08049.
29	HHFCW75	39	1028775	AA682595, AA680176, H17626, H16263, and H16463.
29	HHFCW75	104	858060	H16463 and H17737.
29	HHFCW75	105	545732	AA682595, H17626, AA680176, and H16263.
30	HFCAL39	40	941953	AW245718, AI827785, AI672914, AI963196, AI862438, AA971559, AW163196, AI862437, AW006680, AI803157, AA314949, AI479693, AI610427, AW172629, AW139376, AW001734, AI308852, AW050595, AI214207, AA595030, AI215156, AA973194, AA625250, AA156354, AA905003, AW245362, AI969831, AI263163, AA662453, T91308, AI688460, T58229, AA666071, AI863327, T09220, T06595, W46479, T58273, AA995023, F03011, AI337427, AA780101, AA156131, AA078996, T85311, AI280279, AA078997, AA338971, T84889,

				AI766552, AA865998, AI969431, Z43730, AI611789, AW044338, AI015126, T85525, AA333676, AI928317, AA338970, F01980, T06110, AI376323, Z42464, AI968180, AA463660, AW163719, AA083909, U54717, AA247365, C00475, AI309085, AI247195, AA933873, AA683556, AI356679, N80753, AA932383, AW302341, AI564909, AA970822, AI074289, AA577223, AA830145, AA612779, AA733108, N91547, N25586, N37037, AA176383, AA903827, AI000518, AI095240, T29898, AI500278, AI589518, AW292404, AI335813, AW129360, AA308986, N99258, AI961548, AI572716, AA205875, AA323628, AA987777, N91277, AI188799, AI880534, F04591, AA913625, AW236275, AW084732, AI192781, AI351440, AW303891, AI567420, W94292, AI937440, AA687755, AI199206, AA551681, AI669709, AI598100, AA604187, AI675253, AA427495, F17264, AA251265, AI917558, AC004382, AC008115, AJ224143, and J05448.
30	HFCAL39	106	905835	AW245718, AI672914, AI862438, AI862437, AA314949, AW139376, AW001734, AI214207, AI215156, AW050595, AI688460, T09220, AI337427, AA156131, AA338971, T84889, AI766552, AI969431, Z43730, T85525, W46479, Z42464, AW163719, D80043, D50995, D58283, D80188, C14389, D80253, AA305578, D80022, C14331, D51423, D59859, D80024, D80227, D59275, D80166, C14014, D80195, D59502, D59467, D59619, D57483, D80210, D51799, D80391, D80164, D80240, D80366, D59787, D50979, D81030, D59889, D81026, D80212, D80522, D80196, D80219, D80269, D59927, C15076, D80038, D51022, D59610, AA305409, D80251, D80193, D80248, D80045, D80378, AA514186, AA514188, AW360811, C14429, D80133, AW177440, D80241, D51060, AW178893, AW375405, D80247, D80268, T03269, AW377671, AW177505, AW179328, AW352170, AW366296, AW360844, D80302, AW360817, C75259, AW375406, D80439, AW378534, AW179332, AW377672, AW179023, AW178905, AW378532, AW178906, AW179024, AW177501, D51103, AW177511, C05695, AW352171, AW377676, AW177731, AW178907, AW177733, AW178762, AW179019, D80134, D80132, D59373, D51250, AW360841, AW179020, AW178775, AW178909, D58253, D51079, AW177456, AW179329, AW178980, AW378528, AW178908, AW178754, AW179018, AW352158, AW352117, D80157, AW176467, AW369651, AW179012, D51759, AW179004, AW178914, AW378525, D80014, T11417, C06015, H67854, AW352163, AI905856, F13647, AW179009, AW178774, AW178911, D59653, AI910186, D80168, AW378543, T48593,

				<p>AW177722, AW177728, D45260, D81111, C03092, AA809122, AW352120, H67866, C14227, AW178781, AW360834, C14407, C14298, AW378540, C14077, AW367950, AI525923, D59627, C14344, T03116, AI525917, AW367967, D58246, D80258, D59503, D59317, AI557774, C14973, D60010, D80064, AW177734, AW378533, D51097, AW178986, D51221, Z21582, C14957, D59474, AI525920, D51213, AA514184, AI535686, AI525925, C14046, D58101, D59551, D60214, AI525227, AA285331, AW177508, AI525235, T02974, AI557751, AW177497, C16955, AI525237, Z33452, AI525242, AI525222, AI525912, T03048, AW378542, AI525215, AW378539, D45273, C05763, H67858, AC004382, A62300, AF058696, AR018138, A84916, A62298, AB028859, AJ132110, AR008278, AB002449, X67155, Y17188, D26022, Y12724, A25909, A67220, D89785, A82595, A78862, D34614, A94995, AR060385, D88547, AR008443, I50126, I50132, I50128, I50133, X82626, AR054175, AR066488, I82448, AR016514, AR025207, AR060138, A45456, A26615, AR052274, A43192, A43190, AR038669, Y09669, AR066487, I14842, A30438, Y17187, AR008277, AR008281, A63261, I18367, D50010, AB012117, AR062872, A70867, I79511, AR016691, AR016690, U46128, AR008408, AR066490, A64136, A68321, A85396, D88507, AR066482, X68127, A44171, X64588, A85477, D13509, I19525, A86792, AR060133, X93549, AF123263, and AR032065.</p>
30	HFCAL39	107	905828	<p>N37037, AI937440, AI827785, N25586, AW006680, AA971559, AI803157, AI589518, AW163196, AI479693, AI192781, AA932383, AW172629, N91547, AI610427, AI963196, AI199206, AA830145, AW084732, AI669709, AI567420, AA205875, AA595030, AI961548, AA156354, AA913625, AA251265, AA973194, AA577223, AA625250, AA905003, AI969831, AW245362, AA687755, AI598100, AA933873, AI263163, AI074289, T91308, AA662453, AA662289, AA970822, AA733108, AI095240, N99258, T58229, AI308852, AA666071, AI863327, T58273, AW303891, T06595, AA078997, N91277, AI247195, F03011, AA995023, AA078996, W94292, AA780101, AI564909, T85311, AI280279, AI000518, W60925, AA865998, AI356679, AW129360, N80753, AI880534, AA683556, AW236275, AA176383, AI611789, W79291, AI335813, AW302341, AA903827, AA612779, AA333676, AA323628, AI188799, N47087, AA987777, AA937362, AI015126, AA604187, AA551681, AI928317, AA308986, AI572716, AW044338, N62088, AA338970, AI917558, F01980, F04591, T06110, T29898, AA157092, W60794, AI351440,</p>

				AA427495, U54717, AI376323, AI968180, AA627319, AA463660, T85552, AA402614, AA430656, AW292404, AA083909, AA055214, AA149524, AI687720, AA053558, AA778220, AA481441, AA247365, AA189041, AW275910, R99982, AI081170, AA318013, AA910195, H53297, AI870863, AA594364, AW410072, AI653932, F17264, AI262768, AA826888, AI264450, AA664448, C17952, AI205346, W46479, T84889, AA634657, C00475, AI309085, AI500278, AA156131, W24009, AI675253, AC004382, J05448, AC008115, AJ224143, and AJ224144.
31	HJBAR01	108	857440	AA420750, AA579207, AA420811, AA436475, AA355895, AA436525, AA361021, and AC007066.
32	HE8MH77	42	984097	AA234159, AA985292, AA332617, F02972, AA233911, R15784, F11078, N75139, H17310, R41734, R39159, R41367, R40304, F02789, R52089, R41958, N52368, AI073952, AI783861, AA908294, AI805638, AI432040, AL036403, AI611743, AL119791, AI089970, AW083804, AI636719, AI539153, AI439087, AI249877, AW059713, AI863382, AW023338, AI874166, AI919345, AI889306, AI312542, AI567351, AI619716, AI590021, AI358701, AI446248, AI478123, AW264029, AI916419, AW074172, AL047100, AL041150, AI922707, AI824648, AI863466, AI471909, N75771, AW022682, H89138, AI978703, AI745713, AI539771, AI866608, AI345612, AI866770, AI698391, AI287704, AI801325, AI950664, AI345415, AA830821, AI365256, AI623682, AI567802, AI670009, AI288285, AI554821, AI633125, AI590686, AI522052, AW151136, AI537677, AI345416, AW104108, AI284509, AI815232, AI433157, N71180, AI702073, AI610086, AI677646, AI538716, AI499986, AW088903, AW087455, AL110306, AI798351, AW081255, AW089844, AA572758, AW161579, AW403717, AI929108, AA420722, AI340603, AI679214, AI689420, AW172723, AA493923, AI366992, AI955906, AI312428, AW081528, AA494167, AI500523, AL039086, AI241819, AI582871, AI520785, AI335426, AI348777, AI889189, AI637584, AA635382, AI310575, AI828367, AI915291, AI872910, AW103886, AI345608, AI923989, AI284517, AI494201, AI340533, AI343059, AL036631, AI345347, AW268072, AA493647, AI634219, AI349933, AI307736, N80094, AI583065, AI345737, AI251830, AL040241, AW088899, AI538885, AL036802, AI345471, AI366549, AI345736, AW068845, AA176980, AI446373, AL037454, AI564426, AI699011, AI500061, AW151138, AI590423, AI696626, AI589993, AI345131, AI573032, AI345677, AI364788, AI538342, AI932949,

				AI952920, AL121365, AI866573, AI805769, AW169234, AI251221, AI497733, AL036396, AI554218, AL038605, N33175, AI436429, AI521560, AI670002, AA579232, AL042382, AI912288, AI612885, AW071380, AI582932, AI500706, AW084117, AI349598, AI500662, AI890806, AI345745, AI804983, AL036664, AW075207, AI349256, AI589267, AW169604, AI312152, AI344935, AL048323, AI537303, AW269097, AL119836, AI799195, AI345735, AI345397, AW075084, AI888661, AL048340, AA012905, AW162189, AI349937, AW020693, AW130776, AW089572, AI334884, AI307543, AI348897, AI347701, AI627988, AI307210, AI345224, AI610690, AI307708, AL045500, AI312325, AI500659, AI313320, AI609594, AI336495, AI922901, AI621362, AA974049, AI340627, AI343030, AI340519, AI859464, AI812080, AI307520, AI889147, AW088793, AI445237, AI345370, AI312146, AI312339, AI348854, AI345258, Z82206, AL132985, AC018767, AL035587, AC018769, Z99495, AC004594, Z49258, I48978, AP000247, AC005992, AC004383, U95739, AF110520, AP000697, AC004690, AF090900, Z94277, I89947, A08913, A08910, AL133445, AC009233, A08909, A08916, AC005488, AL078630, I89931, I49625, AP000130, AP000208, AJ238093, AC009501, AC004485, AL022726, AC002500, AL137495, AC004883, AC002457, AL035458, AC007114, AP000344, AL096776, A65341, AC004200, AC005224, U75932, X65873, Z98949, AC004837, Z98036, I48979, AF078844, AL137527, AL137459, AC000400, and A08912.
32	HE8MH77	109	861509	N75139, AA234159, R52182, AA985292, AA332617, AA233911, F02972, R15784, F11078, H17310, R41734, R17281, R39159, H08620, R40304, F02789, and T66410.
32	HE8MH77	110	618326	R41367, R41958, R52089, N52368, AI440263, AW020592, AI537643, AW023351, AW021182, AW162194, AW023863, AW022826, AW021178, AI671642, AI612885, AI440238, AW020397, AI273179, AI866510, AI333104, AW020480, AI557238, AI275956, AI866461, AI432644, AW019988, AW131331, AA715307, AA809974, AA748353, AI557808, AL040459, AI799313, AW022981, AI267185, AI310940, AI860027, Z98527, AI866608, AW020425, AI539260, AA824621, AL045163, AI537677, AI494201, AI500659, AI524654, AI866465, AI815232, AI801325, AI525653, AI500523, AI538850, AI887775, AI582932, AI872423, AI590043, AI923989, AI284517, AI500706, AL135047, AI491776, AI445237, AI289791, AW151138, AI521560, AI889189, AI500662, AW172723, AI284509, AI539800, AI582912, AI538885, AI889168, AI927233, AI866573, AI633493,

				AA729017, AI434256, AI923046, AI866469, AW411235, AI805769, AI434242, AI888661, AI500714, AI284513, AI888118, AI285439, AI859991, AI436429, AI355779, AI889147, AI623736, AI581033, AI371228, AI623941, AI491710, AI440252, AI431307, AL047422, AI866786, AI536912, AI860003, AI431316, AI610557, AA641818, AI242736, AL039086, AA761557, AI828574, AI887499, AW082113, AW151979, AI539781, AI702065, AI539707, AI885949, AI285419, AI559957, AW089557, AI241763, AI521571, AI699865, AI469775, AW088560, AI866581, AW161202, AI918809, AI567953, AI815150, AI446495, AW411265, AW022494, AW410902, AI867068, AW020288, AW020328, AL045500, AL039456, AI263584, AL039276, AI624304, AI401697, AI269862, AI553645, AW022299, AL042745, AW020406, AI571699, N25033, N22276, AI567971, AW104141, AI499325, AI682958, AW020295, AW021662, AA928539, AI887785, AI364788, AI345745, AW029457, AI923509, AW026425, AL048323, AI537191, AW411351, AI539771, AI624084, AL048340, AW021373, AI500061, AI114703, AI349958, AI559872, AI890907, AI433037, AI431323, AW059828, AI799674, AI866820, AL040169, AW020095, AW117882, AI624543, H41759, AL042628, AW020710, AW189802, AW051088, AA908294, AI621341, AI633125, AW071377, AL044305, AI954721, AI698391, AI538564, AI784214, AI915291, AW021693, AW152182, AI371251, AL119748, AL042627, AW055252, AW411043, AI499986, AI434731, AI524179, AI521005, AW022636, AI688854, AI648494, AI538764, AI309306, R10067, AA808175, AW020629, AW196720, AI479292, AW022075, AA502794, AW263569, AI559752, AW191003, AL120987, AL049085, AI557082, AI884318, AW238688, AI638644, AI570056, AL045620, AI690813, AW194014, AI766348, AI859644, AW161402, AW151136, AW021717, AI473536, W74529, AW083573, T69241, AI925402, S68736, A91160, U75932, AF076633, AL122049, I89947, AL133049, A08913, AC004383, A08912, A08911, A18777, Y10080, U76419, M92439, S76508, AR038854, I48978, A08907, AL137478, AL133623, A08910, A08909, AL137521, A08908, AF150103, E12580, S77771, A93016, AL137574, AL137533, AL137429, AF141289, AL080139, AL023657, U62966, E12579, AL049540, AR068753, I89931, Y16645, I09360, Y11254, AL117587, AF106827, AL122093, U67813, I49625, A41575, AF162270, AL117416, AF080622, A07647, AL133072, AR068751, AF043493, I89934, AR050959, L13297, AF207750, AF067728, AF065135, A76337, A76335, AF031147, AF079763, I92592,
--	--	--	--	---

				AF199509, AF036268, U00686, AF040751, AL137292, U88966, AF000167, A08456, AR029490, AF090896, AL137554, AL137558, AL110228, Y08991, AF100931, AL035587, AL050322, AF002985, AL122110, Y10823, AL133080, AF162782, AL133081, AL133077, I03321, AF137367, A08915, AF139373, J05277, AL137550, X57961, AC005968, AL080060, AL136884, AF126247, A83556, X01775, AF090886, AL133016, AL110218, I08319, AC005886, AL049447, AF026816, X98066, AF113019, X82434, L19437, AF145233, AL049300, S36676, A77033, A77035, AF087943, AL122104, AF113699, AL137530, AL137271, Z13966, E12806, I46765, AF111849, AL137529, AL137711, U87620, AF082324, AF061795, AF090903, AF151685, AF058921, AF112208, AF185576, I32738, AR034821, AL110222, X63574, AF032666, AF008439, Z97214, AL137476, D83032, AL133665, AL137537, E12747, Y08769, AL133560, I79595, AF078844, Y10655, A92311, AL049324, AF161699, D83989, X66871, AL110196, X61399, AL049430, Y13350, AL137258, AL122106, M30514, AL117583, AL137648, AF200464, AF153205, AF047716, Z37987, AL110158, AF124728, AL050155, Y07905, AF002672, AL096751, A08916, AL133606, AL137548, L04504, AJ005690, AJ012755, AL137267, AR068466, Z98036, AF113013, AR022283, I89944, AF172930, I33392, AF051325, U53505, AL080127, M27260, AF090900, U37359, U37312, AL080129, AL133565, A03736, AF055917, A90832, AF095901, AF115410, AC005057, X63410, X66862, AL117438, AL137523, U68233, AL050146, AF081195, A21101, E07361, E01573, E02319, Y11505, I52013, AF100781, X97899, E03671, I18355, AL080154, I34392, AB007812, AF026124, AL080162, U95114, AL133014, AL050393, AF061573, X96540, A58524, A58523, AC006288, AL080118, X97332, AR054987, A21103, AL133104, AL050024, and AL137640.
33	HRSMQ86	43	985877	AC007200.
33	HRSMQ86	111	833194	AC007200.
34	HBXCT44	44	1001002	AL046490, AW365307, AW179210, AW179079, AW179071, AW179078, AW179069, AW179070, AW179076, AI457609, AW365281, AW179073, AW375310, AW179072, AA115474, AW263549, AW016073, AA115608, AW026506, AI079243, AW179195, AW375251, AI808188, AW179080, AI909658, AW365309, AW001279, AA587391, AI692766, AW351653, AI492275, AA604140, AA977607, AW375414, AI357774, AW172485, AW375284, AI129412, AI573141, AI858587, AA056674, AW070948, AI982822, W74617, AW273106, AI985841, AA056551, AI288280, AA744681, AA905369, AI493622, AW169906,

				AI076424, AI741139, AI493926, AI493927, AI610741, AI445590, AA283805, AI499352, W32860, AI076427, AW387260, N73162, AA813376, AW365314, AI493611, AA947761, AA593795, AA987539, W57984, AA126907, AA532993, AW242852, H38875, AI418225, AA757923, H16794, AI865212, AI199909, AI961964, AI365957, AA583445, W73551, AA004387, AI636625, AW351609, AW376448, AW027972, W32414, AI336917, W80365, W84628, H54654, AA889321, W58162, AA960782, AW243729, AA454812, AW028148, AA127111, AA766988, AA868775, AA043686, AA775519, AA001756, AI093056, AI559116, AI142963, R92375, AA577532, AA703607, AA741567, R96368, AI962409, AI619811, AI765944, AA531170, AI810770, AA004647, N59408, AA325634, H54655, AI990884, AA700757, W73479, AA928959, AW150844, W03317, AI183370, W80513, AI798992, AA340573, AA247584, AA632623, AI224579, AA001755, F10881, AW014430, AA334014, AA317412, AA582779, AI493916, AW418904, AA748370, AI224575, AA722393, AA679296, AA761724, AA294963, R89561, R89011, AA993661, AA515724, H77999, Z45762, AA723701, AA652314, AI813682, W38733, T31918, AA057049, AA382804, AI926953, AI161411, H82298, AA364809, AA284007, AI678593, AW351979, AI906029, H49939, AI092664, C03804, AA663507, AA347189, H77998, F13282, T32521, AI695478, R01440, AI434836, H48154, AI865202, R01439, AA347190, T32213, W84679, R92379, AI690347, AI363327, AA043687, AA291103, AA765495, AI783773, AI984426, N73286, D20275, N54038, H82205, AI310813, AA761655, AI500021, AA055571, AA954448, AA935528, AA045546, T26003, AA894828, AA669152, AW366009, AA057444, AI309161, D20568, AA743571, and AB002308.
34	HBXCT44	112	889140	AL046490, AW365307, AW179210, AW179079, AW179071, AW179078, AW179069, AW179070, AW179076, AA115474, AW365281, AW179073, AI457609, AW375310, AW179072, AW179195, AW016073, AW026506, AW375251, AW179080, AA115608, AW263549, AI079243, AI909658, AI808188, AW365309, AA977607, AW351653, AA587391, AW001279, AI692766, AW375414, AA604140, AI492275, AW375284, W74617, AA056551, AI357774, AI858587, AI129412, AI573141, AI985841, AW172485, AW070948, AI982822, AA744681, AA056674, AW273106, AI288280, AA905369, W57984, W32860, AA126907, AI493622, AA757923, AW169906, AA283805, N73162, AW387260, AI076424, AW365314, AI741139, AA947761, AI493926,



				AA593795, AI493927, AI610741, AA813376, AI445590, AA532993, H38875, AI499352, AA987539, AI076427, H16794, AI493611, AA583445, AW242852, AI418225, AI365957, W73551, W32414, W84628, AI865212, AI199909, AI961964, AW351609, AW376448, AA454812, AA004387, W80365, H54654, AI636625, AA766988, AI336917, W58162, AA775519, AA889321, AW027972, AA127111, AA001756, AA703607, AA043686, AW243729, AA960782, R96368, AW028148, AA868775, R92375, AA741567, AI142963, AA004647, AI559116, AI093056, AA700757, AA577532, AA531170, H54655, N59408, AI962409, W73479, AI765944, AI619811, AI810770, W03317, W80513, AA325634, AA247584, AI990884, AI798992, AA928959, AA632623, AI183370, AW150844, AA582779, AA001755, AA340573, AA334014, AI224579, AA317412, AA761724, F10881, AA722393, AW014430, AI493916, AW418904, H77999, AA515724, AA294963, R89561, AA748370, AA679296, Z45762, R89011, AA993661, W38733, AI224575, T31918, AA723701, AA382804, AA652314, AA284007, AI678593, AW351979, AI906029, AI926953, H49939, C03804, R01440, AI161411, H82298, AA364809, AA057049, AI813682, F13282, T32521, AI092664, AA663507, AA347189, H48154, AI695478, AI434836, R01439, AA347190, T32213, W84679, AI865202, AA043687, AA291103, AI690347, N73286, R92379, AI783773, AI984426, AI363327, N54038, AA761655, H82205, H77998, AA765495, AI310813, D20275, AA055571, AI500021, AA954448, AA935528, AA045546, T26003, AA894828, AA669152, AW366009, AA057444, AI309161, D20568, AA743571, and AB002308.
34	HBXCT44	113	889270	AA515724, F13282, AI357774, AA334014, AA057444, AA294963, AA317412, and AB002308.
34	HBXCT44	114	882419	AA852277, AI909273, AA515724, AA601333, AW452106, AL040471, AW074332, AA693816, AW207104, R53573, H05742, AW268920, AA812182, AA074996, AI270280, AI049643, AA688303, AI668951, AI420747, AW404543, AA601674, AA551105, T52807, AI613459, AI348780, AA601529, H63007, C14144, R63460, AL040627, AW081951, AA114053, AA225901, AW265468, R29387, AA075078, AI867034, AI114761, AA506544, AA338599, AA513122, AL048969, AI275380, N50597, AA236802, T96028, AB002308, AC002540, AL049696, AC010202, AC006285, AF023268, AL121603, AL132718, AL080245, AL096763, AC009233, AL031767, AC012627, AL109610, AC002364, AC002477, AC004231, AL022316, Z83840, Z93928, AF196779, AC005160, AC004104,

				AL023584, AC005618, AC007487, AC007191, AP000557, AC005358, AC005015, AC002432, X02883, AC004030, AE000662, M94081, AL008710, AC004130, AL033525, AL035086, AC004770, AC006387, AL035071, AC007021, Z94056, AC007214, AC005826, AC006379, AC005216, AL050307, AL021877, AL008637, AP000282, AP000108, AP000040, AP000067, AC006013, AC002394, AC006978, AC007052, AC007899, AC009247, AL133243, AC005775, AC007390, AF051976, AL008635, AC009181, AC007226, AC006371, AC002038, Z68224, AC000007, AC004124, AC002322, AL035072, AL035420, AC006332, AC005411, AC002454, AC005412, AC006139, AC004913, AP000359, Z99570, AF093117, Z97987, AC007172, AC005495, Y14488, AC005519, AC006328, AF207550, AL022145, AF069291, AL049538, AC002077, AC005338, AL031287, AL022100, AB020858, AL031846, Z92844, AC004257, AL049757, AC004953, AL022721, AC005873, AC005484, AL033504, AP000968, AC003681, AC004804, AC005696, AC005261, AC007458, AC007425, AC004228, Z98051, AC000115, AC005999, AL049794, Z84480, AF048727, AC005933, AC004656, AC003119, AL031075, AL021878, AC004003, U82828, AC005036, AF117829, AL020995, AC006210, AC004789, AC004650, Z97196, AL035249, AC006509, AC004821, AL022476, AC004000, AC006480, AL031282, I08101, I08711, M24461, AF097732, AB004907, AL008719, AC006545, AC006546, AL033533, AC006071, AC004878, Z97632, AC004139, AJ010598, AC000111, AC004993, and AC009516.
35	HCWUFU77	45	1001004	AI694305, AI830310, AI797792, AW272682, AI088067, W80985, AI420479, AI382194, T65933, W81088, AW272683, AA482620, AW276108, AA904466, AI356919, AA946851, AA628599, AW340194, AI913090, F25065, AA890080, AA495920, AA810940, AA831163, AA554220, AW403647, AA363273, AA642644, AA363272, AI865465, AA687713, AI351078, AI825795, T64508, and AA495919.
35	HCWUFU77	115	704105	AI694305, AI382194, AA904466, AA495920, AW403647, and AA495919.
35	HCWUFU77	116	745032	AI830310, AW272682, AI088067, W80985, AI797792, T65933, AI420479, W81088, AW272683, AW276108, AA482620, AI356919, AA946851, AA628599, AI913090, AW340194, F25065, AA890080, AA554220, AA810940, AA831163, AA363273, AA642644, AA363272, AA687713, AI865465, AI351078, AI825795, T64508, and AI694305.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Altting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Altting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are

30

commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5            Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10          The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15          These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20          SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25  $\mu\text{l}$  of reaction mixture with 0.5  $\mu\text{g}$  of the above cDNA template. A convenient reaction mixture is
- 25          1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu\text{M}$  each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30          the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A<sup>+</sup> RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

#### **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

**Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

**Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with



high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then  
5 washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-  
10 NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50  
15 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC  
20 Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The  
25 promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with *NdeI* and *XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR  
30 primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or *Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

**Example 6: Purification of a Polypeptide from an Inclusion Body**

5       The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

10       Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

15       The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

20       The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

25       Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

30       To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive

Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

5 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40  
10 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

15 The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL  
20 assays.

### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus**

#### **Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a  
25 polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the  
30 plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral

sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug  
5 of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded  
10 in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed,  
15 as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page  
20 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are  
25 harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the  
30 medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of <sup>35</sup>S-methionine and 5 uCi <sup>35</sup>S-cysteine (available from Amersham) are added.

The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
5 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
10 mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long  
15 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV1, HIV1 and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
20 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

25 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
30 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector

are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for  
5 transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  
ug of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-  
neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an  
enzyme that confers resistance to a group of antibiotics including G418. The cells are  
seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the  
10 cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in  
alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1  
mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in  
6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50  
nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest  
15 concentrations of methotrexate are then transferred to new 6-well plates containing  
even higher concentrations of methotrexate (1 uM, 2 uM, 5 uM, 10 mM, 20 mM).  
The same procedure is repeated until clones are obtained which grow at a  
concentration of 100 - 200 uM. Expression of the desired gene product is analyzed,  
for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

20

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other  
proteins. These fusion proteins can be used for a variety of applications. For  
example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG  
25 domains, and maltose binding protein facilitates purification. (See Example 5; see  
also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to  
IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization  
signals fused to the polypeptides of the present invention can target the protein to a  
specific subcellular localization, while covalent heterodimer or homodimers can  
30 increase or decrease the activity of a fusion protein. Fusion proteins can also create  
chimeric molecules having more than one function. Finally, fusion proteins can  
increase solubility and/or stability of the fused protein compared to the non-fused



protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

5 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be  
10 destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

15 If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

20 Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGC  
CCAGCACCTGAATTTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA  
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG  
25 ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT  
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA  
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
30 GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG

GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

5     **Example 10: Production of an Antibody from a Polypeptide**

          The antibodies of the present invention can be prepared by a variety of  
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells  
expressing a polypeptide of the present invention is administered to an animal to  
induce the production of sera containing polyclonal antibodies. In a preferred  
10    method, a preparation of the secreted protein is prepared and purified to render it  
substantially free of natural contaminants. Such a preparation is then introduced into  
an animal in order to produce polyclonal antisera of greater specific activity.

          In the most preferred method, the antibodies of the present invention are  
monoclonal antibodies (or protein binding fragments thereof). Such monoclonal  
15    antibodies can be prepared using hybridoma technology. (Köhler et al., Nature  
256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.  
Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell  
Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures  
involve immunizing an animal (preferably a mouse) with polypeptide or, more  
20    preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in  
any suitable tissue culture medium; however, it is preferable to culture cells in Earle's  
modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at  
about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids,  
about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

25           The splenocytes of such mice are extracted and fused with a suitable myeloma  
cell line. Any suitable myeloma cell line may be employed in accordance with the  
present invention; however, it is preferable to employ the parent myeloma cell line  
(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are  
selectively maintained in HAT medium, and then cloned by limiting dilution as  
30    described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma  
cells obtained through such a selection are then assayed to identify clones which  
secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### **Example 11: Production Of Secreted Protein For High-Throughput Screening**

##### **Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of  $\text{CaCl}_2$  (anhyd); 0.00130

mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ;  
 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of  
 NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  
 $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
 5 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic  
 Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of  
 Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of  
 Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-  
 Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 10 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-  
 2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0  
 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-  
 $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-  
 Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 15 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22  
 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na- $2\text{H}_2\text{O}$ ; 99.65 mg/ml of L-  
 Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of  
 Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of  
 Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319  
 20 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na  
 Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL;  
 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of  
 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin  
 25 complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal)  
 with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L  
 DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for  
 endotoxin assay in 15ml polystyrene conical.

30 The transfection reaction is terminated, preferably by tag-teaming, at the end  
 of the incubation period. Person A aspirates off the transfection media, while person

B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>		<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
		<u>Jak1</u>	<u>Jak2</u>			
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)



To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCCCTAACTCCGCCCAGTTCGCCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT AGGCTTTTGGCAAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

**Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the  
5 assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and  
10 stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the  
15 positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

20 The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is  
25 U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing  
30 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

- 5 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 10 These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- 15 Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20 **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the
- 25 EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).
- 30 The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

- 5           5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)  
          5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the  
10 EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and  
15 allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is  
20 done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine  
25 growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640  
30 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count

the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### 10 **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID NO:8), 18 bp of sequence

complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

5 The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is  
10 digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
15 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

20

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

25 In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

30 Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described



in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

#### **Example 17: Assay for SEAP Activity**

5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

15 Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

20 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

#### **Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for

20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

#### **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is

unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include  
5 receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

10 Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

15 Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or  
20 polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar  
25 Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of  
30 Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in

Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is  
5 shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after  
10 detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

15 Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for  
20 a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>,  
25 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

30 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

#### **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and

cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

5           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
10       procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

15       **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

          RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
20       is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

          PCR products are then sequenced using primers labeled at their 5' end with T4  
25       polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

30       PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United

States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

#### **Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in



Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

### **Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials

(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,  
5 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped  
10 Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang  
15 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the  
20 optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

25 Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically  
30 acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized

formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

5           The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use  
10       or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate

administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, 5 steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are 10 administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

15 In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), 20 OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), 25 and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 30 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In

another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,



erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be  
5 administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in  
10 combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific  
15 embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the  
20 Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

25 In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives,  
30 arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-

acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

5 In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-  
10 FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl  
15 estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and  
20 etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with  
25 Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered  
30 with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered

with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but

are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example,  
5 radiation therapy.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising  
10 administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the  
15 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily  
20 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

25 The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

30 In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of

decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is

maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

5           The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the  
10   packaging cells are now referred to as producer cells).

          Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is  
15   removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been  
20   efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

          The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

25   **Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

          Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent  
30   NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935

(1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting  
5 sequences, which are homologous to the 5' non-coding sequence of endogenous  
polynucleotide sequence, flanking the promoter. The targeting sequence will be  
sufficiently near the 5' end of the polynucleotide sequence so the promoter will be  
operably linked to the endogenous sequence upon homologous recombination. The  
promoter and the targeting sequences can be amplified using PCR. Preferably, the  
10 amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends.  
Preferably, the 3' end of the first targeting sequence contains the same restriction  
enzyme site as the 5' end of the amplified promoter and the 5' end of the second  
targeting sequence contains the same restriction site as the 3' end of the amplified  
promoter.

15 The amplified promoter and the amplified targeting sequences are digested  
with the appropriate restriction enzymes and subsequently treated with calf intestinal  
phosphatase. The digested promoter and digested targeting sequences are added  
together in the presence of T4 DNA ligase. The resulting mixture is maintained under  
conditions appropriate for ligation of the two fragments. The construct is size  
20 fractionated on an agarose gel then purified by phenol extraction and ethanol  
precipitation.

In this Example, the polynucleotide constructs are administered as naked  
polynucleotides via electroporation. However, the polynucleotide constructs may also  
be administered with transfection-facilitating agents, such as liposomes, viral  
25 sequences, viral particles, precipitating agents, etc. Such methods of delivery are  
known in the art.

Once the cells are transfected, homologous recombination will take place  
which results in the promoter being operably linked to the endogenous polynucleotide  
sequence. This results in the expression of polynucleotide corresponding to the  
30 polynucleotide in the cell. Expression may be detected by immunological staining, or  
any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining  
5 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains  
10 approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with  
15 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the  
20 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap  
25 (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but  
30 the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.



Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following  
5 day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a  
10 patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the  
15 introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in  
20 the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

25 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

30 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or

precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg

body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence  
5 can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
10 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
15 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
20 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

25 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15  $\mu$ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA  
30 in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper

dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 29: Transgenic Animals.**

5           The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are  
10       used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

          Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear  
15       microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic  
20       stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-  
25       mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

          Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into  
30       enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campbell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding

strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of  
5 heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of  
10 interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in  
15 ameliorating such diseases, disorders, and/or conditions.

### **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*,  
20 see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding  
25 regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination,  
30 results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &

Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

5           In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not  
10   limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention,  
15   e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve  
20   expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

          Alternatively, the cells can be incorporated into a matrix and implanted in the  
25   body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

30           When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

### 10 **Example 31: Production of an Antibody**

#### a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line



(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which  
5 secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In  
10 accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention.  
15 Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells  
20 producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO  
25 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed  
polypeptide(s) of the invention From A Library Of scFvs

30 Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the

invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to

stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used  
5 to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification  
10 with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre  
15 plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal  
20 transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

### **Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

25

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current  
30 developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can,

in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with  $^3$ H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice

receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-  
5 arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell  
10 representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

15 Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

### **Example 33: T Cell Proliferation Assay**

#### **Proliferation assay for Resting PBLs.**

25 A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of <sup>3</sup>H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 °C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral  
30 blood and added to quadruplicate wells (5 x 10<sup>4</sup>/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls.

After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0.4 microcuries of <sup>3</sup>H-thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and  
5 incorporation of <sup>3</sup>H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

Alternatively, a proliferation assay on resting PBL (peripheral blood  
10 lymphocytes) is measured by the up-take of <sup>3</sup>H-thymidine. The assay is performed as follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the  
15 plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2 x 10<sup>4</sup> cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T  
20 supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2 (\*), IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants, recombinant human IL-2 (R & D Systems, Minneapolis, MN)  
25 at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of <sup>3</sup>H-thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of <sup>3</sup>H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

30 (\*) The amount of the control cytokines IL-2, IFN $\gamma$ , TNF $\alpha$  and IL-10 produced in each transfection varies between 300pg to 5ng/ml.

**Costimulation assay.**

A costimulation assay on resting PBL (peripheral blood lymphocytes) is performed in the presence of immobilized antibodies to CD3 and CD28. The use of antibodies specific for the invariant regions of CD3 mimic the induction of T cell activation that would occur through stimulation of the T cell receptor by an antigen. Cross-linking of the TCR (first signal) in the absence of a costimulatory signal (second signal) causes very low induction of proliferation and will eventually result in a state of "anergy", which is characterized by the absence of growth and inability to produce cytokines. The addition of a costimulatory signal such as an antibody to CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on activated APCs, results in enhancement of T cell responses including cell survival and production of IL-2. Therefore this type of assay allows to detect both positive and negative effects caused by addition of supernatants expressing the proteins of interest on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with 100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is

pulsed with 1uCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

5 **Costimulation assay: IFN  $\gamma$  and IL-2 ELISA**

The assay is performed as follows. Twenty-four well plates are coated with either 300ng/ml or 600ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 500ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the costimulation assay. The assay is performed in the pre-coated twenty-four well plate using  $1 \times 10^5$  cells/well in a final volume of 900ul. The supernatants (293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 300ul are added to 600ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only(negative control), IL-2, IFN $\gamma$ , IL-12 and IL-18. In addition to the control supernatants recombinant human IL-2 (all cytokines were purchased from R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml, IL-12 at a final concentration of 1ng/ml and IL-18 at a final concentration of 50ng/ml are also used. Controls and unknown samples are tested in duplicate. Supernatant samples (250ul) are collected 2 days and 5 days after the beginning of the assay. ELISAs to test for IFN $\gamma$  and IL-2 secretion are performed using kits purchased from R & D Systems, (Minneapolis, MN). Results are expressed as an average of duplicate samples plus or minus standard error.

30

**Proliferation assay for preactivated-resting T cells.**



A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then  
5 cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would have an effect on a naïve T cell. Therefore the use of this type of cells might enable  
10 to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve ) T cells.

The assay is performed as follows. PBMC are isolated by F/H gradient centrifugation from human peripheral blood, and are cultured in 10% FCS (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the  
15 presence of 2 µg/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5 ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are washed and rested in starvation medium (1% FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to  
20 determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200 µl. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60 µl are added to 140 µl of in 10% FCS/RPMI containing the cells. Control  
25 supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 at a final concentration of 10 ng/ml is also used. After 24 hours of culture, each well is pulsed with 1 µCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing  
30 and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

The studies described in this example test activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

10 Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid  
15 change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3  
20 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to  
30 measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell

cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

5           Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the  
10   antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

          FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or  
15   LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

20           Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be  
25   screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

30

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results

from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACSscan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610

nm. To calculate the amount of H<sub>2</sub>O<sub>2</sub> produced by the macrophages, a standard curve of a H<sub>2</sub>O<sub>2</sub> solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 35: Biological Effects of Polypeptides of the Invention**

#### **Astrocyte and Neuronal Assays**

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

**Fibroblast and endothelial cell assays**

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released.

Subsequently,  $MPP^+$  is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine.  $MPP^+$  is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2-5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a



polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida *et al.*, *J. Biol. Chem.* 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 39: Stimulation of Endothelial Migration**

5 This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

25 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.


**Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**

30 Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be

assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-estradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

30

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cello tape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the

Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow

during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

#### **Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean  $\pm$  SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- 5 a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- 10 d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15 invention.

#### **Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic  
20 strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is  
25 delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the  
30 contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to



test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 48: Ischemic Myocardial Disease Model**

5

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- 10       a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.
- 15       c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

**Example 49: Rat Corneal Wound Healing Model**

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

25

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- 30       c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

#### ***A. Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These

homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

5 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post  
10 treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

15 Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by  
20 treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit  
25 anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated  
30 by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary

antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is  
5 considered significant.

### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-  
10 Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*,  
15 *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth*  
20 *Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing  
25 process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and  
30 are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*

*libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

5           The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue  
10       punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

          Wounds are visually examined and photographed at a fixed distance at the day of  
15       wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

          The polypeptide of the invention is administered using at a range different doses,  
20       from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

          Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue  
25       cassettes between biopsy sponges for further processing.

          Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

          Wound closure is analyzed by measuring the area in the vertical and horizontal  
30       axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8).

The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

5

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 20 **Example 51: Lymphadema Animal Model**

or The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing.

Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.



Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then  
5 dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

10 Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quilltine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee  
15 (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

25 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and  
30 endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and

extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

5 Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

10 To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>.

15 HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for

20 CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90  $\mu$ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are incubated at 37 degree C for

25 either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of

30 diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution

of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with  
5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is  
10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [  
15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
20 invention.

### **Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation**

This assay is based on the ability of human CD34+ to proliferate in the  
25 presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range  
30 of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone

has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l SID (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60  $\mu$ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined

via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

#### **Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)**

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating

stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with  
fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are  
5 plated (1,000 cells/well ) in 0.2 ml of serum-free medium. Cells cultured in the  
presence of IL-3 ( 5 ng/ml ) + SCF ( 50 ng/ml ) would serve as the positive control,  
conditions under which little self-renewal but pronounced differentiation of the stem  
cells is to be expected. Gene products are tested with appropriate negative controls in  
the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent  
10 10% of the total assay volume. The plated cells are then allowed to grow by  
incubating in a low oxygen environment ( 5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$  ) tissue  
culture incubator for 7 days. The number of proliferating cells within the wells is  
then quantitated by measuring thymidine incorporation into cellular DNA.  
Verification of the positive hits in the assay will require phenotypic characterization  
15 of the cells, which can be accomplished by scaling up of the culture system and using  
appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the  
activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or  
antagonists and fragments and variants thereof.

20 If a particular gene product is found to be a stimulator of hematopoietic  
progenitors, polynucleotides and polypeptides corresponding to the gene may be  
useful for the diagnosis and treatment of disorders affecting the immune system and  
hematopoiesis. Representative uses are described in the "Immune Activity" and  
"Infectious Disease" sections above, and elsewhere herein. The gene product may  
25 also be useful in the expansion of stem cells and committed progenitors of various  
blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest  
and/or agonists and/or antagonists thereof, may also be employed to inhibit the  
proliferation and differentiation of hematopoietic cells and therefore may be  
30 employed to protect bone marrow stem cells from chemotherapeutic agents during  
chemotherapy. This antiproliferative effect may allow administration of higher doses

of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as; for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

**Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation**

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5  $\mu$ g/ml hEGF, 5mg/ml insulin, 1 $\mu$ g/ml hFGF, 50mg/ml gentamycin, 50  $\mu$ g/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for

AoSMC contains SM basal media, 50mg/ml gentamycin, 50µg/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls.

- 5 For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO<sub>2</sub> until day 5.

- 10 Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

- 15 On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 µl/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

- On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

- 25 Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 µl/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

- Add 100 µl/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

30 A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or



smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vascularogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

**Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in  
5 both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular  
10 endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is  
15 removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are  
20 aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a  
25 concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with  
30 PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of

the ExtraAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNNP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

#### **Example 57: Alamar Blue Endothelial Cells Proliferation Assay**

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The

plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

#### 15 **Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction**

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM<sup>®</sup>, density 1.0770 g/ml,

Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1  $\mu$ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10  $\mu$ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1  $\mu$ C of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, the contents of U.S. Provisional Applications No. 60/164,735 and 60/221,193 are all hereby incorporated by reference in their entirety.

**ATCC Deposit No. PTA-883****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-883****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit
- 10 No:Z, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
- 20 having biological activity;
- (f) a polynucleotide which is a variant of SEQ ID NO:X;
- (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.



2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

25

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

30

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- 5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
- (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- 10 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- 15 (g) a variant of SEQ ID NO:Y;
- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

20

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

- (a) culturing the recombinant host cell of claim 14 under conditions such that
- 30 said polypeptide is expressed; and
- (b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount  
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of  
10 claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to  
15 a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.  
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the  
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the  
30 method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 35 Human Secreted Proteins

<130> PS713PCT

<140> Unassigned

<141> 2000-11-08

<150> 60/164,735

<151> 1999-11-12

<150> 60/221,193

<151> 2000-07-27

<160> 289

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccc aaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tcccccaaaa	acccaaggac	accctcatga	120
tctcccggac	tcctgaggtc	acatgcgtgg	tgggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcaagg	tctccaacaa	agccctccca	acccccatcg	360
agaaaacccat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccgggagac	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaatat ctgccatctc aattag 86

&lt;210&gt; 4

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

gcggcaagct ttttgcaaag cctagggc 27

&lt;210&gt; 5

&lt;211&gt; 271

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

&lt;210&gt; 6

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

gcgctcgagg gatgacagcg atagaacccc gg 32

&lt;210&gt; 7

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

gcgaagcttc gcgactcccc ggatccgcct c 31

&lt;210&gt; 8

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

ggggactttc cc 12

&lt;210&gt; 9

<211> 73  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 gcggcctcga ggggaactttc ccgggggactt tccggggact ttccgggact ttccatcctg 60  
 ccatctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctcgagggga ctttccccggg gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtcg gcaaccatag tcccgcctt aactccgccc atcccgcctt taactccgcc 120  
 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

<210> 11  
 <211> 1500  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 aatcggcac gagcatttgc taataaggcc ctgccaggct gggaggggaat tgtccctgcc 60  
 tgcttctgga gaaagaagat attgacacca tctacgggca ccatggaact gcttcaagtg 120  
 accattcttt ttcttctgcc cagtatttgc agcagtaaca gcacagggtgt tttagaggca 180  
 gctaataatt cacttggttac tacaacaaaa ccatctataa caacacccaa cacagaatca 240  
 ttacagaaaa atgttggtcac accaacaact ggaacaactc ctaaagggaac aatcaccaat 300  
 gaattactta aaatgtctct gatgtcaaca gctacttttt taacaagtaa agatgaagga 360  
 ttgaaagcca caaccactga tgtcaggaag aatgactcca tcatttcaaa cgtaacagta 420  
 acaagtgtta cacttccaaa tgcgtgttca acattacaaa gtcccaaacc caagactgaa 480  
 actcagagtt caattaaaac aacagaaata ccaggtagtg ttctacaacc agatgcatca 540  
 ccttctaaaa ctggtacatt aacctcaata ccagttacaa ttccagaaaa cacctcacag 600  
 tctcaagtaa taggcactga ggggtgaaaa aatgcaagca cttcagcaac cagccgggtct 660  
 tattccagta ttattttgcc ggtggttatt gctttgattg taataaactt ttcagtattt 720  
 gttctggttg gtttgtaccg aatgtgctgg aaggcagatc cgggcacacc agaaaatgga 780  
 aatgatcaac ctccagtctga taaagagagc gtgaagcttc ttaccgttaa gacaatttct 840  
 catgagtctg gtgagcactc tgcacaagga aaaaccaaga actgacagct tgagggaattc 900  
 tctccacacc taggcaataa ttacgcttaa tcttcagctt ctatgcacca agcgtggaaa 960  
 aggagaaaagt cctgcagaat caatcccgac ttccatacct gctgctggac tgtaccagac 1020  
 gtctgtccca gtaaagtgat gtccagctga catgcaataa tttgatggaa tcaaaaagaa 1080  
 ccccggggct ctctgttct ctcacattta aaaattccat tactccattt acaggagcgt 1140  
 tcctaggaaa aggaatttta ggaggagaat ttgtgagcag tgaatctgac agcccaggag 1200  
 gtgggctcgc tgataggcat gactttcctt aatgttttaa gttttccggg ccaagaattt 1260  
 ttatccatga agactttcct acttttctcg gtgttcttat attacctact gttagtattt 1320  
 attgtttacc actatgttaa tgcagggaag agttgcacgt gtattattaa atattaggta 1380  
 gaaatcatac catgctactt tgtacatata agtattttat tcctgcttcc gtgttacttt 1440  
 taataaataa ctactgtact caatactcta aaaatactat aaaaaaaaaa aaaaaaaaaa 1500

<210> 12  
 <211> 1149  
 <212> DNA

&lt;213&gt; Homo sapiens

```

<400> 12
cagcgggaac taatcatgtt ggtgataata ataatgacag ctctggtctc ccatgtccca      60
agcgtccact ctgtgcctca tgctgttccc ttcaccagca gttagtcttc catctaattct      120
ttcttctgag aaaggcaggg cagtcacggc tccaacttta cagatgagga aattgagggt      180
cggggggaag tcaactgcctg aggtcaatgg gcaagtcggg gggcggtgcc aggacccatg      240
cctaggtcac accccaagta gagttctgac catgggggttc agagtttagca gagggtacgg      300
tggaccaccc catctgcagt cctccctgga ggtcagatcc gggactgctg gactgtgtaa      360
cttcagggag ggactgtact ctctgcctca cagtcttcat caataaaatg aggatgacac      420
gggtccctgc ttcacaggga tcccagggtc cagaacacag tggggctcag ggacaattct      480
caggttcatg cagttgatca acaaatgcac attatagcct gaggaacata gggagacccc      540
atctttacac aatttttttt tttttgagcc agagtctcac tctgttgccc aggtctggagt      600
gcagtggcgc aacctcagct cactgcaacc tctggctccc aggatcaggc cattctcttg      660
cctcagctac tggggaggct gaggcaggag aatagcttga acccgggagg tggagggttg      720
agtgagcgga gatcgcgccg ttgcaactca gcctgggtga cggagagaga ctccatctca      780
aaaaaaaaaa aaacaaaaaa aaaaaaccaa aacaaggctg ggcgcggtgc ttacgcctgt      840
aatctcagca cttttggagg ctggggcagg ggtatcacct gaggtcatga gttgaagacc      900
atcctgacca acatggaaaa acccgtccc tgctgaaaaa tacaaaatta gccgggtgtg      960
gtggtgcatg cctgtaatcc cagctactcg ggaggctgag gcaggagaat ggcttgaacc      1020
tgaggaggcg aggttgcggt gagctgagat ggcgccattg cactccagcc tgggcaacaa      1080
gagagaaact ccgtctcaaa caaaaataaa aacaaaacaa aacaaaccca caaaaaaaaa      1140
aaaaaaaaaa

```

&lt;210&gt; 13

&lt;211&gt; 980

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (937)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (956)

&lt;223&gt; n equals a,t,g, or c

```

<400> 13
ncgttcgcca gctcgaaatt aaccctcact aaaggggaaca aaagctggag ctcgcgcgcc      60
tgcaggtcga cactagtgga tccaaagaat tcggcacgag gggcggtcca tcgaggcctt      120
tgatcgagc atcgacctgc tgggtgtcgc cctgcgccag aagctggggg atgaccccaa      180
ggctcgcgaa ttgatcaaga cggtagcgcg cgaaggctac ctgttcgacg cccgggatat      240
cggttgatgc gcgcgccctt caacacgctg ttcggggcgac tgttcggcct gttgctgggtg      300
gcgattgtgc tggcccatgt gctggcggtt ttctgggttc accactacgg ccgcccgcga      360
ccaccccgcg cggccttcgt cgaacaacca gatggcagcc tcacgccctt gcgcaaagcg      420
cctcgccccct ggttcggcgcg cccgggtggtg cccctgacat ttcaatttat ctgctgatc      480
atcgctgcct ggtacggcgc caaactgctg agccggccaa tccagcgctt gagcgcgcg      540
gccgagcgcc tgagcgtcga cctcgacagc ccgccccctg tggaaccgg ccctcgcgaa      600
gcacgccaag cggcctcgac cttcaacctg atgcaaaagc gcatccgcga acaagtcagc      660
cagcgcgcac gcatgctcgg cgcggtctcc cacgacctgc gcaccccgct ctcgcgccct      720

```



aagttgcgcc	tggaacaaat	cgaagacccc	aagctgcaag	gccagatgcg	ccaggacctg	780
gacgacatga	tcggcatgct	cgatgccacc	ttgagctacc	tgcacgaaca	gcgcaccagc	840
gagacacggc	attggctcga	tgtacaggcg	ttggtggaat	ccctgagtga	aaacgcccag	900
gaccaaggcc	gcgacgtgca	gttttttttt	gggggggnccc	cccccggggg	gggggnccca	960
aaaaccccc	cccttttttt					980

&lt;210&gt; 14

&lt;211&gt; 1632

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

gaaagactcg	atttgggagc	ctactggggc	aaggcgactg	gggaggtgta	cgtgttagtc	60
aagtggaggt	caggtgggtt	atcttctgcc	tccttcactg	gcttcatgtg	aacttgccctg	120
tgacagaata	tcttgcccta	gatgtcctct	tcctcttgct	catcgtgcaa	aagcattcga	180
tcttatgacc	gtgagttctt	atttgtggat	gctaactggg	gtaatctcag	ggagtactgg	240
ggccatggct	ctttcccttg	cttctctttc	tgctcactgc	tttgctttca	ggtgcttagc	300
tgctcctttt	tatttctttg	caggactggg	aaagcatggg	aggaggattt	tgataagttt	360
cttgttctct	gcgtgggtgat	ggggtgggtc	gagggccaag	ttaataagcc	tacctttggt	420
tattaccctg	gaaaattgag	ggttgatggt	agggttatga	ttgtggcctg	tgtatttgca	480
atttttcttt	gtcagtggtg	ctttctgtca	tcttcccttt	tctccagtga	gggttctgcc	540
actgtctcaa	tcccttggtt	cctgcaaaaa	acagctaaat	gtgctctcag	ggccagtggg	600
gatgttctgt	gttgagccc	cagctcttga	aagtgacctg	gcccagatga	gctctgcctg	660
cttgtcatct	ttaggtcctg	ctgcccctgc	tgcttcagcc	ctcaggctcc	taactgctca	720
agccagaagg	agctacaaag	ccaaatcatt	tgctattttt	ctctggcaga	ttgttttaaa	780
atctccctcc	cctcttttat	tttaattatg	ccacctgtgt	taatcctata	gcctgcttct	840
ttgctttgtg	gattactgat	ttcaagttct	ataacttggg	gaaagttagg	ttgagtgaat	900
gggaggacag	acactgaatg	tgtgttttgg	aaaaatggac	tctctatctt	cagattatct	960
agcttctcca	cctatcacct	ctacaacttg	gccttcattg	gagaagtttt	agttggctta	1020
ttcctggaac	aagaccacct	agaggctttt	agccttgtea	gcctgccctc	ttctgaggtt	1080
tggaccttgt	tttaaattgt	gtgcatgggt	ggcttgagac	tctcttgtaa	tggaggtaat	1140
gggactatca	ctgaggggtt	cagcctatcc	aggtaggcta	ccgttctagt	catacccatc	1200
acttaaatct	tgccacagtc	tgccacagacg	gttggctctc	caggcatatt	gtcctattaa	1260
gccaaatagg	tggacatcat	gggatggatg	aggctcatcat	gaaaacagat	ttactggatt	1320
tatggacctg	gtataacta	tgtaacagat	ggaaaactga	attttacaat	ctataggtac	1380
ctttgaaagg	tcataaaggg	taaaagtcta	tagttttcca	gaaaataatt	cttaaaactg	1440
ggttttatgt	ctagatttaa	atcatgtatc	tgtctgtagt	gcttcaaattg	tggccaggtg	1500
tggtagctca	cacctgtaat	tcccagcgct	ttgggaattt	gaggcaagag	gattgctaga	1560
ggccaggatt	ttgagaccag	cttcggcaat	acggtgagac	cttgtctcta	ccaaaaaaa	1620
aaaaaaaaaa	aa					1632

&lt;210&gt; 15

&lt;211&gt; 1594

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ggcacgagca	aggacagcac	aatgccatgg	caaccgcttc	catcaataac	ttaatctcat	60
ctctgctctt	acatctttct	ctcctcagtt	ctaaagctgg	aaaattttta	atctggaaag	120
aacataagac	ggcttgtggg	tgctatgcc	acagcacctg	cctgcttcct	aatgggcttt	180
ccaatcataa	aggaaagtct	tagcaagtca	cagaacttta	gactccaggg	gctctggagg	240
gcactccgca	cagcacggcc	tctcacttgg	ccgaggagac	cactggcacc	caggagggtta	300
agttccctgt	ctgtccacag	caattctact	agcccgcgct	gaagttacac	caaggcaagc	360
agcttaattt	tggccaaccc	gaaggattta	ggcaggattt	gggtggaagg	caggctgggc	420
gacccttgag	gagagttgct	gtaagtatct	ttctaccccc	aaaatccagt	atattagtca	480
gcttgggctg	ctgtaacaaa	gtaccacaga	ctgggcggct	tgaacccagg	aaggtggagg	540

ttgcagtgcg	ccgaggttgc	gccactgcac	tccagcctgg	gtgacagagc	gagactccgt	600
ctcaaaaaaa	aaaagaacgt	gctgtcatca	aaataggcac	cacctgagat	cagagaacac	660
agagtttccc	ctggcaaaaag	gagctccaaa	gggaagacag	acacacccag	ccacccaggc	720
tggccatata	tgggcaactgg	aggaagtgtc	ccggcagcaa	gggctctggg	gactgtctctg	780
tgaggattcc	tcgtggctga	gacgttggcc	cggccccacc	ttggcacaat	ctagttggag	840
catccactag	atgtctccat	gagctgtgca	gcccgaaggtt	gaggtcagag	atagcaaggc	900
cacctgggtg	acagcatggg	ctgctgcatg	ccacgcccct	cccctctttg	tctttgcttt	960
gtgcttttct	ttcctaggag	gtggcagggtg	tacatttctg	gctctgagcc	catgtcagac	1020
ccccaaagga	gccccactg	tcctgatccc	ctgcacggca	ccccaccaca	agcagcaggc	1080
acacgtgggtg	ggaatcaggt	aacgcagttc	ccccgggaag	ccccttccat	ggaagaccac	1140
tcctgctgct	gcagcctgct	ggcctctgtc	cctttcagga	tcagcccttc	gacccagacc	1200
aaggggccctg	gccaggccctc	cactgcccggc	cccaaggctt	aatgcacagc	atgtgcttgc	1260
cagatctgac	tccagaggat	ggaggaaaagg	cccaagacca	cacagccctg	ggccacagca	1320
gagagcagga	cactcctggg	gtgcaggaga	atttccaagg	tgcagcacct	cttgacagat	1380
acaccaggag	gtttaatact	ttgtattacc	ttggtaacca	gagaagagga	atcattaaaa	1440
ctcgaataata	gtgctgtgtg	ctgtgcagtg	gtcacacact	gtaatccctg	tgctttgaca	1500
ggccaaggta	agaggatctc	ttgaaactag	gtgttcagag	ccagcctgga	caacacagggt	1560
tgtattttacc	tctacaaaaa	aaaaaaaaaa	aaaa			1594

&lt;210&gt; 16

&lt;211&gt; 1859

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1185)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1230)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 16

ggttcaagca	aataattcta	ttgtgaagat	gcttggccgg	gatctgtgcc	tcctgcccc	60
gactccagcc	agtactgcc	aggggagagt	ctgagtcgtt	ctcctaata	gagcttcccc	120
ggagatctcc	gcctagcaag	tgcaaaaggc	attgactggc	ctgtgggaca	gttaagaaac	180
ggtagcagtt	actccctttc	caccttcacg	gcccaggagt	tcgatagcag	atgaagacgg	240
tgagtcttct	tctaacccta	tggttctccc	aaactttctc	ctttaactta	ttttttgccc	300
cacctcatte	tcttcttcag	agttctattt	ttttctctgt	gtcttctata	actactgtac	360
accctatcct	ggtctttttt	tttgcatctt	ttagaacttg	attgccacat	ctgtaatccc	420
agctactcag	gaggtcaggg	cagggggatc	acttgagccc	aggattttga	ggctgcagtg	480
agctacgatc	acaccactgt	actccctcca	gtctgggcaa	caaagtga	ccctgtctct	540
taaaaaaaaa	aagaacttga	tggcctttta	ctaaaacata	gacagctttg	taatgctttc	600
ccccaaagtc	cttgggcttc	ctgacgtcct	tgcccttttg	tttgttcttc	ctttcccacc	660
ccaccagac	tcagtaccca	actctacatc	tgtgtctttt	cccctgacta	ctattttttgt	720
tcatgggggt	catgtatgac	tatctttacc	cttttatcct	ttctcttcct	aagtgtgggg	780
ggtaaagcca	gaggaggatt	taggttgagc	agtggaagaa	agattgtgtc	aaaaatgagc	840
cattaatatt	tggaaaattg	ttttaagttt	aaaggcctga	gaaatgcata	aaattgaaat	900
ttaattgata	taggcaagtg	gttatgcaaa	tgattttttg	ccatccctcc	attttagtca	960
ggcaattttt	tagaacaact	ttcaaccagt	actttcttca	gttgtctttg	agattttttat	1020
aaattaaaaga	aaaagaaaca	ggaaaaaaa	gtgatttgga	agctcattta	aagtcactgt	1080
ggttgaaaag	gcaattatgt	ggctcctggc	agttgtagga	gagtggtgtg	ccccaaatcg	1140
agctaccaag	gacagattgc	caaagcccaa	gaagaatcat	tgtgnaaaca	ttagagctca	1200
gctggacctt	cagaggccta	agtgaagttg	ttaccctgtg	taaatcccat	gcagtgttac	1260
agcttcctgc	aaatcactgg	cataggaagg	tctgagtggt	gctgccaagg	tttgatgtct	1320

gctgcttgga	gctctgagga	gcacaattag	catgtgggtc	caccatgagc	agaaaccaca	1380
agatttctgc	acagctgagc	ccactctagc	attgttttaa	agggcctttg	gagaaatact	1440
gaaggccgag	cttcagggtg	taggtaatag	acaatttgag	aaacatttca	tttaatgtgt	1500
cttaactata	ttgagcacac	ttgtccatt	tggctggctc	tagtgtggag	aaatgcagac	1560
atgtccctta	cactgttttc	ccattccttg	gtatttctaa	ctgcataccc	atcatcccca	1620
gtgttgactt	agcctcccag	gagaaggcag	caaggaacag	caactattaa	tagaagggtg	1680
agaggccggg	cagtggctca	tgctgtaat	cccaaagtgc	tgggggttaca	ggcatgtgcc	1740
accacgctca	accagtattt	ctcattttct	tctaataaac	cttctagagt	tccacattag	1800
aaagctctag	atagaacat	tttttaaaga	gctcaggctt	aaaaaaaaa	aaaaaaaaa	1859

&lt;210&gt; 17

&lt;211&gt; 1672

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (62)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 17

agcaaaagct	gcagctcgcg	cgctgcagg	tcgacactag	tggatccaaa	gaatttggca	60
cnagttctct	ctctctctct	cgcttcttcc	agatgttagt	cttgctatct	cttttggcta	120
gtggtgggtc	gccccttctt	ttagtggggg	atgtattagc	ttcaaaatct	tcaacagtgc	180
ttttccctcc	tggcgactct	tctccagggt	gctccatgat	cactccactc	cctccatcta	240
ggatgtgcct	taaagctggg	tcctcagggg	aacagacggt	ggttccactc	tcactgctgc	300
ttargtctaa	atcttctaa	ttaaaggatct	tgggctgatg	catgcttttg	atgaatgttt	360
tctccctctc	gagctttcta	cttgagtga	gctcattcat	gtccacccca	gagtccagac	420
tgggtgtcatt	gctctggggt	ctcttgccct	ttttcagggtc	tataaaggag	tgctcactt	480
gtgcaactgg	ctttccatca	agagacacaa	accagggtct	gggatgckgg	gagggttttc	540
ctttggacag	ctccaggagg	gtctgttctg	aaattccttg	aagttccgat	gaaaatggag	600
tcattacaac	agcctcattt	agtgttccag	gaacagagac	ggattccagt	aagctgcttg	660
agtatcggct	ccaatctgaa	gcctgggatg	gcaggctctg	ttgaccttca	agtatgat	720
cctcttccct	ggcatctggg	ggctgtgcat	gagaatgaat	tggcattttg	ggcaagggtc	780
gcgtaaagtt	ctctcgattt	actggttcca	tcaattggcc	atagactaac	tgtccctttc	840
ttggcaaaag	agctgactta	gcagtatgta	attgttccgg	tgtggagaaa	aggtcagatg	900
tttgaaggat	ggcaatgggt	tggctgtaaa	tatgcataag	ctgttcagga	atatgggaac	960
gcccatacgc	ctcctcatta	cctgtgagat	acctcttttc	atcttgagca	tcacctagag	1020
atgaagatag	attggtgkta	atatgttttag	gttggtttgga	ccctacattg	ggctccaaag	1080
actgtgttg	gtttcttgag	taattatttt	gattgactga	tagaaatgaa	acatcttcat	1140
tgkagatttt	aaaatcgtcc	cgagttttta	ccatggaaac	tctttcttct	gtttctgcct	1200
ttgatgggtc	ctttttctga	ggactatatg	aggagttttt	ggcattgaat	aactgcgact	1260
tgtcctcagc	ttttaatgca	actttaactg	tactgatatg	atztatgtgt	gttggtgaag	1320
ttgtctggtc	tctcttgagg	acctcaagtt	tagtgatatt	tctttctctt	ttctgtggag	1380
taccacactt	gtcccttagag	tagaagagaa	ggcaaaaaat	atttaaaagt	tatgacacaa	1440
atgggttcatt	tattaaaaat	cactcccaat	ctacatatca	tacatgcaat	gctattgtga	1500
gatatgtaga	ttaaaaataa	aaaaggatat	attataagat	taaattttatt	tctacaaata	1560
aacttttcaa	tgtacagaat	atactgaaat	gataccataa	cttgatagtt	ttctgtgttt	1620
atagccattt	tcttacctgc	aataacaaag	tagtacagca	aaaaatccaa	ac	1672

&lt;210&gt; 18

&lt;211&gt; 2433

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ggcacgagct	ttcccccttca	agaagccttag	attagtgtga	ttaaatcagt	gtgatacagt	60
ggtgataaga	gatccagcac	tccactcgac	atcattgtcc	gttgtcatga	caccaagtta	120
cagcatttga	tcaatgggtc	ctgtgccatg	ttgcagtaca	cttggtcat	cttagtcttt	180
ttgtcaagct	gccttttcagc	gacctgggtc	tgcaaagtgg	ttgtggcagc	cattggatcc	240
acagtgggga	gctccaggct	acactttaaa	agaagtggct	agtgtttgag	atgacgggca	300
tgccagttac	cctgatctga	tactataacc	ttataggtat	agaaatgtca	ctagggtgcc	360
agggatatgt	ataattatta	ttaatcagtt	aaaaaataaa	ataaatgatt	gagaaaactt	420
cagttgttca	tatccaagaa	gggaggggct	gcctgagatt	cctgatgggg	agtggggtct	480
catgtcaccc	ccagtcgcca	ccatgtgcta	ttttcttccc	aaaacttgga	gcgtgggtcc	540
tttgctcctt	tatcttgaca	ggtggatgcc	atgaattctc	accattttta	gatatagatc	600
aggtgataac	acattttccc	cataaagttt	catagttttt	tgagttgtct	gcattgtctt	660
tctaagccg	tcttttctaa	cttttctggt	cagaggatat	atcctggatt	agatcagata	720
aacacagatc	tattacatac	attgagagga	ataatttctg	catttgtttc	aactgaacac	780
tttttagaaa	atgaaatagc	tcatgggtat	gaaaagaaca	cggatgctgg	agtcagaaa	840
gcctatgttc	aaatccctct	tactacctgt	acttgaataa	cagcttaggc	agtgtggacg	900
aaggtacct	agtcctactg	agctttttta	tctaagctg	caggaagggg	ataacaccta	960
cctcattagt	gttgccaaaa	taacaaactt	atttcgaaa	catcaggcag	aataaacctt	1020
caacagaaga	gctaagggtc	ctttcttttc	tctgtaacta	ttaaaatgcc	aacatttttag	1080
ctaggggatc	caattcaaac	ttcagtatcc	taaaggggca	ggacaggctc	tcacacagct	1140
cctgggctgg	ttattcaaa	ccaaggtagc	ccagacatcc	tcaggctcct	cacaatgctg	1200
ggaccacttg	tacatgatct	gggaccagta	gctgctatct	gggactgtgg	tccacataat	1260
cacagaaa	aaaaggctca	agcctgttat	gggttggtat	gtatccccct	aaattcccat	1320
gttgatgtct	tgtctccag	cacctcaaaa	catgagctta	tctggagata	gggtctttac	1380
aggggtaatc	aagttcaaat	gtggtcatta	gggtgggccc	caaccagaa	tgactgatgt	1440
ccccataaaa	aggagatttt	agataaagag	gcagacactc	atataggtag	aacactgtgt	1500
ggacatgagg	atgaccatct	acaagccagg	gtaagaggcc	gggaacagac	ctgtccctca	1560
cagcctcaga	aggaaccaac	cctgctgata	ccttgatctc	tgacttccag	cccccagaac	1620
tgtgcgagga	catactgctg	ctgttggaagt	ctgtggtaact	ttgttatcac	agcctcaaga	1680
aactaatata	aagccactat	ccaacaaact	acaaagaggt	acaactocca	ttttcctaca	1740
tattctgaag	ccttacattc	tctcatcag	catctgcctc	ctacaaagca	ccccagctc	1800
cagtggacac	cccctgccct	tctggactcc	ctccgacctc	gtgagcagaa	gacgccttcc	1860
ttttcttaaa	gggccagttc	aggggtactg	ttcagtgaag	ctgagtatga	ctgaaagtca	1920
ctaaaggtaa	ctgggataga	accaggtttc	tggctactgt	aaataaagct	gccatgaaca	1980
cttcatgaac	ctgaaagagc	caatccttcc	aatggatcc	tgagtggcta	actgggtcta	2040
aattcagaat	ggagccagg	cacaaacgtc	ttctgcattc	tctgagaaac	cacaggctcg	2100
cgtgatttgg	ggactttcat	ggctgtctgc	tctattttat	gctccctgat	ttgatgggtg	2160
ctgggaagtc	tcatcttgac	ttctggatct	aacaaataga	cttgtgactt	gcattgacca	2220
atcaaaaacca	aacatacttg	catccctctc	acttgacag	cagaccagag	tggaatctg	2280
ggtgggagct	ttttctataa	aggataacct	gtctctctgt	tctcaggag	agcatctttg	2340
ttttgtactg	aaggctgggt	ctccctgggt	tgcaaaactgc	ttacaggaat	aaaatcattc	2400
tctttttttaa	ggaaaaaaa	aaaaaaaaa	aaa			2433

&lt;210&gt; 19

&lt;211&gt; 3478

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

ggcacgagca	tgcttctact	tctgggtgtt	ttgggtggct	gttttatcaa	caggaaatgc	60
cagaaacaga	ggaagaagaa	gcccgagag	gacatttttg	aagaatatcc	tctgaatacc	120
aaggtagaag	tgcccaagag	gcaccgggac	cgggtggaga	agaacgtgaa	tagacactac	180
tgactgtgc	ggaacgtcaa	catcctgagt	gagcctgagg	cggcttacac	gttcaaagg	240
gctaaaagtc	aaagactgaa	tctagaagtc	agagttcaca	acaatttaca	agatggaaca	300
gaagttaaat	ggaggagacc	tatgtgtatt	tttttctaaa	atcattttta	taaaatgggg	360
ggaaatactg	gtatttttat	aatctcgag	ataaaaaagg	gaaaactata	gctttgagt	420
gcagacagca	cacatcacat	gcataactc	acaactgagc	tacctcattc	agcaaagaac	480
actgagaac	cccagagtat	tacagttatt	tccgtagatc	cctttaatag	tgtcaacaac	540

tgtacacagc	tccttctgta	aggctggtct	tagaaaacaa	gtacttttagt	ttcaggacag	600
gagttgaaca	attaggttag	cagatggaga	tgagaggact	gggtagagta	ccatggcaga	660
tctcagagag	aagaagtagg	tacgggcctt	tggttccctc	ccccagcccc	agctttctcc	720
tacagggctt	ttcctgagtc	cccagacagc	agagtatgaa	ctgctgacac	ccagattcca	780
ttaaaaattc	tgctaatacg	cacaacacat	atatttgctc	atgatttcac	ttgacagcgt	840
atgctccttg	gcctctaatt	gtactttgct	tttccagagc	cctttttacc	tggggatttc	900
agtgtgctta	agtaaaatcc	tctgaaaacc	acgggagcct	ctgcctcctc	agccacagag	960
aactccctcc	tacaaagggg	gagactgaaa	cccaggttaa	ggaggggcct	ggcaggcgta	1020
tcagagcaca	ttagtgatgc	ccttcacccc	agggaggtgt	ctgttcccaa	ctagtattatg	1080
tggcactgag	acatccatcc	ctgaccaagg	atgctgcgaa	acaggatcaa	tgtactacgg	1140
ccttttaatt	caacattgcc	ataaatgctt	taaagaaaac	ccaccacact	ttctccttac	1200
tccggtcttt	gcccgttcct	gtaacagaca	atcccattgtc	ctaggtatgg	ttttttatctc	1260
tgttagtgtc	tcgggaaagt	aagtgattca	tttgaataag	gcaaattagg	agaaaagccca	1320
ggttgggggtg	aaatcagact	taacagatac	atgctgggtc	tccttgctgt	gtgtgacaca	1380
gcagacagag	gcactattcc	tggtgcagta	tttcagggat	ttctctttga	ggggttcttt	1440
tctggtagct	caggcaatta	tttttaccat	atcagcacat	gacaaggcca	tgaacacatg	1500
gctctaaaat	aatttagtgt	tcaagtatca	gcttaactat	tttgtgtagg	ctacacacag	1560
cttgcttttg	tttctcttct	gtttctgcct	tattggcgga	aacataagcg	tgcatgccat	1620
gttgttttga	attggaggca	caatttcatt	attcgagagt	aaaagacatg	tcctcttctg	1680
atgcatggca	caccatagtc	accaagcaaa	taacagagcc	ttcacattgt	gtaatatattg	1740
tatgagaatg	actcaagctc	tttgagaaca	ttccaaacta	gtaacatttc	gctactaaaa	1800
gctagaaaagg	atgaactgtg	aaaggttcta	ggcagctctg	tgagactcca	agctccttga	1860
aagtaggacc	tttgtgagcc	acgcctttca	ttcttcaaca	gtgccttgca	tgtaacaagc	1920
actccagaaa	tgattgttga	atgaatgaat	ggtgtcatgg	gtgaatgatg	gggagtaaat	1980
ttaggaaggg	gaagtggag	agtatggtgg	caatatcaca	agggaggaga	gaggaaaaca	2040
attatcttct	ctacttggat	tatgagataa	ccttttcttg	gaggaaagaa	acaccgcttt	2100
acaaaggcat	gactctggcg	gtggtcctaa	ggaagcatga	gcagaaaatt	cataaaaatg	2160
tatcatcagc	aggagatgag	actatgaatt	ggcatccaga	acaggagatt	tagagcaaaa	2220
tctaatttag	cattctgaga	tgagtgtcag	gttttcagga	gagaatgagt	tggggtgagc	2280
ccagagtctg	aaactcctga	ctggtcaggt	gctacttaag	accagcttgg	gcaattcagg	2340
gcagaactcc	tgtatcagcc	tcattggacac	ccagaattgg	tatctcatgg	ctggagagct	2400
gatcagccag	gcacagaatc	tccagaacaa	cctagagagt	gaatgctaata	ttgtagagcg	2460
aatttccatt	tggcccatca	tttgaactg	tgtaactgct	ccaagtgcc	gaatgcttac	2520
acgttaaagc	agcacctttc	catttgccca	catattcttc	ttgcacaccc	cttcattac	2580
tgctgaatag	gacattgcat	gggaagagta	cagaggtggc	agaatgaagc	tagagtggga	2640
aggactaaag	actgagcccc	agagtgtctc	cagcaaccgc	cacgtacaag	gtctgaaatg	2700
acaagggcaa	gagtgagata	ggaaactgtg	tgtgaaagga	aagcccttgc	agtatttctg	2760
cctccctttc	tttctgcctt	tcacccact	aaatgaacgt	tattgaatgc	cagtacttct	2820
ctagtggatg	cacacttggt	aaatagtgtt	aagagatgtg	gagatgagat	ataccctttt	2880
gatgtagaat	tattcatttg	gtttgtttca	tacttcatta	taggaatcaa	gtaatttgat	2940
gactaatgtg	gattatattt	cagtcaaagc	tctgctttca	atttctctga	tttgctcact	3000
aatgccttat	gtgtgtttta	ctaacccttt	atatcttgcc	ttcaagtgag	aaggaacaaa	3060
caactctcag	tggttactac	ttgcttttat	atgctggctg	tgaagggttaa	aagaaagaat	3120
ggtctgtacc	attttttctg	ccttgctgcc	cttttattgt	accccaggcc	tcctagagga	3180
ctcctgcaga	ttctattgtt	gggtgggaaa	tagtggttga	atgtgtttgc	acagtcttat	3240
gatattcagt	ctcagtctgc	tataggtatt	tgttattctt	ggatactaca	cacctgctca	3300
gactgagtaa	acattttgtg	tgctgtcaac	ctgatttctt	gactctcaaa	tgatttttgt	3360
atttccaata	tgaattttgt	tgttatgaat	ttctgatttc	tccaatagta	tatgccacta	3420
tataaatttg	tattaataaa	tgacagtctt	gttggttttt	aaaaaaaaaa	aaaaaaaaaa	3478

&lt;210&gt; 20

&lt;211&gt; 2987

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ggcacgagct ggtggcatgg acattcaagg taaagctctc tatattagat ttctttctcac 60

cctttgtcag	atggtagtaa	gtgttatggg	gaaacgaagg	caggggagga	gggggctggg	120
tggagcagct	gctgtgggga	gagagatctg	caggaggtgg	ggatgctgtg	tgacttgaga	180
gagtagcttg	ccctctcttg	gctcctgcct	gtgtgtgctg	ggggaacgat	ggcgcccact	240
gcccctgggtg	ctgtctttgc	cacatcattc	cttggggact	tctgcccacc	agctgctcag	300
accgtagctg	tgctggctat	gctcttcctg	tgcaggtatt	gactctgagt	cctcatcacg	360
cctgttatga	tgcgcatttt	acagatcagt	agactgagac	ctgggcaggc	cctctgacta	420
cagactgagc	tcattactgc	acacagcgtg	ctgccagtac	atgctgggct	ctgggggtgct	480
ggagccgcag	tcctggcccc	atcaatacaa	tccaaagtga	gctggctctg	atgaggaaga	540
ggccaagatg	ccccactcag	ggaagtcttc	ctgggagagg	tggtagccag	gcagacctgg	600
gagtaggagg	aggtagggct	gggctttgta	gacaccacac	ttggtgggac	agaggcctgc	660
tagggagagg	gcctgtgtcc	ttgccaccag	cccatcttcc	acgccatgtc	cccctgcact	720
ctttgaaggg	agatggtctc	ttttggggct	aagctggggg	cctggagcca	gaagagaact	780
gagatttgct	gtgggggggt	gggagctggt	ccatttttag	tggtgcttac	aggaagagcg	840
gccgagtgtt	tccccttgtc	cctgcagaag	gctggagtgt	aactgtcctt	gggaactggg	900
tcagctgata	gcagggctgg	gggtgggggt	ggggatcctg	aatcctccag	cagatgtcct	960
cattgccctg	atctgggtgg	ccagtgcctg	tgctggacac	ggtcctcagt	catcgagacc	1020
cactgagtct	ccccctgacc	ctgcagagaa	tttcaaagag	gcgaagttcc	ttccagtggc	1080
ctcacaaagg	ctatctggct	taggagccat	tacctgaagc	cagaatttct	gagttccaag	1140
tcccagctcc	atcacggaac	ttggcccaag	gcccttaacc	cctctggggc	tcagttttgt	1200
catctttgaa	atggggatct	tagagatgcc	tacctgtcaa	gggacttggt	aggcgcaacg	1260
ggaccacacg	cagggcctgg	ccagagtgcc	gtagtttctt	cgggtgccat	gatgggacgg	1320
tgaactcct	cacactcttc	tttctgcctt	gaagattcta	gacctggctg	ggtgttcac	1380
tccctttttg	cctttgcttg	aggcagttta	tggcatggct	gtgttattca	cgtcgccagg	1440
tctcctcctg	gtggacgttg	aggccatttt	cattttttta	ctcttaaaaa	cgacagggca	1500
gtgcacatct	tcgcatctcc	ggggtgggtc	aggctctctga	cctctttgcc	agtgtgactt	1560
attaccctct	tctttctttg	tttttctttt	tgagacagtg	tcttgctctg	tcgccaggct	1620
ggaatgcagt	ggtgtgatca	tagatcatag	ctcactgcaa	cctccagctc	ctggctcaaa	1680
tgatcctccc	acttcagccg	atattaatcc	attttcatgc	tgctgataaa	gacgtatttg	1740
agaccgggca	atttacaaaa	gaaagagggt	taatggagtt	acagttccac	acagctgggc	1800
tggggaagcc	ccacaatcat	ggcagaaggc	aaggaggagc	aagtcacatc	ttatacggat	1860
ggcagctggc	aaagagagtg	agagagcttc	tgcagggaaa	ctcctgtttt	taaaaccatc	1920
agatctcgtg	agacttattc	tctatcacga	gaatagcacg	ggaaagaccc	acccccatga	1980
ttcattgata	tcccactggg	tccctgctac	aacacaaggg	aattatggga	gctacaagat	2040
gagatttggg	tggggacaca	gagccagacc	atatcagcct	cccaagtagc	tggaactaca	2100
ggtgtgcgcc	aacatgcctg	gctaattttt	taaatttctg	tagagacggg	gtctcactgt	2160
gtcaccaggg	ccggtcttga	actcctgggc	tcaagtgatc	caccctcctc	ggcgtcccac	2220
agtgtctggat	aataggcgtg	agccactgtg	cccagccatt	tcccccttat	tttttagcatc	2280
actacagtag	ctgtgatctc	tgagctttgg	ggatatcccc	tcccccaacat	tttactctga	2340
aaattcgaac	atctggaaac	gtcaaggctt	tgtacagtgg	acacctgtgt	actcggcagc	2400
caccttcctg	gatgaacatg	ccttatattt	gctttgtcct	caatctgtga	ttcgggactg	2460
gattttctct	gtttcctggg	gggacccaca	ctgctgtgca	attacttatt	ttgttcccct	2520
tcattcccagt	cttgcctgtg	ctttcagata	ccccggggtc	ttatatacac	tcagggttat	2580
accagaaaaa	cattttctct	gggggatttg	tctctaggta	ggggggccctc	ttgaatagtc	2640
agggggagaa	agaaagactc	aagaccagct	ctgaggaggc	ggcaggggtg	ccccctccct	2700
ctacctgtgg	gctccttggg	gaagaaggac	aagtgagtgc	catgagaaat	acccctgggg	2760
atthttgtgga	gctggaatgt	gctgggtggac	catgaatcca	caaggacttg	ggcatcgaac	2820
tcccttgact	gggacccaca	gcaagggagg	ctctgcagca	tcaccttaat	caaattggact	2880
caccctctct	gggtgatgta	tccctgggtg	tccctctctg	ttcatcagtc	aatcaacaaa	2940
taaatggctg	ggcgtggagg	catatgcctg	taatcccaga	aacttttg		2987

&lt;210&gt; 21

&lt;211&gt; 2827

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

ggcagagacc ttcatcaatt ctgggaaatt ttatctattt tcactttgaa tatgtcccag

60

gtgcattgta	tctatTTTTat	gaccatgaaa	cttatatttag	atctagatga	gacttatttct	120
atTTGCCatg	tctcctaaac	TTTTatttct	atTTctattt	ctttatatct	ctgtgaagag	180
TTTTgattta	gTTTTgtctt	ttaggtcagt	actcttcatg	tcagatctaa	tccactgttt	240
ttaccatcaa	ttgcattTTta	aattataatg	attatgtttc	actttctata	aaatattaca	300
gTtatctTTta	ctaaggTata	atTTacataa	atatataatg	tatttagata	tattttacata	360
taaatacata	catattttaca	taaaattaat	tTcagtgact	tcaagggTac	aattcatcgg	420
atattttatat	atTTcctata	catataatat	atattatata	tatttcatga	ttatacatat	480
aatatagcac	aatatgcaat	atatgtTaata	catatgtata	atcatgcaat	attatatatc	540
ataatatata	atatattata	tatgtgttat	atattataaa	tatatatgtg	taactctgca	600
accaccacca	cagtcattga	aaatatttTgt	atctgttctt	ctgggaattt	ttccccctaa	660
tcttctgtct	catctTTTTt	tatagtatct	tgttgctttc	acataTTtac	atTTattTTta	720
tgtattctat	catttaaaaa	tatttatgtt	ataatgtgca	tccagTaaat	ctataatctg	780
aacctccttt	ttctTTTTtga	gacagagtat	cactctgtcg	cccaagctgg	agtgcagtg	840
cgcgatctcc	ctcacggcaa	cctccgcctc	ccgggtTcaa	agaaattctc	ctgtgtcagc	900
ctcaggagta	gctgggactt	caggtgcatg	ccaccacatc	cggctaattt	tctTTTTtga	960
TTTTtagtag	agacggggTt	tcaccatggT	taggtggct	tccaattcct	gacgtcaggt	1020
gatcaacctg	cctctgcctc	ctgaagtgtc	gagattacag	acttgagcca	cggTgcccc	1080
ccaatctgag	cctcttatgg	tctacttatg	ctTTaatttt	TTTTctgtaa	attaatctca	1140
tggTtgcttc	tctccttgaa	tgttttTgtac	atatgtactg	tgtctgcata	TTTTtgca	1200
TTTTcatctg	tgacaattct	gtatggcctt	tattgtaggt	atgtccttca	agagaagatt	1260
ggcatttgct	tttgctagat	aactcacagg	tgcCaagaa	cacttaaaag	ttTgtattat	1320
gtaatgtttc	acacataaac	agaattttca	tttatctata	taagggaatg	catacatata	1380
tgcatatgtg	tcatgtgtaa	gtaaaacaat	aaaataaatg	cctcttcgat	accgacagat	1440
taagaaacag	aacttttagat	gaacactgat	atggTtaggc	ttcgtgtccc	caccacagatc	1500
tcatattgaa	ttgtaatccc	tataatcccc	ataatcccta	tgtgtcaagg	gagagaccag	1560
gtggaggtag	ttgaatcatg	ggggTggTt	ccccatgct	gttctcatga	tagtgaTga	1620
gttctcacga	gatctgatgg	TTTTtatatgg	ggctctttcc	ccttcaactg	gcacttcttc	1680
ctcctgtctg	cttgtgaaga	aagtgccttg	ctaccccttt	gctttccgca	atgattgtaa	1740
gttttctgag	gcctctcag	ccatgcggaa	ctgtgaatca	attaaacctt	tttcttttat	1800
aaattaccca	gactcagcag	ctctctacag	cagtgtgaga	atggacaaat	acaaccactt	1860
tttacaataa	cttcttagga	cctaactatc	cactctggTg	ttcagtttcc	tccccatttt	1920
TTTTTTtTga	cctgaaaata	tttctTTTTga	ataaatcatg	catttctTTta	tatattcagc	1980
agatatattt	tgaatactga	ctaggtgtca	gacatgattc	taagtgttag	gaacacaaaa	2040
gtgagcgaaa	cgacaaaaac	ctcctgctct	tagaaagtct	ccatttttagt	aggggcaaga	2100
taacaattaa	aaggaataag	taatgcattt	agtataccaa	atgggaatca	atgctacagg	2160
ggaataaata	aggaaaagag	tatagagagt	gtcggTatgg	gcagaaagta	caccttgaaa	2220
tgggaattcg	aggaaggctt	cactgagaag	aaagaattga	agaaggTgac	cagtgaagTt	2280
gtgtggaagc	tgggaccagt	aaaaccaaT	gccctgaagt	gttagggTat	agataaataa	2340
aagcaaggga	gtctgcttgg	ctggagcaga	gtgatcatgg	tgagaggagc	tcagagctat	2400
acaagggtgt	actatgtagg	cactggaaga	aatttgctt	ttactccaag	tggaaactgga	2460
agcctttgga	atgcttccag	aatagaagtg	atgtcatctg	acttatgttt	taaatagatc	2520
aatctggatg	ttgtgttag	atagactgga	attggTcaaa	gataaagcag	ggacacccca	2580
ggaggctatt	atagcaacct	agatgacaaa	gggcagTggT	tttcatcaga	acaatagcag	2640
tggaaagtgac	aggaagtggT	caggTcagat	tctggaagta	TTTTtaaggt	aaagaatata	2700
ggacttgTta	atggattgta	tgtgggtgtg	aaatagaaga	gtcaagaatg	actacattgt	2760
tttggcctga	acaactgcaa	ggatagattt	aatatgaact	gagagagaga	gagagagaga	2820
actagtc						2827

&lt;210&gt; 22

&lt;211&gt; 2476

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

aggtgcacct	ttgggctgcc	ctggccccca	ctctccccgg	ccgccccacca	caggctcttta	60
atggggccgg	gtcagtccta	catgtgagat	gggttagggc	aagtcttttg	catccccag	120
atggctctgt	cttcttTgtg	atggcagggc	tgggactgct	gtcccttgta	cagttttctg	180

tcactggtgg	gcactggaca	ggcatagcag	actctcttgt	ggccacacta	ggttgtcgcc	240
tttcaggcag	tgtcccgcga	cctttgcttc	ccgtcccttc	tggacattcc	agagccctgc	300
accaaaccct	tacttggtgt	ctgcacctcc	tttccctctc	tccatcttcc	aatccctgga	360
aaagtctggt	ctgagtgtga	cttggggaagc	tttcagtgtc	gctgtttggc	ccagctcatt	420
actttctccc	tttctctacc	acagcaaaca	cattctccac	catgtcagtc	taaagagtct	480
aaagggggccg	ggagaagcat	gagcgagggg	cagattctag	tcgggagccc	atgccctgga	540
aatccatctt	tcttcatctt	tcccattgac	cactttgggt	ttgacctgca	catctgcagt	600
gagggcgagaa	ttcaacaagc	acaactcact	ggtctttcag	tcaacgtgct	agaaaccgat	660
gacttattaa	tctctaattt	tttgggcgcct	ctttcattga	atgagaattg	ctttcgtata	720
gttcacatta	gaaaaatgcc	taatatacta	aagtaaacca	aacgttgtca	cttttctctt	780
gttcttgaaa	cattgcaacc	aaaaagggtca	gcacaaaggc	cttcacctac	gtgaagacct	840
cctggtagga	tctgtccatg	ggatggagaa	ccactctgtc	cagatctggg	gttgggtcat	900
gacaccagct	accaatttta	gaatattatt	tcttgggttc	tttatgaaaa	atgggtgcta	960
gtggttaattg	ctttgtggct	tagtaaaacta	ctctgtggat	gatttccaaa	cattcaaagc	1020
caatagcctt	gttattaaca	agatattttg	agtacaatat	ggctcattga	cttttccatt	1080
acatctgagg	attccagagt	cctctgttca	tccctgggat	agagtgcgac	ctcttgcgtc	1140
ttccagggtta	gctcaggttg	gcccagtttg	ggccagtcca	tttttgaggg	tcactctttc	1200
ccccctcatc	ccctcacctc	cttctcttta	cccccttcac	gtacttcctt	tctttcttcc	1260
ctctgttatt	cattcatcaa	gcagggtaaa	gccattgtgc	taagatctaa	tctgaggaca	1320
ctataatggc	cctgtcgtca	gggaagcccg	tgatcgctcg	ttttcagggg	tcttaccggt	1380
cagcaacctt	ggcattgata	cataggcact	ctacagaatt	taagttttca	gaggtaagtc	1440
tgttgttctg	attaatctgc	attcattcag	cgaatgctca	agacaagcca	ggcatgctga	1500
gaagcggcgc	tctagtgtga	tgtaagatgg	gcattcctct	gctctcctct	attctccatg	1560
tcgactgaga	agagtataat	aagaacattg	taccctctcc	acacttaacc	ctctgggatt	1620
ctttattata	atataaacca	ccgtcgtgag	gcatttacct	gttggatgga	aggtagacag	1680
caacaagatt	ttaatcacct	ggtcaccaga	ccctcacggc	ccatatccaa	ttcgaatttc	1740
agaaatttct	ctgtttgctt	taaataactc	tttacaataa	agggtcgggc	acgggtggctc	1800
acgcctgtaa	tcccagctct	ttgggaggcc	gaggtgggca	gatcacgagg	tcaggagatc	1860
gagaccatcc	tggctaacat	ggtgaaaccc	cgtctctgct	aaaaatacaa	aaaattagcc	1920
agatgtggtg	gtgcacacct	gtagtcccaa	ctattcggca	ggctgaggca	gtagaatcgc	1980
ttgaacctgg	gaggcggaga	ttgcagtga	ccaagatcgg	gccactgcac	tccagcttgg	2040
gtgacagagc	aagactccat	ctcaaaaaaa	ttataaataa	ctctttgcaa	ataggaaagt	2100
gaagctcaag	ggtaaccagt	gaggctatga	aattgccagt	gaattaagac	cagggctaga	2160
gtcaacagtc	cagaacccct	atccgtatga	acaggggccc	gtttctgggt	gaaatcaagg	2220
ttaggatgca	actgagaaaa	taaaagactg	cactttggag	aggcaagcac	gctatccggg	2280
ttgttgtttt	gttttatgtc	ttggtgctta	ggtgaggact	tagctgggtt	tattcaaagt	2340
gggcgggtct	gggtatttct	tgagaatgtc	ccttccattt	ctgagaacaa	gtcagccct	2400
tctacctgcc	tccacccagg	agactgatgc	acaagatctg	tttgtgaaag	cctgatttaa	2460
aaaaaaaaaa	aaaaaa					2476

&lt;210&gt; 23

&lt;211&gt; 1292

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1143)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1275)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 23

tggagactcc actcttttggga agattctctt ctgtaaacag aggccgttat gaatgaaaag

60



ttccttcccc	cacttttgatt	gatcctggat	gtgaatccat	ctgcccactg	cagctcgtea	120
ggaggggaagg	aacgaggctc	ccagagcaga	ggccctcgat	gcttctgttg	cgctgtgccc	180
ctagcctggg	gacccatttg	tttcttaaca	tgctgaggcc	acccagatgg	gccctcatgg	240
ctgcctcttc	tcacccccct	ccactttggt	cctgggttct	aggcctggct	gcccaccgga	300
caggcatgag	ccctgggaca	gggccccacc	atggctgggt	ctctgcttcc	tcactcttca	360
gttgagatgg	tgaagcctcc	tttgagggt	actgtgaggg	tgagagggtg	gatgtaattg	420
agcgaatgca	tgttcagccc	agtccaagt	ctttagtaaa	catttggttt	taagattaag	480
ttagatagat	agcctagctg	ttctttttgt	tttccccagt	caggaaagg	acctaaggga	540
ttccattctt	ctcaggagtg	caaagtcttc	ttataaatca	tttaggccag	tcctctgatt	600
tttcagatgg	ggaaactgag	gccagagag	ggttggtcct	taaaaaata	taactgcaa	660
ccccatgcac	tgtggtgccc	acttcatgcc	atccacagtg	ccaccacggt	ctgggagtga	720
ggcaggtatg	gctgctaacc	atccccacct	cacttggggg	aaacagaggt	tcactctggg	780
ggagaagcag	gggagccagc	tctgtcttcc	cctcctcggg	ggccctgctt	ggagaaaaag	840
ctgagaaaga	gggtgggggg	tggggagtta	ggcaggctgt	gtcctccagg	cctgggagcc	900
ttggctgggc	agtgccggcc	tgggtgggt	agtgattctc	ctgctcagca	tctgcccctg	960
taggtgggga	gacttacatt	cttctcagta	acagtaacag	gaaccatgat	ttaaatggac	1020
actctaggat	gggcatggtg	gttcatgccc	gtaatccag	cattttggga	gactgagggtg	1080
ggcggatcac	ttgaggtcag	gagttccaga	ccagcctggc	caacatggca	aaaaccccgt	1140
ctntaccaaa	agcataaaaa	attagccagg	catggtgatg	tgcgcctgta	atcccageta	1200
cttgggaggc	tgagacagga	gaatcgtgcc	actgcactcc	agcctgggca	acacagtgag	1260
acgccgtccc	ccacnaaaaa	aaaaaaaaaa	aa			1292

&lt;210&gt; 24

&lt;211&gt; 2072

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

ctcgtgcccgg	agcagccccac	aggacctggc	caagctgcag	agaatgtcac	catccagact	60
gtgtcctatg	gggtacaaga	ggagctgcgg	gaccaggagg	atgaccagga	ggaagaggag	120
agcgatgcca	cttcaacgga	gagtgaaggt	gaagacaact	tcctcacgct	gcctcccagg	180
gaccacctgg	gacttactct	cttctccatg	ctctgctgct	tctggccact	gggcattgct	240
gccttctact	tctcccaggg	gaccagcaag	gccatctcca	aaggggactt	ccgcctggcc	300
agcaccacct	ccgcgccggc	cctcttccca	gccacactcg	ccatcgccgt	gggggcccgt	360
ctctacgtgg	ctgtggtggt	ggctctggca	gcttacatgt	cccagaacgg	tcattggttag	420
tagccagtag	gcctgcatcc	tgactcccct	gccacactga	ggaagcagtg	gggcttggag	480
ttgcagaccc	tatggaaagg	cccggcccct	gaagatgata	ccgtgagagt	ggcttgetga	540
gggggagacc	cccattccac	agcctgcaga	gctcagcctt	cacttctgct	tgcccgtctc	600
tcccagcccc	agagcagggc	ccggggcgcc	actctctaac	ccaggctaca	gacgggaaac	660
agaaggcagg	gctgcccacc	aggccatccc	agcagggcct	agctccatcc	attctgcccc	720
ttccctagag	gatctcctgc	cctacagcca	gccaccacc	taccctgcca	acctccccac	780
agagaaagag	caggagggtta	caggagaaaa	agggggtgcc	cagagcacia	ggggaccctg	840
ccaatccctt	tcagcccaca	gggatcttca	cctggggaca	gcctgagctt	cccccaactc	900
cactgtctgg	ccccatcatg	cccagacctc	agcaggccaa	gaaggaaata	cgtggaggga	960
agggggcctc	ttgctgtctc	tgattctaga	gggtgcttat	ctctgcatgg	gcttgtgagg	1020
cactgtagat	tctagatagg	gaagaggagc	ctcggtatgt	aaactctgaa	ccaagggcag	1080
gtccttgagg	cttcttcatg	cgggtgcaaa	aggcagttgc	aatgacagag	aatagagggt	1140
cctgaaatat	tgctgtacta	catgactctt	cctactctcc	ccccactccc	cgccccatc	1200
atccttttct	gggcttttgc	tgggggtccg	tgagctgggt	ccatcacaa	tagactagac	1260
ccagagagtg	ccctcagctc	accagccact	gagcgcaggg	ccctaggtcc	agccctacag	1320
aaaacgcagc	aaggagagac	cctagggagt	agtgagtata	gatgaggga	gggactcagg	1380
gaaggaatgg	cctgctgagt	agtcagcgg	gcttaggaag	gcttccctgga	agaggtatcc	1440
cttgagcaag	gcctaggatg	aatagaattc	atctgaggga	tttggtcaca	taactctttg	1500
tattttagtg	cagggatgtg	gcaggaacct	tccatgggaa	gcttccaggc	tgtttggatt	1560
ctgcctggaa	catctgggct	ggagccaaac	tacagccatt	cctaagggtt	ctgccaactc	1620
aaggaggaac	gtcacacctg	tctctcaaag	accaatgatg	ttttccatc	tctgaatgct	1680
aggggggtcag	tggtgggtac	ctggttacc	ctggggcatc	ttcactgata	cctctgctca	1740

gtgccagtct	caacaccctc	agccactagg	gcacatccag	aatttttagag	acatctccag	1800
gtaggcgggg	ggcagcacca	atgtgggcag	gcctgtctgg	actcaagcta	caggccctg	1860
ctgtgcatga	tgtgggaacc	tggtcattcc	catgccccat	ccagagccca	gggctgtggc	1920
tccaccactg	agcatccctt	gtcccactgt	cctcccctgc	ctcgggcact	gcccagccct	1980
ccactcctgc	atcacagcag	ttttaagggtc	ccattattgt	actgatttat	ccttgtaata	2040
aatgtttctg	taacaaaaaa	aaaaaaaaaa	aa			2072

&lt;210&gt; 25

&lt;211&gt; 2777

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

ggcacgaggg	gacatgtctg	ggcacaagga	aaggcaagca	atggaggcag	caagagccct	60
tggcagcaag	tttccatcac	ctttgcctgc	cagtgtgtga	gaggcgcaga	ggggcagtga	120
gcaggtgaca	tgcagcttcc	agatacccac	acactgcttt	tctcccgccc	agctcccacc	180
ccagttaatt	gagatgggat	tgtttctctt	tctggtttct	tcctaagccc	ctctctcata	240
ttcctgggtg	gcttatggcc	tggcacacct	tgtgaaacag	aaaccaagc	tcctcatttc	300
ggagctggga	tttcgattgg	ctatctgcct	ccctaaccac	gctgtccctt	ccacctcatc	360
cctagagtca	ccctctgggtc	tcatcaacat	ccagtgggca	tttcagtggc	ccaggatcct	420
tcaaatgca	gatataaagc	atcaggaccc	cacacctggg	atggaagctt	ctaggaatta	480
atgaagcccc	agtagagggtg	agggtaaacc	taaaacgggc	tggatagggc	ctctcccaag	540
gccctatgga	aagggtgatgg	gaaactgggg	gctgaggcct	catcctagga	gacccttgga	600
gggaccact	taccctagat	aggcagcggg	ggccagaaac	tggaaaacag	ccactcattg	660
tcggtgcatt	accgtgagca	ccacctgtag	ggactctgtt	ggcctccagc	cgctcgcaca	720
cgttectgac	aaccacaaaa	gttcatttga	gggtgcccag	tcagctgact	ttgcttcac	780
caggaatacc	cacctggccc	tggtccttct	gctgagctac	aggaggcatt	cccagggtct	840
tagcaaaaac	aacccctcaa	ataggcccag	tgctacaac	tctagagagg	tttcagatgg	900
tattggagac	ccagagaagt	taactgactt	tcccaaaagt	caccactgt	aaatggcaga	960
cagatctcaa	acccacatct	gagcctgagt	ccagtgtttt	ttctctagta	tcatcattgt	1020
cccttaaagt	tgtttgacac	atcatagttt	acaaatcacc	ttcactcata	ttctctcact	1080
actcatcagt	catgaattca	gccaatgaga	agggctcaga	gagggttaact	aaccagccac	1140
gctgtttaca	tggggcatag	actgcttcat	gaacgcttga	ctgcagcttt	gccttcctca	1200
tgccctcaaa	aaggaaggag	ctgaccaaaag	cttactatac	catagctggg	gtctgggacc	1260
cccagccagg	tctcacagat	gatctgggaa	tggcctccct	ggtgctctca	gggggtccggc	1320
agtcacacag	aagatgcagg	ttgaaatcct	ggcaagactt	tgggtgtggc	ttgggaaactg	1380
ggtttaacct	cttggggact	tcaccaagac	agtggcaaa	gacaccacct	acagcttcca	1440
gtgcctctct	actctccac	ctgtgctcct	gggggtgaat	gagaccagaa	gcagctggga	1500
caagatttgg	aaagataaag	agagccagga	gacaagacct	tgagagaagc	agaggctctgg	1560
ctggctgctg	ccctctgggtg	gtgacaatgg	tgacactgta	aacccctctg	tcaaggtgac	1620
actctcccct	gactattcag	gaggggagaag	caatcgcccc	aggacagaga	cggggacatc	1680
ccaggagcag	ggtacaggct	ctagcaatat	ccatcttgcg	gtactccctc	cctcacaaca	1740
accagaccac	acatgtgtta	aatccttctg	cagggatgga	atgaggctct	cagttttttc	1800
caagaacttc	taatctagga	attaggagag	gtgggtcaaa	ctgaatgaag	cagtgggcaa	1860
agagagggtg	agggatggga	gagaagacag	gtcaaggagg	aggtgggaga	gaaggggagg	1920
gttgcatgag	ggacaaggaa	atggcatggg	ttggagctgt	ccccagtcct	tatctggagg	1980
gacttccaac	cttccagatt	cccagctgat	atcacatgtc	caacctcagc	caggcgattt	2040
ataagagaaa	ggtcagggat	gccactcccc	ttgtaaaaagc	aaacatgcag	catctggaga	2100
agcaaggggt	agatacaaa	attccaaggg	gtcaccaaca	gctaccaga	gaccagcttt	2160
catcctatag	agaaggggtc	cattactttg	cccttccttc	cttccttctc	ctctccttcc	2220
ttccttctct	ccttccttcc	ttccttctct	cctccttctc	tccttcttcc	cttctctttt	2280
tctattctat	tgatcattaa	ttatgggtcaa	aacttctcat	tttttcagcc	aggcaggggtg	2340
gcttaagcct	gtaatcccaa	cactttggga	ggcgaggcag	gcagatcact	taagtctagg	2400
agtttgagac	cagactgggt	gacatggcaa	aacctgtct	ctttaaaaac	aaaaattaag	2460
gccgggcgtg	gtggctcatg	cctgtaatcc	cagcactttg	ggaggccgag	gcaggcgaat	2520
cacgaggtca	gaagatcgag	accatcctgg	ctaacatgg	gaaaccctgt	ctctactaaa	2580
aatacaaaaa	attagctggg	tgtgggtggc	ggcgctgta	gtcccagcta	ctcgggaggc	2640

tgaggcagga	gaatggcgtg	aaccgaggag	gcggaacttg	cagtgcgccc	agattgcgcc	2700
attgcattcc	agcctgggag	acagcgagac	tccgtctcaa	aaaaaaaaaa	aaaaaaaaaa	2760
aaaaaaaaaa	aaaaaaa					2777

&lt;210&gt; 26

&lt;211&gt; 1712

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

cgggatcccc	ttccaaattc	ctccctcctg	tcccctatat	cattgctgtc	atattatttga	60
cttatacatt	agctgtaatt	attaatacgt	cgttacaatt	aacattttga	acaaaatggt	120
atatgttaga	ttacttaaaa	atacaaaaat	agaagttttg	attttacctt	tattttattct	180
ttttctaacg	cttttccttt	ttattcctaa	tggttttttg	tttggttttg	tttctttata	240
tttttagtga	ctgaattaac	ttattagcaa	caaggctaata	ggaaatcact	tgagcctctc	300
taagtctttc	tcctcccttg	acacatttgg	aggactgagg	gaactaagtg	atttctaata	360
tccttccagc	tctatttttc	agtgatttta	gtttaggctt	tttagttctt	tcatttctta	420
caagatttgc	ataccaaatt	gttaattaaa	aacaatccac	attttatcct	atagttgtct	480
agaatgttca	ttgtcttctc	agttctcttg	ctttttttcc	aatttgccat	ctgccagttt	540
gctgacttgg	caatatttcc	actatccatg	tgccagcttt	gcaacctctc	agcaaggctc	600
gcagctcctt	ctgcacgatt	tgagggtctt	ggcataaata	ggaccaggaa	ggcagaggga	660
agccttccaa	ccactgcagt	gcaattgctc	ccctataaaa	gccaagcagt	tcagggtccag	720
catectcagg	ccgtgattgt	agataaaact	tctgtgattt	cattgaggag	tatttgtata	780
gatcagctga	aattcatgga	gatggaaaac	attattaaac	ccggttatgt	gacttcttga	840
agttacattg	tgagttatga	aggctgcatt	cttttaaatg	ggttttggaa	tttagttgtg	900
atgaacattt	gaggatttag	aaatagaaaa	ataaattgtg	taaacccttc	gctttctgtc	960
tgcatgcgtg	aagaccacat	agatagcttg	tttgcttttg	ctacagtctc	attgacttct	1020
ctgccctcgt	cagtcttcct	ctccatgttt	tccccactta	tctttcttac	ttcagtgcag	1080
aatttctttc	tttatttttaa	tgtctatcta	gtttttttatt	atttctatca	gtgctttata	1140
gatttctcag	cttagttttg	ccttggacaa	cttcttctct	attcacaggt	atcagctggg	1200
attgacaagg	gttagtttct	tcgtggaaaa	aaaaaatggg	agctaaactg	actgatggaa	1260
gcagctgcca	ctaatagact	ttggtttttg	ttttaatctt	catggaaggg	tttagtttgc	1320
aaattctttc	tgcttggata	tttaggagcc	tttccctaagg	aagggaccag	aattattttc	1380
tttatgtaaa	attttatatg	tgtttaaaat	tctgtcctct	gtgtgtgtat	atgtgtagta	1440
catatgggta	taactggcct	taggaaatag	gttcaagtgc	ttacacaata	ttatcagtct	1500
aatattttta	acatattatc	tcaagttatt	tgtttgagta	tagtatactt	tgaagggttc	1560
ctcagcttca	cttttaacct	attttttatt	tctatttctc	ctacagtagc	attatcctat	1620
agttatcctg	atatccattt	aatttcagaa	ggactggata	ttactttagt	caagatgcag	1680
tctgatttaa	ttttattttt	aaaacaaca	gc			1712

&lt;210&gt; 27

&lt;211&gt; 2939

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2500)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 27

gcctaggaac	atttttttaag	gactcagctg	tggcttttag	ggcttggttc	ataccatggg	60
ggaaaaaaaa	gtcctaggag	aaagcgacgt	ggctcattag	tggtgcctct	tcagtgcctc	120
agccgcctgg	tggattcccta	tgacacaggg	ggcctggaaa	gaaagggaaa	gtggatttaa	180
aatatatata	tacgtaaccc	aagccccata	acccttaact	ggacaaatga	ggtctgtttc	240
tttgggcctg	aggctgtgca	tataaagtct	tattttggga	ctttacaaac	ttgtcctaac	300

tatcttgtgg	atagtgggct	gtgacaatct	ggaatagaga	acgttcacac	ttcgttcctt	360
taaagaagcg	accccgatc	tgcaaggagg	tagattctgc	tatcttggcc	tcacagccct	420
tcctgttgat	tacaaagccc	gtggaagaaa	acagaacaca	ccctcctcag	ttccgtctaa	480
atgtgtttct	tctgcttcaa	ttacaccagt	tctggggcaa	agacactgat	gaaacaacac	540
ccatacctga	aaagaataaa	tgtgtgactt	tcaaattccc	tttcgcagtg	aaagaaacag	600
caaacactta	agattcagca	tctgttctcc	agttgcactg	aggaatgcac	tgtctcgcag	660
caccagctct	gcagagccct	tgccccagac	tctttgcggt	tttatttata	tgtatttcca	720
tatttcattc	ctgtgtgtca	ctgctgcatt	ggtgtggcag	caagtgacca	aatgctacag	780
gtcttactat	ggacaccagg	tcaggtgcaa	ccacacaaaa	caaagccagt	tccatgagct	840
gcctatgata	tgcattgcgg	aagtaacatt	ttaccaggg	tgtgccattg	cagtgatata	900
aatatatttt	tttcttagac	taaatatgag	ctgactatct	cttttgatgt	gtgtacatag	960
gtgtgagtgt	gtstgtatgc	gtgcctgtct	gtgtgcgggt	gtgtgtatgt	gcertagcctc	1020
atgcttagga	ctacccatga	atgttggtga	atgctacacc	tggagagtcc	tggttttcca	1080
ccagtttcaa	gatgaagaac	tacatgatac	agtggacctg	gagaccatcc	ccttggaag	1140
acaacccaga	gatgttcagc	atcctgtatc	tacacgcac	ctgtatctac	acgtgtattt	1200
tgtagctgtc	acactaacct	taataagaat	tctacagctt	tggacagagg	cattttcacc	1260
ttaatggyga	agtaatttaa	aatataaatc	cattcaggtg	acaacccatc	atcaaaattt	1320
caaattttct	gattgaactc	atctgaatca	tcagttcctt	gatggagaga	gagaaggaga	1380
tggaatgtgt	ctggttaacc	caaagtggag	acaagttagc	tttgttttcc	tgcataaatg	1440
gacttggtga	atgcgaacga	atatatgcaa	ttcatatact	tttgagagtg	aacgtagata	1500
tgtgtgtcag	ctttgagatg	gtgtgyccyg	gattaatact	ttgtctcccc	aatatcacag	1560
aaaaatacat	gcccagtgac	tcttgaggtt	aaggtagttg	ggatgaaatg	gcctcaggca	1620
atttcacatt	ccctaattac	ctggaaagtt	ctacagtaat	taatatgcag	ctaactcctg	1680
ttgccctcac	aagagcatca	gccttctaga	atcggagctc	cggagtgtga	agattcagta	1740
ttgatatgat	atgtatacca	aactccagcc	aacttactgc	catttttcat	aatctgagtg	1800
gctgccttgc	ttatcctaag	ctgtggttgc	agaaaccgtg	gccatttata	taagctataa	1860
catcaaatca	gggaaaaatg	aggaaaaaaa	atagattctg	aaccatttat	tgttgaataa	1920
gtagagaaaa	tcataataaa	atatttatta	cattctgaca	gggtgtgtgg	cattgtgttc	1980
tatgccagag	tgacaaaagt	gattcacccc	tttttgggga	ccttaataata	ttttttaagg	2040
gatgtgccta	tgcattgatg	cctgaaaaat	atgtataaag	aaatgaggtt	gactcttctg	2100
agcagttcat	cttttccaga	ggtaagggtg	ggaggccaac	ttcaggatct	gggtctragc	2160
ccgtgggsaa	gccctggccg	agtgaagctc	aatgctaact	catgtgccga	tctctagagc	2220
agtgggaaac	taccccgctg	caccaaatac	agtagcttca	ccttgtgtat	gcaggcccca	2280
agttattttt	tagcaatctt	acgagtgaag	tgttctgggt	ggttgaaaaa	cgttcttatt	2340
ttaaagaaag	gttgtgtctg	ctacactgct	gggtgtgtgr	ttctgagacc	tcttgatttc	2400
caatctgtga	agggatatgt	gtattaatcc	gtacaccgtg	atagcctcaa	tatttgtctg	2460
aagacactta	aattctgacc	cataaggaaa	gttcctagan	gccaatattt	tcacttattt	2520
aacattctcc	aaacaacatc	aagcattgat	acacactgaa	gagtgcgttt	attttttgta	2580
tcactctaag	tatgttgga	tatgcaagga	ctgtggttca	aattagaatg	tataaggcat	2640
attataattt	agttcatact	gaaaaagaaa	ttaacagAAC	attgttcggt	tcacacgttc	2700
caaaatttga	gtgatttctg	gagttagaca	tagattttct	attttgtttt	aatttgtcaa	2760
ggatattttc	ttcccttcat	gaactttagg	tacacataac	ttatgtcatt	tatttatggg	2820
cttttatacc	tagtttgtaa	aattgtaaaa	tagcaaaact	aatgcaaaga	gtttgcattt	2880
gaaaataata	aagtagttac	cgtatacaac	cctgcaaaaa	aaaaaaaaaa	aaactcgag	2939

&lt;210&gt; 28

&lt;211&gt; 410

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

ggcacgagaa	aaatttctag	cctcactagt	atcagagaaa	tgcaaattga	aacaaggtgc	60
cattttttga	ctctagttga	tgatggtagt	gaaaaccaga	atgggtcctt	ctaaaacagc	120
ctgtgtgtca	aaaccataaa	aatgcttcta	cctcttttta	ccctgttaat	tctacttctg	180
agagtttttc	ctaaagaaat	aattcaaaat	aggaaaaagc	taaaagcaga	aaaatgttga	240
acatgacatt	atttatagct	gtggaaagat	tggaggctgg	gcacagtggc	ttatgcttgt	300
aatctcagca	ctttgtgagg	ccaagtggg	aggattgctt	gaaccaaga	gcttgagacc	360

agcctgggaa acgtagtgag accccatctc ttaaaaaaaaa aaaaaaaaaa 410

<210> 29

<211> 2019

<212> DNA

<213> Homo sapiens

<400> 29

ttcaccatgt	tggccaggat	ggtctcaacc	tcttgacctc	gtgatectcc	ctcctaggcc	60
tcccaaagtg	ctgggattac	aggtgtgagc	caccgcatct	ggctacctta	catttttaaaa	120
taacccttat	cactactgaa	aatgatgtct	ttatatgtct	atctccttat	gttctgtttc	180
cttactctcc	tcccaggaac	ataaacttca	tgagggcaag	gactttgcct	ccttcacttt	240
tgtgtctctg	gtgcttagct	ccgtatttga	atatttggtg	gatgaatgga	taatgactat	300
tccaggactc	gcttgataca	gaactatctt	ctctagagaa	tggaaaggta	aacgtatcat	360
ttaccagcca	cttatcttaa	gtagagtccc	agagtgtagg	cttatgccat	ggagctcatg	420
tgaatttcca	cttggggccat	ctgggattct	tttctcaaaa	gagcctgatg	ccgggtgcac	480
gggcccgtca	gctggcctgg	agggatataa	cccacattta	cctttctcct	cctggcagta	540
ttctagaata	cctcactcac	tgcagcaagg	gagctttctc	tcctgggtcg	gtaggggata	600
tggtttgaat	gtagccctga	ggagcgtctc	aaatgacctt	tggcccagtt	gtcttgtgtc	660
agtctcctgg	ggagaaggat	catttactca	agtgaaaaac	gaatcagtca	agcttgagag	720
ctgtagataa	cagcacaggg	agctgtgttt	tatggcctca	aagagttaa	cccagattgg	780
aaaaaggtat	ttcactccag	cagcaacaga	ggggagctgt	accttgccctc	tgactccaga	840
gaaacgggac	atgtcacagg	ggtgaccaac	agggcaccag	ccacagcagg	gaggggtggaa	900
acttgggcag	caagagtcac	agttaatgcc	tgggtgaggag	tgaccattgg	agtgacgtgg	960
agctgcacgg	taagcactgg	ggacgtgcca	aagaaggagg	ctgggtcagt	cagggttttac	1020
tgcaatgatt	ctacttgaaa	aacacactga	atttcagcga	cttacaacat	caacaccaca	1080
tttatgtatc	tcacctatag	gtgttcagggt	cagctgtggt	ggttctgctt	caggctgtgg	1140
atccagatca	cgtctgcccc	acatggctct	cacgctggga	ccagcagctt	ctcttggcag	1200
ctagcagagg	tttgagaagg	cagcccaaac	catgcaaact	cattgaaaac	ctctgtctcg	1260
gtgacatcct	ttaatatattc	attggcaaga	cccagcgcag	tggctcacac	ctgtaatccc	1320
agcacttttg	tgggcccagg	agggcggatc	acctgagggtc	aggagttaa	gaccagccta	1380
gacaacatgg	cgaaaactca	tctgtactaa	aaaatacaaa	aattagctgg	gcttgggtgg	1440
gggcccctgt	aatctcagct	acttgggatg	ctgaggcagg	agaattgctt	gaacccagga	1500
gtcagagggt	gcagtgagcc	cagatcattc	cactgtactc	tagcctgggt	gacaaagtga	1560
gactttgccca	aaaaaaaaaa	aaaaaaaaaa	attccattgg	caaacaaatc	acatagtcaa	1620
gactagcatc	agtgggttat	gaaaatgtgc	tctgtggact	ctagtggggg	accctgcaaa	1680
gtctggggca	aaggctgtgg	atgctgaatt	ctgttacagg	gagggagtga	aaaattgaga	1740
gtagtaatcc	agtctcccac	ggggcccatc	acggctgttt	ggaggcacac	atgagttacc	1800
atggcgacat	cttgaatgag	aaggggagaaa	ctcaatggta	agggcaagaa	gcagaagatt	1860
gttcctttgt	tcctattact	ttgatacata	ttccttgatt	tgcaccttcc	aggctaaaat	1920
tttgagcctc	cttgattttt	accttcaggc	taaatttgag	cctttggaag	ctcaaattac	1980
aggaccatga	acatctctcc	ctggcaggaa	gcaacaagg			2019

<210> 30

<211> 2274

<212> DNA

<213> Homo sapiens

<400> 30

ggcacgagggt	tttttttttt	tttttttgct	ttaagtttca	ggatacatgt	gcagaatgtg	60
caggtttgtt	acataggtat	acgggtgcca	tgggtggttg	ttacacagat	atacctgtgc	120
catggtgggt	tgctacacct	attgacccat	cctctaagtt	ccttcccctc	actgccacc	180
cgctaacaag	ccctgggtgtg	tgttgttccc	tcctgtgcc	catgtgttct	cattgttcag	240
ctcccactta	tgagtgagaa	catgtggtgt	ttggttttct	gttcctgtgt	tagtttgccg	300
aggatgatgg	cttcagctt	catccatgac	atagcaaaaag	acatgatctc	attccttttt	360
atgagtgcac	ggtattacac	gtattttaat	agctttgaaa	tttatcgatt	tcaattttaca	420

tttattgagt	actcactatg	ggcacaacac	catgcttctt	taccaggggt	acaataaaca	480
gagccaaaat	tttattttaac	ttgtatatac	aactttacta	tcaacattag	ccattgaggt	540
gtaaaaataa	agaagcaatt	tgtattaaaa	gtcaatttcc	acataatcac	gtcttataaa	600
tgccatttac	ttttattata	cataactcag	gaaggtagt	tttagtaaac	agctgaaaag	660
ctatttactg	aaattttatta	attgcttttag	aatgaaaaa	aaacaaaatg	cttgtaagca	720
attacagaga	aaagagaggt	acacatggta	aaatatttta	aataaagttc	atacaattaa	780
aaatattatc	ataccactga	cctttgggtt	aaaaaaacaa	ctatgattca	aggataaaat	840
atgttaaato	cataaaataa	tacaacataa	tttctagaga	atttggtctt	ttctactact	900
ctaaatgtgt	cacatcctaa	tagcatcaca	aaatttaatt	atgatactaa	taattattct	960
aattattatt	aaagcattat	aattctatta	ttagaattac	ttggcactca	ttcaaagaga	1020
tataaacata	tcaattaaaa	accatgtatt	tttcaaaaaa	taaaactgaa	ctaattataa	1080
aaaataaaga	ttcctgtaac	ggattttaat	cttaataccc	tggagaacct	taatgttaat	1140
cacattcaga	atttggtttt	tcagctctcc	cttctgactg	gagctgaggc	taagatagga	1200
aaaaaaagtc	cacttcccag	tcagctcctg	gtttctgctg	cttttgtctt	cacactgtat	1260
cttttagttt	atgcagcagt	ccaaggcttg	taattcttct	gatgacacat	ccatgccatt	1320
gcggctgtct	ccgaactcca	ccaaagagca	tggagactct	gtaagactgt	ttcggagctt	1380
gtcaacatcc	ttctctctgt	gctattgtgg	tagcatgaat	tttgtgaagc	atgatgcctt	1440
ttaatctact	cttggtttcc	cagacataaa	aaggacctag	tatgcttccc	tttgcagaag	1500
caataggaaa	gcaaaggaag	caatgtacag	ctcaggatcc	aaaccaacct	cggagaaagt	1560
ctctttgtct	atttctaaca	gtctccagcc	tactctccag	ctaaaaagtc	aagaagagac	1620
caaaccatt	ggttcttccc	cattgcatct	ccaattcact	ttctgttgta	gactgggaaa	1680
ataacttttt	aagttaaaag	ttaagaattt	gactggccgc	agtggctcat	gcctataatc	1740
caagcacttc	gggaggcaca	ggcaggcgga	tcacctgagg	tcaggagttc	gaggctagcc	1800
tggccaacat	ggtgaagccc	tgtcaccact	aaaaatacaa	aaatcagccg	ggcgtgggtg	1860
cacataccta	taattctagc	taatggggag	gctgaggcag	caggagaact	gcttgaacct	1920
gggaggtgga	gattgcagtg	agccaagatc	acgccactgc	cctccagggt	gggcaacaaa	1980
gcaggacact	ctgtctcaaa	aaaacaaaaa	caaaaaacaa	aaaaacagtt	aacaatttga	2040
taattgtgct	cttcttctaa	ggtgaggttt	ttactcccaa	ccaccatata	ggagaatgat	2100
tagaaaacaa	tcttttttaa	agaacaaaaa	gaaaaatcca	ctagcatttt	gttttatatt	2160
gtgttttgtt	acaagataca	tcgtactcta	ggccaggcgc	ggtggctcac	acctgtaatc	2220
tcagcactct	gggagaccaa	ggcagactga	tcacttgagg	tccagggggg	gcc	2274

&lt;210&gt; 31

&lt;211&gt; 2458

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

ggcagagcgc	ggatcccgtt	gaggccagga	gtctgagaca	aaccagggca	acatagtgag	60
acccccatct	ctacaaaaat	tagaaaagaa	aaaaaaaata	tgtttcatag	attctttatt	120
ctcagtgtct	taagcaggat	cagagccctt	accacttttc	ttgatgacct	gggtatgact	180
caccagactc	tgcttctgtc	ccttggacca	tccattttata	gtttctgctg	actcttgcta	240
ggctacctgg	ctcctgtatc	ctttgtttgt	gatttttaga	tcacagttgt	tctttaagac	300
tgaaattttt	caagcacttt	gaaagtctct	tttttaaagca	ttatttgta	ttagtatttt	360
ctgtttacata	taaaaacaag	ccaaattttt	aaacttattg	cctactgcat	tacaggttat	420
attctgtttc	cctttatgtt	tccagtggat	cacttttagtc	ctcgctttat	tgcttttcac	480
cttccctgat	gcttcagaat	catcatgttt	tgtcagcttc	ttaggtgact	tatagtcttg	540
tcacagcact	cctaagttcc	attttagctc	tttgtgcagc	tcttgccctg	ccacttgaac	600
ttccctcag	ccaacttttt	tcatatgcat	taaaagtatt	tctcagaaat	gcaaattaaa	660
acactactga	aatactattt	cttacctctt	atgttggtga	aatttaaaaa	gtgtggcaac	720
ctagtgtctg	gaagaatgca	agctggtaca	acaaccgtgt	tggaggggaa	tttgacaaga	780
cctaacacag	ctacacttgt	actcttttga	cccagcagtc	ccacttctag	gaatttacct	840
taaaatacac	ctccagcaat	atgaaactac	atatcatgta	gttattttatt	ttagtacttt	900
tttgtaataca	caaaatgttg	gaaataacct	gaatgaccat	acatagggaa	gcagtaaaat	960
gaatttggtg	catgcataaa	tggaatacac	tgtacctgta	agaaagaaca	aggaagacct	1020
tgagaaactc	atatgaaatt	atttccaaaa	tatattaagt	gagaaaagta	aagtgcatac	1080
agatatctag	agtgctctgc	cctaaagtaa	gaaatagggg	ctataaggaa	atctacaaac	1140

gtctactcat	ttttgcaaaa	gatgtaaaga	aagataagtc	agaaaccaac	aagactgttt	1200
acctacagga	aataaagcga	aatggggtat	aaaaatggag	caatgagagg	gggagttgga	1260
gggacacttc	tctgagtaca	cttttgtata	taactctgac	ccttagaaaa	aacctgacct	1320
ttcacctacc	caatcagtta	ggatgtggga	gaacccaaaa	tgaatacga	actgtaaaaa	1380
atgaacctaa	atgtattcaa	atgaataaat	aactatgctg	ggggtatagg	gaagaaaaga	1440
gcaacctaag	tacctttaga	aaatgattat	tttgactata	tactgtaacg	ccaaaagcaa	1500
ccaaaaatat	atatatgaat	gtactatagt	tgtatatttg	tttcttctac	aaacaggagc	1560
atggaccagc	aattctgaca	ctattttaatg	tccatgctag	gattgaacaa	agtaaataatt	1620
ttctgggtaa	tgagagctag	ttttctcact	gtcagagaaa	aatgatacat	atgaggaaag	1680
tgagaagact	agaatgaacc	ctgtggcatt	gggttggaat	tagagggatc	agtatgagtt	1740
tattcactgt	agggtggatgc	acatagaaat	atagatgtat	gcacgtgtgt	tggtatacaa	1800
ttgtatgttt	cttaatgctg	cctgctgaga	ggctcctagaa	gcaatgatat	ctcagtagca	1860
ataaatgtac	ttagcactca	tctcttggtt	ttttaacacc	attctccaat	aaaatgaaca	1920
aggacttttg	ggatatggg	tgattccagg	gctaagaagg	gccaaccaca	agtaaagctt	1980
ggaatatcta	atgggtccag	aaaataagta	ctcaaaaaat	tgtgaagaca	tgtaaaaagg	2040
acttaggagc	caacctgaag	gagcagctaa	tggccaaagt	tggaacaact	cgaacaaagt	2100
aaataagtat	agtattggat	tattactcaa	taaatgtatg	atccatgagt	ccacactgaa	2160
agattgaata	gataaagaat	agatagttcg	agaccagccc	ggtcaatatg	ataaaaacct	2220
gtctccacaa	aaaatacaaa	aattagccag	ccatgggtggc	atgtgcctat	agttccagct	2280
attcaagagg	ctgaggtggg	aggatcgctt	gatcccatga	gattgaggct	gcagtaagct	2340
gagattgcac	cactgcactc	cagcctcgga	gcctgggtaa	cagagtgaga	cccagtatca	2400
caagaaaaaa	aaaaaaaaaag	aagtggggaga	gagagagaga	gagaactagt	ctcgagag	2458

&lt;210&gt; 32

&lt;211&gt; 1692

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

ggcacgagag	gaaagtgaca	tggctaggtg	gctcttacc	tgccttccgc	ctctccacag	60
tgtgacaagc	tggctgctga	ctgtgcccac	gagctgcggc	gccatggggg	cagctgtgtg	120
tctctgtggc	cggggattgt	gcagacagaa	ctgctgaagg	agcatatggc	aaaggaggag	180
gtcctgcagg	atcctgtgtt	gaagcagggt	ggcaagggga	gggcgaagga	agcagagaac	240
aggggagtcg	gcctctgcat	cctcaataac	aagatcagat	actcccactc	accagggtgct	300
tactgtggca	gggtgcagggc	tgagcatggg	acacacatta	tttctttaa	tcctgtaagg	360
gagataccag	ctccattcta	cagatggcaa	aactgaaacc	cagagagggt	tagaaacttg	420
ttgaagggtca	catatgtcct	aagtggaaag	gctgtctagc	tccaaagacc	atgcacttga	480
ccccacacc	agctagctta	gaaggtccaa	acactatttg	gcactaccag	atccttccac	540
ttagcaaaag	cagcagatcc	tgggtgccagg	gcacagggct	cacctggatg	tggggaggag	600
tggctctggc	acttggccaat	actttgggtc	ctacaggccc	tgcttgagggt	ctttggcctc	660
tttggctctt	gggtctttttc	tcctggaaca	gaagttgaaa	tggggaggag	acctgggcag	720
tgtcttggga	aattaaccct	tcacttctct	gcccctgtgt	ttcagttcaa	atcagccttc	780
tcactctgcg	aaaccacaga	attgagtggc	aaatgtgtgg	tggctttggc	aacagggtgaa	840
gtttgggggc	agctggtaat	aagaaagggc	atggaggatg	tgtagtgcgg	tagcatccag	900
tgcccagatc	tggctcgggga	gttgggtgag	gaacatgtca	ttcttttctc	tgctttttga	960
ggcccaaggg	gtcagcattc	ccagtttgag	gtctgagagc	cttaggagca	ggctcctggg	1020
aagtgtggaa	aaagtccaag	gccaagaga	aagagctctc	cagggatcct	gagctccagg	1080
gctctcagca	gtgcctgtgc	caactgggcc	caaaccttgt	cactctgcat	actcccctgc	1140
ctgccatctc	cacctgtctg	tgtgcccgca	tatcccaata	tcctgagcct	gagtggtaag	1200
gtgctgccat	cctgtgacct	tgtctgacgc	tatggccttc	gggatgtgga	cggccgcccc	1260
gtccaagact	atttgtcttt	gagctctgtt	ttttcacacg	tgtccggcct	gggctggctg	1320
gcctcctacc	tgcctctcct	cctccgtgtg	cccaagtggga	ttattgccct	caacactagc	1380
aagttctaac	cctcctggtc	tgacactacg	tctctgcttg	tcttctcatt	tggacttggt	1440
ggtttgtcct	gtctcagtgga	aacagcagcc	tttcttggtt	acccataccc	ttgatatgaa	1500
gagaagccct	ctgctgtgtg	tccgtgggtga	gttctggggg	gcgcctaggt	cccttctttg	1560
tgccttggtt	ttccttgtcc	ttctttttac	tttttgccct	agtattgaaa	aatgctcttg	1620
gagctaataa	aagtctcatt	tctctttcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1680

aaaaaaaaaa aa

1692

<210> 33  
 <211> 2160  
 <212> DNA  
 <213> Homo sapiens

<400> 33  
 cccccgggct gcaggaattc ggcacgagag aaaatgaaag cccgacgtcca cagggaccca 60  
 ggcagggttg ggtgttgtga ctcaactccac ctctgtgccc tgcagaggta ctgttgggtc 120  
 cttgtcttgt gagcctgggg tgagctctct gtacatgttg ttgttccacg tatgggttga 180  
 cttggcatgc tgggggggtcc tcgttcactc tctgaagttg gcctcctttc actggggatt 240  
 gaaaagcacc tccaccacct ccctagtgat gtcccctgag gaccgggtg atagtacagt 300  
 caatattgtc agtactttgc tttgattgaa ggctgtagag ctgagttacc aaaatttcta 360  
 tttcaaagga aaccaaacct taaaaaaaaa aaacaaaac tgggctgggt cttccaaacc 420  
 taccatgaaa ccctgggtgtg caggctgcac tcaatgacct caaccaaca cctccctgag 480  
 tgtgtcttctt ggaagagcct agaagattcc tggatggaga cccatttgtt tcagcctcaa 540  
 gtctggcccc tcttcgaaaa aacaaacaca tttgtaagct ttgtgggagc ttccaggcct 600  
 gctctaagat gccttgcttg tcccttgacc catcagcatg gagctcagt gttgtgtgtt 660  
 ggttctgcag ctgggtgggg aggccgcccc ttgtgggtgg gcactctgtc agccccattg 720  
 ccaactcaggg catccaaaca ggaggcacc gctgggaagg gtctaaagat actccttgtg 780  
 gccactgcta ctgttcacac ttgacttgtg gagaagcgaa gggctgaggg gaggtttgtg 840  
 tacacccatg tatttaaaag tgactgactg actgaaatga gcacataccg acatatgcaa 900  
 catactaata ccttcctgat tttcgagact ttctaattac tacaactaac ctgttgtgtc 960  
 cacctctgga attcagaaaag agagccactg cgagcactga ccacaagggc tgccttagga 1020  
 aggaaatgtg tgctttcagg agttcttatt aggggaattt taagagcaca aaaattttat 1080  
 tgaaccaccc ttagtgaaca acagaaaatg atttgtaga ttgtcagttg gaaggggttt 1140  
 attatgactg ctgggtgaaat aaacagtgc cagtttctgc caacatttat ggaaataacg 1200  
 tttctagggt ttaaagtga gccgtaaaact gaagctactt cagttaaaaa aaaaaaatc 1260  
 aatacttaaa ctgtaggga aaggtggatt ggtgccagag aaaacattat ttaatagtgt 1320  
 cagaacatgg aactgcaaca cagtttgtag caaggcactg agaaaaaccc acaactaatc 1380  
 cttcatcgca gctgtctgaa ctcttgatca tctgccatcc cccaaacagt gacttctttt 1440  
 tttctgggtga ctccaggcct gaatgacct gtgtggagag tttaaactat gtacaaggga 1500  
 ggaaagaaaa aaaggaaagg aaccttaagt aagcctcagc caaagggttt atgcattgga 1560  
 cttcctgtgc ctgccccag gggcaagact gatcccatg cctgtgcca tgacatctcc 1620  
 ctgaaagagg acaccatgac agcccggtt tgccttgact gacccactgc taccacgaa 1680  
 ataagaatca agagcagcta ttgttatcct tagagtgttt tccgtctagg gccggctcgt 1740  
 gaacagccac atatccttgc acctgacact gtccccacac aaatagctgg ctttcgttgc 1800  
 ttgttgaatg aatgagttag ttggctctat atccccttg agctggccgg taagatatta 1860  
 gtgcctcatt ttacaagaag agaataggaa ggaattaagc aatttggcca acagatacaa 1920  
 gatagattcc agagttttat ctcccacttt aggggtggcag ccagtaggcc aaactccaaa 1980  
 gaccgttgct gatgtctttt tctgcctccc ctctttgggt tagtgtggtg tgtacaagct 2040  
 cactcttggt gaaaattaga aaatagttga aaacaaaagg tttttgtttt tctttttaa 2100  
 tcacattaaa tgttttacat tgcttaaaaa aaaaaaaaaa aaaaactcga gggggggccc 2160

<210> 34  
 <211> 1349  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (105)  
 <223> n equals a,t,g, or c  
 <220>



<221> SITE  
 <222> (394)  
 <223> n equals a,t,g, or c

<400> 34  
 tttattttaaa taaacttata cagctaaaga aactgacttt cacttctca gtgacttaat 60  
 ttcactacat gctgatttgt cctttgcagt atttagctca gaccnagaca gaattgtatg 120  
 tgctattaga tttgcaaatt gctgatctcc cagtgacttt ccctcttaga tcccagttga 180  
 gtatggttac cttgagaact gtggtattag ccatgtaga gcatgctcca ctggggagtt 240  
 ctgtgcagtc tttttttaat gctattttaat gaaggagcga gcgcctcact tcagcaataa 300  
 aagaagcatg agggaagaca gagcagtgc tgggttatgga tactggacaa ggatatttgg 360  
 aaaggtaaag gctgaccatt ggatatggga attntaatga agtcctaata taccatakg 420  
 awggaaatak ggattttkgt tagagaatta tacatgaata gttcaatagg tgttttcgta 480  
 aacctcttca ctagtcttta gaaagaagac tcaataattt gagtttttaa aacttgaggg 540  
 acatactaac cagggagttc ctgcatgcag actattttta atacaagctg tcatattctt 600  
 ggggtggtgag aastacagaa ataatttcaa attcctaaaa tattgttcgg tgaaagggtt 660  
 ggagcttgta aaacgttctg cgaataaaaat aactaatatg cttctaagat actacaataa 720  
 cctgaagctc tgccttgtag attgcttcat tttcttttat gaacttgag tctaggtcca 780  
 gaattgtcac aactaagaga agcagaaktt ttgtttggac ttgatagaat atttgggggtg 840  
 ttttctctcc ttagaattaa gataagccct acagattatc ttactgaart ctaaattattt 900  
 taaaaatata agtagcagag gcagcactgg taacttttgt aatgtcacia taaagggcaa 960  
 aatatcttaa cattatagt tgtacaatgc aagaagccat ctgtctgcaa catttgtata 1020  
 tatgcagaac acctgtcttg aggtagaaag tgagaatggt caatcagaaa ggtcttgtgt 1080  
 tgattttcat attaacaaca tactataatc aggttattct tttgttcaga gtaaagctaa 1140  
 ttagacaaaa tgcttaagta gttgcaaggt taataaacat aagagaaagt aagcagtttc 1200  
 tattaaatgg ggaagttagt catataattt ttaaataag ctgttagaac aatgtgcaaa 1260  
 gttgatctgg atttttgcca attcctatga aaaataatcc ccagaaataa actactaagg 1320  
 aaaataaaaa aaaaaaaaaa aaaactcga 1349

<210> 35  
 <211> 2658  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1817)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1832)  
 <223> n equals a,t,g, or c

<400> 35  
 gagtaggcat agcgggttag ataggaaatt ttaagaatga caaattaaag aatcctggaa 60  
 aatacactgt acattctgcc aagggttgtc aatatggatg ctggtatagt aatgagaata 120  
 aatcggtaaa ttcttttcat aaaatgaagg aaagaaatta ctatgtgctc tttaaaatgt 180  
 gttgcatcag tgcctgattt gattgtaagg gtcacatctt caagacatgt gataccaccc 240  
 tttataccac attatagcat tgtctaattg tgtaaagttt ataaattgct ttcactcagt 300  
 cttcatctga ttctcagaat gaccctatcc aattgggaat atgggtttca ttagtcttac 360  
 attactaagg agattcagag agtctcaatt ggccaacatc atgcagttaa aaatgacaaa 420  
 tggggatttt gaacccaagt ctctctgacc ccagaacccg tgatctttgt actacatcat 480  
 gcttcttgag aaattaaatg gacctgtctt gcagaactgt tcttcttcta actagggatc 540  
 tggaggagtc tcaagtaaat aggcatgtg ccttagggag ggatgtctgg aagcacctgt 600  
 ttggagtcac agcaggttgg tggttttctg tctgtaggtc tggcagctgg gcatggtaac 660  
 ttagccatgg aaaggggctg caggaggagg tcctcagtg cagacccag ggcagaggac 720

tgtgtggctc	ctgtttgttt	ctccagatct	actctctaca	cgccctcacc	ctgctctctg	780
tttgggatgg	aatcaaagga	cccctttgcc	ccctggctta	tggttgcctt	ttgccaatgg	840
aagcagtgc	agaggatcag	attagaggta	gaaggggagt	gaggaaggag	agtgaagagg	900
gataaattct	ccttctgcct	ctgatccctc	gtcgctgctt	ccactgccac	ctactgcttc	960
cattggcaaa	aggaaggatg	ccgtgagggt	gccatgagca	tgctgcagcc	ttccagtctc	1020
ctataagaca	gcttccccat	ggggtccttt	tcctattcct	cctcttgccc	cttctgacct	1080
agccccaggt	acagtactgt	attacttacc	ttctcttata	ccttttccat	acctttgtcg	1140
atggctctct	tgttggactc	ctcacattac	ccagtttgag	tgtgctttct	atttctctgat	1200
gggctcctgg	ctgatcagac	ctgacccag	aggacctggg	taccagaatc	taatgcctgg	1260
attaaggcac	atgagcaaga	cgcagaccct	gcaaatggaa	ttgaaattac	aatgacctag	1320
aacaagggag	atagggccaa	gcatgcccta	tggaacgagg	gacccaaatg	gggtaggact	1380
gggaagaaat	ctgacttgag	actgatgggc	taggactctg	ctagaagggc	ccttctgggc	1440
ttccaggaga	caagactatt	cacagacgct	gcaaattggg	ggtgcaagga	aggcagcagg	1500
agctcaatag	ggtacagagt	ctaaggagag	ctggaggcat	gaaccaagca	gagtggctgg	1560
gtgtttgaat	ccttgcttct	agtggcagag	actgaccggc	tattcatcga	acccattttt	1620
atttctctct	gggcacatgg	actatgggtc	tcgtgttctt	gagttctagc	caatggaatg	1680
tgggcagaag	ggatgtgcta	gcccttaaac	cttccttact	ctctccctcc	tccttgacgc	1740
tgttaaggaag	agtctcagta	acatctatta	tttacttatt	cattctttca	ttcattttatt	1800
tcattcactc	cctgaancaa	gagccaaggg	tncagcctct	ctaggagggtg	actctcatgc	1860
ccttttatta	tgtctgcttg	atactaattg	agatgcgggt	gaccattgca	aaaacccttg	1920
ttgagacaca	gcagagttgg	ccagcattct	tatgggtact	cggatgtgga	tcctgtgatg	1980
gctacagcat	aaaacactgc	attagcctcc	atcttctatc	cttttccctt	caaaaatgat	2040
gatcatttca	ttgagtggcc	accctgcacc	agggtgcttct	gatactttat	gaaatatgat	2100
gttttaata	tgaatatggg	ggcttacata	atgctgtgac	taatttgagc	cttgctcagc	2160
agttaggcag	cttcaatctt	cttattaata	tacagggagt	ggttgctgat	aataggcaca	2220
ttttcaagcc	caaaggcatc	ttgacagtgc	atgctgagga	ttgggggaaa	taggaaacct	2280
ccaaggaata	ctcctgatat	ctttgcatct	gtatacacat	atgagttgtc	ttagtgtttt	2340
taccatagaa	gatccttaaa	agttgacaca	ggcaggctct	gggtatgtgc	atcgagagat	2400
atttcccaga	gtctgttttt	ttgacatcct	ttcaccatca	ttttatctct	tagcaggaat	2460
cagttgcccc	acaactcctg	tgatcatctg	caaacctctt	tacagttttc	agtgtctcaa	2520
ggtaatacat	aaagaaggaa	gaaacaaaag	agtatgagta	tcactattca	tggatactaa	2580
ttaccaaattg	tacttttttg	aattaaatcc	ttgtttgaat	ggaggttgca	cagagatgaa	2640
tgttttgtta	gcagactt					2658

&lt;210&gt; 36

&lt;211&gt; 3761

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

ggcacgagtg	ataattaacg	aaacaataaa	caccacctta	acacagccaa	cagctcttgt	60
acctgctttg	tcacataacg	tgactgaaaa	tgactcttgc	agacctcact	attttatttt	120
caactcacag	actgtctatg	ctgtgccaat	tctgatcttt	tcatttgtct	gtcatcctgc	180
tgttctttcc	atctatgaag	aactgaaaga	ccgcagccgt	agaagaatga	tgaatgtgtc	240
caagattttca	ttttttgcta	tgtttctcat	gtatctgctt	gccgcctctc	ttggatacct	300
aacatttttac	gaacatgttg	agtcagaatt	gcttcatacc	tactcttcta	tcttgggaac	360
tgatattctt	cttctcattg	tccgtctggc	tgtgttaatg	gctgtgaccc	tgacagtacc	420
agtagttatt	ttcccaatcc	ggagttctgt	aactcacttg	ttgtgtgcat	caaaagattt	480
cagttgggtg	cgtcatagtc	tcattacagt	gtctatcttg	gcattttacca	atttacttgt	540
catctttgtc	ccaactatta	gggatattct	tggttttatt	ggtgcatctg	cagcttctat	600
gttgattttt	attcttctct	ctgccttcta	tatcaagttg	gtgaagaaag	aacctatgaa	660
atctgtacaa	aagattgggg	ctttgttctt	cctgttaagt	ggtgtactgg	tgatgaccgg	720
aagcatggcc	ttgattgttt	tggattgggt	acacaatgca	cctggagggtg	gccattaatt	780
ggcaccactc	aaactcaaac	tcagtcctac	tgatgccagt	gttgagtaaa	ctcaactact	840
atgaaatttc	acctaattgt	ttcagtttca	cttccttttg	aagtgcagat	tcctcgctgg	900
ttcttctgag	tgcagaataa	gtgaactttt	ttgttttggt	ttgttttttt	aagaaactta	960
tctgtatgtt	agaaatggat	atgaacaaca	aaaccacgag	tctcggtgta	agggagtgaa	1020

caat	tttatt	ccattccaga	gaatggacaa	actcttaact	tttatcaagc	cacatgcttg	1080
gctgtg	tcat	tgtttaactt	ggatatttta	tgattttact	tgaatgtgcc	taatggaacc	1140
at	ttgatgtg	agaaacaatt	ctttttaatt	tacagcaaaa	tattgaataa	ccattgacaa	1200
aaacactatt	at	ttttttgta	ccaaaaatac	ttaaagacct	cagaagcact	cttttacttt	1260
taagaaaattg	ct	ttttttgaa	ctttattcag	aagcagttat	caataaattc	cataaaaataa	1320
tgtcattgggt	att	taaaaaat	gaatattaat	ataatgaaat	ggtttgctt	ttttagaggca	1380
taataagcca	aata	cttttt	tacccaaaat	aattttttaga	gaaaatgatg	taatgaaaaa	1440
ttgtaccatg	aattaggagc	atagtttttt	ccattttaa	gtcaccatta	cttaaaagat		1500
gattgattat	tgctatacca	aatcagatga	actctgttca	tcacttttct	tctctgtccc		1560
caaacaattt	ggttcattca	gactgaaatg	tttgtgtctt	caacttatta	gaatggaaga		1620
taatgcagat	at	ttctgtgg	gaaataaaat	aactaatttt	gaggtagcaa	atagtgcaat	1680
tgggtaaaac	aggggtttatt	cagttgcatc	tgtctccagt	gttgtattga	cagctctggg		1740
tctttttttg	ggccagccct	tttttgacat	tgcttcacgc	agtggaaaaat	gggcatttga		1800
tggcaatagg	ccgaaattat	tgtgtccaga	gagtacactt	tttcaaaatg	ctcacctact		1860
ggaaagtgtga	attacttgac	aatgtatggc	ttagttgtgt	tcatgttttg	tctacagtag		1920
aggtctaate	cacagggttac	acctatgttt	gatatgatat	aagttctctt	tgcgtaggcc		1980
actgggtttc	tcatgcagta	agctttataa	aaactcattt	gcactggact	gtcatctcat		2040
tcttgtacaa	cgtagaatta	cttgtttaca	tccaacaaat	ggtagctag	ggaaaacagt		2100
gcaaactgag	tgtagtagt	catttttggtc	caactgcatg	tcaacccttc	catttcaatc		2160
ccagttagaa	atgaaaaataa	ttactttgaa	acttggtctt	aagagcacat	ttatcgtacg		2220
tcactgtgta	tgggtgaatat	attattaaat	aatgtggtac	ttcgctcatc	aggcataatg		2280
tctaaaatct	aataatacata	attccattaa	gtggttgaag	gaagcaaata	atggaattgt		2340
caattgggtca	tctggctgta	aggtttgccc	ttgaaactaaa	aatgttggtt	ggggcaaggg		2400
ccagaaatgt	ggagacatgg	tttttggtac	gcattcttgt	attatatgtg	actaaattta		2460
caaacaagat	acatgtgtaa	ttaaagaccc	ttatggaaact	ggaagacgtc	ttgtagtgtc		2520
acattgggtg	aaaccgttgg	tccatttttg	tctgtttcta	tgaagataaa	ataattgggg		2580
gccatctaga	aatagaaagg	cagtgggaag	acagattcta	cggcactgct	ttcattttaat		2640
tgggcttttag	gcactccatt	cgaatgcaga	acctcacctc	tagttgagac	caagaattgg		2700
caaatttgca	tgagctcctg	gaaagagttg	ctgactttgt	atctaagacc	tgccagggaa		2760
taccaagagt	tgtttctaca	gacttttttt	ttttttttgt	atgggagaag	atactgtggc		2820
aaccaggaag	gaatggaaaa	aaaattcctt	tctctacagc	aaattaatgt	gaggaagctc		2880
ctccaatcct	ctggctattt	aagggttcaaa	atcaagtgcc	tagggaaaaat	tccaatggat		2940
gattttctgg	gagctatctt	gtctaccttg	aggttcctga	acaatgaatt	cccatthaatg		3000
agcagctctc	agtattaaaa	ccactgtctt	gtcacctcat	tttgcattac	tgtcttccgt		3060
ggatgtttca	gttacaactg	taatgttatt	tatagaacaa	cattaatcca	ttaaagctaa		3120
cctatttttc	aatattttatg	ataatctatg	tacatatatt	gtctgtccat	atgtatttgt		3180
aaataggttg	tatataatgt	caggtttggg	tcttgggttc	aagtgtatat	attcctgtaa		3240
gtttcttaac	tgcattttga	tgaattcaca	ttatgtaact	ataagaattg	tcccaaaagt		3300
acctgtacag	aaaattgaat	attgaaaaat	tgacaaattg	tgtacaaaca	ctaaaaaac		3360
ttgtttaaat	tgattttgca	ataaacaaca	tcaaattttt	tcatgaaatc	ttggtacaaa		3420
ttcagatctc	ttatttaaaa	tttaaataag	gaatacattt	tcaaaatgca	gtaatcaaaa		3480
tgtgatctag	tgtaatgaaa	taaaatgtga	tctagtgtaa	tgggaagacct	ttgagaacct		3540
gggtgtatta	actttgtgta	tatagtgtaa	atatccccac	tgtactgtta	gaggccaaca		3600
attctagtat	ggcttggttg	caaagagtgc	tacaccgttt	caatgaaaca	atgtatgttt		3660
gttttaactg	aactaaaaata	aatacatgct	taatcctgaa	aaaaaaaaaa	aaaaaaaaaa		3720
aaaaaaaaaa	aaaaaacaaa	aaaaaaaaaa	aaaaaaaaaa	a			3761

&lt;210&gt; 37

&lt;211&gt; 438

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (26)

&lt;223&gt; n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (371)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (411)  
 <223> n equals a,t,g, or c

<400> 37  
 gttttctatg cacatattat gtcattnttca aacagggaaa atttgacatc cttgcccttt 60  
 atttctttct cttgcctgat ttctctggcc aagacttcca gcactatgct gaataaaagt 120  
 ggtgaagggt ggcataatttr twttgttcca gttcttagag gaaaagcttt cagtgtttcc 180  
 ccattttgta tgatgggtggc tgtggatttt tcatgcctat cttttatttt gttaggtata 240  
 cttgttctat atatttattt tgttatgtat gcttggttcta tacctacttt gtttagtggt 300  
 ttttatcagk aagaaatgtt gaatttatca aagctttcct gcattttattg agagattata 360  
 tgggttttgc nattcactcg ttgctcttca ataaatatga tgtgagtcac ntttttattt 420  
 gaatagtcaa aacatcct 438

<210> 38  
 <211> 944  
 <212> DNA  
 <213> Homo sapiens

<400> 38  
 ggcacgagtt ggagaagggt ccggacctca tcagccaggt gttggccacc taccctgcag 60  
 atgggggaaat ggcggaagcc agctgcggag tcttctggct gctgtccctg ctgtgctgca 120  
 tcaaggagca gcagtttgaa caagtgggtg cgctgctcct gcaaagcatc cggctgtgcc 180  
 aggacagagc cctgctgggt aacaatgcct accaggggact ggccagcctg gtgaagggtg 240  
 cagagctggc ggccttcaag gtggtgggtg aggaggagg cggcagtggc ctcagcctca 300  
 tcaaggagac ctaccagctc cacagggacg acccggaggt ggtgggagaa gtgggcatgc 360  
 tgctgggtcca cctgggttcc tatgaggaga tcctgccgga gctgggtgtcc agtagtatga 420  
 aggccctgct ccaggagatc aaggagcgtc tcacctccag cctggaactg gtttcttgcg 480  
 tggaaaaagt gctcttgagg ctggaggcag ccacctctcc agcccccctg ggtggggaag 540  
 cagctcagcc ctgatgtggg ggagaagaca gatacccccac agcccccctc ctccacgtgt 600  
 gccctctccc tgccttccct ttccatgggc cactgtttcc cttgggggtg ggggaagggt 660  
 catccagcac cagaatgcgc acctcacact cctcttaggt gactaataaa gaggcccaag 720  
 gccagtttct gccttaatca tttctggcaa gaggtgtgta ctggccagtg ggatacttaa 780  
 ttctgccgtc tctatagacc tcgcccctgg acagagcagt ccttccagac cattctagat 840  
 gagagtcaac actgagcctc cacaggctcc attccaagta aacatctgca tttattttaa 900  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 944

<210> 39  
 <211> 1441  
 <212> DNA  
 <213> Homo sapiens

<400> 39  
 ggcacgagta cacatgatgt tgccctgtcat tagcctgttt ttaattagtt tacaccttcc 60  
 tatcttttgc ttccaaagac tcttactttt taaaggattt cttttttatag ccaacagtag 120  
 taaccttcat ataaaaataa tattttctgg tgttttctctg tttttttact tttgggtggt 180  
 tttctgtata cttacatggt ttattcatgg acgccatcct ttgccactgt gtcttttatt 240  
 ccaaaaccag gaagtgttcc ccaccttcgt atttttatcc ttttccccct gtgaactcac 300  
 catttggtga tcttctttcc atgtctgtct tgctttgttg cctgcagtta tttgtaaaat 360  
 attcaaaata ttacccaaat tgagatgagt tgtagtatct ggattttatt gagtgttact 420

aagcacattt	gacattagaa	ctaaaggcag	taggctgggtg	attagaagca	gccccagtgg	480
gtttgcttga	aattcagtc	agaatatctg	tctgggtccct	tgctatcttc	tcgaatgggc	540
taatggatc	agggctatat	ttcgtagaca	ggaaggcaaa	aacagaaggg	aaagtgactt	600
agtttcattg	agagagacta	gatcagggtc	agaacatgaa	ctttcatgtc	cctaagtttc	660
actgaagaaa	gctcaggcct	ctttgcttag	tggtctgtaa	agcctaagag	aagggtggcc	720
ggctcgttttc	ctgtttgtcc	aaatgtcgtg	agaatgatga	cattaataag	agaagtttct	780
aggggcttgc	tatttcatgt	cactcaaggt	agtagatcct	aactctagga	actgtaggct	840
gtgggtgaca	gattccctaa	aatgcctcac	tgctgggcag	acctgatgtg	tgtggcaa	900
taccctgctt	gaaggagtc	atgctggcct	ggcaaaggca	gtaacctgtg	tacttgggga	960
actgttaaga	tgcaccctta	aggagctgag	atgattgcag	agtcataaac	tcttaagtct	1020
atttgccact	ggacatttgc	agagatgatc	atatttactt	ccctcctccc	accactcttc	1080
ctctcagttt	cctttttact	ttattttttt	ctccctttcc	tggtaaaa	attagtatgt	1140
ttaacatagt	gttaggtggc	agataggctg	ggaagagcta	gtattgtaaa	ggaacactga	1200
tgtgtactgg	agcctactag	ctctcaatcc	attgccccag	acttggggag	agagagcaca	1260
ttctctatcc	agagaaataa	gaatatgcag	tttatgggtg	tcctgtggac	attaactgac	1320
tgtgaaggta	aggtatatgc	caaaggcagt	gatatgcagg	tgatagattc	accaggagat	1380
gatatgtgac	ttttcttgta	ttttaaaagct	ctgcttcttt	tttaaaaaaa	aaaaaaaaaa	1440
a						1441

&lt;210&gt; 40

&lt;211&gt; 2805

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

ggcacgagag	agaaagatgt	cactgtctct	aatctccctg	tcatttttat	ttccagcagg	60
cgcgggcgga	aggagctgct	agaacaatgc	tgaggcgggg	gaggtgagga	gcagcccctc	120
gcggcagccc	cgacagagtg	tctggaacag	gtgattggag	gagccggaga	cccaggcacc	180
tgggcatcct	tccccctgcc	tctgccaggc	ccgcgcgcc	taaaagggtg	gaaaaccatg	240
gcgaccaatt	tcagtgcacat	cgtcaagcaa	ggctacgtga	agatgaagag	caggaagctc	300
gggatctacc	ggaggtgctg	gctggtgttc	cggaaatcct	ccagcaaggg	gccccagcgg	360
ctggagaagt	atccagatga	gaagtccgtg	tgctccggg	gctgccccaa	ggtgactgag	420
atcagcaacg	tcaagtgtgt	tacgcggctc	cccaaggaga	ccaagcggca	ggcgggtggc	480
atcatattca	ctgatgactc	ggcacgtacc	ttcacctgcg	actcagagct	agaggcagag	540
gagtgggtaca	agacactatc	tgtggagtgt	ctgggggtccc	gcctcaacga	catcagctctg	600
ggagaacctg	acctcctggc	cccaggggtg	cagtgtgaac	agacagatcg	cttcaatgtc	660
ttcctgctgc	cctgccccaa	cctggacgtg	tatggcgagt	gcaagctgca	gatcacccac	720
gagaacatct	acctctggga	catccacaac	ccccgtgtga	agctcgtctc	gtggcccctc	780
tgtcactgc	gcgctatgg	cgggtagtgc	acacgcttta	ccttcgaggc	tggccggatg	840
tgtgatgctg	gggaaggact	ctataccttc	cagacacaag	agggggagca	gatttaccag	900
cccgctccaca	gtgccaccct	ggccatcgca	gagcagcaca	agcgggtcct	gctggaaatg	960
gagaagaacg	tgaggctgct	gaacaagggc	acggaacatt	actcgtatcc	ctgcacaccc	1020
acgaccatgc	tgccgcgcag	tgcctactgg	caccacatca	ctgggttcca	gaacatcgcc	1080
gaagcctcca	gctatgctgg	tgagtgcctt	ccatgcccc	caccacctg	ccaggaggct	1140
ttgtggagga	tgaggcctat	tgggcagggg	tcttttgacc	tagctctgag	ttctgagcct	1200
gcttctgtgc	ccacaggtga	ggggtatggg	gcagcccagg	ccagctcgga	aacagacctc	1260
ctcaacagat	tcatcctgct	aaagccaaa	cccagccagg	gggacagcag	tgaggccaa	1320
accccatccc	atgaccaca	gtgctggcga	gcaccgatga	ctgctggggg	ctgcctgctg	1380
cggggctggc	tgcagtgtac	cgtggacagc	ctcagggggc	tgtcggccaa	gagcctggag	1440
aaaggggagca	agctgcccc	tccttgcccc	caaggatgag	gctggactga	ggcaaagggc	1500
tggccacacc	acctgagcat	gtgtgagggg	ttggagctac	cgtgggacta	tatactgtta	1560
atgattttaa	tatatatggc	ttatgacata	ctctgtatca	atgagatccc	ctcacccctca	1620
ccccatcctt	ccccaccaat	acacacaaat	tttttaaatcc	catgaccagg	ccacggtcaa	1680
ggctgttttt	gagtatgagt	gcagtctgtg	ccatcctcca	tggcacagcc	ctcctgctgc	1740
caggacctgc	ttgaactacc	agggccacag	gaggggggata	atcagagctt	gaggtcgga	1800
ctctgactgc	tggcttttcc	caaacagccc	aaggggcggga	acagcaggtg	gcttctcagt	1860
tcctctgggc	ctggagtgtg	acaggaagga	tctgcacttc	ctctgtgctg	cttgccagcc	1920

ttgcagttgg	agttttaagc	agaggtgaca	tctgggtgac	gcctcaggtg	aaaatctggt	1980
tttaaaatgt	aacttctgca	caggctcctt	cctgctttgt	aggctgggaa	gatgcccctg	2040
gggtaggggt	gctgattacc	tcagccatgt	ggaggaaggc	tggagcttgt	tcctgccccca	2100
ggaataggcc	aggaggggaag	gccgcagcag	gactgccgtg	gggagcacc	ctgctgcccc	2160
cctctcactg	accaggggtg	gacaatgccc	aagcagaggg	agcccccttg	ccctgttttg	2220
ccaccctctg	gccagccaaa	agcactctga	aaccaagacc	ttcccatttc	ctcctcccca	2280
catggtgctg	aggctccctg	ctgcaatgca	attaaagcaa	ttgattttct	agtgtctggt	2340
tttggtgact	accatgcaga	agggctatct	ttctattcac	gtcaaacttt	tggttgtgtg	2400
gggttttttg	ttgctttttg	ggttttgttt	tttaataact	tagggctcctg	atttgtggga	2460
acagaccttc	ttgtaaataa	ccactatttg	agttgtggca	ggaggatgat	aaagcacgcg	2520
gcccccccca	aaggagccct	tgagctaggg	aggtggtgca	gtcagcctcg	ctctcaacgt	2580
gacccgggga	atgaccaccc	agagggatga	gctagcctgt	agaggggaac	tggggtccaa	2640
aggctcttgg	ggagggaggc	agagctggct	ggctcagcta	agtggcacga	tgacgcatga	2700
aggagattat	gttgtgctct	ttattgccaa	aaataaacac	ttttaaaaag	acaacttctg	2760
ttaatcaata	aatatccttt	cctttcaaaa	aaaaaaaaaa	aaaaa		2805

&lt;210&gt; 41

&lt;211&gt; 1672

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

ggcacgagct	ccctcccacc	tgcttccatg	ccatatgccg	atcattacag	tacattttcc	60
cctcgagatc	gaatgaattc	ttctccttac	cagcctcctc	ctccgcagcc	gtatggacca	120
gttcctccag	taccttcttg	aatgtatgct	cctgtgtacg	acagcaggcg	catctggcgc	180
ccacctatgt	accaacgaga	tgacattatt	agaagcaatt	ctttacctcc	aatggatgtg	240
atgcactcat	ctgtctatca	gacatctttg	cgggaaagat	ataactcatt	agatggatat	300
tattcggtgg	cttgtcagcc	accaagttag	ccaaggacaa	ctgtgccttt	accaaggttc	360
tcagagagtg	tgagtggtag	aaaatttgaa	gaagatcatc	tttcccatta	ttctccctgg	420
tcttgtggca	ccataggctc	ctgtataaat	gccattgatt	cagagcccaa	agatgtcatt	480
gctaattcaa	atgctgtgtt	aatggacctg	gacagtgggtg	atgttaagag	aagagtacat	540
ttatttgaaa	cccagagaag	gacaaaagaa	gaagatccaa	taattccctt	tagttagtga	600
cccatcatct	caaaatgggg	tgcgatttcc	agatcttccc	gtacagggtta	ccataccaca	660
gatectgtcc	aggccactgc	ttcccaggga	agtgcgacta	agcccatcag	tgtatcagat	720
tatgtccctt	atgtcaatgc	tgttgattca	aggtggagtt	catatggcaa	cgaggccaca	780
tcacacgac	actatgttga	aagggacaga	ttcattgtta	ctgatttatc	tggatcataga	840
aagcattcca	gtactgggga	ccttttgagc	cttgaacttc	agcaggccaa	gagcaactca	900
ttacttcttc	agagagaggg	caatgctttg	gccatgcaac	cagaagtggga	attccctgga	960
tgaaggccgt	caccttacct	taaacccttt	aagcaaggaa	attgaactaa	gaaatggaga	1020
gttacagagt	gattatacag	aagatgcaac	agatactaaa	cctgataggg	atatcgagtt	1080
agagctttca	gcacttgata	ctgatgaacc	tgatggacaa	agtgaaccaa	ttgaagagat	1140
cttggacata	cagcttggtg	tcagttctca	aaatgatcag	ttgctaaaatg	gaatggcagt	1200
ggaaaatggg	catccagtac	agcagcacca	aaaggagcca	ccaaagcaga	agaaacagag	1260
tttaggtgaa	gaccatgtga	ttctggagga	gcaaaaaaca	attctgccgg	taacttcttg	1320
ctttagccag	ccactcccag	tgtctattag	caatgcaagt	tgctcccca	tcaccacatc	1380
tgtcagtgct	ggcaacctca	ttctgaaaac	tcattgttatg	tctgaagata	aaaacgactt	1440
tttaaaacct	gttgcaaatg	ggaagatggt	taacagctga	aaggagggtc	atctttcaaa	1500
tttgtgacca	caccatggaa	gcatttacac	tagcttttta	tatatataat	atatattata	1560
taatgtatat	tttttttaaa	aaaaagatat	tactgggggc	atccatttcc	tgtggactct	1620
ttgatacttc	aagccctctt	gcattagcat	tatgaaaaaa	aaaaaaaaaa	aa	1672

&lt;210&gt; 42

&lt;211&gt; 1228

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

ggcacgagat	ctcatgagag	gaatggctag	tgacccaact	ctccaaatgt	ctaagttagt	60
agttacagct	gattttttat	gatgcataat	tggaatgtgg	agcctctgag	gttgtgatat	120
cttgtagatg	aattttcaaat	gtcattctaa	agaatgaggg	gtgggagggg	tttatagtta	180
gaaacgacag	tgcaggaagg	ggtattttct	tggtgtcagg	gctggaatga	atcactgctg	240
ctcaagtcaa	aggttcttga	atatecttag	tttttgcatt	tcccctcctt	ttcctttgac	300
ctttatttat	ttaattatgt	atttatttat	ttatttatat	acttttgctc	cattcagcac	360
aaacacaaag	caaagcaaaa	aaaaaaaaata	tatatatata	tctgtatatg	tgttgtaggc	420
aaaacactgt	gaatttcaca	acaaccacca	ccaagcaact	attttgccat	cttaacatac	480
atctcaggag	acgaaatgag	aaaagatggg	gatgtcattt	tttagtctat	gcgtttgagg	540
ccaggtccat	gtttatttat	ttcttttagtc	tatgcattaa	tgaaaatgat	cctgagtggg	600
ggttagctga	acgttcaatg	tactggagca	agcatcataa	aagctgctag	tagccatgtg	660
tttgaacagg	aaaaatatta	cagaaaatga	aatgtaaagg	cctatatctt	gcagcttgta	720
tatcttacta	ttgcttaaaa	aatgtataaa	gcagctggaa	atgttttaaa	tacaaggctc	780
ttgaattaaa	tgtggatttt	aaatatgtaa	tcccttgaca	aatgaccaa	ttatggtgaa	840
ctattgctcc	ctgcttctt	tgatcattac	ctatgactta	caaactctgc	tggagatgtg	900
gacattctgc	atttgcttct	gtatctggag	agatgtttgt	atataatccag	gccgtataca	960
cacacatttc	catatctctc	tacagatata	tttccccttc	aatcgtgacc	tggtatttgg	1020
aactctcctt	ttcatttggc	ttatcttctt	tttaatgtga	tgtctctgtg	ctaatactta	1080
ccagttcttg	ttttgcaatc	tgttttgagg	tccattgctt	tactaagacc	cactgcatct	1140
tggtgtgatt	caaagtgaca	cctgaataca	gtgttttaaaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				1228

&lt;210&gt; 43

&lt;211&gt; 599

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

aattcttttt	tttttttttt	ttttctgcat	tgccagggtg	aggaaagaca	ggcagcctac	60
ttccaagcaa	gtgatctggt	ataggtggga	tagtgaaact	gtcacttaca	acattcttgt	120
agagaattgaa	cacaagacaa	cactcatact	ggcaaagaga	gaagctttga	ggggagggtg	180
gtgatatatt	gagtctacct	ttatccctct	ttccctatcg	aaccaccttc	ccctcatggt	240
aaagctggga	cctagggtata	ttgggtggcaa	catttctctg	ctgctgacct	caaagagact	300
aaaagcatac	gtgattgaaa	tgaaaaataa	atgagcagct	atltataaat	aactcctgtt	360
aacgaaggca	tgtgtttcat	ggaaataatc	tcatacaaat	gactgcttta	ttttgctccc	420
tcctccattc	ccttgatatcc	ctcctgctac	ccactaagtg	gggccagggc	aaggctttcc	480
ttacagggtcc	cctatttttct	taatttttct	ggtggcaagc	agcagaacag	agtggtgtca	540
ctgggttgcc	tttagaactt	tagtcattaa	atcaaaaaaa	aaaaaaaaaa	aaaaaaaaag	599

&lt;210&gt; 44

&lt;211&gt; 2466

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

agtccattct	cctgggtgtct	ctggatctgc	tccccacctc	catectctctg	gtgtctctgt	60
ggactgtgct	cccacctcca	tcctcctggg	tgaatcctgg	ttctttcgtt	ggctacctgg	120
aaagaaaaag	acagaagctt	atltgccaga	tgacaagaac	aaatcgattg	tttgggatga	180
aaagaaaaac	cagtgggtga	atltaaatga	gccagaagag	gagaagaaag	ccccgcccc	240
acctccaacc	tcgatgcccc	agactgtgca	agctgccccg	cctgccctcc	cagggcctcc	300
tgagagcccc	gtgaacatgt	actctagaag	agcagcagga	accagagctc	gctacgttga	360
cgctctgaac	ccaagcgagg	cccagcggag	cgagccggct	ctcgctcctg	cggactttgt	420
cgctccactc	gcgccactcc	caattccttc	taacttgttc	gtgccaaacc	cagatgcaga	480
agaaccacag	cttccagacg	ggactggcag	ggaaggccct	gcagcagcta	ggggcctggc	540
caatccagag	cctgccccag	agcccaaggt	tttaagctct	gcagcgctac	tccttggtc	600

tgaactcccc	tectccaggg	ctgaggggttc	ccaggggagga	gaggctcctg	gcgacctccc	660
tgctgcaggg	ggccctccca	gcgggggcat	gcccttctac	aacctgctc	agctggcaca	720
ggcctgcgcc	acctccggga	gctcaaggct	agggaggatt	ggccagagga	agcacctggt	780
gctgaactag	gcttgccctg	ctgtgaactt	gcacttgagg	ccctgacgct	gctgttctcc	840
ccgaagaacc	cgaccgacct	ccgcgatctc	cgtcccggcc	ccagggagac	acagcagtga	900
ctcagagctg	gtcgcacact	gtgcctccct	cctcaccgcc	catcgtaatg	aattattttg	960
aaaattaatt	ccaccatcct	ttcagattct	ggatggaaag	actgaatctt	tgactcagaa	1020
ttgtttgccg	aaaagaatga	tgtgactttc	ttagtcattt	aggatgattt	aaggatatag	1080
tattcctggt	catttaagaa	tgttcattca	ttgaagccgg	agctgtctct	gccacaggag	1140
agccacatgg	tcggtagtaa	ccagggcctc	tccaagccca	gctgtgagtc	actgccaggt	1200
gagtcgccg	cttcctttaa	ggtgctggga	gcaaagagag	ggtgactgag	gcagacccca	1260
acccttgctc	tgaccatct	gggccctcgc	cgtgtttgaa	cctggctgaa	tgagtggagg	1320
gcgctgtgtt	ctcaatcagc	gcctccgagg	agccgtgggg	ttccttcggc	attagttcac	1380
ggtttttgag	agaggcccta	gttactgcag	tgaatttctt	tcctgttgca	aagacgcttc	1440
cagcctcact	ttactttctg	tggcctgatg	aggaccatgg	gtgattttgt	gtacccaaag	1500
cgctggggac	tgcccaccgt	gtggcccagt	cactgggaag	gagccccaga	gagccggctg	1560
tctgacatga	tggctcaggg	tggtcatcca	ggttgaaaac	tgaccgtgtg	atgtttgatt	1620
tgggcttcat	ttcgtgtgta	ggagcacggt	tagactcact	gttaaggaaag	ctggatgcac	1680
ttctctaaaa	ggctgcactt	tccgtgagca	cttttcgtgg	tacaatccac	atgaccact	1740
ttctccccctg	ggggagcttg	gttcagaggt	tggtagcact	tggggagagt	atcttaacac	1800
agtttcttga	cagcagctct	ggaacttagt	atctctgccc	cgagttttgc	cacactgaga	1860
ctttgagtag	ctcctgggtg	actcaaccct	gttcaactca	gagacggggc	tcctctcact	1920
gatgcaaagc	tttaaggctt	ctctgactgt	tctgaaactc	ttcgtattct	tgtcaagtct	1980
aaagagactg	aagaaaagat	ttaaatacta	ataaaaaatca	gtagataatt	tctgtagggt	2040
ctgctggagg	aatacaaaact	gtttgggtgtt	ttaaattttaa	gtgtagaaat	tgtagaatgt	2100
ggaattagca	cagatccttc	ctggctttct	gtttcacttg	atcatttagc	ccagaccacc	2160
caggatgttt	tccaaaatgt	tccacaggcg	tgtcccgtg	gatccatttg	tccttgtcac	2220
ttggagaaaag	gccagtcctc	gtgacggggc	agccctctct	gtccctcggt	cagctcgtgt	2280
gaatcctggg	acctcctcgg	gtcggctctg	cccgtgttcc	tggggctcgac	tgccacgact	2340
tttgattcaa	gaagcttctc	ccaggcgggga	gcggctattt	ttcctaaatg	agaattgtta	2400
cattgcaaat	tgttgaaata	aatattttgc	gctccttcaa	gcaccttcaa	aaaaaaaaa	2460
aaaaaa						2466

&lt;210&gt; 45

&lt;211&gt; 1446

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

tttttttttt	ttttttttta	gatcaatatt	cattcttcat	ttgccctcgt	aacgaaaata	60
gattttttaa	tgccctcaat	atacaaacat	cattgatgca	cacacattcc	agaaatgcag	120
aggatgctg	ctgccacggg	gtaggggtgc	gggaggcggc	ctggcctcat	ggccgcagac	180
cgtgccccag	ccggggcctg	gcaggtagct	ggccactgat	aaatgccact	gggatcctag	240
gagaagctgg	ggaccatgcg	tgaggtagct	aaggggacca	tggtaggag	catcctgggc	300
actttgttag	ttgtctgagg	gaaaggcctc	tgctggccata	gaaaagctgg	acacatgtca	360
ccctggggcc	ctgacatcct	aaaatgcccc	actgactacc	agtcactagg	agaaaggtct	420
ccggtatgc	ccttcccagt	gatgcttgcc	ccagagtgc	tggtcacagg	tgggggacag	480
gtttgtctca	gaaaccgtag	gcctttcttg	tctggcccc	ttaaaggagg	ccaagatcag	540
gaaaactccc	cagtttataa	aaatatctgt	ccatctgtat	ataaaatacc	tattatttagc	600
tggagttgca	cacatgcagg	accaggagag	actgcctgag	gttctgctg	gaccgaagga	660
ggcctcgctc	acagcacctc	tgtgagggga	ctggtgctcc	tgggaagtca	cttctcttgg	720
tgaccgagct	gacacccctc	ccacttgga	agcacaggga	ctgagcaggc	gggacctgtg	780
ctggaggggag	acctcctg	tgagggaacta	tgcgggcctt	ctgggcctca	gcagctccag	840
cccactctg	gcctggcagg	ccacctgccc	ccccccac	ccatctgcct	ctgggcccc	900
agtgaagtca	gaagaggcag	gagccccgca	ggctgtgagc	ctggcgagc	tcggctgaca	960
gcgagcttct	catctgcctg	gtggtagagc	ggacgctctc	ggcagcctgc	acggccccgc	1020
tcagggcctt	gttgagctcc	tctaggtcgc	ccaggtcgag	ctggatggag	tgccgggtgc	1080



tccgggctgg	tgggggagag	gctgtgggcg	gccacttggc	agctgggttg	gctgaggtag	1140
gtcctgcagg	cgcatagtac	acagcggcag	gtggataagg	catgatggga	accgaggaga	1200
tgtaggcaaa	ggctggaggg	gctgggtgctg	ggggcgctgt	tgccagatac	cacagtccgg	1260
ggggtgggcg	tggcgacgac	cccgcctgct	tgctcctctg	cttggggctg	ggagttgaag	1320
gtgcttttct	cctcgtggtg	gccttctctg	ccccagaggt	ggctgagcct	ggaccatctg	1380
cctctggggg	agacccaact	tgaccacaca	ggggacactg	aagggtatca	gcgggagggc	1440
gtccca						1446

&lt;210&gt; 46

&lt;211&gt; 2583

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

ggcagagct	gaactcccaa	agggagtgtg	tgtatttcct	cccgttcttt	atcagagccc	60
ccaaaataag	taggaatggg	cagtggstat	tcacattcac	tacacctttt	ccatttgcta	120
ataaggccct	gccaggctgg	gaggaattg	tccttgctg	cttctggaga	aagaagatat	180
tgacaccatc	tacgggcacc	atggaactgc	ttcaagtgc	cattcttttt	cttctgccc	240
gtatttgag	cagtaacagc	acagggtgtt	tagaggcagc	taataattca	cttgttgtta	300
ctacaacaaa	accatctata	acaacaccaa	acacagaatc	attacagaaa	aatgttgtca	360
caccaacaac	tggaacaact	cctaaaggaa	caatcaccaa	tgaattactt	aaaatgtctc	420
tgatgtcaac	agctactttt	ttaacaagta	aagatgaagg	attgaaagcc	acaaccactg	480
atgtcaggaa	gaatgactcc	atcatttcaa	acgtaacagt	aacaagtgtt	acacttccaa	540
atgctgtttc	aacattacaa	agttccaaac	ccaagactga	aactcagagt	tcaattaaaa	600
caacagaaat	accaggtagt	gttctacaac	cagatgcac	accttctaaa	actggtacat	660
taacctcaat	accagttaca	attccagaaa	acacctcaca	gtctcaagta	ataggcactg	720
aggggtggaaa	aaatgcaagc	acttcagcaa	ccagccggtc	ttattccagt	attattttgc	780
cgggtggttat	tgctttgatt	gtaataacac	tttcagttat	tgttctgggtg	ggtttgtacc	840
gaatgtgctg	gaaggcagat	ccgggcacac	cagaaaatgg	aatgatcaa	cctcagtcctg	900
ataaagagag	cgtgaagctt	cttaccgtta	agacaatttc	tcagtgtct	ggtagcact	960
ctgcacaagg	aaaaaccaag	aactgcagc	ttgaggaatt	ctctccacac	ctaggcaata	1020
attacgctta	atcttcagct	tctatgcacc	aagcgtggaa	aaggagaaag	tcctgcagaa	1080
tcaatcccga	cttccatacc	tgctgctgga	ctgtaccaga	cgtctgtccc	agtaaagtga	1140
tgtccagctg	acatgcaata	atgtgatgga	atcaaaaaga	accccggggc	tctcctgttc	1200
tctcacattt	aaaaattcca	ttactccatt	tacaggagcg	ttcctaggaa	aaggaatttt	1260
aggaggagaa	tttgtgagca	gtgaatctga	cagcccagga	ggtgggctcg	ctgataggca	1320
tgactttcct	taatgtttta	agttttccgg	gccagaat	tttatccatg	aagactttcc	1380
tacttttctc	ggtgttctta	tattacctac	tgttagtatt	tattgtttac	cactatgtta	1440
atgcagggaa	aagttgcacg	tgtattatta	aatattaggt	agaaatcata	ccatgtctact	1500
ttgtacatat	aagtatttta	ttcctgcttt	cgtgttactt	ttaataaata	actactgtac	1560
tcaatactct	aaaaatacta	taacatgact	gtgaaaatgg	caatgttatt	gtcttcctat	1620
aattatgaat	atttttggat	ggattattag	aatacatgaa	ctcactaatg	aaaggcattt	1680
gtaataagtc	agaaagggac	ataggattca	cataatcagac	tgtagggggg	agagtaattt	1740
atcagttctt	tgggtctttct	atgtgtcatt	catactatgt	gatgaagatg	taagtgcag	1800
ggcattttata	acactatact	gcattcatta	agataatagg	atcatgattt	ttcattaact	1860
catttgattg	atattatctc	catgcatttt	ttattttctt	tagaaatgta	attattttgtt	1920
ctagcaatca	tgctaacctc	tagtttgtag	aaaatcaaca	ctttataaat	acataattat	1980
gatatttatt	ttcattgtat	cactgttcta	aaaataccat	atgattatag	ctgccactcc	2040
atcaggagca	aattcttctg	ttaaaagcta	actgatcaac	cttgaccact	tttgactcat	2100
gtgagatcaa	agtgtcaagt	tggctgaggt	tttttgaaa	gctttagaac	taataarctg	2160
ctgggtggcac	tttgtaacgt	atgattatct	aagctgattt	tgatgctaaa	ttatcttagt	2220
gatctaaggg	gcagtttagt	gaagatggaa	tcttgatttt	aaaatagcct	tttaaaattt	2280
gttttgatgat	gatgtatttt	gacaacttcc	atcttttagga	gttatataat	caccttgatt	2340
ttagtttctc	gatgttttga	ctattttata	tcaaggacac	caagcaagca	taagcatatc	2400
tatatttctg	actggtgtct	ctttgagaag	gatgggaagt	agaaaaaaa	aaaagaaaga	2460
aaggaaagga	agagaggaga	gaagaaggca	gggatctcca	ctatgtatgt	tttcacttta	2520
gaactgttga	gcccatgctt	aattttaatc	tagaagtctt	taaatggtga	gacagtgact	2580

gga

2583

<210> 47  
 <211> 610  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (587)  
 <223> n equals a,t,g, or c

<400> 47									
ggcacaggta	atccagcggg	aactaatcat	gttggtgata	ataataatga	cagctctggt				60
ctcccatgtc	ccaagcgccc	actctgtgcc	tcatgctgtt	cccttcacca	gcagttagtt				120
ctccatctaa	tctttcttct	gagaaaggca	gggcagtcac	ggctccaact	ttacagatga				180
ggaaattgag	gctcgggggg	aagtcactgc	ctgaggtcaa	tgggcaaktc	ggggggcggt				240
gccaggaccc	atgcctaggt	cacaccccaa	gtagarttct	gaccatgggg	ttcaragtta				300
gcagaraggta	cggtggacca	ccccatctgc	agtcctccct	ggaggwcaga	tccgggactg				360
ctggactgwg	yaacttcagg	gagggactgt	actctctgcc	tcacagyctt	catcaataaa				420
awgaggatga	cacgggtccc	tgcttcacag	ggatcccagg	gctcagaaca	cagtggggct				480
caggggacaat	tctcagggtt	atgcagttga	tcaacaaatg	cacattatag	cctgaggaac				540
atagggagac	cccatcttta	cacaattttt	ttttttttga	gccagantct	cactctgttg				600
cccaggtgga									610

<210> 48  
 <211> 249  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (235)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (241)  
 <223> n equals a,t,g, or c

<400> 48									
aagcatgcac	caccacaccc	ggctaatttt	gtattttttca	gmagggacgg	ggttttttcca				60
tggtggtcag	gatgggtctt	aactcatgac	ctcaggtgat	acccctgccc	cagmctccaa				120
aagtgctgag	attacaggcg	taagccaccg	cgcccagcct	tgttttgggt	tttttttttt				180
gttttttttt	tttttgagat	ggagtctctc	tccgtcacc	aggtggaagt	gcaanggcgc				240
natctccgc									249

<210> 49  
 <211> 888  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (845)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (864)

<223> n equals a,t,g, or c

<400> 49

ggcacgaggg	gcgttccatc	gaggcctttg	atcgcagcat	cgacctgctg	gtgtcgcgcc	60
tgcgccagaa	gctgggggat	gaccccaagg	ctccgcaatt	gatcaagacg	gtacgcggcg	120
aaggctacct	gttcgacgcc	cgggatatcg	gttgatgcgc	gcgcccttca	acacgctgtt	180
cgggcgactg	ttcggcctgt	tgctggtggc	gattgtgctg	gcccatstgc	tggcgttcct	240
ctggttccac	cactacggcc	cgccgccacc	acycckygcg	kccttcgctg	aacaaccaga	300
tggcagyctc	acgcccttgc	gcaaagcgcc	tcgcccctgg	ttcggcggcc	cggtggtgcc	360
cttgacattt	caatttatct	cgctgatcat	cgctgcctgg	tacggcgcca	aactgctgag	420
ccggccaatc	cagcgctga	gcgcagcgcc	cgagcgctg	agcgtcgacc	tcgacagccc	480
gcccctggtg	gaaaccggcc	ctcgcgaagc	acgccaaagc	gcctcgacct	tcaacctgat	540
gcaaaagcgc	atccgcgaac	aagtcagcca	gcgcgcacgc	atgctcggcg	cggtctccca	600
cgacctgcgc	accccgctct	cgcgctcaa	gttgcgcctg	gaacaaatcg	aagaccccaa	660
gctgcaaggc	cagatgcgcc	aggacctgga	cgacatgac	ggcatgctcg	atgccacctt	720
gagctacctg	cacgaacagc	gcaccagcga	gacacggcat	tggctcgatg	tacaggcggt	780
ggtggaatcc	ctgagtga	acgccagga	ccaaggccgc	gacgtgcagt	tttttttttg	840
gggncccccc	cccggggggg	gggncccaaa	aacccccccc	cctttttt		888

<210> 50

<211> 1674

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1210)

<223> n equals a,t,g, or c

<400> 50

ggcacgagtg	aaaggatatg	aatctgggaa	aggggtgggg	gcaagcnaac	caaataggga	60
tgctaggggt	gggtggggaa	ttaaggactc	ttctgtgctt	ttattgtagg	gctggggatc	120
gaggatctgg	ggcaaaaaat	atgacatttc	caaccaggga	caaaatggag	gcttgggctt	180
agtgatgggt	aaatggaaga	ctggttgagt	gggatgataa	tgggagaact	tactgatgct	240
cttttgggaa	aagggtgctt	aaagactcga	tttgggagcc	tactggggca	aggcgactgg	300
ggagggtgtac	gtgttagtca	agtggaggtc	aggtgggtta	tcttctgcct	ccttcactgg	360
cttcatgtga	acttgccctg	gacagaatat	cttgccctag	atgtcctctt	ccctcttgcc	420
atcgtgcaaa	agcattcgat	cttatgaccg	tgagttctta	tttgtggatg	ctaactgggg	480
taatctcagg	gagtactggg	gccatggctc	tttcccttgc	ttctctttct	gctcactgct	540
ttgtcttcag	gtgcttagct	gctccttttt	atttcttttg	aggactggga	aagcatggga	600
ggaggatttt	gataagtttc	ttgttctctg	cgtgggtgatg	gggtgggtctg	agggccaagt	660
taataagcct	acctttgggt	attaccctgg	aaaattgagg	gttgatggta	gggttatgat	720
tgtggcctgt	gtatttgcaa	tttttctttg	tcagtgtggc	tttctgtcat	cttccctttt	780
ctccagttag	ggttctgcca	ctgtctcaat	cccttgggtc	ctgcaaaaaa	cagctaaatg	840
tgctctcagg	gccagtgggt	atgttctgtg	ttgcagcccc	agctcttgaa	agtgcactgg	900
cccagatgag	ctctgcctgc	ttgtcatctt	taggtcctgc	tgcccctgct	gcctcagccc	960
tcaggctcct	aactgctcaa	gccagaagga	gctacaaagc	caaatacatt	gtcatttttc	1020

tctggcagat	tgytttaaaa	tctccctccc	ctctttttatt	ttaattatgc	cacctgtgtt	1080
aatcctatag	cctgcttctt	tgctttgtgg	attactgatt	tcaagttcta	taacttgggg	1140
aaagttaggt	tgagtgaatg	ggaggacaga	cactgaatgt	gtgttttgga	aaaatggact	1200
ctctatcttn	cagatwatyc	agcttctcca	cctatcacct	ctacaacttg	gccttcattg	1260
gagaagtttt	agttggctta	ttcctggaac	aagaccacct	agaggctttt	agccttgtca	1320
gcctgccctc	ttctgaggtt	tggaccttgt	tttaaattgt	gtgcatgggtg	ggcttgagac	1380
tctcttgtaa	tggaggtaat	gggactatca	ctgaggggtt	cagcctatcc	aggtaggcta	1440
ccgttctagt	catacccatc	acttaaattc	tgccacagtc	tgcacagacg	gttggtcctc	1500
caggcatatt	gtcctattaa	gccaaatagg	tggacatcat	gggatggatg	aggtcatcat	1560
gaaaacagat	ttactggatt	tatggaccta	gtatatacta	tgtaacagat	ggaaaactga	1620
attttacaat	ctataggtac	ctttgaaagg	tcataaaggg	taaaagtcta	tagt	1674

&lt;210&gt; 51

&lt;211&gt; 603

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

ggcacgagca	aggacagcac	aatgccatgg	caaccgcttc	catcaataac	ttaatttcat	60
ctctgctctt	acatctttct	ctectcagtt	ctaaagctgg	aaaattttta	atttggaag	120
aacataagac	ggcttgtggt	tgctatgcc	acagcacctg	cctgcttctt	aatgggcttt	180
ccaatcataa	aggaaagtct	tagcaagtca	cagaacttta	gactccaggg	gctctggagg	240
gcactccgca	cagcacggcc	tctcacttgg	ccgaggagac	cactggcacc	caggagggtta	300
agttccctgt	ctgtccacag	caattctact	agcccgcgct	gaagttacac	caaggcaagc	360
agcttaattt	tggccaaccc	gaaggattta	ggcaggattt	gggtggaagg	cagctgggctg	420
acccttgagg	agagttgctg	taagtatctt	tctaccccca	aaatccagta	tatttagtca	480
gcttgggctg	ctgtaacaaa	gtaccacaga	ctgggsggct	tgaaccaga	aggtggagggt	540
ttcagtgagc	cgaggttgcg	ccatgcactc	arcctgggtg	acagagcgga	ctccgtctca	600
aaa						603

&lt;210&gt; 52

&lt;211&gt; 1016

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (999)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 52

ctcagagtttt	tttttttttt	ttttgtagag	gtaaatacaa	cctgtgttgt	ccaggctggc	60
tctgaacacc	tagtttcaag	agatcctctt	accttggcct	gtcaaagcac	agggattaca	120
ggtgtgagcc	actgcacagc	acacagcact	attttcagag	tttaatgatt	cctcttctct	180
ggttaccaag	gtaatacaaa	gtattaaacc	tcctgggtgta	tctgtcaaga	ggtgctgcac	240
cttggaattt	ctcctgcaca	ccaggagtgt	cctgctctct	gctgtggccc	agggctgtgt	300
ggtcttgggc	ctttctcca	tcctctggag	tcagatctgg	caggcacatg	ctgtgcatta	360
agccttgggg	ccggcagtg	aggcctggcc	agggcccttg	gctggggctg	aagggctgat	420
cctgaaaggg	cacaggacca	gcaggctgca	gcagcaggag	tggcttcca	tgggaagggc	480
ttcccggggg	aactgcgtta	cctgattccc	accacgtgtg	cctgctgctt	gtgggtgggt	540
gccgtgcagg	ggatcaggac	agtgggggct	cctttggggg	tctgacatgg	gctcagagcc	600
agaaatgtac	acctgccacc	tcctaggaaa	agaaagcaca	aagcaaagac	aaagagggga	660
ggggcggtgg	atgcagcaga	ccatgctgtc	acccagggtg	ccttgctatc	tctgacctca	720
accttgggct	gcacagctca	tgggagcatc	tagtggatgc	tccaactaga	ttgtgccaa	780
gtggggccgg	gccaacgtct	cagccacgag	gaatcctcac	agagcagtcw	ccagagccct	840
tgctgccggg	acacttctct	cagtgccccg	atatggccag	cctgggtggc	tgggtgtgtc	900

tgtcttcctt	ttggagctcc	ttttgccagg	ggaaactctg	tggtctctga	tctcaggtgg	960
tgctattttt	gatgacagca	cgttcttttt	ttttttgana	cggagtctcg	ctctgt	1016

<210> 53  
 <211> 459  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (24)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (39)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (377)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (379)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (413)  
 <223> n equals a,t,g, or c

<400> 53	
tgcgactaca	cggcgacact agangatcca aagactttnc caccgaggttc aagcaaataa 60
ttctattgtg	aagatgcttg gccgggatct gtgcctcctg ccccagactc cagccagtac 120
tgcccagggg	agagtctgag tctgttctcct aatgagagct tcccaggaga tctccgccta 180
gcaagtgcaa	aargcattga ctggcctgtr ggacagttaa gaaacggtag cagttactcc 240
ctttccacct	tcacggccca ggagttcgat agcagatgaa gacggtgagt cttcttctaa 300
ccctatgggt	ctcccaaact ttctccttta acttattttt tgccccacct cattctcttc 360
ttcagagttc	tattttntnc tctgtgtctt ctataactac tgtacaccct atnctgggtc 420
ttttgttttg	cattcttttag aacttgattg ccacatctg 459

<210> 54  
 <211> 994  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (21)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (66)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (248)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (387)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (970)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (972)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (974)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (976)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (994)

<223> n equals a,t,g, or c

<400> 54

atgggatttta	cacagggttaa	ncaactcact	taggcctctg	aagggtccagc	tgagctctaa	60
tgtttncaca	atgattcttc	ttgggctttg	gcaatctgtc	cttggttagct	cgatttgggg	120
acagccactc	tcctacaact	gccaggagcc	acataattgc	cttttcaacc	acagtgactt	180
taaatgagct	tccaaatcac	ttttttttcc	tgtttctttt	tctttaattt	ataaaaaatct	240
caaagcanct	gaagaaaagta	ctgggtgaaa	gttggttctaa	aaaattgcct	gactaaaatg	300
ggaggatggg	caaaaatcat	ttgcataacc	acttgccctat	atcaattaaa	tttcaatttt	360
atgcatttct	caggccttta	aacttanaac	aattttccaa	atattaatgg	ctcatttttg	420
acacaatctt	tcttccactg	ctcaacctaa	atcctcctct	ggcttawacc	ccccacactt	480
aggaagagaa	aggataaaaag	ggtaaagata	gtcatasrtg	accccccata	acaaaaatag	540
tagtcagggg	aaaagacaca	gatgtagagt	tgggtactga	gtctgggtgg	ggtgggaaag	600
gaagaacaaa	caaaagggca	aggacgtcag	gaagcccaga	gagcttgggg	gaaagcattw	660
caaagctgtc	tatgttttag	ttaaaggcca	tcaagttctt	ttttttttta	agagwcaggg	720
tttacttttg	ttgcccagac	tggaggaggat	acagtgggtg	grksgrtrgst	cactgcagcc	780
tcaaaatcct	gggctcaagt	gatccccctg	ccctgacctc	ctgagtagct	gggattacag	840
atgtggcaat	caagttctaa	agaatgcaaa	aaaaaagacc	aggatagggt	gtacagtagt	900
tatagaagac	acagagaaaa	aaatagaact	ctgaagaaga	gaatgagggt	gggcaaaaaa	960
tgggttaatn	gncnanattt	ggtaggagaa	tttn			994

<210> 55

35

<211> 1000  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (48)  
 <223> n equals a,t,g, or c

<400> 55

ctcgaagtttt	tttttttttt	ttttgaataa	aattagcata	atccccgnac	atctggtatg	60
actactgacc	tggcaaatgc	cttcttttct	atcaccatca	gtaaggacaa	tgagatgcaa	120
attgcatgaa	gtggcagaaa	ggcagtatac	cttcattgtc	tcacctgagg	gctatgtctg	180
aattgccata	atatagtctg	gagagtcctt	gatcatcttg	acagcccaca	gatcaccaca	240
ctgggtccatc	acatggatac	cattatctta	actggacctg	gtgaacaaaa	actascaagc	300
accttgagca	cctgtgtaag	acacatacac	aagccagagg	atggaawaaa	actcatgaaa	360
gttcagggat	tcactacact	gatggcttct	aggatttccc	tggtctgacc	caggatatcc	420
cacctcaagt	gagagaaata	actacacctt	gcaccacttc	cactgagaaa	gaggtaaaac	480
aaatagttag	tttcaatact	tggatatgct	gttctgaccc	atttactggg	taacctatga	540
gcctgccaag	ttttactgaa	gcccattcca	agagaagggt	ctagagcaat	gaaagctgcc	600
ctaacccttg	agcctatgcc	tcagcacacc	cagtagtact	ggaaatgaca	tggcaaacag	660
gaatgaatta	aggacccctc	tctctaaca	gcaccaagaa	aagggttaaga	gtttcagacc	720
cttaggggtt	gccagcaatc	actgtctgtg	gttccctggc	tggtactagg	cccaggaaga	780
gatgcaatga	ccgcctatgg	aaaaccaaga	gactatgtaa	aaacaacagc	ccatcgtgaa	840
cagagtattg	ctgggttca	gaatcataaa	actggacatg	tacagcagta	atccacttgg	900
tacagtaaaa	gcaagactgg	gcttaagcag	gtctggacgg	cacaagtaaa	ctgcagggat	960
taacagccca	gacttcccta	ctgcttggtc	cttcttcttg			1000

<210> 56  
 <211> 964  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (62)  
 <223> n equals a,t,g, or c

<400> 56

agcaaaagct	gcagctcgcg	cgccctgcagg	tcgacactag	tggatccaaa	gaatttgga	60
cnagttctct	ctctctctct	cgcttcttcc	agatgttagt	cttgctatct	cttttggtca	120
gtgggtggtc	gcccccttct	ttagtggggg	atgtattagc	ttcaaaatct	tcaacagtgc	180
ttttccctcc	tggcgactct	tctccagggt	gctccatgat	cactccactc	cctccatcta	240
ggatgtgcct	taaagctggg	tcctcagggg	aacagacggg	ggttccactc	tcactgctgc	300
ttaggtctaa	atcttctaag	taaaggatct	tgggctgatg	catgcttttg	atgaatgttt	360
tctccctctc	gagctttcta	cttgartgaa	gctcattcat	gtccacccca	gagtcagac	420
tggtgtcatt	gctctgggtt	ctcttgccct	ttttcagggt	tataaaggag	tgccctcact	480
gtgcaactgg	ctttccatca	agagacacaa	accaggctct	gggatgctgg	gagggctttc	540
ctttggacag	ctccagragg	gtctgttctg	aaatttcctg	aagttccgat	gaaaatggag	600
tcattacaac	agcctcattt	agtgttccag	gaacagagac	ggattccagt	aagctgcttg	660
agtatcggct	ccaatctgaa	gcctgggatg	gcaggctctg	ttgaccttca	agtatgatat	720
cctcttccct	ggcatctggg	ggctgtgcat	gagaatgaat	tggcattttg	ggcaagggtc	780
gcgtaaaagt	ctctcgattt	actggttcca	tcaattggcc	atagactaac	tgctcccttc	840
ttggcaaaagt	agctgactta	gcagtatgta	attgttccgg	tgtggagaaa	aggtcagatg	900
tttgaaagat	ggcaatgggt	tggctgtaaa	tatgcataag	ctgttcagga	atatgggaac	960
gccc						964

<210> 57  
 <211> 546  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (16)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (22)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (24)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (28)  
 <223> n equals a,t,g, or c

<400> 57	
cgtcgggcgga tgaagnccctt cncnttantt tacgtaaccy ttcctgagtg tttcaggatt	60
gtctgctgcg ctgttggaact tggcttyttt yakttcaaca gatattctca ttctagaccc	120
cagggtgaag gaataacaac tctctgggct atgctattca catattagaa gtcttgagca	180
agagggcaga gccacacat gcaaactcat ttaatatgct cacatttcat tggttaaagc	240
gagtcagtca attaagccaa aggatagggg aggtttactt caccatagg gaaatctgtc	300
ataggagggg ggcaaacaaa taaaagtatg tacacttatt caatttgcct caccaggat	360
gtgacatagt tgagaatttg atctaaaata acattttctc tttgtttata ttgaaccatg	420
taggttcagg tataaatgaa gattccaagg acataactgc ctaccacaca gtgtttctta	480
cagccatatt aggaggaaca atagtcattg tcattggatt ttttgctgta ctactttggt	540
attgca	546

<210> 58  
 <211> 609  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (7)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (19)  
 <223> n equals a,t,g, or c



&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (31)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 58

natactnccg	cgaaaattnc	ccacataccc	ngtaccaccac	ccgggtggaa	aatcgatggg	60
cccgcggtcg	ctctagaagt	actcttatca	caatggcatt	cgtatacgta	tgttctcata	120
gcaggaggat	agttggtcag	ttgtgctctg	ttcactctag	agcccaggta	gaaggagctg	180
caactcttaa	tgcttcaagt	tttagaattt	ttgtattcta	tttctttaga	cccctgctta	240
at ttggtaaa	tccttttttt	gaatttgtct	ttaaaatatt	taaagattaa	atatctagat	300
aaaaaataaa	tgacagctgat	aatcaacatt	ctatcttaaa	atctctttgc	acaaagctca	360
agttagttaa	aaatatatttc	gccagtttta	ttttaccaat	ttttttgkta	cttgggtcac	420
cagttttacg	gcctcttgaa	acagttttct	cactgcctgg	cctagaagcc	aatgtcatat	480
gttttaagct	ttctatagca	gcattctcagc	atcttctgtc	atatccattg	ctgcagkaac	540
aaacaaccct	gctgtctcgg	tggttaacag	tatcaaacgc	ttatttgcta	cttaacattt	600
catgagtgg						609

&lt;210&gt; 59

&lt;211&gt; 894

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (726)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (771)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (775)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (816)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (849)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 59

gaattcggca	cgagctttcc	ccttcaagaa	gcttagatta	gtgtgattaa	atcagtgtga	60
tacagtgggtg	ataagagatc	cagcactcca	ctcgacatca	ttgtccgttg	tcatgacacc	120
aagttacagc	atttgatcaa	tggttcctgt	gccatgttgc	agtacacttg	gctcatctta	180
gtctttttgt	caagctgcct	ttcagcgacc	tggttctgca	aagtggttgt	ggcagccatt	240
ggatccacag	tggggagctc	caggctacac	tttaaaagaa	gtggtcagtg	tttgagatga	300
cgggcatgcc	agttaccctg	atctgatcac	tataaccttat	aggtatagaa	atgtcactag	360
gtgcccaggg	atatgtataa	ttattattaa	tcagttaaaa	aataaaaataa	atgattgaga	420

aaacttcagt	tgttcata	caagaaggga	rgggctgcct	gagattcctg	atgggggagt	480
gggtctcatg	tcacccccag	tcgccaccat	gtgctawttt	cttcccaaaa	cttgggagcgt	540
ggttcctttg	ctcctttatc	ttgacagggt	gatgccatga	attctcacca	ttttaagata	600
tagatcaggt	gataacacat	tttccccata	aagtttcata	gttttttgag	ttgtctgcat	660
gtcttttcta	atgccgtctt	ttctaacttt	tctgttcaga	ggatatatcc	tggattagat	720
cagatnaaca	cagatctatt	acatacattg	gagaggaata	atttctgcat	ntgtntcaac	780
tgaacacttt	ttagaaaatg	aaatagctca	tggttntgaa	aagaacacgg	atgctggagt	840
cagaaaggnc	tatgttcaaa	tcctctttac	tacctgtact	tgaataacag	ctta	894

<210> 60  
 <211> 666  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (611)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (627)  
 <223> n equals a,t,g, or c

<400> 60						60
acgggcccc	tcgagttttt	tttttttttt	tttttccctt	aaaaaagaga	atgattttat	120
tcctgtaagc	agtttgcaaa	ccaggagagc	ccagccttca	gtacaaaaca	aagatgctct	180
ccctgagaac	agagagacag	gttatccttt	atagaaaaag	ctcccaccca	gattccact	240
ctgggtctgct	ctgcaagtga	gagggatgca	agtatgtttg	gttttgattg	gtcaatgcaa	300
gtcacaagtc	tatttgtag	atccagaagt	caagatgaga	cttcccagca	cccatcaa	360
cagggagcat	aaataggagc	agacagccat	gaaagtcccc	aaatcacgcg	agcctgtggt	420
ttctcagaga	atgcagaaga	cgtttgtagc	ctgggtccat	tctkaattta	gayccagtta	480
gccactcagg	atccatttgg	aaggattggc	tctttcaggt	tcatgaagtg	ttcatggcag	540
ctttattttac	agtagccaga	aactgggttc	tatcccagtt	acctttagtg	actttcagtc	600
atactcagct	tactgaaca	gtaccctga	actggccctt	taagaaaagg	aaggcgtctt	660
ctgctcacga	ngtcggaggg	agtcanaaa	ggcagggggg	gtccactgga	gctggggggtg	666
ctttgt						

<210> 61  
 <211> 1512  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1359)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1466)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1478)

<223> n equals a,t,g, or c

<400> 61

ggaccaagtc	aagaatggca	ccaatatgaa	gtccctgaat	ctggagatgc	aagagttggc	60
ggtagctgcg	tccctgtcac	agactggggc	gtccattggc	agtgccctgg	ctgcaatcat	120
gcttctactt	ctgggtgttt	tggtggcttg	ttttatcaac	aggaaatgcc	agaaacagag	180
gaagaagaag	cccgcagagg	acattttgga	agaatatcct	ctgaatacca	aggtagaagt	240
gcccaagarg	cacccggacc	gggtggagaa	gaacgtgaat	agacactact	gcactgtgcg	300
gaacgtcaac	atcctgagtg	agcctgaggc	ggcttacacg	ttcaaagggtg	ctaaagtcaa	360
aagactgaat	ctagaagtca	gagttcacaa	caattttacaa	gatggaacag	aagtttaatg	420
gaggagacct	atgtgtatatt	ttttctaaaa	tcattttttat	aaaatggggg	gaaatactgg	480
tattttttata	atctcgcaga	taaaaaaggg	aaaactatag	ctttgagtg	cagacagcac	540
acatcacatg	catcaactca	caactgagct	acctcattca	gcaaagaacc	actgagaacc	600
ccagagtatt	acagttatatt	ccgtagatcc	ctttaatagt	gtcaacaact	gtacacagct	660
ccttctgtaa	ggctgggtctt	agaaaacaag	tacttttagtw	tcaggacagg	agttgaacaa	720
ttaggttagc	agatggagat	gagaggactg	ggtagagtac	catggcagat	ctcagagaga	780
agaagtaggt	acgggccttt	ggttccctcc	cccagcccca	gctttctcct	acagggcctt	840
tcctgagtc	ccagacagca	gagtatgaac	tgctgacacc	cagattccat	taaaaattct	900
gctaatacgac	acaacacata	tatttgctca	tgatttcact	tgacagcgta	tgctccttgg	960
cctctaattg	tacttttgctt	ttccagagcc	ctttttacct	ggggatttca	gtgtgcttaa	1020
gtaaaatcct	ctgaaaacca	cgggagcctc	tgccctcctca	gccacagaga	actccctcct	1080
acaaaggggg	agactgaaac	ccgagttaag	gagggggcctg	gcaggcgtat	cagagcacat	1140
tagtgatgcc	cttcacccca	gggaggtgtc	tgttcccaac	tagtttatgt	ggcactgaga	1200
catccatccc	tgaccaagga	tgctgcgaaa	caggatcaat	gtactacggc	cttttaattc	1260
aacattgcc	taaatgcttt	aaagaaaacc	caccacactt	tcctcctact	ccggtctttg	1320
cccgtcctgt	aacagacaat	cccatgtcct	aggtatggnt	ttttattctg	gtagtgtctc	1380
gggaaagtaa	gtgattcatt	tgaataaggc	aaattaggag	aaagcccagg	ttggggtgaa	1440
atcagactta	acagatacat	gctggntctc	cttgctgngt	gtgacacagc	agacagagggc	1500
actattcctg	gg					1512

<210> 62

<211> 2598

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (80)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1123)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1495)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2004)

<223> n equals a,t,g, or c

<220>

<221> SITE

&lt;222&gt; (2019)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2036)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2595)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 62

ctaccttttg	tcctgggaaa	ccttccttaa	aatcctctga	aaaccacggg	agcctctgcc	60
tcctcagcca	cagtgaattn	cctcctacaa	agggggagac	tgaaaccgga	gttaaggagg	120
ggcctggcag	gcgtatcaga	gcacattagt	gatgcccttc	acccagggga	gggtgtctgtt	180
cccaactagt	ttatgtggca	ctgagacatc	catccctgac	caaggatgct	gcgaaacagg	240
atcaatgtac	tacggccttt	taattcaaca	ttgccataaa	tgctttaaag	aaaaccacc	300
acactttcct	cctactccgg	tctttgccc	ttcctgtaac	agacaatccc	atgtcctagg	360
tatggttttt	tattctgtta	gtgcttcggg	aaagtaagt	attcatttga	ataaggcaaa	420
ttaggagaaa	gccaggttg	gggtgaaatc	agacttaaca	gatacatgct	ggttctcctt	480
gctgtgtgtg	acacagcaga	cagaggcact	attcctgggtg	cagtatttca	gggatttctc	540
tttgaggggt	tcttttctgg	tagctcaggc	aattattttt	accatatcag	cacatgacaa	600
ggccatgaac	acatggctct	aaaataat	agtgttcaag	tatcagctta	actattttgt	660
gtaggctaca	cacagcttgc	ttttgtttct	cttctgttcc	tgctttattg	gcggaaacat	720
aagcgtgcac	gccatgttgt	tttgaattgg	aggcacaatt	tcattattcg	agagtaaaag	780
acatgtcctc	ttctgatgca	tggcacacca	tagtcaccaa	gcaaataaca	gagccttcac	840
attgtgtaat	atttgtatga	gaatgactca	agctctttga	gaacattcca	aactagtaac	900
atttcgctac	taaaagctag	aaaggatgaa	ctgtgaaagg	ttctaggcag	ctctgtgaga	960
ctycaagctc	cttgaaagta	ggacctttgt	gagccacgcc	tttcattctt	caacagtgcc	1020
ttgcatgtaa	caagcactcc	agaaatgttt	gttgaatgaa	tgaatggkgk	catgggtgaa	1080
tgatggggag	kaaatttagg	aaggggaagt	gagagagtat	gngggcaata	tcacaaggga	1140
ggagagagga	aaacaattat	cttctctact	tggattatga	agataacctt	ttcttgagg	1200
aaagaaacac	cgcttttcaa	aggcatgact	ctggcggtgg	tcctaaggaa	gcatgagcag	1260
aaaattcata	aaaatgtatc	atcagcagga	gatgagacta	tgaattggca	tccagaacag	1320
gagatttaga	gcaaaatcta	atttagcatt	ctgagatgag	tgctcagggtt	tcaggagaga	1380
atgagttggg	gtgagcccag	agtctgaaac	tcctgactgg	tcargtgcta	cttaagmcca	1440
gcttgggcaa	ttcagggcag	aactcctgta	tcagcctcat	ggacaccag	aaaanggttt	1500
atggtgaagt	gtcagcaggc	acagaatctc	cagaacaacc	tagagagtga	atgctaattt	1560
gtagagcgaa	tttccatttg	gcccattatt	tgtaactgtg	taactgctcc	aagtgccaga	1620
atgcttacac	gttaaagcag	cacctttcca	tttggccaca	tattcttctt	gcacaccctt	1680
tccattactg	ctgaatagga	cattgcatgg	gaagagtaca	gaggtggcag	aatgaagcta	1740
gagtgggaag	gactaaagac	tgagccccag	agtgtcctca	gcaaccgcca	cgtacaagggt	1800
ctgaaatgac	aagggaaga	gtgagatagg	aaactgtgtg	tgaaaggaaa	gcccttgtag	1860
tatttctgcc	tccctttctt	tctgcctttc	acccactaa	atgtaygtta	ttgaatgcca	1920
gtacttctct	agtggatgca	cacttggtta	atagtgttaa	gagatgtgga	gatgagatat	1980
acccctttkg	atgtagaatt	attncatttg	gtttgtttnc	atacttcatt	ataggnaatc	2040
aagtaatttg	atgactaatg	tggattatat	ttcagtcaaa	gctctgcttt	caatttctct	2100
gatttgctca	ctaattgcctt	rtgtgtgttt	tactaacctt	ttatatcttg	ccttcaagtg	2160
agaaggaaca	aacaactctc	agtgggtact	acttgctttt	atatgctggc	tgtgaagggt	2220
aaaagaaaga	atggtctgta	ccattttttc	tgctttgctg	cccttttatt	gtacccagg	2280
cctcctagag	gactcctgca	gattctattg	ttgggtggga	aatagtgttg	gaatgtgttt	2340
gcacagtctt	atgatattca	gtctcagtct	gctataggta	tttgttattc	ttggatacta	2400
cacacctgct	cagactgagt	aaacatttgt	gggtgctgtca	acctgatttc	ttgactctca	2460
aatgattttt	gtattttcaa	tatgaatttg	tgtgttatga	atctctgatt	tctccaatag	2520
tatatgccac	tatataaatt	tgtattaata	aatgacagtc	ttgttggttt	aaaaaaaaaa	2580
aaaaaaaaaa	aattnctc					2598

<210> 63  
 <211> 1924  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1723)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1732)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1804)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1899)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1907)  
 <223> n equals a,t,g, or c

<400> 63  
 ggcacgagcc tgggctgccg gtgacctggg ccgagccctc ccggtcggct aagattgctg 60  
 aggaggcggc gggtagctgg caggcgccga cttccgaagg ccgccgtccg ggcgagggtg 120  
 cctcatgact tctcttggtg accatgtccg tgatcttttt tgccctgcgtg gtacggggtaa 180  
 gggatggact gccctctca gcctctactg atttttacca cacccaagat tttttggaat 240  
 ggaggagacg gctcaagagt ttagccttgc gactggccca gtatccagggt cgagggttctg 300  
 cagaaggytg tgactttagt atacatTTTT cttcttttcgg ggacgtggcc tgcattggcta 360  
 tctgctcctg ccagtgtcca gcagccatgg ccttctgctt cctggagacc ctgtgggtggg 420  
 aattcacagc ttcctatgac actacctgca ttggcctagc ctccaggcca tacgcttttc 480  
 ttgagtttga cagcatcatt cagaaagtga agtggcattt taactatgta agttcctctc 540  
 agatggagtg cagcttggaa aaaattcagg aggagctcaa gttgcagcct ccagcgggttc 600  
 tcaactctgga ggacacagat gtggcaaatg ggggtgatgaa tgggtcacaca ccgatgcact 660  
 tggagcctgc tcttaatttc cgaatggaac cagtgcagc cctgggtatc ctctccctca 720  
 ttctcaacat catgtgtgct gccctgaatc tcattcagag agttcacctt gcagaacatt 780  
 ctttacagggt tgcccatgag gaaattggaa acattctggc ttttcttggt cctttcgtag 840  
 cctgcatttt ccaggatcca aggagctggt tctgctgggt ggaccaaacc tcgtgagcca 900  
 gccacccctg acccaaatga ggagagctct gattctccca tccgggagca gtgatgtcaa 960  
 acttctgctg ctgggggaaat ctcacagca gggagcctgt ggaaaagggc atgtcagtga 1020  
 aatctgggaa tggctggatt cggaaacatc tgcccatgtg tattgatggc agagctgttg 1080  
 cccacaagcg ctttttattt agggtaaaat taacaaatcc attctattcc tctgacccat 1140  
 gcttagtaca tatgaccttt aacccttaca tttatatgat tctgggggtt cttcagaagt 1200  
 gttatttcat gaatcattca tatgatttga tccccagga ttctattttg tttaatgggc 1260  
 ttttctacta aaagcataaa atactgaggc tgatttagtc agggcaaaac catttacttt 1320  
 acatattcgt tttcaatact tgctgttcat gttacacaag cttcttacgg ttttcttgta 1380  
 acaataaata ttttgagtaa ataatgggta cattttaaca aactcagtag tacaacctaa 1440  
 acttgtataa aagtgtgtaa aaatgtatag ccatttatat cctatgtata aattaaatga 1500

ggtggcttca	gaaatggcag	aataaatcta	aagtgtttat	taaaaaaaaa	aaaaaaaaask	1560
sgagggkggg	ccrrtaccc	aattcgccct	atagtgaagtc	gtattacaat	tcactggccg	1620
tcgttttaca	acgtcgtgac	tgggaaaacc	ctggcggttac	ccaacttaat	cgcttgacgc	1680
acatccccct	ttcgccagct	ggcgtaatag	cgaagaggcc	cgnaccgatc	gnccttccaa	1740
cagttgcgca	gcctgaatgg	cgaatggcaa	attgtaagcg	gtaatatattt	ggtaaaattc	1800
gcgntaaatt	tttggttaaat	caagctcatt	ttttaaccaa	taggcccmaa	tcggcamaat	1860
ccttataaat	caaaagaata	gaccgagata	gggttggaang	ggtggtncag	ggtggaacaa	1920
gagt						1924

&lt;210&gt; 64

&lt;211&gt; 2248

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 64

ctcagagtttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	60
tttttttttt	ttttaacctt	tattcattca	gaatgcaatt	ctggggccact	ctacaaccaa	120
gagaaaaacc	taaactttta	agtagtggtta	acggactaca	taataataata	gtattgctcc	180
tatatgtaca	agcaagaagt	caattttttat	tcttttcata	aaacctcttt	gtaaacatgt	240
accttttctt	cccatcaaaa	atgcattaac	aagatcatgc	ttatagttag	tcagcacaag	300
aaaaaaacga	caattttatac	tgaactattt	aagtcttgca	gtagagtgc	cacaactccg	360
agctgtatct	gttaaccttt	tcaatagcat	tcattatgtg	acattgtcac	caattacagt	420
aaaagaactt	cactaatttt	tgaagctag	aattactcaa	aaaattctgc	attgtaaata	480
ataccaggaa	tattgcattt	aagcctagga	tggcaaaatt	acttaaatct	tttctatact	540
tttttgtgta	atataggtag	gaaaatgaat	actatataag	agaatgaaat	atatcaagtt	600
cttatatttt	tacctaagag	gctattttatt	ttaaggaaag	ttgattaata	tttaaatgat	660
taaaaaataa	atcaatgtta	agtatttaact	gcacaaaatc	taaaaaaaag	accacattac	720
atcatactac	attatataga	tagatttaaa	gcagctaact	agaagccttt	ttaaaaattt	780
aaagtttctg	acatcatttt	ccaccattcc	atcaattctt	ccttctcctc	ttctttcctt	840
tcagaaaaatg	actccagttc	aaaatcaacc	ccagcagcag	ggctgtaagg	aactgccact	900
ttctttgtta	ttgccagata	gcctggagct	gaggctgtaa	gtttatagtt	tccaggtata	960
agcaatctcc	agtaatcacc	atcctttgcg	gatgtaacat	cgtggtctat	tccttccacg	1020
gagatgggtg	cattcgcaat	tgggttacct	tgaaggcttc	ggacaaatcc	tttaactcct	1080
cgggtgatct	gctcaaggta	gctaattgag	gagtttttgt	tatcctccca	gtaggctctc	1140
agagtctctt	caggtgggaa	cttctcacag	ctaagctcca	cgggtgatctc	aaaacagttg	1200
ctgctaagggt	aattgaagtc	ttgcatccct	ccaggtagcg	tgtaccaagc	accaccgttg	1260
gtggttccat	ctacaaagct	gctgtcatca	tcattcttgc	gacatggtgg	ccgattgggg	1320
tcagacatgg	ccgggttgaa	agaagagtat	gcccgggcca	agcttttgaa	aatggcgta	1380
tctggggagg	agctgtattc	gtgagcacta	ccactccgcg	tctcatcata	tggaataattg	1440
gccacaagggt	ctcctccatg	gagattggca	gaaagcacaa	aaggaatatc	cataatccaa	1500
tgaatgacag	ccttggtctc	aggagcaagc	tttgtgtttt	gatccacaat	tttcttcata	1560
tttttcaaca	gatgattatt	tggaccacct	tctttctcat	tcacgtacac	tatcctatcc	1620
aggtctggaa	agttccggtt	cagatctatt	ccctgggcat	tgcttcgacc	cacaaaccag	1680
tccttgagtt	caccaggctg	agacgctgcc	ttctcaaaagc	catctgggtt	caggggaaggc	1740
atgatgtgaa	tgcgggtact	gtggatcagg	ttgacaattg	tctcgttccc	cttctggtat	1800
tcgttgcata	ggtactgggc	caagaaaatg	agcagttctc	gtccaacagc	ctcattccca	1860
tgcataattcc	caatgtattt	aaattcaggc	tcaccaggct	catggacgcc	aggggtgtcg	1920
gacagctcga	tgaccaggag	ctcccggccc	togaagctgc	gccccaccgt	gtaaatcctg	1980
ctgatggcgg	tgcactgcag	ccacacggac	acgagcgctc	cgcgcagctc	ggggtagcgg	2040
tggtactcga	aggagatgcc	gtcctcttgc	tgcagccgcc	ggcgccgcct	catgcccgc	2100
gcggggcgccc	cgggmtcmtg	ggmttcgggc	cccaggagcc	accgcagggc	agccgcggcc	2160
ccgcacagag	ccagcagcgc	gctgccccct	cgcgggcca	tcgctgcgct	ccgcgcggcc	2220
cggcgtgccc	ttcctacgcg	ggcggccc				2248

&lt;210&gt; 65

&lt;211&gt; 636

<212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (122)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (581)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (588)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (601)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (628)  
 <223> n equals a,t,g, or c

<400> 65  
 acactagtg atccaaagaa ttccggcacga gctggtggca tggacattca aggtaaagct 60  
 ctctatatta gatttcttct caccctttgt cagatggtag taagtgttat ggggaaacga 120  
 angcagggga ggagggggct ggggtggagca gctgctgtgg ggagagagat ctgcaggagg 180  
 tggggatgct gtgtgacttg agagagtagc ttgccctctc tgggctcctg cctgtgtgtg 240  
 ctgggggaac gatggcgccc actgcccctg gtgctgtctt tgccacatca ttccttgggg 300  
 acttctgccc accagctgct cagaccgtag ctgtgctggc tatgctcttc ctgtgcaggt 360  
 attgactctg agtcctcata cagcctgtta tgatgcgcac tttacagatc agtagactga 420  
 gacctgggca ggccctctga ctacagactg agctcattac tgcacacagc gtgctgccag 480  
 tacatgctgg gctctggggg gctggagccg cagtcctggc cccatcaata caatccaaag 540  
 tgagctgggt ctgratgarg aarargccca agatgcccc ntcagggnag tcttctctggg 600  
 ngaggtggta gccaggcaga ccttgggnag taagaa 636

<210> 66  
 <211> 898  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (884)  
 <223> n equals a,t,g, or c

<400> 66  
 ggcgggcttt gtagacacca cacttggtgg gacagaggcc tgctagggag agggcctgtg 60  
 tccttgccac cagcccatct tccacgccat gtccccctgc actctttgaa gggagatggg 120  
 ctcttttggg gctaagctgg ggtcctggag ccagaagwga actgagatct gctgtggggg 180  
 gttgggagct gttccatttt tagtggctgc tacaggaaga gcggccgagt gtttcccctt 240  
 gtccctgcag aaggctggag tgtaactgtc cttgggaact gggtcagctg atagcagggc 300

tggggggtggg	ggtggggatc	ctgaatcccty	cagcagatgt	cctcattgcc	ctgatctggg	360
tggccagtgc	ctgtgctgga	cacggctcctc	agtcatecga	gcccactgag	tctccccctg	420
accctgcaga	gaattttcaaa	gaggcgaagt	tccttccagt	ggcctcacia	aggctatctg	480
gcttaggagc	cattacctga	agccagaatt	tctgagttcc	aagtcccagc	tccatcacgg	540
aacttgcccc	aaggccmtta	acccctctgg	gcctcagttt	tgwcatcttt	gaaatgggga	600
tcttakagat	gcctacctgt	caagggactt	gtgaggcgca	acgggaccac	acgcagggcc	660
tggccagagt	gccgtagttt	cttcggttgc	catgatggga	cggtgaaact	cctcacactc	720
ttctttctgc	cttgaagatt	ctagacctgg	ctgggtgttc	atctcccttt	ttgcctttgc	780
ttgargcagt	ttatggcatg	gctgtgttat	tcacgtmcca	ggtctcctcc	tggtggacgt	840
tgaggccatt	ttcatttttt	tactcttaaa	aacgcacagg	cagngcacat	cttcgcat	898

&lt;210&gt; 67

&lt;211&gt; 449

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (348)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (413)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 67

agatgttcgc	attttcagag	taaaatgttg	gggaggggat	atccccaaag	ctcagagatc	60
acagctactg	tagtgatgct	aaaaataagg	gggaaatggc	tgggcacagt	ggctcacgcc	120
tattatccag	cactgtggga	cgccgaggag	ggtggatcac	ttgagcccag	gagttcaaga	180
ccggcctggg	tgacacagtg	agaccccgtc	tctacagaaa	tttaaaaaat	tagccaggca	240
tggtggcgca	cacctgtagy	tccagctact	tgggaggtcg	atatgggtctg	gctctgtgtc	300
cccacccaaa	tctcatcttg	tagctcccat	aattcccttg	tgttggtanca	gggaccacgt	360
gggagatcaa	tgaatcatgg	gggtgggtct	ttcccgtgct	attctcgtga	tanagaataa	420
tctcacgara	tctgatgggt	ttaaaaaca				449

&lt;210&gt; 68

&lt;211&gt; 1192

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (6)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (902)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1041)

&lt;223&gt; n equals a,t,g, or c



<220>  
 <221> SITE  
 <222> (1054)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1138)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1145)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1166)  
 <223> n equals a,t,g, or c

<400> 68

ccaaantgaa	cataagctgs	agctcscgcg	cctgcaggtc	gacactagt	gatccaaaga	60
attcggcacg	agccttcac	aattctggga	aattttatct	attttcactt	tgaatatgtc	120
ccaggtgcat	tgtatctatt	ttatgaccat	gaaacttata	ttagatctag	atgagactta	180
ttctatttgc	catgtctcct	aaacttttat	ttctatttct	atttctttat	atctctgtga	240
agagttttga	tttagttttg	tcttttaggt	cagtactctt	catgtcagat	ctaattccact	300
gtttttacca	tcaattgcat	tttaaattat	aatgattatg	tttcactttc	tataaaatat	360
tacagttatc	tttactaagg	tataattttac	ataaatatat	aatgtattta	gatatatatta	420
catataaata	catacatatt	tacataaaat	taatttcagt	gacttcaagg	gtacaattca	480
tcggatattt	atatattttcc	tatacatata	atatatatta	tacatatttc	atgattatac	540
atataatata	gcacaatatg	caatatatgt	aatacatatg	tataatcatg	caatattata	600
tatcataata	tataatata	tatatatgtg	ktatatatta	taaatatata	tgtgkaatca	660
tgcaaccacc	accacagtca	ttgaaaatat	ttgkatctgk	tcttctggga	atttttcccc	720
ctaattcttct	gkctcatctt	tttttatagk	atcttgktgs	tttcacatat	ttacatttat	780
tttatgtatt	ctatcattta	aaaatattta	tgttataatg	tgcattccagt	aaatctataa	840
tctgaacctc	ctttttcttt	ttgagacaga	gtatcactct	gtcgcccaag	ctggagtgca	900
gnggcgcgat	ctccctcacg	gcaacctccg	cctccccggg	tcaaagaaat	tctcctgtgt	960
cagcctcagg	agtagctggg	acttcagggt	catgccacca	catccggcta	atttttctttt	1020
tgtattttta	gtagagacgg	ngtttcacca	tggntaggct	ggcttcgaat	tccctgacgtc	1080
aggtgatcaa	cccgcctctg	cctcctgaag	tgctgagatt	acagacttga	gccacggngc	1140
cccgncaatc	tgagcctctt	aatggcnctac	ttaagcttta	attttttttt	cg	1192

<210> 69  
 <211> 626  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (8)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (18)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (515)  
 <223> n equals a,t,g, or c

<400> 69  
 ngacttcnacc gggaatcncc acactamtcy ggtacccccac ccgggtggaa aatcgatggg 60  
 cccgcggccg ctctagaagt actctcgaga ctagttctct ctctstctct ctstcagttc 120  
 atattaaatc tacccttgca gttgttcagg ccaaaacaat gtagtcattc ttgactcttc 180  
 tatttcacac ccacatacaa tccattaaca agtcctgkat tctttacctt aaaaatactt 240  
 ccagaatctg acctgaccac ttccctgtcac ttccactgct attgttctga tgaaaaccac 300  
 tgccctttgt catctagggt gctataatag cctcctgggg tgtccctgct ttatctttga 360  
 ccaattccag tctatctcaa cacaacatcc agattgatct atttaaaaca taagtcagat 420  
 gacatcactt ctattctgga agcattccaa aggcttccag ttccacttgg agtaaaagcc 480  
 aaatttcttc cagtgccctac atagtacacc cttgntatag ctctgagctc ctctcaccat 540  
 gatcactctg ctccagccaa gcagactccc ttgcttttat ttatctatac cctaacactt 600  
 cagggcattt ggttttactg gtccca 626

<210> 70  
 <211> 1913  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1286)  
 <223> n equals a,t,g, or c

<400> 70  
 tcgacccacg cgtccgaaga cctcatccag ctctgtccaaa ggcttcagrg atggaaacaa 60  
 accagctcgt ctccagaggcc agcaagctgg ggccctgtccg ccacgggtgcc ctgtgcacct 120  
 ttgggctgcc ctggcccccct ctctcccggg ccgcccacca caggctctta atggggccgg 180  
 gtcagtccta catgtgagat gggttagggc aagtctttgc catccccacg atggctctgt 240  
 cttcttgtgt atggcagggc tgggactgct gtcccttgta cagttttctg tcaactgggtgg 300  
 gcaactggaca ggcatagcag actctcttgt ggccacacta ggtgtgcgcc ttccaggcag 360  
 tgtcccgcca cctttgcttc ccgctccttc tggacattcc agagccctgc accaaacctt 420  
 tacttggtgt ctgcacctcc ttccctctct tccatcttcc aatccctgga aaagtctggt 480  
 ctgagtgtga cttgggaagc ttccagtgtc gctgtttggc ccagctcatt actttctccc 540  
 ttctctctacc acagcaaaca cattctccac catgtcagtc taaagagtct aaaggggccc 600  
 ggagaagcrt gagcgagggg cagattctag tccggagccc atgccctgga aatccatctt 660  
 tcttcatctt tcccattgac cactttgggt ttgacctgca catctgcagt gagggcagaa 720  
 ttcaacaagc acaactcact ggtctttcag tcaacgtgct agaawccgat gacttattaa 780  
 tctctaattt ttggcgccct ctttcattga atgagaattg ctttcgtata gtccacatta 840  
 gaaaaatgcc taatatacta aagtaaacca aacgttgtca cttttctctt gttcttgaaa 900  
 cattgcaacc aaaaagggtca gcacaaaggc cttcacctac gtgaagacct cctggtagga 960  
 tctgtccatg ggatggagaa ccactctgtc cagatctggg gttgggtcat gacaccagct 1020  
 accaatttta gaatattatt tcttggtttc tttatgaaaa atgggtgcta gtggtaattg 1080  
 ctttgtggct tagtaaaacta ctctgtggat gatttccaaa cattcaaagc caatagcctt 1140  
 gttattaaca agatattttg agtacaatat ggctcatgac ttttccatta catctgagga 1200  
 ttccagagtc ctctgttcat ccctggggat agagtggacc ctcttgctgc ttccagggta 1260  
 gctcaggttg gccagtttg ggcagntcca ttttggagg tcaactcttc csscctcatc 1320  
 cctcacctc cttctcttta ccccttcac gtaacttcct tctttcttcc ctctgttatt 1380

cattcatcaa	gcagggtaaa	gccattgtgc	taagatctaa	tctgaggaca	ctataatggc	1440
cctgtcgtca	gggaagcccg	tgatcgctcg	ttttcagggg	tcttaccggg	cagcaacctt	1500
ggcattgata	cataggcact	ctacagaatt	taagttttca	gaggtaagtc	tgttgttctg	1560
attaatctgc	attcattcag	cgaatgctca	agacaagcca	ggcatgctga	gaagcggcgc	1620
tctagttgta	tgtaagatgg	gcattcctct	gctctcctct	attctccatg	tcgactgaga	1680
agagtataat	aagaacattg	taccctctcc	acacttaacc	ctctgggatt	ctttattata	1740
atataaacca	ccgctcgtgag	gcatttacct	gttggatgga	aggtagacag	caacaagatt	1800
ttaatcacct	ggtcaccaga	ccctcacggc	ccatatccaa	ttcgaatttc	agaaatttct	1860
ytgtttgctt	taataaacty	tttacaataa	aqqgttcqqq	cacgtggttc	aaq	1913

```
<210> 71
<211> 617
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (601)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (612)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (616)
<223> n equals a,t,g, or c
```

<400> 71						
gtgcacacct	gtagtcccaa	ctattcggca	ggctgaggca	gtagaatcgc	ttgaacctgg	60
gagggcggaga	ttgcagtgaa	ccaagatcgg	gccactgcac	tccagcttgg	gtgacagagc	120
aagactccat	ctcaaaaaaaaa	ttataaataa	cyctttgcaa	ataggaaaagt	gaagctcaag	180
ggtaaccagt	gagggctatga	aattgccagt	gaattaagac	cagggctaga	gtcaacagtc	240
cagaaccctt	atccgtatga	acagggggccc	gtttctgggt	gaaatcaagg	ttaggatgca	300
actgagaaaa	taaaagactg	cactttgggag	aggcaagcac	gctatccggg	ttgttgtttt	360
gttttatgtc	ttggtgctta	ggtgaggact	tagctgggtt	tattcaaagt	gggcgggtct	420
gggctattct	tgagaatgtc	ccttccattt	ctgagaacaa	gtcagccctt	tctacctgcc	480
tccacccagg	agactgatgc	acaagatctg	tttgtgaaag	cctgatttaa	aaaraaaaaa	540
aaaatttcct	aagccaaatg	gtgttccaag	ttggttgctg	tgacaacttc	ccaggagggg	600
nccctttgtt	anccnt					617

```
<210> 72
<211> 413
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (315)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (377)
```

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (410)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (413)

<223> n equals a,t,g, or c

<400> 72

actccactct	ttggaagatt	ctcttctgta	aacagaggcc	ggtatgaatg	aaaagttcct	60
tccccacttt	tgattgatcc	tggatgtgaa	tccatctgcc	cactgcagct	cgtcaggagg	120
gaaggaacga	ggctcccaga	gcagaggccc	tcgatgcttc	tggtgcgctg	tgcccctagc	180
ctggggaccc	atgtgtttct	taacatgctg	aggccaccag	atgggccctc	atggctgcct	240
cttctcaccc	ccctcccact	tttgggtccct	gggtttccta	ggccctggct	tgccccaccc	300
cgaacaggca	ttganccctt	tgggaacagg	gccccacccc	atggctgggt	tctcttgctt	360
ccctccatcc	ttccganttt	gaaaattggt	gaaacctccc	tttggaggtn	tgn	413

<210> 73

<211> 691

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (88)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (132)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (666)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (677)

<223> n equals a,t,g, or c

<400> 73

gtgggggacg	gcgtctcact	gtgttgccca	ggctggagtg	cagtggcacg	attctcctgt	60
ctcagcctcc	caagtagctg	ggattacngg	cgcacatcac	catgcctggc	taatttttta	120
tgcytttggt	anagaggggt	ttttgccatg	ttggccaggc	tggtctggaa	ctcctgacct	180
caagtgatcc	gcccacctca	gtctcccaaa	atgctgggat	tacgggcatg	aaccaccatg	240
cccatacctag	agtgtccatt	taaatacatg	ttcctgttac	tgttactgag	aagaatgtaa	300
gtctccccac	ctrcagggca	gatgctgagc	aggagaatca	ctacccccacc	caggccggca	360
ctgcccagcc	aaggctccca	ggcctggagg	acacagcctg	cctaactccc	cacccccac	420
cctctttctc	agctttttct	ccaagcaggg	cccccgagga	ggggaagaca	gagctggctc	480
ccctgcttct	ccccagagt	gaacctctgt	ttcccccaag	tgaggtgggg	atgggttagca	540
gccatacctg	cctcactccc	agaccgtggt	ggcactgtgg	atggcatgaa	gtggggacca	600

cagtgcattgg ggttggcagt tatatttttt taaggamcaa ccctctctgg gcctcagttt 660  
 ccccanttga aaaatcngag gactggccta t 691

<210> 74  
 <211> 1313  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1274)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1286)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1294)  
 <223> n equals a,t,g, or c

<400> 74  
 gaattcggca cgagctcgtg ccggagcagc ccacaggacc tggccaagct gcagagaatg 60  
 tcaccatcca gactgtgtcc tatgggggtac aagaggagct gcgggaccag gaggatgacc 120  
 aggaggaaga ggagagcgat gccacttcaa cggagagtga aagtgaagac aacttcctca 180  
 cgctgcctcc cagggaccac ctggggactt actctcttct ccatgctctg ctgcttcttg 240  
 ccactgggca ttgctgcctt ctacttctcc cagggggacca gcaaggccat ctccaaaggg 300  
 gacttccgcc tggccagcac cacytcccgc cgggcccctc tcctagccac aytccgccatc 360  
 gccgtggggg ccggtctcta cgtggctgtg gtgggtggctc tggcagctta catgtcccag 420  
 aacggtcattg gctagtagcc agtagggcct gcctcctgac tcccctgccc acctgaggaa 480  
 gcagtggggc ttggagttgc agaccctatg gaaaggcccg gccctgaag atgatcccg 540  
 gagagtggct tgcaggggg gagaccccca ttccacagcc tgcagagctc agccttccat 600  
 tctgcttgcc cgtgctccc agccccagag cagggcccgg ggcgccactc tctaaccag 660  
 gctacagacg ggaaacagaa ggcagggctg cccaccaggc catcccagca gggcctagct 720  
 ccatccattc tgcccattcc ctagaggatc tcctgccccta cagccagccc accacctacc 780  
 ctgscaacct ycccacagag aaagagcagg aggttacagg gagaaaaggg ggtgscacga 840  
 gcacaagggg acccgtccaa tcctttcaag ccacagggat cttcacctgg ggacagsgt 900  
 agcttcccca actycactgt ctggcccat catgscacga cctcagcagg ccaagaagga 960  
 aatacgtgga ggcaaggggg cctcttgctg tctctgattc tagaggggtg ttatctctgc 1020  
 atgggcttgt gaggcactgt agattctaga tagggaagag gagcctcggg atgtaaactc 1080  
 tgaaccaagg gcaggtcctt ggagcttctt catgcgggtg caaaaggcag ttgcaatgac 1140  
 agagaataga gggtcctgaa atattgctgt actacatgac tcttctact ctccccccac 1200  
 tccccgccc tatcatcctt ttctggggct ttgctggggg gtccgtgagc tgggtgccatc 1260  
 acaagtagac tagncccaga gagtgnccct cagnttcacc agccacttag gcg 1313

<210> 75  
 <211> 814  
 <212> DNA  
 <213> Homo sapiens

<400> 75  
 aggtgcctca gctcaccagc cactgagcgc agggccctag gtccagccct acagaaaacg 60  
 cagcaaggag agaccctagg gactagtgag tatagatgag ggaagggact cagggaagga 120  
 atggcctgct gactagtcag cgggtgcttag gaaggcttcc tgggaagggt atcccttgag 180

caaggcctag	gatgaataga	attcatctga	gggatttggt	cmcataactc	tttgtatttg	240
taggcaggga	tgtggcagka	accttccatg	ggaagcttcc	aggctgtttg	gattctgcct	300
ggaacatctg	ggctggagcc	aaactacagc	cattcctaag	ggttctgcca	actcaaggag	360
gaacgtcaca	cctgtctctc	aaagaccaat	gatgttttcc	catctctgaa	tgctaggggg	420
tcagtgggtg	gtacctgggt	acccctgggg	catcttcaact	gatayctctg	ctcagtgccca	480
gtctcaacac	cctcagccac	tagggcacat	ccagaatttt	agagacatct	ccaggtaggc	540
ggggggcagc	accaatgtgg	gcaggcctgt	ctggactcaa	gctacaggcc	cctgctgtgc	600
atgatgtggg	aacctggtea	ttcccatgcc	ccatccagag	cccagggctg	tggtccacc	660
actgagcatc	ccttgtecca	ctgtcctccc	ctgcctcggg	cactgcccag	ccctccactc	720
ctgcatcaca	gcagttttaa	ggtcccatta	ttgtactgat	ttatccttgt	aataaatgtt	780
tctgtaacaa	aaaaaaaaaa	aaaaaaaaaa	aaaa			814

&lt;210&gt; 76

&lt;211&gt; 1651

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1648)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 76

ggggacatgt	ctgggcacaa	ggaaaggcaa	gcaatggagg	cagcaagagc	ccttggcagc	60
aagtttccat	cacctttgcc	tgccagtgtg	tgagaggcgc	agaggggcag	tgagcaggtg	120
acatgcagct	tccagatacc	cacacactgc	ttttctccc	cccagctccc	acccagttta	180
attgagatgg	gattgtttct	ctttctgggt	tcttcctaag	ccccctctct	atattcctgg	240
tgtgcttatg	gcctggcaca	ccttgtgaaa	cagaaaccca	agctcctcat	ttcggagctg	300
ggatttctgat	tggctatctg	cctccctaac	caagctgtcc	cttccacctc	atccctagag	360
tcacctctctg	gtctcatcaa	catccagtgg	gcatttcagy	ggcccaggat	ccttcmaatt	420
gcagatataa	agcatcagga	ccccacacct	gggatggaa	cttctaggaa	ttaatgaagc	480
cccagtagag	gtgagggtaa	acctaaaacg	ggctggatag	ggcctctccc	aaggccctat	540
ggaaagggtga	tgggaaactg	ggggctgagg	cctcactcta	ggagaccctt	ggagggaccc	600
acttacccta	gataggcagc	ggaggccaga	aactggaaaa	cagccactca	ttgtcgggtg	660
attaccgtga	gcaccacctg	tagggactct	gttggcctcc	agccgtcgtc	acacgttctt	720
gacaaccaca	aaagttcatt	tgagggtgcc	cagtcagctg	actttgcttc	caccaggaat	780
acccacctgg	ccctggtect	tctgctgagc	tacaggaggc	attcccaggg	tcttagcaaa	840
aacaaccctt	caaataggcc	cagtgcctac	aactctagag	aggtttcaga	tggtattgga	900
gaccagaga	agttaactga	ctttcccaaa	agtcacccac	tgtaaattggc	agacagatct	960
caaaccacaca	tctgakkctg	agtccagtgt	tttttctcta	gtatcatcat	tgtcccttaa	1020
atgtgtttga	cacatcatag	tttacaatc	accttcaactc	atattctctc	actactcatc	1080
agtcatgaat	tcagccaatg	agaagggtct	agagagggtta	actaaccagc	cacgtgtgtt	1140
acatggggca	tagactgctt	catgaacgct	tgactgcagc	tttgccctcc	tcatgccctc	1200
aaaaaggaag	gagctgacca	aagcttacta	taccatagct	ggggctctggg	acccccagcc	1260
aggctctaca	gatgatctgg	gaatggcctc	cctgttgctc	tcaggggtcc	ggcagtcaca	1320
cagaagagtc	aggttgaaat	cttggcaaga	ctttggtgtg	gctttgggaa	ctgggtttaa	1380
cctcttgggg	acttcaccaa	gacagtggca	aaggacacca	cctacagctt	ccagtgcctc	1440
tctactctcc	cacctgtgct	cctgggggtg	aatgagacca	gaagcagctg	ggacaagatt	1500
tggaaagata	aagagagcca	ggagacaaga	ccttgagaga	agcasaggtc	tggtgtggctg	1560
ctgscctctg	gtggcgacaa	tgggtgacac	tgtaaacccc	tctgcaaggc	gacactctcc	1620
cctgactatt	caggragggg	agaagcantt	g			1651

&lt;210&gt; 77

&lt;211&gt; 770

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> SITE  
 <222> (43)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (48)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (49)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (708)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (731)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (738)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (762)  
 <223> n equals a,t,g, or c

<400> 77  
 gctcgcgcgc ctgcaggtcg acactagtggt atccaaagaa ttnggcanna gcgggatccc 60  
 gttccaaatt cctccctcct gtcccctata tcattgctgt catttatttg acttatacat 120  
 tagctgtaat tattaatacg tcgttacaat taacattttg aacaaaatgt tatatgtag 180  
 attacttaaa aatacaaaaa taraagtttt gattttacct ttatttatc tttttctaac 240  
 gcttttcctt tttattccta atgggttttt gtttgttttt gtttctttat attttttagtg 300  
 actgaattaa cttatttagca acaaggctaa tggaaatcac ttgagcctct ctaagtcttt 360  
 ctccctccctt gacacatttg gaggactgag ggaactaagt gatttctaata gtctttccag 420  
 ctctattttt cagtgatttt agtttaggct ttttagttct ttcatttctt acaagatttg 480  
 cataccaaat tgtaattaa aaacaatcca cattttatcc tatagttgtc tagaatgttc 540  
 attgtcttct cagttctctt gctttttttc caatttgcca tctgccagtt tgctgacttg 600  
 gcaatatatt cactatccat gtgccagctt tgcaacctct cagcaaggct cgcagcttct 660  
 tctgcacgaa tttgagggtc tggcataaat aggaccagga aggagangg aagcctttca 720  
 acccctgcag ngcaatgntt ccctataaag cccaagcaat tnaggtccag 770

<210> 78  
 <211> 622  
 <212> DNA  
 <213> Homo sapiens

<220>

<221> SITE  
 <222> (5)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (6)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (10)  
 <223> n equals a,t,g, or c

<400> 78									
cgcannacgn	gaawacttcc	cgaawtrtgt	acacttaccy	ggtacccac	ccgggtggaa				60
aatcgatggg	cccgcggycg	ctctagaagt	actgctgttt	gttttaaaaa	taaaattaaa				120
tcagactgca	tcttgactaa	agtaatatcc	agkccttctg	aaattaaatg	gatatcagga				180
taactatagg	ataatgctac	tgkagaggaa	atagaaataa	aaaatagggt	aaaagtgaag				240
ctgaggaacc	cttcaaagta	tactatactc	aaacaaataa	cttgagataa	tatgttttaa				300
atattagact	gataatattg	tgtaagcact	tgaacctatt	tcctaaggcc	agttataccc				360
atatgtacta	cacatatata	cacacagagg	acagaatttt	aaacacatat	waaattttac				420
ataaagaaaa	taattctggg	cccttcctta	ggaaaggctc	ctaaatatcc	aagcaggaag				480
aatttgcaaa	ctaaaccctt	ccatgaagat	taaaacaaaa	accaaagtct	attagtggca				540
gctgcttcca	tcagtcagtt	tagctcccat	ttttttttty	cacgaagaaa	ctaacccttg				600
gcaatcccag	ctgatacctg	tg							622

<210> 79  
 <211> 344  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (266)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (292)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (306)  
 <223> n equals a,t,g, or c

<400> 79									
ggcacagaaa	aatttctagc	ctcactagta	tcagagaaat	gcaaattgaa	acaagggtgcc				60
atTTTTggac	tctagttagt	gatggtagtg	aaaaccagaa	tggtcctttc	taaaacagcc				120
tgtgtgtcaa	aaccataaaa	atgcttctac	ctctttttac	cctgttaatt	ctacttctga				180
gagtttttcc	taaagaaata	attcaaaaata	ggraaaaagct	aaaagcagaa	aaatgttggg				240
acatgacatt	atTTatagct	gtgggnaaga	tgggaggctg	gggcacatgg	gntatgctgg				300
aaatcncagc	acttttgtgaa	ggcccagttg	gggaggatgc	cttg					344

<210> 80



<211> 312  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (273)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (312)  
 <223> n equals a,t,g, or c

<400> 80  
 cgggggggatg tgctgcaagg cgattaagtt gggtaacgcc agggttttcc cagtcacgac 60  
 gttgtaaaac gacggccagt gaattgtaat acgactcact atagggcgaa ttgggtwcac 120  
 ttacctggta cccaccccg gtggaaaatc gatggggcccg cgcccgctct agaagtactc 180  
 tcgagttttt tttttttttt tttaagagat ggggtctcac tacgtttccc aggctggtct 240  
 caagctckgg ggttcaagca atcctcccaa ctnggcctca caaagtgctg agattacaag 300  
 cataagccac tn 312

<210> 81  
 <211> 712  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (660)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (668)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (698)  
 <223> n equals a,t,g, or c

<400> 81  
 gttcaccatg ttggccagga tggctctcaac ctctgacct cgtgacctc cctcctagggc 60  
 ctcccaaagt gctgggatta cagggtgtgag ccaccgcac tggctacctt acattttaaa 120  
 ataaccctta tcaactactga aaatgatgtc tttatatgtc tatctcctta tgttctgttt 180  
 ccttactctc ctcccaggaa cataaacttc atgagggcaa ggactttgcc tccttcactt 240  
 ttgtgtctct ggtgcttagc tccgtatttg aatatttgtt ggatgaatgg ataagtacta 300  
 ttccaggact cgcttgatac agaactatct tctctagaga atggaaagggt aaacgtatca 360  
 tttaccagcc acttatctta agtagagtcc cagagtgtag gcttatgcca tggagctcat 420  
 gtgaatttcc acttggggcca tctgggattc ttttctcaaa agagcctgat gccgggtgca 480  
 cgggcccgtc agctggcctg gagggatata acccacattt acctttctcc tcctggcagt 540  
 attctagaat acctcactca ctgcagcaag ggagcttctc tcctgggtcg ggtaggggga 600  
 tatgggttga atgtagccct gaaggagcgt ctcaaatac ctttgggccc agttgggtctn 660  
 gtgtcagntc cctggggggag aaggatcatt tagctcangt ggaaaaacga at 712

<210> 82  
 <211> 1082  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (909)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (943)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (966)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1035)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1040)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1055)  
 <223> n equals a,t,g, or c

<400> 82									
gcaaactcat	tgaaaacctc	tgctcgggtg	acatccttta	atatttcatt	ggcaagaccc				60
agcgagtg	ctcacacctg	taatcccagc	actttggtgg	sccgaggagg	gcggatcacc				120
tgaggtcagg	agttcaagac	cagcctagac	aacatggcga	aaactcatct	gtactaaaaa				180
atacaaaaat	tagctgggct	tggtggtggs	cgcctgtaat	ctcagctact	tgggatgctg				240
aggcaggaga	attgcttgaa	cccaggagtc	agagggttgca	gtgagcccag	atcattccac				300
tgtactctag	cctgggtgac	aaagtgagac	tttgccaaaa	aaaaaaaaaa	aaaaaaaaatt				360
ccattggcaa	acaaatcaca	tagtcaagac	tagcatcagt	gggttatgaa	aatgtgctct				420
gtggactcta	gtggggggacc	ctgcaaagtc	tggggcгааag	gctgtggatg	ctgaattctg				480
ttacagggag	ggagtgaaaa	attgagagta	gtaatccagt	ctcccacggg	gcccatacag				540
gctgttttga	ggcacacatg	agttaccatg	gcgacatcct	gaatgagaag	ggagaaactc				600
aatggtaagg	gcaagaagca	gaagattggt	cctttgttcc	tattactttg	atacatattc				660
cttgatttgc	accttccagg	ctaaaatttt	gagcctcctt	gattttttacc	ttcagggtaa				720
atltgagcct	ttggaagctc	aaattacagg	accatgaaca	tctctccctg	gcaggaagca				780
acaaggctga	gaactcgaga	gtacttctag	agcgcccgcg	ggcccatcga	ttttccaccc				840
gggtggggta	ccaggtaagt	gtacccaatt	cgcctatagt	gagtcgtatt	acaattcact				900
ggccgctcgt	ttacaacgtc	cgtgactggg	aaaaccctgg	cgntacccac	ttaatcgcc				960
tgcagnacat	ccccctttcg	ccagctggcg	taataagcga	aaaggcccgc	accgatcgcc				1020
cttccaacaa	gttgngcaan	cctgaatggc	caaanggaga	tccaattttt	aaaggggatt				1080
aa									1082

<210> 83

<211> 1378  
<212> DNA  
<213> Homo sapiens

<400> 83

ggttttttttt	ttttttttttt	gctttaagtt	tcaggatata	tgtgcagaat	gtgcagggttt	60
gttacatagg	tatacgggtg	ccatgggtgg	ttgttacaca	gatatacctg	tgccatgggtg	120
gtttgtctaca	cctattgacc	catcctctaa	gttccttccc	ctcactcgcc	acccgctaac	180
aagccctggg	gtgtgtgtgt	ccctccctgt	gcccattgtg	tctcattgtt	cagctcccac	240
ttatgagtga	gaacatgtgg	tggttggttt	tctgttcctg	tgtaggtttg	ccgaggatga	300
tggcttccag	cttcatccat	gacatagcaa	aagacatgat	ctcatccctt	tttatgagtg	360
catggtatta	cacgtatttt	aatagctttg	aaatttatcg	atttcaatty	acattttattg	420
agtactcact	atgggtcaaa	caccatgctt	ctttaccagg	ggtacaataa	acagagccaa	480
aatttttatt	aacttgtata	tacaacttta	ctatcaacat	tagccattga	ggtgtaaaaa	540
taaagaagca	atttgtatta	aaagtcaatt	tccacataat	cacgtcttat	aaatgccatt	600
tactttttatt	atacataact	caggaagggtg	agtttttagta	aacactgaaa	agctattttac	660
tgaaattttat	taattgcttt	agaatgaaaa	caaaacaaaa	tgcttgtaag	caattacaga	720
gaaaagagag	gtacacatgg	taaaatatatt	aaaataaagt	tcatacaatt	aaaaatatta	780
tcataccact	gacctttggg	ttaaaaaaac	aactatgatt	caaggataaa	atatgttaaa	840
tcsataawat	aatacaacat	amtttctaga	gaatttggct	ttttctacta	ctctaaatgt	900
gtcacatcct	awtagcatca	caaaatttaa	ttatgatact	arkaattatk	staattatta	960
ttaaagcatt	ataattctat	tattagaatt	acttggcact	cattcaaaga	gatataaaca	1020
tatcaattaa	aaaccatgta	tttttcaaaa	aataaaaactg	aactaattat	aaaaaataaa	1080
gattcctgta	acggatttta	atcttaatac	cctggagaac	cttaatgtta	atcacattca	1140
gaatttgttt	tttcagctct	cccttctgac	tggagctgag	gctaagatag	gaaaaaaaag	1200
tccacttccc	agtcatgcc	tggtttctgc	tgcttttgtc	ttcacactgt	atcttttagtt	1260
ttatgcagca	gyccaaggct	tgtaattctt	ctgatgacac	atccatgcca	ttgcggctgt	1320
ctccgaactc	caccaaagag	catggagact	ctgtaagact	gtttcggagc	ttgtcaac	1378

<210> 84  
<211> 789  
<212> DNA  
<213> Homo sapiens

<400> 84

tggacctcaa	gtgatcagtc	tgctttgggtc	tcccagagtg	ctgagattac	aggtgtgagc	60
caccgcgcct	ggcctagagt	acgatgtatc	ttgtaacaaa	acacaatata	aaacaaaatg	120
ctagtggatt	tttctttttg	ttcttttaaaa	atgattgttt	tctaattcatt	ctcctatatg	180
gtggttgagg	gtaaaaacct	caccttagaa	gaagagcaca	attatcaaat	tggttaactgt	240
tttttttggt	tttgtttttg	tttttttgag	acagagtgtc	ctgctttgtt	gcccagcctg	300
gagggcagtg	gcgtgatctt	ggctcactgc	aatctccacc	tcccagggtt	aagcagttct	360
cctgctgcct	cagcctcccc	attagctaga	attataggta	tgtgtcacca	cgcccggctg	420
atttttgtat	ttttagtggg	gacagggctt	caccatgttg	gccaggctag	cctcgaactc	480
ctgacctcag	gtgatccgcc	tgctgtgtgc	tcccgaagtg	cttggattat	aggcatgagc	540
cactgcggcc	agtcaaattc	ttacttttta	acttaaaaag	ttattttccc	agtctacawc	600
agaaagtgaa	ttggagatgc	aatggggaag	aaccaatggg	tttgggtctct	tcttgacttt	660
ttagctggag	agtaggctgg	agactgttag	aaatgagcaa	agagactttc	tccgaggttg	720
gtttggatcc	tgagctgtac	attgcttctt	ttgctttcct	attgcttctg	caaaggggaag	780
catactaga						789

<210> 85  
<211> 539  
<212> DNA  
<213> Homo sapiens

<220>

<221> SITE  
 <222> (466)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (513)  
 <223> n equals a,t,g, or c

<400> 85  
 gagcgggata ccggtgaggc caggagtctg agacaaaccc aggcaacata gtgagacccc 60  
 catctctaca aaaattagaa aagaaaaaaa aataatgttt catagattct ttattctcag 120  
 tgctttaagc aggatcagag cccttaccac ttttcttgat gacctgggta tgactcacca 180  
 gactctgctt ctgctccttg gaccatccat ttatagtctt tgctgactct tgctargcta 240  
 cctggctcct gtatcctttg ttgtggattt ttagatcaca gttgttcttt aagactgaaa 300  
 tttttcaagc actttgaaar tcctttttta agcattattk gttattagta ttttcygtta 360  
 catwtaaaaa caasccaaat ttttaaaact attgcctact gcattacagg ttwtatyckg 420  
 ttccctttat gtttccagtg gatcacttta gtcctcgctt tattgntttt caccttcctt 480  
 gatgcttcag aatcatcatg ttttgtcagc ttnttaggtg acttatagtc ttgtcacag 539

<210> 86  
 <211> 621  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (5)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (29)  
 <223> n equals a,t,g, or c

<400> 86  
 tcaangggaa atactccgag aattgtgtnc acttaccygg taccacaccc ggggtggaaaa 60  
 tcgatgggce cgcggctcgt ctagaagtag tctcgagact agttctctct ctctctctct 120  
 ccactctctt tttttttttt tttcttgtag tactgggtct cactctgtta ccagggctcc 180  
 gaggctggag tgcagtggag caatctcagc ttactgcagc ctcaatctca tgggatcaag 240  
 cgatcctccc acctcagcct cttgaatagc tggaaactata ggcacatgcc accatggctg 300  
 gctaattttt gtattttttg tggagacagg tttttatcat attgaccggg ctggtctcga 360  
 actatctatt ctttatctat tcaatctttc agtgtggact catggatcat acatttattg 420  
 agtaataatc caatactata cttatttact ttgttcgagt tgttccaact ttggccatta 480  
 gctgctcctt caggttggct cctaagtcct ttttaacatgk cttcacaatt ttttgagtac 540  
 ttattttctg gaaccattag atattccaag cttatcttgg ggttggccct tcttagccct 600  
 ggaatcaacc atatacccaa a 621

<210> 87  
 <211> 1333  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1140)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1196)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1210)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1246)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1285)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1287)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1306)

<223> n equals a,t,g, or c

<400> 87

cagggcagga	aagtgcacatg	gctaggtggc	tcttacccctg	ccttcgcgct	ctccacagtg	60
tgacaagctg	gctgctgact	gtgcccacga	gctgcggcgc	catgggggtca	gctgtgtgtc	120
tctgtggccg	gggattgtgc	agacagaact	gctgaaggag	catatggcaa	aggaggaggt	180
cctgcaggat	cctgtgttga	agcaggttgg	caaggggagg	gcgaaggaag	cagagaacag	240
gggagtcggc	ctctgcatcc	tcaataacaa	gatcagatac	tcccactcac	caggtgctta	300
ctgtggcagg	tgacgggctg	agcatgggac	acacattatt	tcctttaatc	ctgtaaggga	360
gataccagct	ccattctaca	gatggcaaaa	ctgaaaccca	gagaggttta	gaaacttggt	420
gaaggtcaca	tatgtcctaa	gtggaaaggc	tgtctagctc	caaagaccat	gcacttgacc	480
cccacaccag	ctagcttaga	aggtccaaac	actatttggc	actaccagat	ccttccactt	540
agcaaagaca	gcagatcctg	gtgccagggc	acagggctca	cctggatgtg	gggaggagtg	600
gctctggcac	ctgccaatac	tttgggtcct	acaggccctg	cttgaggtct	ttggcctctt	660
tggtcttttg	tctttttctc	ctggaacaga	agttgaaatg	gggaggagac	ctgggcagtg	720
ctcttggaat	ttaacccttc	acttctctgc	ccctgtgttt	cagttcaaata	cagccttctc	780
atctgcgga	accacagaat	tgagtggcaa	atgtgtgggtg	gctttggcaa	caggtgaagt	840
ttgggggcag	ctggttaata	gaaagggcat	ggaggatgtg	tagtgcggtg	gcacccagtg	900
cccagatctg	gctcgggagt	tggttgagga	acatgtcatt	cttttctctg	ctttttgagg	960
cccaaggggt	cagcattccc	agtttgaggt	ctgagagcct	taggagcagg	ctcctgggaa	1020
gtgtggaaaa	agtccaaggc	ccaagagaaa	gagctctcca	gggatcctga	gctccagggc	1080
tctcarcagt	gccctgtcca	actgggcccc	aaccttgtca	ctctgcatac	tcccctgcyn	1140
gccatmwcca	cctgtmtgtg	tgcccgcaga	tcccaatatc	ctgarccctga	rtgggnaagg	1200
tgctggcatn	ctggggacct	tgcttcgacg	ctatgggcct	tcgggnatgt	gggaccgggc	1260
cgccccggtc	caagaactat	ttggncnttt	gaacctctgg	gtcctnttta	acaacgtggt	1320
tccccggccc	tgg					1333

<210> 88  
 <211> 943  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (25)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (111)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (832)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (842)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (866)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (896)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (921)  
 <223> n equals a,t,g, or c

<400> 88									
gccactgaac	ctttgggggt	ccctncttcc	gccttttcca	cagtgtgaca	agctggctgc				60
tgactgtccc	acgagctgcg	gcgccatggg	gtcagctgtg	tgtctctgtg	nccggggatt				120
gtgcagacag	aactgctgaa	ggagcatatg	gcaaaggagg	aggtcctgca	ggatccaggt				180
gcttactgtg	gcaggtgcag	ggctgagcat	gggacacaca	ttatttcctt	taatcctgga				240
tgtggggagg	agtggctctg	gcacctgccca	atactttggg	tcctacaggc	cctgcttgag				300
gtctttggcc	tctttggctt	ttgggtcttt	tctcctggaa	cagaagtga	aatggggagg				360
agacctgggc	agtgtctctg	gaaattaacc	cttcacttct	ctgcccctgt	gtttcagttc				420
aaatcagcct	tctcatctgc	ggaaaccaca	gaattgagtg	gcaaattgtg	ggtggctttg				480
gcaacaggtg	aagtttgggg	gcagctggta	ataagaaagg	gcatggagga	tgtgtagtgc				540
ggtagcatcc	agtgcccgag	tctggctcgg	gagttggttg	aggaacatgt	cattcttttc				600
tctgcttttt	gaggcccaag	gggtcagcat	tcccagtttg	aggctctgag	gccttaggag				660
caggctcctg	ggaagtgtgg	aaaaagtcca	aggcccaaga	gaaagagctc	tccagggatc				720
ctgagctyca	gggtctctcag	cagtgcctgt	ccaactggcc	caaaccttgk	cactytcgat				780
actyccctgc	ctgscatctc	cacctgtctg	tgtgcccgca	gaatccaata	tnctgacctg				840
antggtaaaag	gtgcttgcca	tcctgngacc	cttgcttcaa	cgcttatggg	ccttcnggga				900
aggtggaccg	gccgccccgt	ncaagaacta	ttttggcctt	tga					943

<210> 89  
 <211> 846  
 <212> DNA  
 <213> Homo sapiens

<400> 89  
 tcgagttttt tttttttttt tttttttttt tttttttttt tttttttttg aaagagaaat 60  
 gagactttta ttagctccaa gagcattttt caatactaag gcaaaaagta aaaagaagga 120  
 caaggaaaac caaggcacia agaagggacc taggcgcacc ccagaactca ccacggacac 180  
 acagcagagg gcttctcttc atatcaaggg tatgggtaaa caagaaaggc tgctgtttca 240  
 ctgagacagg acgaaccacc aagtccaaat gagaagacaa gcagagacgt agtgtcagac 300  
 caggagggtt agaacttgct agtgtagagg gcaataatcc acttgggcac acggaggaag 360  
 gagggcaggg aggaggccag ccagcccagg ccggacacgt gtgagagaac agagctcaaa 420  
 gacaaatagt cttggacggg gcggccgtcc acatcccga ggccatagcg tcgagcaagg 480  
 tcacaggatg gcagcaccct accactcagg ctccaggatat tgggatctgt tgccaaagcc 540  
 accacacatt tgccactcaa ttctgtgggt tccgcagatg agaaggctga tttgaactgc 600  
 ttcaacacag gatcctgcag gacctcctcc ttggccatat gctccttcag cagttctgtc 660  
 tgcacaatcc ccggccacag agacacacag ctgaccccat ggccgcgcag ctctgtggga 720  
 cagtcagcag ccagcttgct acacaktytg mccactgggg attgtacctc ctgagctata 780  
 ggtaacatca ctgtctttta ctcctcagc tcctatgcca ctgggtcctc accgcagctt 840  
 tgcccc 846

<210> 90  
 <211> 664  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (562)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (642)  
 <223> n equals a,t,g, or c

<400> 90  
 gaatccctt ctcgaaatca accctcacta aagggaacaa aagctggagc tccaccgcgg 60  
 tggcgccgc tctagaacta gtggatcccc cgggctgcag gaattcggca cgagagaaaa 120  
 tgaaagccga cgtccacagg gaccaggca ggggtgggtg ttgtgactca ctccacctct 180  
 gtgccttgc gaggtactgt tgggtccttg tcttgtagac ctggggtgag ctctctgtac 240  
 atgttggtgt tccacgtatg ggttgacttg gcatgctggg gggtcctcgt tcaactctctg 300  
 aagttggcct cttttcactg gggattgaaa agcacctcca cccctaccct agtgatgtcc 360  
 cctgaggacc cgggtgatag tacagtcaat attgtcagta ctttgctttg attgaaggct 420  
 gttagactga gttacaaaaa ttctattttc aaaggaaacc aaaccttaaa aaaaaaaac 480  
 aaaaacttgg ctgggtcttc caaacctacc atgaaacctt ggtgtgcagg ctgcactcaa 540  
 tgacctcaac ccaacacctc cntgagtgtg cttcttggaa garcctagaa gattcctgga 600  
 tggagacccc attgggtcagc tcaagtctgg ccccgctctt cnaaaaaacc aaaacaccat 660  
 tttg 664

<210> 91;  
 <211> 364  
 <212> DNA  
 <213> Homo sapiens

```
<220>
<221> SITE
<222> (2)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (7)
<223> n equals a,t,g, or c
```

<400>	91						
tncgccnctt	gcagcccttc	gcttctccac	aagtcaagtg	tgaacagtag	cagtggccac		60
aaggagtatc	tttagacctt	tcccagcggg	tgctctctgt	ttggatgcc	tgagtggcaa		120
tggggctgga	cagatgcccc	accacratgg	gcggctctcc	caccagcctg	cagaaccaaa		180
cagcaaccac	tgagctccat	gctgatgggt	caaaggacaa	gcaaggcatc	ttagagcagg		240
cctggrrgct	scacaaaagc	ttacaaatgt	gtttgttttt	tcgaagacgg	gccagacttg		300
aggctgaacc	aatagggtct	ccatccagga	atcttctagg	ctcttccaag	aagcacacgg		360
gtgg							364

```
<210> 92
<211> 517
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (514)
<223> n equals a,t,g, or c
```

<400> 92								
ctc	gag	t t t t	t t t t t t t t t t	t t t t t t a a g c	a a t g t a a a a c	a t t t a a t g t g	a t t t a a a a a g	60
a a a a a c a a a a	a c c t t t t g t t	t t c a a c t a t t	t t c t a a t t t t	c a a c a a g a g t	g a g c t t g t a c			120
a t a c c a c a c t	a a c c c a a a g a	g g g g a g g c a g	a a a a a g a c a t	c a g c a a c g g t	c t t t g g a g t t			180
t g g c c t a c t g	g y t g c c a c c c	t a a a g t g g g a	g a t a a a a c t c	t g g a a t c t a t	c t t g t a t c t g			240
t t g g c c a a a t	t g c t t a a t t c	c t t c t a t t c	t c t t c t t g t a	a a a t g a g g c a	c t a a t a t c t t			300
a c c g g c c a g c	t c c a a g g g g a	c a t a g a g c c a	a c t c a c t c a t	t c a t t c a a c a	a g c a a c g a a a			360
g c c a g c t a t t	t g t g t g g g g a	c a g t g t c a g g	t g c a a g g a t a	t g t g g c t g t t	c a c g a g c c g g			420
c c c t a g a c g g	a a a a c a c t c t	a a g g r t a a c a	a t a g c t g c t c	t g g a t c c t a t	t t c t g g g g g a			480
g c a g t g g g t c	a g t y a a a g g c	a a a g c c g g g g	c t g n c a t					517

```
<210> 93
<211> 1357
<212> DNA
<213> Homo sapiens
```

<400> 93						
ggtttagagg	acgtatat	aaataaaact	atacagctaa	agaaactgac	tttcacttcc	60
tcagtgactt	aatttcacta	catgctgatt	tgtcctttgc	agtatttagc	tcagaccaag	120
acagaattgt	atgtgctatt	agatttgcaa	attgctgatc	tcccagtgac	tttccctcct	180
agatcccagt	tgagtatgg	tacctgaga	actgtggat	tagccatgtt	agagcatgct	240
ccactgggga	gttctgtgca	gtctattttt	aatgctattt	aatgaaggag	cgagcgccct	300
actcagcaat	aaaagaagca	tgagggaaga	cagagcagtg	catggttatg	gatactggac	360
aaggatattt	ggaagaagtaa	aggctgacca	ttggatatgg	taattttaat	gaagtcctaa	420
tatatcatat	gaaatggaat	atggattttt	gtagagaat	tatacatgaa	tagttcaata	480
qqtgttttcg	taaacctcct	cactagttct	tagaaagaag	actcaataat	ttgagttttt	540



aaaacttgag	ggacatacta	accagggagt	tcctgcatgc	agactatttt	taatacaagc	600
tgtcatattc	ttgggtggtg	agaagtacag	aaataatttc	aaattcctaa	aatattgttc	660
ggtgaaaggt	ttggagcttg	taaaacgttc	tgcgaataaa	ataactaata	tgcttctaag	720
atactacaat	aacctgaagc	tctgccttgt	gaattgcttc	attttctttt	atgaacttgg	780
agtctaggtc	cagaattgtc	acaactaaga	gaagcaggaa	gttttgtttg	gacttgatag	840
aatatttggg	gtgttttctc	tccttagaat	taagataagc	cctacagatt	atcttactga	900
agtctaaata	ttttaaaaaat	ataagtagca	gaggcagcac	tggtaacttt	tgtaatgtca	960
caataaaggg	caaaatatct	taacattata	gtgtgtacaa	tgcaagaagc	catctgtctg	1020
caacatttgt	atatatgcag	aacacctgtc	ttgaggtaga	aagtgagaat	gttcaatcag	1080
aaaggtcttg	tgttgatttt	catattaaca	acatactata	atcaggttat	tcttttggtc	1140
agagtaaagc	taattagaca	aaatgcttaa	gtagttgcaa	ggttaataaa	cataagagaa	1200
agtaagcagt	ttctattaaa	tggggaagtt	agtcataata	tttttaaatg	aagctgttag	1260
aacaatgtgc	aaagttgatc	tggatttttg	ccaattccta	tgaaaaataa	tccccagaaa	1320
taaactacta	agggaaaataa	aaaaaaaaaa	aaaaaaa			1357

&lt;210&gt; 94

&lt;211&gt; 897

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 94

gagtgaggca	tagcggttta	gataggaaat	tttaagaatg	acaaattaaa	gaatcctgga	60
aaatacactg	tacattctgc	caaggtttgt	caatatggat	gctggtatag	taatgagaat	120
aaatcggtaa	attcttttca	taaaatgaag	gaaagaaatt	actatgtgct	ctttaaaatg	180
tgttgcatca	gtgcctgatt	tgattgtaag	ggtcacatct	tcaagacatg	tgataccacc	240
ctttatacca	cattatagca	ttgtctaata	ttgtaaagtt	tataaattgc	tttcaactcag	300
tcttcatctg	attctcagaa	tgaccctatc	caattgggaa	tatgggtttc	attagtctta	360
cattactaag	gagattcaga	gagtctcaat	tggccaacat	catgcagtta	aaaatgacaa	420
atggggattt	tgaacccaag	tcttcttgac	cccagaaccc	gtgatctttg	tactacatca	480
tgcttctctg	gaaattaaat	ggacctgtct	tgcagaactg	ttcttcttct	aactagggat	540
ctggaggagt	ctcaagtaaa	taggsagatg	gccttaggga	gggatgtctg	gaagsacctg	600
tttgaggtcc	cagcaggttg	gtggttttct	gtctgtaggt	ctggcagctg	ggcatggtta	660
cttagccatg	gaaaggggct	gcargaggag	gtcctcagtg	ctcagaccga	gggcagagga	720
ctgtgtggcy	ccygttttgt	tcyccagatc	taytctctac	acgccttcac	cctgctctct	780
gtttgggatg	gaatcaaagg	acccctttgc	cccctggctt	atggttgect	tttgccaatg	840
gaagcagtga	cagaggatca	gattagaggt	agaaggggag	tgaggaagga	gagtgaa	897

&lt;210&gt; 95

&lt;211&gt; 755

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 95

ctcgagaagt	ctgctaacaa	aacattcatt	tctgtgcaac	ctccattcaa	acaaggattt	60
aattcaaaaa	agtacatttg	gtaattagta	tccatgaata	gtgatactca	tactcttttg	120
tttcttcctt	ctttatgtat	taccttgaga	cactgaaaac	tgtaaagagg	tttgcagatg	180
atcacaggag	ttgttgggca	actgattcct	gctaagagat	aaaatgatgg	tgaaaggatg	240
tcaaaaaaac	agactctggg	aaatatctct	cgatgcacat	accagagccc	tgccctgtgtc	300
aacttttaag	gatcttctat	ggtaaaaaca	ctaagacaac	tcatatgtgt	atacagatgc	360
aaagatatca	ggagtattcc	ttggagggtt	cctattttccc	ccaatcctca	gcatgcactg	420
tcaagatgcc	tttgggcttg	aaaatgtgcc	tattatcagc	aaccactccc	tgtatatata	480
taagaagatt	gaagctgcct	aactgctgag	caaggctcaa	attagtcaca	gcattatgta	540
agccccatt	ttcatattta	aaacatcata	tttcataaag	tatcagaagc	acctgggtgca	600
gggtgggcac	tcaatgaaat	gatcatcatt	tttgaagggr	aaaaggatag	aagatggagg	660
ctaattgcagt	gttttatgct	gtagccatca	caggrtccac	atccgaagta	ccataagaat	720
gctggccaac	tctgctgtgt	ctcaacaggg	gtttt			755

<210> 96  
<211> 3963  
<212> DNA  
<213> Homo sapiens

<400> 96  
cttgtttctg ttttctttag attgtggtat ctgaacggga actatttgggt tctgttggtg 60  
tcattgggtg tcattcttcc tttgtcgtg ttttagaaatt taggatattt gggatatacc 120  
agtggccttt ccttgttgtg tatgggtgtc tttctgattg tggtcatttg caagaaattt 180  
caggttccgt gtccctgtga agctgctttg ataattaacg aaacaataaa caccacctta 240  
acacagccaa cagctcttgt acctgctttg tcacataacg tgactgaaaa tgactcttgc 300  
agacctcact attttatttt caactcacag actgtctatg ctgtgccaat tctgatcttt 360  
tcatttgtct gtcacctgc tgttcttccc atctatgaag aactgaaaga ccgcagccgt 420  
agaagaatga tgaatgtgtc caagatttca ttttttgcta tgtttctcat gtatctgctt 480  
gccgccctct ttggatacct aacattttac gaacatggtg agtcagaatt gcttcatacc 540  
tactcttcta tcttggaac tgatattctt cttctcattg tccgtctggc tgtgttaattg 600  
gctgtgaccc tgacagtacc agtagttatt ttcccaatcc ggagttctgt aactcacttg 660  
ttgtgtgcat caaaaagatt cagttgggtg cgtcatagtc tcattacagt gtctatcttg 720  
gcatttacca atttacttgt catctttgtc ccaactatta gggatatctt tggttttatt 780  
ggtgcatctg cagcttctat gttgattttt attcttctt ctgccttcta tatcaagttg 840  
gtgaagaaag aacctatgaa atctgtacaa aagattgggg ctttgttctt cctgttaaagt 900  
ggtgtactgg tgatgaccgg aagcatggcc ttgattgttt tggattgggt acacaatgca 960  
cctggaggtg gccattaatt ggcaccactc aaactcaaac tcagtccatc tgatgccagt 1020  
gttgagtaaa ctcaactact atgaaatttc acctaatgtt ttcagtttca cttccttttg 1080  
aagtgcagat tcctcgtctg ttcttctgag tgcagaataa gtgaactttt ttgttttgtt 1140  
ttgttttttt aagaaactta tctgtatggt agaaatggat atgaacaaca aaaccacgag 1200  
tctcgggtta agggaagtga caattttatt ccattccaga gaatggacaa actcttaact 1260  
tttatcaagc cacatgcttg gctgtgtcat tgtttaactt ggatatttta tgattttact 1320  
tgaatgtgcc taatggaacc atttgatgtg agaaacaatt ctttttaatt tacagcaaaa 1380  
tattgaataa ccattgacaa aaacactatt attttttgta ccaaaaatac ttaaagacct 1440  
cagaagcact cttttacttt taagaaattg cttttttgaa ctttattcag aagcagttat 1500  
caataaattc cataaaataa tgtcattggt atttaaaaaat gaatattaat ataatgaaat 1560  
ggtttgcctt tttgtaggca taataagcca aatacttttt tacccaaaat aattttttaga 1620  
gaaaatgatg taatgaaaaa ttgtaccatg aattaggagc atagtttttt ccatttaaac 1680  
gtcaccatta cttaaaagat gattgattat tgctatacca aatcagatga actctgttca 1740  
tcacttttct tctctgtccc caaacaattt ggttcattca gactgaaatg tttgtgtctt 1800  
caacttatta gaaatggaaga taatgcagat atttctgtgg gaaataaaat aactaatttt 1860  
gaggtaccaa atagtgcaat tgggtaaaac agggtttatt cagttgcatc tgtctccagt 1920  
gttgatttga cagctctggg tctttttttg ggccagccct tttttgacat tgcttccagc 1980  
agtggaaaat gggcatttga tggcaatagg ccaaaattat tgtgtccaga gagtacactt 2040  
tttcaaaatg ctcacctact ggaagtgtga attacttgac aatgtatggc ttagttgtgt 2100  
tcatgttttg tctacagtag aggtctaata cacaggttac acctatgttt gatatgatat 2160  
aagttctctt tgcgtaggcc actgggttcc tcatgcagta agctttataa aaactcattt 2220  
gcactggact gtcactctcat tcttgtacaa cgtagaatta cttgtttaca tccaacaaat 2280  
ggttagctag ggaaaacagt gcaaaactgag tgttagtagt cattttgggt caactgcatg 2340  
tcaacccttc catttcaatc ccagttagaa atgaaaataa ttactttgaa acttggtctt 2400  
aagagcacat ttatcgtagc tcacagtgtg tgggtgaatat attattaaat aatgtggtag 2460  
ttcgtctatc aggcataatg tctaaaatct aatatacata attccattaa gtgggtgaaag 2520  
gaagcaaata atggaattgt caattggtca tctggctgta aggtttgccc ttgaaactaaa 2580  
aatgttggtt ggggcaaggg ccagaaatgt ggagacatgg tttttgttac gcattcttgt 2640  
attatatgtg actaaattta caaacaagat acatgtgtaa ttaaagacct ttatggaaact 2700  
ggaagacgtc ttgtagtgtc acattgggtg aaaccgttgg tccattttttg tctgtttcta 2760  
tgaagataaa ataattgggg gccatctaga aatagaaagg cagtgggaag acagattcta 2820  
cggcactgct ttcatttaat tgggcttttag gcactccatt cgaatgcaga acctcacctc 2880  
tagttgagac caagaattgg caaatttgca tgagctcttg gaaagagttg ctgactttgt 2940  
atctaagacc tgccaggga taccaagagt tgtttctaca gacttttttt ttttttttgt 3000

atgggagaag	atactgtggc	aaccaggaag	gaatggaaaa	aaaattcctt	tctctacagc	3060
aaattaatgt	gaggaagctc	ctccaatcct	ctggctatct	aagggtcaca	atcaagtgcc	3120
tagggaaaa	tccaatggat	gattttctgg	gagctatctt	gtctaccttg	agggtccctga	3180
acaatgaatt	cccattaatg	agcagtcctc	agtattaaaa	ccactgtctt	gtcacctcat	3240
tttgcatcatt	tgtcttccgt	ggatgtttca	gttacaactg	taatgttatt	tatagaacaa	3300
cattaatcca	ttaaagctaa	cctatttttc	aatatttatg	ataatctatg	tacatatatt	3360
gtctgtccat	atgtatttgt	aaatagggtg	tatataatgt	caggtttggg	tcttgggttc	3420
aagtgtatat	attcctgtaa	gtttcttaac	tgcattttga	tgaattcaca	ttatgtaact	3480
ataagaattg	tcccaaaagt	acctgtacag	aaaattgaat	attgaaaaat	tgacaaattg	3540
tgtacaaaca	ctaaaaaaa	cttgtttaaa	ttgtatttgc	aataaacaac	atcaaatttt	3600
ttcatgaaat	cttggtacaa	attcagatct	cttattttaa	atttaaataa	ggaatacatt	3660
ttcaaaatgc	agtaatcaaa	atgtgatcta	gtgtaatgaa	ataaaatgtg	atctagtgtg	3720
atggaagacc	tttgagaacc	tgggtgtatt	aacttttgtg	atatagtgtg	aatatcccca	3780
ctgtactgtt	agaggccaac	aattctagta	tggcttgttg	gcaaagagtg	ctacaccgtt	3840
tcaatgaaac	aatgtatgtt	tgttttaact	gaactaaaa	aaatacatgc	ttaatcctga	3900
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3960
aag						3963

&lt;210&gt; 97

&lt;211&gt; 2196

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 97

ccccccctt	tttttttttt	tttttttttt	tttaagtttt	atcaactgcc	aagatccttt	60
atttttttcca	ggcccccttc	tgcccactcc	acatcggggc	agctccagca	taaggagat	120
gacatgatga	aggggctaag	agtagggcct	ggccagcatc	cactgagggc	ccaaccaggg	180
aacagttgct	agccgctctc	ttccatgcag	ctggagcact	agcaaggcct	tccagaggct	240
cccagggcga	cctccacatc	actcccgtt	gtctctgccc	tccaggggtg	tccgggcctc	300
ctctccctgt	gtaccctaga	ggtgtgaggg	ccacagtcct	cctcaggtga	acctccctcc	360
ccaagcccag	ggccctagca	caggctgcag	ttggacggct	tcgagctgcg	gctctggggc	420
tagagcaaag	agaggggaag	gaggggaaga	cacagtgcga	cgtcaaggaa	atgagggaca	480
gccctcattt	cagagctcag	catgggctgg	agtcatactg	aaaaccagac	gataaccacc	540
attccaaaac	tctgcaccac	taggaagaac	ccccatccct	gacttcttcc	tcccttccac	600
tgcagcatat	atcttcagcc	cagcctcata	cctgctgccc	ctggtattct	gcctcactgg	660
ctgacagtgc	ttgtgctaaa	gctaggtcct	cttccctcctg	acaactggga	gggagaaaca	720
gtttaagttg	gatgatggta	agatctgaaa	tttgaacatc	tgatctgtgt	gtgttggggc	780
tcatggtgct	gagcactgct	gaggattatc	tcaatcttca	tagcaacact	acaaggtggg	840
tattagtatt	gtccccgttt	tatagaggaa	atgaaggctc	catgggttaa	ataacttgtc	900
aaagatcata	tagttcatct	taattttgag	accaagttgc	cagcgattat	cttgcattgt	960
gtcagagtgg	tcccacctac	ctgcctccag	accaagccct	tgcccacagc	ttcgctctc	1020
tttcacaaga	gggtaaggta	ccttgggaacc	tgggggttgg	tttctgccag	ggacatttcc	1080
agggcccgct	gcagagcttc	atcctcactc	tacaaaggga	gaaagaagac	cagcgtcctt	1140
ggacttcact	ctctgtgtgt	ttgtttctgt	ccatccaacc	tctgccaac	tcaccaggcc	1200
attctgcaaa	gcaatcactg	gaggggctgt	ccaggacgga	gatcgggttg	tggctctgct	1260
gggagaggta	caggaaggca	tggtttgact	tgggctgggg	acagtgcttg	tagaagccac	1320
agcttgtgct	ctggagatgg	cagcaagtcc	tgcccggctg	gttgggtgcc	cctccccaga	1380
gcaatcatgg	tccagtggat	gccgggtgct	gatgcagaag	tttcggctac	agcgttcaca	1440
ggtcagtttc	atcatttctc	gctgcgggca	gccagcgcgt	tcacacttat	tggtgaagat	1500
ctgaggtgaa	gtgagaagg	tgtctctgct	gagactctga	ttagctgttt	gggtttccag	1560
gcatccgtag	tcccagctgg	gttgtggctg	acccctacaa	tgtttacctt	acgtttttgc	1620
tgtgctggat	cagagcgaca	gtctctgtca	atgtgctctc	ccacagcacg	gtcagggggc	1680
tcccctctgg	ccacaggcac	aggcacatta	cagagagggc	acacaggtac	ctggatatcc	1740
tgtagtcaag	gagcaagggt	cagtctgtgg	cccactccag	tccaacaaat	ctctgggtct	1800
gaaagaactt	ggatatgacc	caccacaaac	acgcraaaaa	acagtgtttc	ccagcactga	1860
cagcytcaga	aggacaaaag	ggagaagaaa	cgtgagacac	agatttgggg	gattctgcac	1920
gcattctcca	tctgctgtct	ttcaccttga	ggatcgcccc	ctcacctttt	ggtaagcaga	1980

tccacagtga	tgctgggctg	aggccacatg	gtctgcgcag	aagatgcctg	agcaggcatc	2040
acacttaagc	ggcagaaaaat	ccaagcgctg	acagctcggc	tccgaacagt	gagcgccgag	2100
gtccggaac	tccatcgcca	agccgggcag	ggctctgctag	gagaagcgac	gagtgtctgag	2160
cgtcttttagg	gctcgtgctc	gaagtccgca	ccgcgc			2196

<210> 98  
 <211> 1724  
 <212> DNA  
 <213> Homo sapiens

<400> 98						60
ggcagcagggt	tttctatgca	catattatgt	catcttcaaa	cagggaaaaat	ttgacatcct	120
tgccctttat	ttctttctct	tgctgattt	ctctggccaa	gacttccagc	actatgctga	180
ataaaagtgg	tgaaggtggg	catatttggt	ttgttccagt	tcttagagga	aaagctttca	240
gtgtttcccc	atthttgtatg	atggtggctg	tggttttttc	atgcctatcc	tttattttgt	300
taggtatact	tgttctatat	atthattttg	ttatgtatgc	ttgttctata	cctactttgt	360
ttagtgttct	ttaacatgaa	gaaatgctga	atthtatcaa	atgcttttcc	tgcatthatt	420
gagatgatta	tatggttttt	gctattcact	ctgttgctct	tcaataaata	tgatgtgatg	480
tcattttttt	tatttgaata	tgtcaaaaaca	tccttgcatc	cctgggataa	atctcaattg	540
atcatagtaa	attatctttg	tagtgtgctg	gtggatttga	tttcctagta	tgatcattgag	600
aattattgca	cttctattca	tcagcgatat	tggtctgctg	ttttcatttc	ttcttgtgtc	660
ccattctggg	tttgggtataa	gggtaatgct	gccttcatag	aatgaattaa	gaagaactct	720
cttttctttg	atthtttgaa	cagtttgaaa	agaatgggta	ttaagtattt	tttttaattg	780
ttggtagaat	tcagcattga	agccatcagg	tcctgggctt	ttctttgatg	agagagtttt	840
tattactggg	tataatttcat	tacttgtaat	tagtctgttt	agactctcta	ttcttttttg	900
gttcaatctt	gataggttgt	atatgcctga	gaaattatac	atthttacta	ggctttccaa	960
tttgttgact	catgggtgat	tgtaatatag	tcctaatgatt	ctttgtattt	ctgtgggtatc	1020
aattgtcatg	tctctttttt	catttctgat	ttcatttatt	tgagtctttc	ttttttctta	1080
ctttgttttag	ctaaacattt	gttaattttg	tttatttttt	tacaaacaaa	actctttgtt	1140
ttattgatct	tttgtatttt	atthtttactt	tcaatttcat	ttatttttgc	tctgatcttc	1200
attagttcat	ttttcctact	aattttgagt	ttgggttgct	tttgtttttc	ttgttccttg	1260
aggtgcatca	ttagatttgt	tatttgaaat	attctctact	tttttcgatg	taggtgttta	1320
ttgctataaa	attccttctt	aatactgctt	ttgctgtatc	ccatagcttt	tgatacattg	1380
tgtttatact	ttcatgtgat	tcaagaaaat	ttaaatgtac	ttcctaattt	tttattaatc	1440
cattgggtgt	tcaagagcat	gttggttaatt	ttgatgtatt	tgtagcagtt	tgaaagtatt	1500
ttctgttact	gatttctagc	tttaattcct	tgccatcaga	aagtatactt	gatgtgattt	1560
cagtactttt	aaacttggtg	agacttgctt	tgtagcccaa	tggtgtggtc	ctccaggaga	1620
tttttccatg	tgctaataa	aaaaaaatgt	gtattctgca	gctgttgcat	gaactattct	1680
gtcaatgtct	gttaagtcta	tttgggtctaa	agtgaatttt	aaatacaatg	tatctttgtt	1724
gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa		

<210> 99  
 <211> 251  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (8)  
 <223> n equals a,t,g, or c

<400> 99						60
ctgggctnnt	aaccctgtts	mgacttgctt	tgtagcccaa	tgtgtggtct	ctccaggaga	120
tttttccatg	tgctaataa	aaaaaaatgt	gtattctgca	gctgttgcat	gaactattct	180
gtcaatgtct	gttaagtcta	tttgggtctaa	agtgaatttt	aaatacaatg	tatctttgtt	240
gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	

aaaaaactcg a

251

<210> 100  
<211> 1075  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (745)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (984)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1001)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1023)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1052)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1068)  
<223> n equals a,t,g, or c

<400> 100  
ctgttttcat ttcttcttgt gtcccatctt ggttttggt taagggtaat gctgccttca 60  
tagaatgaat taagaagaac tctcttttct ttgatttttg gaacagtttg aaaagaatgg 120  
gtattaagta ttttttttaa tgtttggtag aattcagcat tgaagccatc aggtcctggg 180  
cttttctttg atgagagagt ttttattact gggtatatatt cattacttgt aattagtctg 240  
tttagactct ctatttcttt ttggttcaat cttgatagggt tgtatatgcc tgagaaatta 300  
tacattttta ctaggctttc caatttggtg actcatgggt gattgtaata gactccaatg 360  
attcttttga tttctgtggt atcaattgtc atgtctcctt tttcatttct gatttcattt 420  
atttgagtct ttcttttttc ttacttttgt tagctaaaca tttgttaatt ttgtttattt 480  
ttttacaaac aaaactcttt gttttattga tcttttgtat tttattttta ctttcaattt 540  
catttatttt tgctctgac ttcataggt catttttctt actaattttg agtttggttt 600  
gcttttggtt ttcttgktcc ttgaggtgca tcattagatt gtttatttga aatatttcta 660  
cttttttcga tgtagggtgtt tattgctata aaattccttc ttaatactgc ttttgctgta 720  
tcccatagct tttgatacat tgtgnttata ctttcatgtg attcaagaaa ttttaaatgt 780  
acttcctaatt tttttattaa tccattgggt gttcaagagc atgttggttaa ttttgatgta 840  
tttgtagagt tttgaaagt atttctgtta ctgatttcta gctttattts ctyrccatca 900  
gaaagtatac ttgatgtgat ttcagtactt ttaaacttgt tgagacttgc tttgtagccc 960  
aatgtgtggc ctctccagga gatnttccat gtgctaata naaaaaaaaat ggggtattctg 1020  
canctgtgca tgaactattc tggcaatggc cngttaagtc tatttggnct aaaag 1075

<210> 101  
 <211> 460  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (178)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (393)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (418)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (440)  
 <223> n equals a,t,g, or c

<400> 101									
aattcggcac	gagttggaga	agggtcccga	cctcatcagc	caggtgttgg	ccacctaccc				60
tgcagatggg	gaaatkgcgg	aakcakctgc	ggagtcttct	ggctgctgtc	cctgctgtgc				120
tgcataaagg	agcagcagtt	tgaacaagt	gtggcgctgc	tcctgcaaag	catccggntg				180
tgccaggaca	gagccctgct	ggtgaacaat	gcctaccagg	gactggccag	cctgggtgaag				240
gtgtcagagc	tggcggcctt	caagggtggt	gtgcaggagg	agggcggcag	tggcctcagc				300
ctcatcaagg	agacctacca	gytccacagg	ggacggaccc	ggaggtgggt	ggagAACgtg				360
ggcatgttgc	tggttccacc	tgggttccta	ttnaggagat	cctgccggag	ctggtgtncA				420
gtagtatgaa	ggccctgttn	caagagttca	aggagcgttt						460

<210> 102  
 <211> 777  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (708)  
 <223> n equals a,t,g, or c

<400> 102									
gcaaaaagct	atttaggtga	cactatagaa	ggtacgccts	caggtaccgg	tccggaattc				60
ccgggtcgac	ccacgcgtcc	ggttaagttc	tatggccgct	gcagggtctg	tgaaggcggc				120
gttgacaggt	gccgaggtgc	tgaagccat	cgtgagctgc	tgctggtggc	ccgagggacg				180
gcaagttttg	tgtacgaagc	ccactggcga	ggtgcttctc	agccggaatg	gagggccgct				240
cctggaggcg	ctacacttag	agcatcccat	agccaggatg	atagtggact	gtgtttccag				300
tcatctcaaa	aaaacaggag	atggtgcAAA	aacattttatt	atctttcttt	gccatttgct				360
tagaggactt	catgcaatca	cagacagaga	aaaggatcct	ttgatgtgtg	aaaacattca				420
aacccatgga	aggcattgga	aaaattgttc	tcggtggaaa	tttatttccc	aggctctcct				480
aacgtttcag	acacaaatat	tagacggtat	tatggaccag	tacctaagta	gacacttttt				540
gtctatcttt	tcgtctgcta	aagagagaac	attgtgtagg	arctctttar	agttgtctct				600

67

agaagcatat	ttttgtggaa	aagtgggaag	aaataatcat	aaattttattt	cacagttgat	660
gtgtgactac	tttttcaagt	gtatgacttg	kaaaagtggg	attggtgnat	ttgagttagg	720
ggatgaccat	tttgtaaart	tgaatgttgg	tgyactggcc	ttcctgttta	aattcca	777

<210> 103  
 <211> 878  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (3)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (747)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (763)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (854)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (858)  
 <223> n equals a,t,g, or c

<400> 103						
acncactaat	agggcggaatt	gggtaccggg	ccccccctcg	agttttttat	tttctagttt	60
caattacaat	ttcatcttta	accataaat	tattaagaaa	aaaattttac	taaatatggt	120
gtttttaact	tattttttatt	tcttaaccta	attgacttgt	agccccaaaa	taccagttta	180
tgatatagat	tttattaaat	gtgtcaaaaa	aaatttacat	agttgattgt	cagttttttt	240
taatgttctg	tatacttaaa	aaaaaatggt	ccccagttgc	tggctgtcgt	ggttcaatat	300
atgccaatga	agtaaaatga	attgattgtc	tcgtgccgaa	ttcctgcagc	ccgggggatc	360
cactagttct	agagcggccg	ccaccgcggt	ggagctccag	cttttgttcc	ctttwgtgag	420
ggttaatttc	gagcttggcg	taatcatggt	catagctstt	tcctgtgtga	aattgttatc	480
cgctcacaat	tccacacaac	atacgagccg	gaagcataaa	gtgtaaagcc	tggggtgcct	540
aatgagttag	ctaactcaca	ttaattgcgt	tgcgctcact	gcccgccttc	cagtcgggaa	600
acctgtcgtg	ccagctgcac	taatgaatcg	gccaacgcgc	ggggagaggc	ggtttgcgta	660
ttgggcgctc	ttccgcttcc	tcgctcactg	actcgtgcg	ctcggtcggt	cggtgcggc	720
gagcgaaca	gtcactcaa	aggcgggnata	cggtatccac	agnatcaggg	gataacgcag	780
gaaagaacat	gtgagccaaa	ggccagcaaa	aagccaggaa	ccgtaaaaag	gccgcgttgc	840
cggcgttttt	ccanaggntc	cggcccccct	gacgggagc			878

<210> 104  
 <211> 853  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (820)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (832)  
 <223> n equals a,t,g, or c

<400> 104  
 gctgcagctc cgggtggaaat aataagatat aaaccacgag gttgttattt gcatagaaat 60  
 agcatggagc cccaggcagc aagggagaag gacacagggg tgatttgtct aaaattttta 120  
 tgaaaacttt tgctgaggca gagattttta aaaactttct ttctccctgc ttttcccctt 180  
 ccttccccta cccccaaac cccatcattg attttactta acatggttca gtttgaagag 240  
 aaaagggttg cactccacat atcatactcc cataatgcag caacctgtaa attgtttctt 300  
 cctttaatag atatgaagct gaagagacat gcattttcaa cttatacat tgcattgtgtg 360  
 cgckkggctt tatggctata ctccatcttg ggcatacaca tgatgttgcc tgcatttagc 420  
 ctgtttttta ttagtttaca ccttcctatc ttttgcttcc aaagactctt acttttttaa 480  
 ggatttcctt ttatagccaa cagtagtaac cttcatataa aataaatatt ttctgggtgtt 540  
 ttctgttttt tttacttttg gtgggttttc tgtatactta catgttttat tcatggacgc 600  
 catcctttgc cactgtgtct tttattccaa aaccaggaag tgcttccac cttcgtattt 660  
 ttatcctttt cccctgtga actcaccatt tgtgtatctt ctttccatgt ctgtcttgct 720  
 ttgttgctg cagttatttg taaaatattc aaaatattac ccaaattgag rtgagttgta 780  
 gkatctggat tywattgakt gttactaagc acatttgacn ttacaactaa angcagtacg 840  
 ctggtgatta gaa 853

<210> 105  
 <211> 441  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (431)  
 <223> n equals a,t,g, or c

<400> 105  
 ctcgagtttt tttttttttt ttttaaaaaa gaagcagagc tttaaaatac aagaaaagtc 60  
 acatatcatc tcctggtgaa tctatcacct gcatatcact gcctttggat ataccttacc 120  
 ttcacagtca gttaatgtcc acaggacaac cataaactgc atattcttat ttctctggat 180  
 agagaatgtg ctctctctcc ccaagtctgg ggcaatggat tgagagctag taggctccag 240  
 tacacatcag tgttccctta caatactagc tcttcccagc ctatctgcca cctaactacta 300  
 tgttaaacad actaatactt tttaccaggg aaagggagaa aaaaataaag taaaaaggaa 360  
 actgagaggg aggagttggt tgggaaggag ggggaaggtaa atatggatcc atcttctggc 420  
 caaatgttcc ngttggccaa a 441

<210> 106  
 <211> 2181  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (63)  
 <223> n equals a,t,g, or c



<220>  
 <221> SITE  
 <222> (2052)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2063)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2080)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2107)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2120)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2157)  
 <223> n equals a,t,g, or c

<400> 106  
 taacaaaagc tgcagctcca ccgcggtggc ggccgctcta gaactagtgg atcccccggg 60  
 ctncaggaat tcggcacgag agagaaagat gtcactgtct ctaatctccc tgtcattttt 120  
 atttccagca ggccgcgggc gaaggagctg ctagaacaat gctgaggcgg gtgaggtgag 180  
 gagcagcccc tcgcggcagc cccgacagag tgtctggaac aggtgattgg aggagccgga 240  
 gacccaggca cctgggcata cttcccctcg cctctgccag gccccgcgcc cctaaaaggt 300  
 gggaaaacca tggcgaccaa tttcagtgc atcgtcaagc aaggctacgt gaagatgaag 360  
 agcaggaagc tcgggatcta ccggagggtgc tggctgggtgt tccggaaatc ctccagcaag 420  
 gggccccagc ggctggagaa gtatccagat gagaagtcgg tgtgcctccg gggctgcccc 480  
 aaggtgactg agatcagcaa cgtcaagtgt gttacgcggc tccccaaagg gaccaagcgg 540  
 caggcggtgg ccatcatatt cactgatgac tcggcacgta ccttcacctg cgactcagag 600  
 cttagaggcag aggagtggta caagacacta tctgtggagt gtctgggggtc ccgcctcaac 660  
 gacatcagtc tgggagaacc tgacctcctg gccccagggg tgcagtgtga acagacagat 720  
 cgcttcaatg tcttcctgct gccctgcccc aacctggacg tgtatggcga gtgcaagctg 780  
 cagatcaccc acgagaacat ctacctctgg gacatccaca acccccgtgt gaagctcgtc 840  
 tcgtggsccc tctgctyamt gcgccgctat ggccgggatg ccacacgctt taccttcgag 900  
 gctggccgga tgtgtgatgc tggggaagga ctctatacct tccagacaca agagggggag 960  
 cagatttacc agcgcgtcca cagtgccacc ctggccatcg cagagcagca caagcgggtc 1020  
 ctgctggaaa tggagaagac gtgaggctgc tgaacaaggg cacggaacat tactcgtatc 1080  
 cctgcacacc cagcaccatg ctgcsgcgca gtgcctactg gcaaccacatc actggttccc 1140  
 agaacatcgc cgaagcctcc agctatgctg gtgagtcgct tccatgcccc acaccacct 1200  
 gccaggaggc tttgtggagg atgaggcctg ttgggcaggg gtcttttgac cttagctctga 1260  
 gttctgagcc tgcttctgtg cccacagggtg acgggtatgg ggcaagccca ggccagctcg 1320  
 gaaacagacc tcctcaacag attcatcctg ctaaagccaa agcccagcca gggggacagc 1380  
 agtgaggcca agaccccatc ccagtgaaca cagtgtggc gagcaccgat gactgctggg 1440  
 ggctgcctgc tgcggggctg gctgcagtgt accgtggaca gcctcagggg gctgtcgccc 1500  
 aagagcctgg agaaaggag caagctgccc cctccttgcc cccaaggwtg aggstggact 1560

gaggcaaagg	gctggccaca	ccacctgagc	atgtgtgagg	ggttggagct	accgtgggac	1620
tatatactgt	taatgatttt	aatatatatg	gcttatgaca	tactctgtat	caatgagatc	1680
ccctcaccct	caccccatcc	ttccccacca	atacacacaa	atTTTTtaat	cccatgacca	1740
ggccacggtc	aaggctgttt	ttgagtatga	gtgcagtcgt	gtccatcctc	catggcacag	1800
ccctcctgct	gccaggacct	gcttgaacta	ccagggccac	aggaggggga	taatcagagc	1860
ttgaggctgg	cactctgact	gctggctttt	cccaaacagc	ccaagggccg	gaacagcagg	1920
tggcttctca	gttcctctgg	gcctggagtg	acacaggaag	gatctgcact	tcctctgtgc	1980
tgcttgccag	ccttgcaagt	ggagttttta	gcagaggtga	catctgggtg	acgcctcagg	2040
tgaaaatctg	gnttttaaaa	gtnaacttct	gcamagsgtg	ccttcckgct	ttgtwaggcy	2100
ggggaanawg	cccyggggtn	arggggtgcy	gattatccca	gtggaagaaa	gccggangct	2160
gtttcctgcc	ccaggaataa	g				2181

&lt;210&gt; 107

&lt;211&gt; 1466

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 107

ggcagagcca	gcagggtggct	tctcagttcc	tctgggcctg	gagtgcacaca	ggaaggatct	60
gcacttcctc	tgtgctgctt	gccagcttgc	agttggagtt	ttaagcagag	gtgacatctg	120
gttgacgcct	cagggtgaaaa	tctggtttta	aaatgtaact	tctgcacagg	ctccttcctg	180
ctttgtaggc	tgggaagatg	cccctggggg	aggggtgctg	attacctcag	ccatgtggag	240
gaaggctgga	gcttgttcct	gccccaggaa	taggccagga	gggaaggccg	cagcaggact	300
gccgtgggga	gcacccctgc	tgccccctc	tcactgacca	gggggtggaca	atgcccagc	360
agagggagcc	cccttgccct	gtttggccac	cctctggcca	gccaaaagca	ctctgaaacc	420
aagaccttcc	catttctctc	tccccacatg	gtgctgaggc	tccctgctgc	aatgcaatta	480
aagcaattga	ttttctagtg	ctgggtattg	ttgactacca	tgcagaaggg	ctatctttct	540
attcacgtca	aacttttggt	tgtgtggggg	ttttttgttg	ttttttgggt	tttgtttttt	600
aatacttttag	ggtcctgatt	tgtgggaaca	gaccttcttg	taaataacca	ctatttgagt	660
tgtggcagga	ggatgataaa	gcacgcggcc	cctcccaaag	gagcccttga	gctagggagg	720
tggtgcagtc	agcctcgctc	tcaacgtgac	ccggggaatg	accacccaga	gggatgagct	780
agcctgtaga	ggggaactgg	ggtccaaagg	tctttgggga	gggaggcaga	gctggctggc	840
tcagctaagt	ggcacgatga	cgcatgaagg	agattatgtt	gtgctcttta	ttgccaaaaa	900
taaaacacttt	taaaaagaca	acttctgtta	atcaataaat	atcctttcct	ttctgtactg	960
gatctctggt	tttctccagg	ctgcctaatt	aactgctttg	tgcagtgttc	tatctggaga	1020
cagtgtctgag	gggttagggc	cagagccttc	attaaggaga	aatgaaatac	tcctcctgtg	1080
tatgtgggag	gggcccttgc	tcctgcggct	gcttccaccc	ccacccccac	ccccacaaa	1140
ctaaatgatc	aggtcattgg	aggtgaaggg	gttcatgact	gctggacaga	gaatgaaata	1200
tcattgtttat	ttggtgggga	ggggacagcc	agggctaat	gctattccaa	aagggttactt	1260
ctcaaattag	ggacacctgg	gaatttgaag	cgctaagggc	cagccctggg	gcaagaactg	1320
gaagggttta	taggccccct	gaataaaggc	tatggcactt	gatcctcaac	accagwcatc	1380
taaggkakac	tgaaaatgac	tcatttttga	cagaaagggt	tagagtaaag	agctggacta	1440
acaggagaga	agtcyagttg	gktccc				1466

&lt;210&gt; 108

&lt;211&gt; 904

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 108

ggttggcgct	aatggtcaga	atgctgctgg	gccctctgca	gattctgtaa	ctgaaaataa	60
aatgtgttct	ccacccaaga	ctcctgttaag	taatgtagca	gctacctcag	ctggggcctc	120
taattgttga	acagagctga	attctgtgcc	tcaaaaatcc	agcccatctc	taactagagt	180
accagtatat	cctccgcatt	ctgaaaacat	tcagtatttt	caagatccaa	ggactcagat	240
accctttgaa	gtcccacagt	acccacagac	aggatactak	ccaccacctc	caacgggtacc	300
agctgggtgtg	gctccctgtg	ttcctcgctt	tgtgaggtcc	aataacgttc	cagagtcctc	360

cctccccact	gcttccatgc	catatgccga	tcattacagt	acattttccc	ctcgagatcg	420
aatgaattct	tctccttacc	agcctcctcc	tccgcagccg	tatggaccag	ttcctccagt	480
acctttctgga	atgtatgctc	ctgtgtacga	cagcaggcgc	atctggcgcc	acctatgtac	540
caacgagatg	acattattag	aagcaattct	ttacctcaa	tggatgtgat	gcactcatct	600
gtctatcaga	catctttgcg	ggaaagatat	aactcattag	atggatatta	ttcgggtggct	660
tgtcagccaa	agtgaagcaa	ggacaactgt	gcctttacca	aggttctcag	agagtgtgag	720
tggtaaaaa	tttgaagaag	atcatctttc	ccattattct	ccctgggtctt	gtggcaccat	780
aggctcctgt	ataaatgcca	ttgattcaga	gccccaaagat	gtcattgcta	attcaaatgc	840
tgtgttaatg	gacctggaca	gtgggtgatgt	taagagaaga	gtacatttat	ttgaaaccca	900
gaga						904

&lt;210&gt; 109

&lt;211&gt; 1474

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (12)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1471)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 109

ctacattgag	tnctttctct	ggctccttgc	aaagaaagat	acttttgtaa	tggtccagga	60
aaggaacatt	gctttctttt	tgtctttcag	cacatttgta	ttatgctcac	cttgtctctg	120
tctcactgtg	acccctttac	acttgagttc	agagttcaag	cattccaaat	ataaatggga	180
atggtggcag	cccagtggct	tgaaggccaa	tgatgagcag	tccaagacc	cacagcgaga	240
tgagcaactc	ttaggaattc	ccacatccta	gagtgaatgc	accaactaac	agtatagaat	300
gctgtccttt	tcaaagcgtc	ctaacagcag	gattacctgg	tcaagtatgg	actttctttg	360
aatctttctt	ttcacaaatt	ggactgcctg	taataccaat	aacattgttg	tatctaacta	420
aataaatgac	tgcataata	cacataccct	caattctctt	gcttccccat	tttctttttc	480
atccctgtc	tcaggacttt	tattttcart	gttgaccttt	ggtttgcca	tatatcactg	540
ttataggaaa	tctcatgaga	ggaatggcta	gtgacccaac	tctccaaatg	tctaagttag	600
tagttacagc	tgatttttta	tgatgcataa	ttggaatgtg	gagcctctga	ggttgtgata	660
gcttgtagat	gaatttcaaa	tgtcattcta	aagaatgagg	ggtgggaggg	atttatagtt	720
agaaacgaca	gtgcaggaag	gggtattttc	ttgttgtcag	ggctggaatg	aatcactgct	780
gctcaagtca	aagggtcctg	aatatcctta	gtttttgcat	ttccctcctt	tttcttttga	840
cctttatttta	tttaattatg	tattttattta	tttatttata	tacttttgct	ccattcagca	900
caaacacaaa	gcaaagcaaa	aaaaaaawat	atatatatat	atctgtatat	gtgttgtagg	960
caaaacactg	tgaatttcac	aacaaccacc	accaagcaac	tattttgcca	tcttaacata	1020
catctcagga	gacgaaatga	gaaaagatgg	ggatgtcatt	ttttagtcta	tgcgtttgag	1080
gccagggtcca	tgttttattta	tttcttttagt	ctatgcatta	atgaaaatga	tcctgagtggt	1140
agggttagctg	aacgttcaat	gtactggagc	aagcatcata	aaagctgcta	gtagccatgt	1200
gtttgaacag	gaaaaatatt	acagaaaatg	aaatgtaaag	gcctatatct	tgacagctgt	1260
atatcttact	attgcttaaa	aaatgtataa	agcagctgga	aatgttttaa	atacaaggct	1320
tttgaattaa	atgtggattt	taaatatgta	atcccttgac	aaatgamcaa	attatggtga	1380
actattgctc	cctgcgttct	ttgatcatta	cctatgactt	acaaatctgc	ctggagatgt	1440
ggacattctg	catttgcttc	ygtatctgga	naaa			1474

&lt;210&gt; 110

&lt;211&gt; 501

&lt;212&gt; DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (29)

<223> n equals a,t,g, or c

<400> 110

ttnccgggcc	cccccttgag	ttttttttnt	tttttttttt	tttttttttt	tttttttttt	60
tttttttttt	ttaaacactg	tattcaggtg	tcactttgaa	atcagccaag	atgcagtggg	120
tcttagtaaa	gcaatggacc	tcaaaacaga	ttgcaaaaca	agaactggta	agtattagca	180
cagagacatc	acattaaaag	gaagataagc	caaatgaaaa	ggagagtcc	aaataccagg	240
tcacgattga	aggggaaata	tatctgtaga	gagatatgga	aatgtgtgtg	tatacggcct	300
gggatatata	caaacatctc	tccagatata	gaaggcaaat	gcaggaatgt	ccacatctcc	360
ggggcagatt	tgtaaagtca	tagggtaatg	attcmaagga	acgcggggga	ggcattagtt	420
tcaccatatt	ttgggtcctt	ttgtycaggg	ggtttacatt	ttttaaatcc	ccccctttta	480
tttcaagggc	cttggttttt	t				501

<210> 111

<211> 408

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (139)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (355)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (389)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (407)

<223> n equals a,t,g, or c

<400> 111

tttttttttt	tttttttttc	tgcatgtcca	gggtaaggaa	agacaggcag	cctacttcca	60
agcaagtgat	ctgttatagg	tgggtagtg	aaactgtcac	ttacaacatt	cttgtagaga	120
atgaacacaa	gacaacacnc	atactggcaa	agagagaagc	tttgagggga	gggtgtgtgat	180
atattgagtc	tacctttatc	cctctttccc	tatcgaacca	ccttcccctc	atggtaaagc	240
tgggacctag	gtatattggg	ggcaacattt	ctctgctgct	gacctcaaag	agactaaaag	300
catacgtgat	tgaaatgaaa	aataaatgag	cagctattta	taaataactc	ctgtnaacga	360
aggcatgtgt	ttcatggaaa	taatctcana	caaatgactg	ctttatnt		408

<210> 112  
 <211> 2510  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (36)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (39)  
 <223> n equals a,t,g, or c

<400> 112  
 tgcgactgca ggtcgacact agtaggatcc aaatgnggng gcacgagtcc attctcctgg 60  
 tgtctctgga tctgctcccc acctccatcc tcctgggtgtc tctgtggatc tgctccccac 120  
 ctccatcctc ctgggtgaat cctgggttctt tcgttggtcta cctggaaaga aaaagacaga 180  
 agcttatttg ccagatgaca agaacaaatc gattgttttg gatgaaaaga aaaaccagtg 240  
 ggtgaattta aatgagccag aagaggagaa gaaagccccg cccccacctc caacctcgat 300  
 gcccaagact gtgcaagctg ccccgctgc cctcccaggg cctcctggag ccccggtgaa 360  
 catgtactct agaagagcag caggaaccag agytctgtac gttgacgtcc tgaacccaag 420  
 cgggacccag cggasgagcc ggctctcgct cctgcggact ttgtcgctcc actcgcgcca 480  
 ctcccaattc cttctaactt gtctgtgcca accccagatg cagaagaacc acagcttcca 540  
 gacgggactg gcagggaagg gcctgcagca gctaggggccc tggccaatcc agagcctgcc 600  
 ccagagccca aggttttaag ctctgcagcg tcaactccctg gctctgaact cccctcctcc 660  
 aggccctgagg gttcccaggg aggagaggct cctggcgacc tccctgctgc agggggccct 720  
 cccagcgggg ccatgccctt ctacaaccct gctcagctgg cacaggcctg cgccacctcc 780  
 gggagctcaa ggctagggag gattggccag aggaagcacc tgggtgctgaa ctaggcttgc 840  
 cctgtctgtga acttgcaact ggagccctga cgctgctgtt ctccccgaag aaccgcaccg 900  
 acctccgcga tctccgtccc gccccaggg agacacagca gtgactcaga gctggtcgca 960  
 cactgtgcct cctcctcac cgccatcgt aatgaattat ttgaaaatt aattccacca 1020  
 tcctttcaga ttctggatgg aaagactgaa tctttgactc agaattgttt gccgaaaaga 1080  
 atgatgtgac tttcttagtc atttaggatg atttaaggat atagtattcc tgggtcattta 1140  
 agaatgttca ttcattgaag ccggagctgt ctctgccaca ggagagccac atggctcggta 1200  
 gtaaccaggg cctctccaag cccagctgtg agtcaactgcc cagtgaagtc cgcgttccct 1260  
 ttaaggtgct gggagcaaaag agaggggtgac tgaggcagac cccaaccctt gctctgcacc 1320  
 atctgggccc tcgccgtgtt tgaacctggc tgaatgagtg gagggcgctg tggttcaat 1380  
 cagcgcctcc gaggagccgt ggggttccct cggcattagt tcacggtttt tgagagagggc 1440  
 cytagttact gcagtgaatt tcttccctgt tgcaaagacg cttccagcct cactttactt 1500  
 tctgtggcct gatgaggacc atgggtgatt ttgtgtaccc aaagcgctgg ggactgcccc 1560  
 ccgtgtggcc cagtcactgg gaaggagccc cagagagccg gctgtctgac atgatggctc 1620  
 aggggtggtca tccaggttga aaactgaccg tgtgatgttt gatttgggct tcatctcgtg 1680  
 tgtaggagca cggtagact cactgttaag gaagctggat gcacttctct aaaaggctgc 1740  
 actttccgtg agcacttttc gtggtacaat ccacatgacc cactttctcc cctgggggac 1800  
 gttggttcag aggttggtag cacttgggga gagtatctta acacagtttc ttgacagcag 1860  
 ctctggaact tagtatttct gccccgagtt ttgccacact gagactttga gtagctcctg 1920  
 gtggactcaa cctgttcaa ctccagagcg ggcctcctct cactgatgca aagctttaaag 1980  
 gcttctctga ctgttctgaa actcttcgta ttcttgtcaa gtctaaagag actgaagaaa 2040  
 agatttaaat actaataaaa atcagtagat aatttctgta ggttctgctg gaggaatata 2100  
 aactgttttg tgttttaaat ttaagtgtag aaattgtaga atgtggaatt agcacagatc 2160  
 cttcctggct ttctgtttca cttgatcatt tagcccagac caccaggat gttttccaaa 2220  
 atgttccaca ggcgtgtccc gctggatcca tttgtccttg tcaactggag aaaggccagt 2280  
 ccctgtgacg gggcagccct ctctgtccct cggtcagctc gtgtgaatcc tgggacctct 2340  
 tccggctcgt ctgcccgtg ttttggggtc gactgccacg acttttgatt caagaagctt 2400  
 cctccaggcg ggagcggcta ttttccctaa atgagaattg ttacattgca aattgttgaa 2460

taaaatattt tgcgctcctt caagcaaaaa aaaaaaaaaa aaaactcgag

2510

```
<210> 113
<211> 641
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (7)  
<223> n equals a,t,g, or c
```

```
<220>  
<221> SITE  
<222> (8)  
<223> n equals a,t,g, or c
```

```
<220>  
<221> SITE  
<222> (18)  
<223> n equals a,t,g, or c
```

```
<220>  
<221> SITE  
<222> (64)  
<223> n equals a,t,g, or c
```

```
<220>  
<221> SITE  
<222> (634)  
<223> n equals a,t,g, or c
```

[illegible]

```
<210> 114
<211> 1036
<212> DNA
<213> Homo sapiens
```

[illegible]

gccctccggg	cctggcctcc	cacctggtgt	gccacctctg	caggaaagga	gacacttgct	360
ccaggaagcc	aggagcccag	accagggat	agtgccgcag	gaggcgctg	ttggaaactc	420
actttccgag	ctaagcgaag	aaaattttga	tggaaaattt	gctaactctga	ccccctcgag	480
gacggtgcca	gactcggagg	cccccccagg	gtgggatcgt	gccgactcgg	gtcccacgca	540
gccacctctg	tctctctcac	ccgctcccga	aacaaagaga	cccggacagg	cagccaagaa	600
agaaacgaag	gaacctaaaga	agggtgaatc	ctgggtcttt	cgttgggtac	ctggaaagaa	660
aaagacagaa	gcttattttgc	cagatgacaa	gaacaaatcg	attgtttggg	atgaaaagaa	720
aaaccagtgg	gtgaattttaa	atgagccaga	agaggagaag	aaagccccgc	ccccacctcc	780
aacctcgatg	cccaagactg	tgcaagctgc	cccgcctgcc	ctcccagggc	ctcctggagc	840
ccccgtgaac	atgtactcta	gaagagcagc	aggaaccaga	gctcgctacg	ttgacgtcct	900
gaacccaagc	gggacccagc	ggagcgagcc	kgytctcgct	cygcggactt	tgctcgctcca	960
ctccagcctg	ggtgacaaga	gcaaaactcc	atctcaaaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	ctcgta					1036

&lt;210&gt; 115

&lt;211&gt; 619

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 115

ccagcccca	cttccttggc	ccttggcagg	ccacttgccc	accaccaac	ccatctgcct	60
ctgggcccc	artgaartca	raaaragcag	rasccccgca	ggctgtgagc	ctggcgagc	120
tcggctgaca	gcgagcttct	catctgcctg	gtggtagagc	ggacgctctc	ggcarcctgc	180
acggcccggc	tcagggcctt	gttgagctcc	tctaggctgc	ccaggctcag	ctggatggag	240
tgccgktgtc	tccgggctgg	tgggggagag	gctgtgggag	gccacttggc	agctgggttg	300
gctgaggtag	gtcctgcagg	cgcatagtag	acagcggcag	gtggataagg	catgatggga	360
accgaggaga	tgtaggcaaa	ggctggaggg	gctgggtgctg	ggggcgctgt	tgccagatac	420
cacagtcagg	gggggtgggag	tggcgacgac	cccgcctgct	tgctcctctg	cttggggctg	480
ggagttgaag	gtgcttttct	cctcgtgggtg	gccttctctg	ccccagaggt	ggctgagcct	540
ggaccatctg	cctctggggg	agacccaact	tgaccacaca	ggggacactg	aagggtatca	600
gcgggaggcg	gtcccagtc					619

&lt;210&gt; 116

&lt;211&gt; 899

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (894)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 116

accacgcgt	ccggccagga	gtgggctgga	gctgctgagg	cccagaaggc	ccgcatagtt	60
cctcaccagg	agggtctccc	tccagcacag	gtcccgcctg	ctcagtcctt	gtgctttcca	120
agtggagggg	gtgtcagctc	ggtcaccaag	agaagtgact	tcccaggagc	accagtcccc	180
tcacagaggt	gctgtgagcg	aggcctcctt	cggtccaggc	agaacctcag	gcagtctctc	240
ctggctcctg	atgtgtgcaa	ctccagctaa	taataggtat	tttatataca	gatggacaga	300
tattttttta	aactggggag	tttctctgat	cttgggtcct	ctttaggggg	ccagacaaga	360
aaggcctacg	gtttctggag	caaacctgtc	ccccacctgt	gaccagtcac	tctggggcaa	420
gcatcactgg	gaagggcata	gccggagacc	tttctcctag	tgactggtag	tcagtggggc	480
attttaggat	gtcaggggccc	cagggtgaca	tgtgtccagc	ttttctatgg	cagcagaggc	540
ctttccctca	gacaagctac	aaagtgccca	ggatgccatc	caccatgggtc	cccttcagta	600
cctcacgcat	ggtccccagc	ttctcctagg	atcccagtg	catttatcag	tggccagcta	660
cctgccaggc	ccgggctggg	gcacggctctg	cgccatgagg	ccaggccgcc	tcccgcaccc	720
ctaccccgctg	gcagcagcat	acctctgcat	ttctggaatg	tgtgtgcatc	aatgatgttt	780

gtatatattga ggcatttaaa aatctatattt cgttacgagg gcaaatagaag aatgaatatt 840  
gatcttaaaa aaagaaaaga agacaaaaaa aaatacccaa aaaaaaaaaa aaanaaaaaa 899

<210> 117

<211> 260

<212> PRT

<213> Homo sapiens

<400> 117

Met Glu Leu Leu Gln Val Thr Ile Leu Phe Leu Leu Pro Ser Ile Cys  
1 5 10 15  
Ser Ser Asn Ser Thr Gly Val Leu Glu Ala Ala Asn Asn Ser Leu Val  
20 25 30  
Thr Thr Thr Lys Pro Ser Ile Thr Thr Pro Asn Thr Glu Ser Leu Gln  
35 40 45  
Lys Asn Val Val Thr Pro Thr Thr Gly Thr Thr Pro Lys Gly Thr Ile  
50 55 60  
Thr Asn Glu Leu Leu Lys Met Ser Leu Met Ser Thr Ala Thr Phe Leu  
65 70 75 80  
Thr Ser Lys Asp Glu Gly Leu Lys Ala Thr Thr Thr Asp Val Arg Lys  
85 90 95  
Asn Asp Ser Ile Ile Ser Asn Val Thr Val Thr Ser Val Thr Leu Pro  
100 105 110  
Asn Ala Val Ser Thr Leu Gln Ser Ser Lys Pro Lys Thr Glu Thr Gln  
115 120 125  
Ser Ser Ile Lys Thr Thr Glu Ile Pro Gly Ser Val Leu Gln Pro Asp  
130 135 140  
Ala Ser Pro Ser Lys Thr Gly Thr Leu Thr Ser Ile Pro Val Thr Ile  
145 150 155 160  
Pro Glu Asn Thr Ser Gln Ser Gln Val Ile Gly Thr Glu Gly Gly Lys  
165 170 175  
Asn Ala Ser Thr Ser Ala Thr Ser Arg Ser Tyr Ser Ser Ile Ile Leu  
180 185 190  
Pro Val Val Ile Ala Leu Ile Val Ile Thr Leu Ser Val Phe Val Leu  
195 200 205  
Val Gly Leu Tyr Arg Met Cys Trp Lys Ala Asp Pro Gly Thr Pro Glu  
210 215 220  
Asn Gly Asn Asp Gln Pro Gln Ser Asp Lys Glu Ser Val Lys Leu Leu  
225 230 235 240  
Thr Val Lys Thr Ile Ser His Glu Ser Gly Glu His Ser Ala Gln Gly  
245 250 255



77

Lys Thr Lys Asn  
260

<210> 118  
<211> 29  
<212> PRT  
<213> Homo sapiens

<400> 118  
Met Leu Val Ile Ile Ile Met Thr Ala Leu Val Ser His Val Pro Ser  
1 5 10 15  
Val His Ser Val Pro His Ala Val Pro Phe Thr Ser Ser  
20 25

<210> 119  
<211> 244  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (231)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (237)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 119  
Met Arg Ala Pro Phe Asn Thr Leu Phe Gly Arg Leu Phe Gly Leu Leu  
1 5 10 15  
Leu Val Ala Ile Val Leu Ala His Val Leu Ala Phe Phe Trp Phe His  
20 25 30  
His Tyr Gly Pro Pro Pro Pro Arg Ala Ala Phe Val Glu Gln Pro  
35 40 45  
Asp Gly Ser Leu Thr Pro Leu Arg Lys Ala Pro Arg Pro Trp Phe Gly  
50 55 60  
Gly Pro Val Val Pro Leu Thr Phe Gln Phe Ile Ser Leu Ile Ile Ala  
65 70 75 80  
Ala Trp Tyr Gly Ala Lys Leu Leu Ser Arg Pro Ile Gln Arg Leu Ser  
85 90 95  
Ala Ala Ala Glu Arg Leu Ser Val Asp Leu Asp Ser Pro Pro Leu Val  
100 105 110  
Glu Thr Gly Pro Arg Glu Ala Arg Gln Ala Ala Ser Thr Phe Asn Leu  
115 120 125  
Met Gln Lys Arg Ile Arg Glu Gln Val Ser Gln Arg Ala Arg Met Leu

130                      135                      140  
 Gly Ala Val Ser His Asp Leu Arg Thr Pro Leu Ser Arg Leu Lys Leu  
 145                      150                      155                      160  
 Arg Leu Glu Gln Ile Glu Asp Pro Lys Leu Gln Gly Gln Met Arg Gln  
                     165                      170                      175  
 Asp Leu Asp Asp Met Ile Gly Met Leu Asp Ala Thr Leu Ser Tyr Leu  
                     180                      185                      190  
 His Glu Gln Arg Thr Ser Glu Thr Arg His Trp Leu Asp Val Gln Ala  
                     195                      200                      205  
 Leu Val Glu Ser Leu Ser Glu Asn Ala Gln Asp Gln Gly Arg Asp Val  
                     210                      215                      220  
 Gln Phe Phe Phe Gly Gly Xaa Pro Pro Gly Gly Gly Xaa Pro Lys Thr  
 225                      230                      235                      240  
 Pro Pro Pro Phe

<210> 120  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 120  
 Met Leu Thr Gly Val Ile Ser Gly Ser Thr Gly Ala Met Ala Leu Ser  
   1                    5                    10                    15  
 Leu Ala Ser Leu Ser Ala His Cys Phe Ala Phe Arg Cys Leu Ala Ala  
                     20                    25                    30  
 Pro Phe Tyr Phe Phe Ala Gly Leu Gly Lys His Gly Arg Arg Ile Leu  
                     35                    40                    45  
 Ile Ser Phe Leu Phe Ser Ala Trp  
                     50                    55

<210> 121  
 <211> 58  
 <212> PRT  
 <213> Homo sapiens

<400> 121  
 Met Ala Thr Ala Ser Ile Asn Asn Leu Ile Ser Ser Leu Leu Leu His  
   1                    5                    10                    15  
 Leu Ser Leu Leu Ser Ser Lys Ala Gly Lys Phe Leu Ile Trp Lys Glu  
                     20                    25                    30  
 His Lys Thr Ala Cys Gly Cys Tyr Ala Asn Ser Thr Cys Leu Leu Pro  
                     35                    40                    45

79

Asn Gly Leu Ser Asn His Lys Gly Lys Ser  
 50 55

<210> 122  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 122  
 Met Lys Thr Val Ser Leu Leu Leu Thr Leu Trp Phe Ser Gln Thr Phe  
 1 5 10 15  
 Ser Phe Asn Leu Phe Phe Ala Pro Pro His Ser Leu Leu Gln Ser Ser  
 20 25 30  
 Ile Phe Phe Ser Val Ser Ser Ile Thr Thr Val His Pro Ile Leu Val  
 35 40 45  
 Phe Phe Phe Ala Phe Phe Arg Thr  
 50 55

<210> 123  
 <211> 76  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (71)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 123  
 Met Leu Val Leu Leu Ser Leu Leu Ala Ser Gly Gly Leu Pro Leu Leu  
 1 5 10 15  
 Leu Val Gly Asp Val Leu Ala Ser Lys Ser Ser Thr Val Leu Phe Leu  
 20 25 30  
 Pro Gly Asp Ser Ser Pro Gly Cys Ser Met Ile Thr Pro Leu Pro Pro  
 35 40 45  
 Ser Arg Met Cys Leu Lys Ala Gly Ser Ser Gly Glu Gln Thr Val Val  
 50 55 60  
 Pro Leu Ser Leu Leu Leu Xaa Ser Lys Ser Ser Lys  
 65 70 75

<210> 124  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<400> 124  
 Met Leu Gln Tyr Thr Trp Leu Ile Leu Val Phe Leu Ser Ser Cys Leu  
 1 5 10 15

80

Ser Ala Thr Trp Phe Cys Lys Val Val Val Ala Ala Ile Gly Ser Thr  
                   20                  25                  30  
 Val Gly Ser Ser Arg Leu His Phe Lys Arg Ser Gly Gln Cys Leu Arg  
                   35                  40                  45

<210> 125  
 <211> 99  
 <212> PRT  
 <213> Homo sapiens

<400> 125  
 Met Leu Leu Leu Leu Val Phe Leu Val Ala Cys Phe Ile Asn Arg Lys  
   1                  5                  10                  15  
 Cys Gln Lys Gln Arg Lys Lys Lys Pro Ala Glu Asp Ile Leu Glu Glu  
                   20                  25                  30  
 Tyr Pro Leu Asn Thr Lys Val Glu Val Pro Lys Arg His Pro Asp Arg  
                   35                  40                  45  
 Val Glu Lys Asn Val Asn Arg His Tyr Cys Thr Val Arg Asn Val Asn  
                   50                  55                  60  
 Ile Leu Ser Glu Pro Glu Ala Ala Tyr Thr Phe Lys Gly Ala Lys Val  
   65                  70                  75                  80  
 Lys Arg Leu Asn Leu Glu Val Arg Val His Asn Asn Leu Gln Asp Gly  
                   85                  90                  95  
 Thr Glu Val

<210> 126  
 <211> 53  
 <212> PRT  
 <213> Homo sapiens

<400> 126  
 Met Asp Ile Gln Gly Lys Ala Leu Tyr Ile Arg Phe Leu Leu Thr Leu  
   1                  5                  10                  15  
 Cys Gln Met Val Val Ser Val Met Gly Lys Arg Arg Gln Gly Arg Arg  
                   20                  25                  30  
 Gly Leu Gly Gly Ala Ala Ala Val Gly Arg Glu Ile Cys Arg Arg Trp  
                   35                  40                  45  
 Gly Cys Cys Val Thr  
                   50

81

<210> 127  
 <211> 53  
 <212> PRT  
 <213> Homo sapiens

<400> 127  
 Met Arg Leu Ile Leu Phe Ala Met Ser Pro Lys Leu Leu Phe Leu Phe  
           1                  5                  10                  15  
 Leu Phe Leu Tyr Ile Ser Val Lys Ser Phe Asp Leu Val Leu Ser Phe  
                   20                  25                  30  
 Arg Ser Val Leu Phe Met Ser Asp Leu Ile His Cys Phe Tyr His Gln  
                   35                  40                  45  
 Leu His Phe Lys Leu  
           50

<210> 128  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<400> 128  
 Met Ala Gly Leu Gly Leu Leu Ser Leu Val Gln Phe Ser Val Thr Gly  
           1                  5                  10                  15  
 Gly His Trp Thr Gly Ile Ala Asp Ser Leu Val Ala Thr Leu Gly Cys  
                   20                  25                  30  
 Arg Leu Ser Gly Ser Val Pro Pro Pro Leu Leu Pro Ala Pro Ser Gly  
                   35                  40                  45  
 His Ser Arg Ala Leu His Gln Thr Leu Thr Trp Cys Leu His Leu Leu  
                   50                  55                  60  
 Ser Leu Ser Pro Ser Ser Asn Pro Trp Lys Ser Leu Val  
           65                  70                  75

<210> 129  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 129  
 Met Leu Arg Pro Pro Arg Trp Ala Leu Met Ala Ala Ser Ser His Pro  
           1                  5                  10                  15  
 Pro Pro Leu Trp Ser Trp Val Leu Gly Leu Ala Ala His Pro Thr Gly  
                   20                  25                  30  
 Met Ser Pro Gly Thr Gly Pro His His Gly Trp Val Ser Ala Ser Ser  
                   35                  40                  45  
 Ser Ser Ser  
           50

<210> 130  
 <211> 68  
 <212> PRT  
 <213> Homo sapiens

<400> 130  
 Met Pro Leu Gln Arg Arg Val Lys Val Lys Thr Thr Ser Ser Arg Cys  
           1                  5                  10                  15  
 Leu Pro Gly Thr Thr Trp Asp Leu Leu Ser Ser Pro Cys Ser Ala Ala  
                   20                  25                  30  
 Ser Gly His Trp Ala Leu Leu Pro Ser Thr Ser Pro Arg Gly Pro Ala  
                   35                  40                  45  
 Arg Pro Ser Pro Lys Gly Thr Ser Ala Trp Pro Ala Pro Pro Pro Ala  
           50                  55                  60  
 Gly Pro Ser Ser  
           65

<210> 131  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 131  
 Met Gly Leu Phe Leu Phe Leu Val Ser Ser  
           1                  5                  10

<210> 132  
 <211> 118  
 <212> PRT  
 <213> Homo sapiens

<400> 132  
 Met Phe Ile Val Phe Ser Val Leu Leu Leu Phe Phe Gln Phe Ala Ile  
           1                  5                  10                  15  
 Cys Gln Phe Ala Asp Leu Ala Ile Phe Pro Leu Ser Met Cys Gln Leu  
                   20                  25                  30  
 Cys Asn Leu Ser Ala Arg Leu Ala Ala Pro Ser Ala Arg Phe Glu Gly  
                   35                  40                  45  
 Leu Gly Ile Asn Arg Thr Arg Lys Ala Glu Gly Ser Leu Pro Thr Thr  
           50                  55                  60  
 Ala Val Gln Leu Leu Pro Tyr Lys Ser Gln Ala Val Gln Val Gln His  
           65                  70                  75                  80  
 Pro Gln Ala Val Ile Val Asp Lys Leu Ser Val Ile Ser Leu Arg Ser  
                   85                  90                  95

83

Ile Cys Ile Asp Gln Leu Lys Phe Met Glu Met Glu Asn Ile Ile Lys  
                   100                  105                  110

Pro Gly Tyr Val Thr Ser  
                   115

<210> 133  
 <211> 95  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (13)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 133  
 Met Arg Ala Cys Leu Cys Ala Gly Val Cys Met Cys Xaa Ala Ser Cys  
   1                  5                  10                  15

Leu Gly Leu Pro Met Asn Val Val Glu Cys Tyr Thr Trp Arg Val Leu  
                   20                  25                  30

Val Phe His Gln Phe Gln Asp Glu Glu Leu His Asp Thr Val Asp Leu  
                   35                  40                  45

Glu Thr Ile Pro Leu Glu Arg Gln Pro Arg Asp Val Gln His Pro Val  
                   50                  55                  60

Ser Thr Arg Ile Leu Tyr Leu His Val Tyr Phe Val Ala Val Thr Leu  
   65                  70                  75                  80

Thr Leu Ile Arg Ile Leu Gln Leu Trp Thr Glu Ala Phe Ser Pro  
                   85                  90                  95

<210> 134  
 <211> 32  
 <212> PRT  
 <213> Homo sapiens

<400> 134  
 Met Leu Leu Pro Leu Phe Thr Leu Leu Ile Leu Leu Leu Arg Val Phe  
   1                  5                  10                  15

Pro Lys Glu Ile Ile Gln Asn Arg Lys Lys Leu Lys Ala Glu Lys Cys  
                   20                  25                  30

<210> 135  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens

84

&lt;400&gt; 135

Met Arg Ala Arg Thr Leu Pro Pro Ser Leu Leu Cys Leu Trp Cys Leu  
 1 5 10 15

Ala Pro Tyr Leu Asn Ile Cys Trp Met Asn Gly  
 20 25

&lt;210&gt; 136

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

Met Trp Cys Leu Val Phe Cys Ser Cys Val Ser Leu Pro Arg Met Met  
 1 5 10 15

Ala Ser Ser Phe Ile His Asp Ile Ala Lys Asp Met Ile Ser Phe Leu  
 20 25 30

Phe Met Ser Ala Trp Tyr Tyr Thr Tyr Phe Asn Ser Phe Glu Ile Tyr  
 35 40 45

Arg Phe Gln Phe Thr Phe Ile Glu Tyr Ser Leu Trp Val Lys His His  
 50 55 60

Ala Ser Leu Pro Gly Val Gln  
 65 70

&lt;210&gt; 137

&lt;211&gt; 43

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 137

Met Phe His Arg Phe Phe Ile Leu Ser Ala Leu Ser Arg Ile Arg Ala  
 1 5 10 15

Leu Thr Thr Phe Leu Asp Asp Leu Gly Met Thr His Gln Thr Leu Leu  
 20 25 30

Leu Leu Leu Gly Pro Ser Ile Tyr Ser Phe Cys  
 35 40

&lt;210&gt; 138

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 138

Met Ala Arg Trp Leu Leu Pro Cys Leu Pro Pro Leu His Ser Val Thr  
 1 5 10 15

Ser Trp Leu Leu Thr Val Pro Thr Ser Cys Gly Ala Met Gly Ser Ala  
 20 25 30



85

Val Cys Leu Cys Gly Arg Gly Leu Cys Arg Gln Asn Cys  
                   35                                  40                                  45

<210> 139  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 139  
 Met Leu Leu Phe His Val Trp Val Asp Leu Ala Cys Trp Gly Val Leu  
       1                                  5                                  10                                  15

Val His Ser Leu Lys Leu Ala Ser Phe His Trp Gly Leu Lys Ser Thr  
                   20                                  25                                  30

Ser Thr Pro Thr Leu Val Met Ser Pro Glu Asp Pro Gly Asp Ser Thr  
                   35                                  40                                  45

Val Asn Ile Val Ser Thr Leu Leu  
                   50                                  55

<210> 140  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<400> 140  
 Met Leu His Trp Gly Val Leu Cys Ser Leu Phe Leu Met Leu Phe Asn  
       1                                  5                                  10                                  15

Glu Gly Ala Ser Ala Ser Leu Gln Gln  
                   20                                  25

<210> 141  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<400> 141  
 Met Pro Phe Tyr Tyr Ala Gly Leu Ile Leu Met Glu Met Arg Leu Thr  
       1                                  5                                  10                                  15

Ile Ala Lys Thr Pro Val Glu Thr Gln Gln Ser Trp Pro Ala Phe Leu  
                   20                                  25                                  30

Trp Tyr Phe Gly Cys Gly Ser Cys Asp Gly Tyr Ser Ile Lys His Cys  
                   35                                  40                                  45

Ile Ser Leu His Leu Leu Ser Phe Ser Leu Gln Lys  
                   50                                  55                                  60

<210> 142  
 <211> 183  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 142

Met Met Asn Val Ser Lys Ile Ser Phe Phe Ala Met Phe Leu Met Tyr  
 1 5 10 15

Leu Leu Ala Ala Leu Phe Gly Tyr Leu Thr Phe Tyr Glu His Val Glu  
 20 25 30

Ser Glu Leu Leu His Thr Tyr Ser Ser Ile Leu Gly Thr Asp Ile Leu  
 35 40 45

Leu Leu Ile Val Arg Leu Ala Val Leu Met Ala Val Thr Leu Thr Val  
 50 55 60

Pro Val Val Ile Phe Pro Ile Arg Ser Ser Val Thr His Leu Leu Cys  
 65 70 75 80

Ala Ser Lys Asp Phe Ser Trp Trp Arg His Ser Leu Ile Thr Val Ser  
 85 90 95

Ile Leu Ala Phe Thr Asn Leu Leu Val Ile Phe Val Pro Thr Ile Arg  
 100 105 110

Asp Ile Phe Gly Phe Ile Gly Ala Ser Ala Ala Ser Met Leu Ile Phe  
 115 120 125

Ile Leu Pro Ser Ala Phe Tyr Ile Lys Leu Val Lys Lys Glu Pro Met  
 130 135 140

Lys Ser Val Gln Lys Ile Gly Ala Leu Phe Phe Leu Leu Ser Gly Val  
 145 150 155 160

Leu Val Met Thr Gly Ser Met Ala Leu Ile Val Leu Asp Trp Val His  
 165 170 175

Asn Ala Pro Gly Gly Gly His  
 180

&lt;210&gt; 143

&lt;211&gt; 52

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (39)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 143

Met Val Ala Val Asp Phe Ser Cys Leu Ser Phe Ile Leu Leu Gly Ile  
 1 5 10 15

Leu Val Leu Tyr Ile Tyr Phe Val Met Tyr Ala Cys Ser Ile Pro Thr  
 20 25 30

Leu Phe Ser Val Phe Tyr Xaa Glu Glu Met Leu Asn Leu Ser Lys Leu

87

35

40

45

Ser Cys Ile Tyr  
50

&lt;210&gt; 144

&lt;211&gt; 161

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 144

Met Ala Glu Ala Ser Cys Gly Val Phe Trp Leu Leu Ser Leu Leu Cys  
1 5 10 15

Cys Ile Lys Glu Gln Gln Phe Glu Gln Val Val Ala Leu Leu Leu Gln  
20 25 30

Ser Ile Arg Leu Cys Gln Asp Arg Ala Leu Leu Val Asn Asn Ala Tyr  
35 40 45

Gln Gly Leu Ala Ser Leu Val Lys Val Ser Glu Leu Ala Ala Phe Lys  
50 55 60

Val Val Val Gln Glu Glu Gly Gly Ser Gly Leu Ser Leu Ile Lys Glu  
65 70 75 80

Thr Tyr Gln Leu His Arg Asp Asp Pro Glu Val Val Glu Asn Val Gly  
85 90 95

Met Leu Leu Val His Leu Ala Ser Tyr Glu Glu Ile Leu Pro Glu Leu  
100 105 110

Val Ser Ser Ser Met Lys Ala Leu Leu Gln Glu Ile Lys Glu Arg Phe  
115 120 125

Thr Ser Ser Leu Glu Leu Val Ser Cys Val Glu Lys Val Leu Leu Arg  
130 135 140

Leu Glu Ala Ala Thr Ser Pro Ser Pro Leu Gly Gly Glu Ala Ala Gln  
145 150 155 160

Pro

&lt;210&gt; 145

&lt;211&gt; 41

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 145

Met Met Leu Pro Val Ile Ser Leu Phe Leu Ile Ser Leu His Leu Pro  
1 5 10 15

Ile Phe Cys Phe Gln Arg Leu Leu Leu Phe Lys Gly Phe Leu Phe Ile  
20 25 30

88

Ala Asn Ser Ser Asn Leu His Ile Lys  
35 40

<210> 146  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 146  
Met Ser Leu Ser Leu Ile Ser Leu Ser Phe Leu Phe Pro Ala Gly Ala  
1 5 10 15

Gly Arg Arg Ser Cys  
20

<210> 147  
<211> 42  
<212> PRT  
<213> Homo sapiens

<400> 147  
Met Asp Gln Phe Leu Gln Tyr Leu Leu Glu Cys Met Leu Leu Cys Thr  
1 5 10 15

Thr Ala Gly Ala Ser Gly Ala His Leu Cys Thr Asn Glu Met Thr Leu  
20 25 30

Leu Glu Ala Ile Leu Tyr Leu Gln Trp Met  
35 40

<210> 148  
<211> 63  
<212> PRT  
<213> Homo sapiens

<400> 148  
Met Asn His Cys Cys Ser Ser Gln Arg Phe Leu Asn Ile Leu Ser Phe  
1 5 10 15

Cys Ile Ser Pro Pro Phe Pro Leu Thr Phe Ile Tyr Leu Ile Met Tyr  
20 25 30

Leu Phe Ile Tyr Leu Tyr Thr Phe Ala Pro Phe Ser Thr Asn Thr Lys  
35 40 45

Gln Ser Lys Lys Lys Lys Tyr Ile Tyr Ile Ser Val Tyr Val Leu  
50 55 60

<210> 149  
<211> 34  
<212> PRT  
<213> Homo sapiens

<400> 149

89

Met Thr Ala Leu Phe Cys Ser Leu Leu His Ser Leu Val Ser Leu Leu  
 1 5 10 15

Leu Pro Thr Lys Trp Gly Gln Gly Lys Ala Phe Leu Thr Gly Pro Leu  
 20 25 30

Phe Ser

<210> 150

<211> 65

<212> PRT

<213> Homo sapiens

<400> 150

Ser Ile Leu Leu Val Ser Leu Asp Leu Leu Pro Thr Ser Ile Leu Leu  
 1 5 10 15

Val Ser Leu Trp Ile Cys Ser Pro Pro Pro Ser Ser Trp Val Asn Pro  
 20 25 30

Gly Ser Phe Val Gly Tyr Leu Glu Arg Lys Arg Gln Lys Leu Ile Cys  
 35 40 45

Gln Met Thr Arg Thr Asn Arg Leu Phe Gly Met Lys Arg Lys Thr Ser  
 50 55 60

Gly  
 65

<210> 151

<211> 23

<212> PRT

<213> Homo sapiens

<400> 151

Ile Cys Leu Trp Gly Arg Pro Asn Leu Thr Thr Gln Gly Thr Leu Lys  
 1 5 10 15

Gly Ile Ser Gly Arg Arg Ser  
 20

<210> 152

<211> 261

<212> PRT

<213> Homo sapiens

<400> 152

Met Glu Leu Leu Gln Val Thr Ile Leu Phe Leu Leu Pro Ser Ile Cys  
 1 5 10 15

Ser Ser Asn Ser Thr Gly Val Leu Glu Ala Ala Asn Asn Ser Leu Val  
 20 25 30

Val Thr Thr Thr Lys Pro Ser Ile Thr Thr Pro Asn Thr Glu Ser Leu

90

35                                      40                                      45  
 Gln Lys Asn Val Val Thr Pro Thr Thr Gly Thr Thr Pro Lys Gly Thr  
     50                                      55                                      60  
 Ile Thr Asn Glu Leu Leu Lys Met Ser Leu Met Ser Thr Ala Thr Phe  
     65                                      70                                      75                                      80  
 Leu Thr Ser Lys Asp Glu Gly Leu Lys Ala Thr Thr Thr Asp Val Arg  
                                     85                                      90                                      95  
 Lys Asn Asp Ser Ile Ile Ser Asn Val Thr Val Thr Ser Val Thr Leu  
                                     100                                      105                                      110  
 Pro Asn Ala Val Ser Thr Leu Gln Ser Ser Lys Pro Lys Thr Glu Thr  
                                     115                                      120                                      125  
 Gln Ser Ser Ile Lys Thr Thr Glu Ile Pro Gly Ser Val Leu Gln Pro  
     130                                      135                                      140  
 Asp Ala Ser Pro Ser Lys Thr Gly Thr Leu Thr Ser Ile Pro Val Thr  
     145                                      150                                      155                                      160  
 Ile Pro Glu Asn Thr Ser Gln Ser Gln Val Ile Gly Thr Glu Gly Gly  
                                     165                                      170                                      175  
 Lys Asn Ala Ser Thr Ser Ala Thr Ser Arg Ser Tyr Ser Ser Ile Ile  
                                     180                                      185                                      190  
 Leu Pro Val Val Ile Ala Leu Ile Val Ile Thr Leu Ser Val Phe Val  
     195                                      200                                      205  
 Leu Val Gly Leu Tyr Arg Met Cys Trp Lys Ala Asp Pro Gly Thr Pro  
     210                                      215                                      220  
 Glu Asn Gly Asn Asp Gln Pro Gln Ser Asp Lys Glu Ser Val Lys Leu  
     225                                      230                                      235                                      240  
 Leu Thr Val Lys Thr Ile Ser His Glu Ser Gly Glu His Ser Ala Gln  
                                     245                                      250                                      255  
 Gly Lys Thr Lys Asn  
                                     260

&lt;210&gt; 153

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Met Leu Val Ile Ile Ile Met Thr Ala Leu Val Ser His Val Pro Ser  
     1                                      5                                      10                                      15

Val His Ser Val Pro His Ala Val Pro Phe Thr Ser Ser  
                                     20                                      25

<210> 154  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (3)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 154  
 Ala Glu Xaa Ala Pro Leu His Phe His Leu Gly Asp Gly Glu Arg Leu  
           1                          5                          10                          15  
 His Leu Lys Lys Lys Lys Asn Lys Lys Lys Lys Pro Lys Gln Gly Trp  
                           20                          25                          30  
 Ala Arg Trp Leu Thr Pro Val Ile Ser Ala Leu Leu Glu Xaa Gly Ala  
                   35                          40                          45  
 Gly Val Ser Pro Glu Val Met Ser  
           50                          55

<210> 155  
 <211> 244  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (25)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (40)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (41)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (43)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (231)  
 <223> Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (237)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 155

```

Met Arg Ala Pro Phe Asn Thr Leu Phe Gly Arg Leu Phe Gly Leu Leu
 1           5           10           15

Leu Val Ala Ile Val Leu Ala His Xaa Leu Ala Phe Phe Trp Phe His
      20           25           30

His Tyr Gly Pro Pro Pro Pro Xaa Xaa Ala Xaa Phe Val Glu Gln Pro
      35           40           45

Asp Gly Ser Leu Thr Pro Leu Arg Lys Ala Pro Arg Pro Trp Phe Gly
      50           55           60

Gly Pro Val Val Pro Leu Thr Phe Gln Phe Ile Ser Leu Ile Ile Ala
      65           70           75           80

Ala Trp Tyr Gly Ala Lys Leu Leu Ser Arg Pro Ile Gln Arg Leu Ser
      85           90           95

Ala Ala Ala Glu Arg Leu Ser Val Asp Leu Asp Ser Pro Pro Leu Val
      100          105          110

Glu Thr Gly Pro Arg Glu Ala Arg Gln Ala Ala Ser Thr Phe Asn Leu
      115          120          125

Met Gln Lys Arg Ile Arg Glu Gln Val Ser Gln Arg Ala Arg Met Leu
      130          135          140

Gly Ala Val Ser His Asp Leu Arg Thr Pro Leu Ser Arg Leu Lys Leu
      145          150          155          160

Arg Leu Glu Gln Ile Glu Asp Pro Lys Leu Gln Gly Gln Met Arg Gln
      165          170          175

Asp Leu Asp Asp Met Ile Gly Met Leu Asp Ala Thr Leu Ser Tyr Leu
      180          185          190

His Glu Gln Arg Thr Ser Glu Thr Arg His Trp Leu Asp Val Gln Ala
      195          200          205

Leu Val Glu Ser Leu Ser Glu Asn Ala Gln Asp Gln Gly Arg Asp Val
      210          215          220

Gln Phe Phe Phe Gly Gly Xaa Pro Pro Gly Gly Gly Xaa Pro Lys Thr
      225          230          235          240

Pro Pro Pro Phe

```

&lt;210&gt; 156

&lt;211&gt; 56



93

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 156

```

Met Leu Thr Gly Val Ile Ser Gly Ser Thr Gly Ala Met Ala Leu Ser
 1             5             10             15

Leu Ala Ser Leu Ser Ala His Cys Phe Ala Phe Arg Cys Leu Ala Ala
      20             25             30

Pro Phe Tyr Phe Phe Ala Gly Leu Gly Lys His Gly Arg Arg Ile Leu
      35             40             45

Ile Ser Phe Leu Phe Ser Ala Trp
 50             55

```

&lt;210&gt; 157

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 157

```

Met Ala Thr Ala Ser Ile Asn Asn Leu Ile Ser Ser Leu Leu Leu His
 1             5             10             15

Leu Ser Leu Leu Ser Ser Lys Ala Gly Lys Phe Leu Ile Trp Lys Glu
      20             25             30

His Lys Thr Ala Cys Gly Cys Tyr Ala Asn Ser Thr Cys Leu Leu Pro
      35             40             45

Asn Gly Leu Ser Asn His Lys Gly Lys Ser
 50             55

```

&lt;210&gt; 158

&lt;211&gt; 134

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 158

```

Ser Pro Ala Arg His Pro Thr Thr Ser Ser Arg His Thr Trp Trp Glu
 1             5             10             15

Ser Gly Asn Ala Val Pro Pro Gly Ser Pro Phe His Gly Arg Pro Leu
      20             25             30

Leu Leu Leu Gln Pro Ala Gly Pro Val Pro Phe Gln Asp Gln Pro Phe
      35             40             45

Asp Pro Ser Gln Gly Pro Trp Pro Gly Leu His Cys Arg Pro Gln Gly
      50             55             60

Leu Met His Ser Met Cys Leu Pro Asp Leu Thr Pro Glu Asp Gly Gly
      65             70             75             80

Lys Ala Gln Asp His Thr Ala Leu Gly His Ser Arg Glu Gln Asp Thr

```

94

85

90

95

Pro Gly Val Gln Glu Asn Phe Gln Gly Ala Ala Pro Leu Asp Arg Tyr  
 100 105 110

Thr Arg Arg Phe Asn Thr Leu Tyr Tyr Leu Gly Asn Gln Arg Arg Gly  
 115 120 125

Ile Ile Lys Thr Arg Lys  
 130

&lt;210&gt; 159

&lt;211&gt; 54

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (34)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (46)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 159

Met Lys Thr Val Ser Leu Leu Leu Thr Leu Trp Phe Ser Gln Thr Phe  
 1 5 10 15

Ser Phe Asn Leu Phe Phe Ala Pro Pro His Ser Leu Leu Gln Ser Ser  
 20 25 30

Ile Xaa Xaa Ser Val Ser Ser Ile Thr Thr Val His Pro Xaa Leu Gly  
 35 40 45

Leu Leu Phe Cys Ile Leu  
 50

&lt;210&gt; 160

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 160

Ile Leu Leu Gly Leu Trp Gln Ser Val Leu Gly Ser Ser Ile Trp Gly  
 1 5 10 15

Gln Pro Leu Ser Tyr Asn Cys Gln Glu Pro His Asn Cys Leu Phe Asn  
 20 25 30

95

His Ser Asp Phe Lys  
35

<210> 161  
<211> 85  
<212> PRT  
<213> Homo sapiens

<400> 161  
Gly Ile Gly Ser Arg Val Arg Ala Ala Phe Ile Ala Leu Glu Pro Ser  
1 5 10 15  
Leu Gly Met Gly Phe Ser Lys Asn Trp Gln Ala His Arg Leu Pro Ser  
20 25 30  
Lys Trp Val Arg Thr Ala Tyr Pro Ser Ile Glu Thr His Tyr Leu Phe  
35 40 45  
Tyr Leu Phe Leu Ser Gly Ser Gly Ala Arg Cys Ser Tyr Phe Ser His  
50 55 60  
Leu Arg Trp Asp Ile Leu Gly Gln Thr Arg Glu Ile Leu Glu Ala Ile  
65 70 75 80  
Ser Val Val Asn Pro  
85

<210> 162  
<211> 76  
<212> PRT  
<213> Homo sapiens

<400> 162  
Met Leu Val Leu Leu Ser Leu Leu Ala Ser Gly Gly Leu Pro Leu Leu  
1 5 10 15  
Leu Val Gly Asp Val Leu Ala Ser Lys Ser Ser Thr Val Leu Phe Leu  
20 25 30  
Pro Gly Asp Ser Ser Pro Gly Cys Ser Met Ile Thr Pro Leu Pro Pro  
35 40 45  
Ser Arg Met Cys Leu Lys Ala Gly Ser Ser Gly Glu Gln Thr Val Val  
50 55 60  
Pro Leu Ser Leu Leu Leu Arg Ser Lys Ser Ser Lys  
65 70 75

<210> 163  
<211> 42  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE

<222> (21)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (23)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (42)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 163  
 His Ser Pro Glu Ser Cys Tyr Ser Phe Asn Leu Gly Ser Arg Met Arg  
   1                  5                  10                  15  
 Ile Ser Val Glu Xaa Lys Xaa Ala Lys Ser Asn Ser Ala Ala Asp Asn  
                   20                  25                  30  
 Pro Glu Thr Leu Arg Lys Gly Tyr Val Xaa  
           35                  40  
  
 <210> 164  
 <211> 64  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (55)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (59)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (63)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 164  
 Ser Ile Lys Ser Cys Ser Ser Phe Tyr Leu Gly Ser Arg Val Asn Arg  
   1                  5                  10                  15  
 Ala Gln Leu Thr Asn Tyr Pro Pro Ala Met Arg Thr Tyr Val Tyr Glu  
                   20                  25                  30  
 Cys His Cys Asp Lys Ser Thr Ser Arg Ala Thr Ala Gly Pro Ser Ile  
           35                  40                  45  
 Phe His Pro Gly Gly Val Xaa Gly Met Trp Xaa Ile Phe Ala Xaa Val  
           50                  55                  60

<210> 165  
<211> 48  
<212> PRT  
<213> Homo sapiens

<400> 165  
Met Leu Gln Tyr Thr Trp Leu Ile Leu Val Phe Leu Ser Ser Cys Leu  
1 5 10 15  
Ser Ala Thr Trp Phe Cys Lys Val Val Val Ala Ala Ile Gly Ser Thr  
20 25 30  
Val Gly Ser Ser Arg Leu His Phe Lys Arg Ser Gly Gln Cys Leu Arg  
35 40 45

<210> 166  
<211> 70  
<212> PRT  
<213> Homo sapiens

<400> 166  
Leu Leu Asp Leu Thr Asn Arg Leu Val Thr Cys Ile Asp Gln Ser Lys  
1 5 10 15  
Pro Asn Ile Leu Ala Ser Leu Ser Leu Ala Glu Gln Thr Arg Val Gly  
20 25 30  
Ile Trp Val Gly Ala Phe Ser Ile Lys Asp Asn Leu Ser Leu Cys Ser  
35 40 45  
Gln Gly Glu His Leu Cys Phe Val Leu Lys Ala Gly Ser Pro Trp Phe  
50 55 60  
Ala Asn Cys Leu Gln Glu  
65 70

<210> 167  
<211> 99  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (44)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 167  
Met Leu Leu Leu Leu Val Phe Leu Val Ala Cys Phe Ile Asn Arg Lys  
1 5 10 15

98

Cys Gln Lys Gln Arg Lys Lys Lys Pro Ala Glu Asp Ile Leu Glu Glu  
                   20                                  25                                  30  
 Tyr Pro Leu Asn Thr Lys Val Glu Val Pro Lys Xaa His Pro Asp Arg  
                   35                                  40                                  45  
 Val Glu Lys Asn Val Asn Arg His Tyr Cys Thr Val Arg Asn Val Asn  
                   50                                  55                                  60  
 Ile Leu Ser Glu Pro Glu Ala Ala Tyr Thr Phe Lys Gly Ala Lys Val  
                   65                                  70                                  75                                  80  
 Lys Arg Leu Asn Leu Glu Val Arg Val His Asn Asn Leu Gln Asp Gly  
                                   85                                  90                                  95  
 Thr Glu Val

<210> 168  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 168  
 Met Pro Val Leu Leu  
   1                                  5

<210> 169  
 <211> 255  
 <212> PRT  
 <213> Homo sapiens

<400> 169  
 Leu Leu Leu Trp Thr Met Ser Val Ile Phe Phe Ala Cys Val Val Arg  
   1                                  5                                  10                                  15  
 Val Arg Asp Gly Leu Pro Leu Ser Ala Ser Thr Asp Phe Tyr His Thr  
                   20                                  25                                  30  
 Gln Asp Phe Leu Glu Trp Arg Arg Arg Leu Lys Ser Leu Ala Leu Arg  
                   35                                  40                                  45  
 Leu Ala Gln Tyr Pro Gly Arg Gly Ser Ala Glu Gly Cys Asp Phe Ser  
                   50                                  55                                  60  
 Ile His Phe Ser Ser Phe Gly Asp Val Ala Cys Met Ala Ile Cys Ser  
                   65                                  70                                  75                                  80  
 Cys Gln Cys Pro Ala Ala Met Ala Phe Cys Phe Leu Glu Thr Leu Trp  
                                   85                                  90                                  95  
 Trp Glu Phe Thr Ala Ser Tyr Asp Thr Thr Cys Ile Gly Leu Ala Ser  
                   100                                  105                                  110  
 Arg Pro Tyr Ala Phe Leu Glu Phe Asp Ser Ile Ile Gln Lys Val Lys  
                   115                                  120                                  125

Trp His Phe Asn Tyr Val Ser Ser Ser Gln Met Glu Cys Ser Leu Glu  
 130 135 140  
 Lys Ile Gln Glu Glu Leu Lys Leu Gln Pro Pro Ala Val Leu Thr Leu  
 145 150 155 160  
 Glu Asp Thr Asp Val Ala Asn Gly Val Met Asn Gly His Thr Pro Met  
 165 170 175  
 His Leu Glu Pro Ala Pro Asn Phe Arg Met Glu Pro Val Thr Ala Leu  
 180 185 190  
 Gly Ile Leu Ser Leu Ile Leu Asn Ile Met Cys Ala Ala Leu Asn Leu  
 195 200 205  
 Ile Arg Gly Val His Leu Ala Glu His Ser Leu Gln Val Ala His Glu  
 210 215 220  
 Glu Ile Gly Asn Ile Leu Ala Phe Leu Val Pro Phe Val Ala Cys Ile  
 225 230 235 240  
 Phe Gln Asp Pro Arg Ser Trp Phe Cys Trp Leu Asp Gln Thr Ser  
 245 250 255

&lt;210&gt; 170

&lt;211&gt; 491

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (42)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (43)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (44)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 170

Ala Ala Arg Val Gly Arg His Gly Arg Arg Arg Arg Ser Ala Ala Met  
 1 5 10 15  
 Ala Gly Arg Gly Gly Ser Ala Leu Leu Ala Leu Cys Gly Ala Leu Ala  
 20 25 30  
 Ala Cys Gly Trp Leu Leu Gly Ala Glu Xaa Xaa Xaa Pro Gly Ala Pro  
 35 40 45  
 Ala Ala Gly Met Arg Arg Arg Arg Arg Leu Gln Gln Glu Asp Gly Ile  
 50 55 60

100

Ser Phe Glu Tyr His Arg Tyr Pro Glu Leu Arg Glu Ala Leu Val Ser  
 65 70 75 80  
 Val Trp Leu Gln Cys Thr Ala Ile Ser Arg Ile Tyr Thr Val Gly Arg  
 85 90 95  
 Ser Phe Glu Gly Arg Glu Leu Leu Val Ile Glu Leu Ser Asp Asn Pro  
 100 105 110  
 Gly Val His Glu Pro Gly Glu Pro Glu Phe Lys Tyr Ile Gly Asn Met  
 115 120 125  
 His Gly Asn Glu Ala Val Gly Arg Glu Leu Leu Ile Phe Leu Ala Gln  
 130 135 140  
 Tyr Leu Cys Asn Glu Tyr Gln Lys Gly Asn Glu Thr Ile Val Asn Leu  
 145 150 155 160  
 Ile His Ser Thr Arg Ile His Ile Met Pro Ser Leu Asn Pro Asp Gly  
 165 170 175  
 Phe Glu Lys Ala Ala Ser Gln Pro Gly Glu Leu Lys Asp Trp Phe Val  
 180 185 190  
 Gly Arg Ser Asn Ala Gln Gly Ile Asp Leu Asn Arg Asn Phe Pro Asp  
 195 200 205  
 Leu Asp Arg Ile Val Tyr Val Asn Glu Lys Glu Gly Gly Pro Asn Asn  
 210 215 220  
 His Leu Leu Lys Asn Met Lys Lys Ile Val Asp Gln Asn Thr Lys Leu  
 225 230 235 240  
 Ala Pro Glu Thr Lys Ala Val Ile His Trp Ile Met Asp Ile Pro Phe  
 245 250 255  
 Val Leu Ser Ala Asn Leu His Gly Gly Asp Leu Val Ala Asn Tyr Pro  
 260 265 270  
 Tyr Asp Glu Thr Arg Ser Gly Ser Ala His Glu Tyr Ser Ser Ser Pro  
 275 280 285  
 Asp Asp Ala Ile Phe Gln Ser Leu Ala Arg Ala Tyr Ser Ser Phe Asn  
 290 295 300  
 Pro Ala Met Ser Asp Pro Asn Arg Pro Pro Cys Arg Lys Asn Asp Asp  
 305 310 315 320  
 Asp Ser Ser Phe Val Asp Gly Thr Thr Asn Gly Gly Ala Trp Tyr Ser  
 325 330 335  
 Val Pro Gly Gly Met Gln Asp Phe Asn Tyr Leu Ser Ser Asn Cys Phe  
 340 345 350  
 Glu Ile Thr Val Glu Leu Ser Cys Glu Lys Phe Pro Pro Glu Glu Thr  
 355 360 365



101

Leu Lys Thr Tyr Trp Glu Asp Asn Lys Asn Ser Leu Ile Ser Tyr Leu  
 370 375 380  
 Glu Gln Ile His Arg Gly Val Lys Gly Phe Val Arg Asp Leu Gln Gly  
 385 390 395 400  
 Asn Pro Ile Ala Asn Ala Thr Ile Ser Val Glu Gly Ile Asp His Asp  
 405 410 415  
 Val Thr Ser Ala Lys Asp Gly Asp Tyr Trp Arg Leu Leu Ile Pro Gly  
 420 425 430  
 Asn Tyr Lys Leu Thr Ala Ser Ala Pro Gly Tyr Leu Ala Ile Thr Lys  
 435 440 445  
 Lys Val Ala Val Pro Tyr Ser Pro Ala Ala Gly Val Asp Phe Glu Leu  
 450 455 460  
 Glu Ser Phe Ser Glu Arg Lys Glu Glu Glu Lys Glu Glu Leu Met Glu  
 465 470 475 480  
 Trp Trp Lys Met Met Ser Glu Thr Leu Asn Phe  
 485 490

&lt;210&gt; 171

&lt;211&gt; 53

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (28)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 171

Met Asp Ile Gln Gly Lys Ala Leu Tyr Ile Arg Phe Leu Leu Thr Leu  
 1 5 10 15  
 Cys Gln Met Val Val Ser Val Met Gly Lys Arg Xaa Gln Gly Arg Arg  
 20 25 30  
 Gly Leu Gly Gly Ala Ala Ala Val Gly Arg Glu Ile Cys Arg Arg Trp  
 35 40 45  
 Gly Cys Cys Val Thr  
 50

&lt;210&gt; 172

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 172

Leu Cys Trp Thr Arg Ser Ser Val Ile Gly Ala His  
 1 5 10

—